n-Butyric acid by Asch

Query Query

Results

Date

628 substances in Reaxys

2017-08-01 06h:39m:32s (EST)

23 substances in Reaxys

2017-08-01 06h:43m:21s (EST)

1. Query OH

Search as: As drawn, No mixtures 2. Query

(1. Query) AND itemno in (2,4,5,6,7,8,9,10,12,13,15,17,18,20,21,22,23,24,25,26,27,28, 29)

1/365

2017-08-01 06:49:42

Reaxys ID 1850441 View in Reaxys

1/23 CAS Registry Number: 3122-09-6 Chemical Name: 1-carboxy-propyl; 1-Carboxy-propyl-Radikal; Buttersaeureradikal Linear Structure Formula: C4H7O2 Molecular Formula: C4H7O2 Molecular Weight: 87.0984 Type of Substance: acyclic InChI Key: WOPPAKOZWUGURL-UHFFFAOYSA-N Note:

H C

HO O

Substance Label (4) Label References CH3CH2C(.)HCO Grodkowski, Jan; Neta, Pedatsur; Wishart, James F.; Journal of Physical Chemistry A; vol. 107; nb. 46; 2H (2003); p. 9794 - 9799, View in Reaxys Tab.1, run 3 radical

Courtneidge, John L.; Davies, Alwyn G.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1985); p. 385 - 388, View in Reaxys

Bascetta, Emanuele; Gunstone, Frank D.; Walton, John C.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 3; (1984); p. 401 - 406, View in Reaxys

Ayscough; Olsen; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 68; (1972); p. 1635,1641, 1643, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.886

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

ESR Spectroscopy (8) 1 of 8

Description (ESR Spectroscopy)

ESR-hyperfine coupling constants

Solvents (ESR Spectroscopy)

H2O

Comment (ESR Spectroscopy)

1H.

Gilbert, Bruce C.; Smith, John R. Lindsay; Milne, Elizabeth C.; Whitwood, Adrian C.; Taylor, Philip; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1993); p. 2025 2032, View in Reaxys 2 of 8

Description (ESR Spectroscopy)

g-factor

Courtneidge, John L.; Davies, Alwyn G.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1985); p. 385 - 388, View in Reaxys; Gilbert, Bruce C.; Smith, John R. Lindsay; Milne, Elizabeth C.; Whitwood, Adrian C.; Taylor, Philip; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1993); p. 2025 - 2032, View in Reaxys 3 of 8

Description (ESR Spectroscopy)

Signals

Solvents (ESR Spectroscopy)

H2O

Description (ESR Spectroscopy)

ESR-hyperfine coupling constants

2/365

2017-08-01 06:49:42

Temperature (ESR Spectroscopy) [°C]

Comment (ESR Spectroscopy)

1H. Solvent(s): further solvent(s)

Courtneidge, John L.; Davies, Alwyn G.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1985); p. 385 - 388, View in Reaxys 5 of 8

Description (ESR Spectroscopy)

Spectrum

Temperature (ESR Spectroscopy) [°C]

Comment (ESR Spectroscopy)

Solvent(s): further solvent(s)

Courtneidge, John L.; Davies, Alwyn G.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1985); p. 385 - 388, View in Reaxys 6 of 8

Description (ESR Spectroscopy)

ESR-hyperfine coupling constants

Temperature (ESR Spectroscopy) [°C]

-23.2

Comment (ESR Spectroscopy)

1H. .

Bascetta, Emanuele; Gunstone, Frank D.; Walton, John C.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 3; (1984); p. 401 - 406, View in Reaxys 7 of 8

Description (ESR Spectroscopy)

ESR

Paemel et al.; Journal of Physical Chemistry; vol. 79; (1975); p. 839,843, View in Reaxys; Neilson; Symons; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1973); p. 397,398, View in Reaxys; Sevilla et al.; Journal of Physical Chemistry; vol. 82; (1978); p. 2589,2592, View in Reaxys; Ayscough; Olsen; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 68; (1972); p. 1635,1641, 1643, View in Reaxys; Ayscough; Lambert; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 74; (1978); p. 2481,2482,2485,2486,2489, View in Reaxys 8 of 8

Description (ESR Spectroscopy)

Spectrum

Hewgill; Proudfoot; Australian Journal of Chemistry; vol. 29; (1976); p. 637, View in Reaxys

Reaxys ID 3601060 View in Reaxys

2/23 CAS Registry Number: 461-55-2 Chemical Name: butyrate; anhydrous ethylacetate; n-butanoate (ester); ethyl-acetate; n-PrCOO(-); n-butyrate; butanoate Linear Structure Formula: C4H7O2 (1-) Molecular Formula: C4H7O2 Molecular Weight: 87.0984 Type of Substance: acyclic InChI Key: FERIUCNNQQJTOY-UHFFFAOYSA-M Note:

–O

Substance Label (4) Label References BUTA

Wang, Xiaohua; Wang, Jie; Kamal, Ghulam Mustafa; Jiang, Bin; Sun, Peng; Zhang, Xu; Liu, Maili; Chinese Journal of Chemistry; vol. 34; nb. 11; (2016); p. 1183 - 1193, View in Reaxys

Lamichhane, Santosh; Yde, Christian C.; Schmedes, Mette S.; Jensen, Henrik Max; Meier, Sebastian; Bertram, Hanne Christine; Analytical Chemistry; vol. 87; nb. 12; (2015); p. 5930 - 5937, View in Reaxys

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys

3/365

2017-08-01 06:49:42

but

Pacha, Jiri; Lisa, Vera; Miksik, Ivan; Steroids; vol. 67; nb. 2; (2002); p. 119 - 126, View in Reaxys

Patent-Specific Data (1) Location in Patent References Claim

Patent; Alfa Chemicals Italiana S.r.l.; EP143371; (1995); (B2) english, View in Reaxys; Patent; CHINOIN, Gyogyszer es Vegyeszeti Termekek Gyara RT.; EP437567; (1994); (B1) english, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Derivative (3) Comment (Derivative)

References

Natrium-Salz: Ferloni; Franzosini; Gazzetta Chimica Italiana; vol. 105; (1975); p. 391,398,399, View in Reaxys Fluessig-, mesomorphe- u. Festkoerperphasen <Uebergangstemp., Δ H(Transition), Δ S(Transition), C(p)> Kalium-Salz: Ferloni; Franzosini; Gazzetta Chimica Italiana; vol. 105; (1975); p. 391,398,399, View in Reaxys Fluessig-, mesomorphe- u. Festkoerperphasen <Uebergangstemp., Δ H(Transition), Δ S(Transition)> W(OOC-C3H7)2: IR

Cotton; Jeremic; Synthesis in Inorganic and Metal-Organic Chemistry; vol. 1; (1971); p. 265,270-272, View in Reaxys

Association (MCS) (4) 1 of 4

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

D2O

Partner (Association (MCS))

Mg(2+)

Panyushkin; Sukhno; Vodopetova; Russian Journal of General Chemistry; vol. 73; nb. 4; (2003); p. 507 - 510, View in Reaxys 2 of 4

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

D2O

Partner (Association (MCS))

Tm(3+)

Panyushkin; Sukhno; Vodopetova; Russian Journal of General Chemistry; vol. 73; nb. 4; (2003); p. 507 - 510, View in Reaxys 3 of 4

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

H2O; various solvent(s)

4/365

2017-08-01 06:49:42

Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

alpha cyclodextrin

Tee, Oswald S.; Bozzi, Massimo; Hoeven, Jorgen J.; Gadosy, Timothy A.; Journal of the American Chemical Society; vol. 115; nb. 20; (1993); p. 8990 - 8998, View in Reaxys 4 of 4

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

H2O; various solvent(s)

Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

β-CD

Tee, Oswald S.; Bozzi, Massimo; Hoeven, Jorgen J.; Gadosy, Timothy A.; Journal of the American Chemical Society; vol. 115; nb. 20; (1993); p. 8990 - 8998, View in Reaxys Further Information (2) Description (Fur- References ther Information) Further information

Ferloni; Franzosini; Gazzetta Chimica Italiana; vol. 105; (1975); p. 391,398,399, View in Reaxys

Further information

Cotton; Jeremic; Synthesis in Inorganic and Metal-Organic Chemistry; vol. 1; (1971); p. 265,270-272, View in Reaxys

Heat Capacity Cp0 (1) References Desnoyers et al.; Journal of Solution Chemistry; vol. 5; (1976); p. 605,615, View in Reaxys Liquid/Liquid Systems (MCS) (1) 1 of 1

Description (Liquid/ Liquid Systems (MCS))

Distribution between solvent 1 + 2

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Partner (Liquid/Liquid Systems (MCS))

nitrobenzene

Gulaboski, Rubin; Riedl, Kai; Scholz, Fritz; Physical Chemistry Chemical Physics; vol. 5; nb. 6; (2003); p. 1284 1289, View in Reaxys Mechanical & Physical Properties (MCS) (3) 1 of 3

Description (Mechanical & Physical Properties (MCS))

Isothermal compressibility

Temperature (Mechanical & Physical Properties (MCS)) [°C]

5 - 45

Partner (Mechanical & Physical Properties (MCS))

H2O

Kaulgud, M. V.; Rao, K. Surya Mohan; Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical; vol. 27; nb. 1; (1988); p. 12 - 17, View in Reaxys 2 of 3

Description (Mechanical & Physical Properties (MCS))

Adiabatic compressibility

Temperature (Mechanical & Physical Properties (MCS)) [°C]

5/365

2017-08-01 06:49:42

Partner (Mechanical & Physical Properties (MCS))

Na(+), water

Bhowmik, S.; Mohanty, R. K.; Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical; vol. 25; nb. 5; (1986); p. 416 - 419, View in Reaxys 3 of 3

Description (Mechanical & Physical Properties (MCS))

Partial molal volume

Temperature (Mechanical & Physical Properties (MCS)) [°C]

25 - 55

Partner (Mechanical & Physical Properties (MCS))

H2O

Mohanty, Rajani Kanta; Basumallick, Indranarayan; Das, Arun Kumar; Bhowmik, Saktibrata; Journal of the Indian Chemical Society; vol. 63; (1986); p. 301 - 305, View in Reaxys Mechanical Properties (1) Description (MeReferences chanical Properties) Molar volume

Leduc; Desnoyers; Canadian Journal of Chemistry; vol. 51; (1973); p. 2993,2994, View in Reaxys

Other Thermochemical Data (1) Description (Oth- References er Thermochemical Data) Heat capacity

Leduc; Desnoyers; Canadian Journal of Chemistry; vol. 51; (1973); p. 2993,2994, View in Reaxys

NMR Spectroscopy (7) 1 of 7

Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)

Temperature (NMR Spectroscopy) [°C]

24.84

Frequency (NMR Spectroscopy) [MHz]

600

Wang, Xiaohua; Wang, Jie; Kamal, Ghulam Mustafa; Jiang, Bin; Sun, Peng; Zhang, Xu; Liu, Maili; Chinese Journal of Chemistry; vol. 34; nb. 11; (2016); p. 1183 - 1193, View in Reaxys 2 of 7

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- aq. phosphate buffer; water-d2 scopy) Temperature (NMR Spectroscopy) [°C]

24.84

Description (NMR Spec- Chemical shifts; Spectrum troscopy) Nucleus (NMR Spectroscopy)

Frequency (NMR Spectroscopy) [MHz]

600

Lin, Manna; Xie, Zhiyong; Zhou, Yuting; Li, Yemeng; Ren, Jian; Peng, Xuan-Xian; Yao, Meicun; Yang, Zhongzhou; Liao, Qiongfeng; RSC Advances; vol. 5; nb. 80; (2015); p. 65415 - 65426, View in Reaxys

6/365

2017-08-01 06:49:42

4 of 7

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- chloroform-d1 scopy) Temperature (NMR Spectroscopy) [°C]

26.84

Frequency (NMR Spectroscopy) [MHz]

600.1

Liu, Guangmang; Yang, Genjin; Fang, Tingting; Cai, Yimin; Wu, Caimei; Wang, Jing; Huang, Zhiqing; Chen, Xiaoling; RSC Advances; vol. 4; nb. 45; (2014); p. 23749 - 23758, View in Reaxys 5 of 7

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- water-d2 scopy) Location

supporting information

Bradley, Scott A.; Ouyang, Anli; Purdie, Jennifer; Smitka, Tim A.; Wang, Tongtong; Kaerner, Andreas; Journal of the American Chemical Society; vol. 132; nb. 28; (2010); p. 9531 - 9533, View in Reaxys 6 of 7

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- D2O; various solvent(s) scopy) Temperature (NMR Spectroscopy) [°C]

Comment (NMR Spectroscopy)

in the presence of organic compounds

Ishihara, Kenji; Katsutani, Naruo; Aoki, Toyohiko; Basic and Clinical Pharmacology and Toxicology; vol. 99; nb. 3; (2006); p. 251 - 260, View in Reaxys 7 of 7

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- D2O scopy) Temperature (NMR Spectroscopy) [°C]

34.1

Dillon, K. B.; Harrison, M. R.; Rossotti, F. J. C.; Journal of Magnetic Resonance (1969-1992); vol. 39; nb. 3; (1980); p. 499 - 508, View in Reaxys IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Spectrum

Temperature (IR Spectroscopy) [°C]

46.9 - 239.9

Comment (IR Spectroscopy)

1800 - 1200 cm**(-1)

Harrison, Phillip G.; Maunders, Barry M.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 80; (1984); p. 1329 - 1340, View in Reaxys Mass Spectrometry (1)

7/365

2017-08-01 06:49:42

Description (Mass References Spectrometry) spectrum; neutral- Schroeder, Detlef; Soldi-Lose, Heloise; Schwarz, Helmut; Australian Journal of Chemistry; vol. 56; nb. 5; ization-reioniza(2003); p. 443 - 451, View in Reaxys tion mass spectrometry (NRMS) Other Spectroscopic Methods (1) Description (Oth- Comment (Other er Spectroscopic Spectroscopic Methods) Methods) Photoelectron spectrum

References

temperature dependence. Object(s) of Study: gas

Wang, Xue-Bin; Woo, Hin-Koon; Kiran, Boggavarapu; Wang, Lai-Sheng; Angewandte Chemie - International Edition; vol. 44; nb. 31; (2005); p. 4968 - 4972, View in Reaxys

Concentration in the Environment (3) 1 of 3

Media (Concentration in the Environment)

garbage slurry

Location

Tsukuba, Japan

Contamination Concentration

3030 - 8330 mg/l

Method, Remarks (Concentration in the Environment)

garbage slurry containing shredded papers collected from restaurants and offices of the National Institute of Advanced Industrial Science and Technology; average conc.: 5600 mg/l

Ueno, Yoshiyuki; Fukui, Hisatomo; Goto, Masafumi; Environmental Science and Technology; vol. 41; nb. 4; (2007); p. 1413 - 1419, View in Reaxys 2 of 3

Media (Concentration in the Environment)

landfill leachate

Location

Italy

Contamination Concentration

9.0E-3 mol/l

Method, Remarks (Concentration in the Environment)

leachate samples from the leachate collection system of a municipal sanitary landfill; GC analysis

Majone, Mauro; Papini, Marco Petrangeli; Rolle, Enrico; Water Research; vol. 32; nb. 3; (1998); p. 882 - 890, View in Reaxys 3 of 3

Media (Concentration in the Environment)

soil microcosms

Location

Italy

Contamination Concentration

< 10 μmol/l

Method, Remarks (Concentration in the Environment)

planted and unplanted soil samples collected in the wetland rice fields located in valley of the river Po in April 1992; soil pore water collected by centrifugation, filtered; HPLC

Wind; Conrad; FEMS Microbiology Ecology; vol. 18; nb. 4; (1995); p. 257 - 266, View in Reaxys Biodegradation (13) 1 of 13

Type (Biodegradation)

anaerobic

Inoculum

groundwater

Concentration (Biodegradation)

23.9 mmol/l

Method, Remarks (Biodegradation)

dechlorinating consortium from a wastewater treatment facility; enriched with methanol; microcosms incubated at room temp. for 112 d; title comp. utilization monitored periodically; title comp. conc. decreased after 112 d

Daprato, Rebecca C.; Loeffler, Frank E.; Hughes, Joseph B.; Environmental Science and Technology; vol. 41; nb. 7; (2007); p. 2261 - 2269, View in Reaxys

8/365

2017-08-01 06:49:42

2 of 13

Type (Biodegradation)

anaerobic

Inoculum

butyrate-degrading/methanogen bacteria coculture

Concentration (Biodegradation)

20.7 mmol/l

Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

bacteria isolated from flooded paddy soil, Kanagi Farm, Hirosaki, Japan; butyrate-degrading bacterial strain close to Syntrophomonas sp.; Methanobacterium formicicum as methanogen; GC analysis; degradation suppressed by 20 mmol/l 2-bromoethanesulfonate

Degradation Product (Biodegradation)

acetate; methane

Zou, Bi-Zhen; Takeda, Kiyoshi; Tonouchi, Akio; Akada, Shinji; Fujita, Takashi; Bioscience, Biotechnology and Biochemistry; vol. 67; nb. 10; (2003); p. 2059 - 2067, View in Reaxys 3 of 13

Type (Biodegradation)

anaerobic

Inoculum

soil; flooded paddy, Kanagi Farm, Hirosaki, Japan

Concentration (Biodegradation)

20 mmol/l

Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

soil contained 1.7E3 MPN/g dry soil syntrophic butyrate-degrading bacteria; 30 g soil and 80 ml distilled water incubated with title comp. for 14 d under N2; GC analysis; title comp. degradation completely suppressed by 50 mmol/l 2-bromoethanesulfonate

Degradation Product (Biodegradation)

acetate; methane

Zou, Bi-Zhen; Takeda, Kiyoshi; Tonouchi, Akio; Akada, Shinji; Fujita, Takashi; Bioscience, Biotechnology and Biochemistry; vol. 67; nb. 10; (2003); p. 2059 - 2067, View in Reaxys 4 of 13

Type (Biodegradation)

anaerobic

Inoculum

microcosm of gas-contaminated sediment

Concentration (Biodegradation)

5 mmol/l

Degradation Rate (Biodegradation) [%]

100 percent

Exposure Period (Biode- 60 d gradation) Method, Remarks (Biodegradation)

microcosm was obtained from gas condensate-contaminated site near Ft. Lupton, CO, USA; title comp. was incub. with microcosm at room temp. in the dark

Elshahed; McInerney; FEMS Microbiology Ecology; vol. 35; nb. 2; (2001); p. 163 - 169, View in Reaxys 5 of 13

Type (Biodegradation)

anaerobic

Inoculum

microcosm of gas-contaminated sediment

Concentration (Biodegradation)

5 mmol/l

Method, Remarks (Biodegradation)

microcosm was obtained from gas condensate-contaminated site near Ft. Lupton, CO, USA; title comp. was incub. with microcosm at room temp. in the dark; at day 14, 5 mM of bromoethanesulfonic acid (BESA) was added; BESA inhibited title comp. degradation

Degradation Product (Biodegradation)

acetate

Elshahed; McInerney; FEMS Microbiology Ecology; vol. 35; nb. 2; (2001); p. 163 - 169, View in Reaxys 6 of 13

Type (Biodegradation)

anaerobic

Inoculum

microcosm amended with Desulfovibrio strain G11

Concentration (Biodegradation)

5 mmol/l

9/365

2017-08-01 06:49:42

Method, Remarks (Biodegradation)

title comp. was incub. with microcosm at room temp. in the dark; at day 14, 5 mM of bromoethanesulfonic acid (BESA) was added; at day 44, 5 mM sulfate and Desulfovibrio G11 were added; sulfate and bacteria restored BESA-inhibited title comp. degradation

Elshahed; McInerney; FEMS Microbiology Ecology; vol. 35; nb. 2; (2001); p. 163 - 169, View in Reaxys 7 of 13

Type (Biodegradation)

anaerobic

Inoculum

sludge from anaerobic treating brewery wastewater

Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

upflow anaerobic sludge blanket reactor; food waste from a dinning hall; pH 6.4-6.8; residual title comp. (mg COD/l) in the effluent at various COD loading rate (g/l d) (figure)

Shin; Han; Song; Lee; Water Research; vol. 35; nb. 14; (2001); p. 3441 - 3447, View in Reaxys 8 of 13

Type (Biodegradation)

anaerobic

Inoculum

sludge

Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

sludge content of suspended solids 25-30 g*l-1; in dark; degradation products: methane, CO2

Herrmann; Willems; Janke; Water Research; vol. 35; nb. 11; (2001); p. 2575 - 2582, View in Reaxys 9 of 13

Type (Biodegradation)

anaerobic

Inoculum

sludge

Concentration (Biodegradation)

500 - 9000 mg/l

Degradation Rate (Biodegradation) [%]

100 percent

Exposure Period (Biode- > 200 h gradation) Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

anaerobic sludge was obtained from a UASB reactor; batch experiment; estimation of title comp. utilization during 500 h of incubation; diagram of specific degradation rate of title comp. depending on concn. was presented

Comment (Biodegradation)

Further degradation product(s)

Degradation Product (Biodegradation)

acetate; methane; Isobutyrate

Fang, Herbert H. P.; Jia, Xiao-Shan; Water Research; vol. 33; nb. 8; (1999); p. 1791 - 1798, View in Reaxys 10 of 13

Type (Biodegradation)

anaerobic

Inoculum

sludge

Concentration (Biodegradation)

800 - 960 mg/l

Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

anaerobic sludge was obtained from a UASB reactor; batch experiment; estimation of title comp. utilization in the presence of formate (3000 and 6000 mg/l for low and high concn. of title comp., resp.)

Comment (Biodegradation)

Further degradation product(s)

Degradation Product (Biodegradation)

acetate; methane; Isobutyrate

Fang, Herbert H. P.; Jia, Xiao-Shan; Water Research; vol. 33; nb. 8; (1999); p. 1791 - 1798, View in Reaxys

10/365

2017-08-01 06:49:42

11 of 13

Type (Biodegradation)

anaerobic

Inoculum

methanogenic bacteria enriched from refuse

Concentration (Biodegradation)

10.0 mmol/l

Degradation Rate (Biodegradation) [%]

87.8 percent

Exposure Period (Biode- 72 d gradation) Temperature (Biodegradation) [°C]

Method, Remarks (Biodegradation)

multi-stage continuous culture system; phosphate-buffered mineral salts medium; refuse (appr. 1 month old) from the Wilderness Site; effect of volatile fatty acids on degradation

Degradation Product (Biodegradation)

acetate; methane

James; Watson-Craik; Senior; Water Research; vol. 32; nb. 3; (1998); p. 792 - 800, View in Reaxys 12 of 13

Type (Biodegradation)

sealed-bottle test

Inoculum

sludge, industrial

Concentration (Biodegradation)

30 mmol/l

Method, Remarks (Biodegradation)

composite sludge samples from full-scale anaerobic reactor (Archer, Daniels and Midlands) citric acid production plant after 5 years of reactor operation; degradation rates: 63.6-77.5 ml CH4/gVSS/d (STP); effect of presence of sulphate or molybdate; GC

Degradation Product (Biodegradation)

methane

O'Flaherty; Lens; Leahy; Colleran; Water Research; vol. 32; nb. 3; (1998); p. 815 - 825, View in Reaxys 13 of 13

Type (Biodegradation)

anaerobic

Inoculum

digested sludge

Concentration (Biodegradation)

900 microelectron equiv.

Method, Remarks (Biodegradation)

digested sludge from municipal WWPs; basal medium contained 20 percent yeast extract; threshold hydrogen concn. for methanogenesis detd.; title comp. was consumed within 2 weeks; eventual hydrogen threshold concn.: 10-13 nM

Degradation Product (Biodegradation)

methane

Yang, Yanru; McCarty, Perry L.; Environmental Science and Technology; vol. 32; nb. 22; (1998); p. 3591 - 3597, View in Reaxys Use (5) Laboratory Use and Handling

energy substrate for chlorate-reducing mixed cultures of microor-

Use Pattern

References

increasing cyclooxygenase 2 activity

Patent; Turini, Marco; German, Bruce; Pecquet, Sophie; US2003/232057; (2003); (A1) English, View in Reaxys

Drug acting on the immune system

Patent; Turini, Marco; German, Bruce; Pecquet, Sophie; US2003/232057; (2003); (A1) English, View in Reaxys

Antiallergic

Patent; Turini, Marco; German, Bruce; Pecquet, Sophie; US2003/232057; (2003); (A1) English, View in Reaxys

Inducing tolerance to antigen

Patent; Turini, Marco; German, Bruce; Pecquet, Sophie; US2003/232057; (2003); (A1) English, View in Reaxys Ginkel, C. G. van; Plugge, C. M.; Stroo, C. A.; Chemosphere; vol. 31; nb. 9; (1995); p. 4057 - 4066, View in Reaxys

11/365

2017-08-01 06:49:42

ganisms originating from activated sludge (0) Medchem (131) 1 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3601060View in Reaxys

Substance Name

1479191

Qualitative Results

inhibits the proliferation of mammalian cells: rat 3Y1 fibroblasts; incomplete inhibition for human IMR-90; human embryo lung HEL; human embryo kidney HEK; toxic activity against monkey kidney BSC-1 cells

Measurement Parameter

Qualitative

Yamada; Ohtsu; Sugano; Kimura; Bioscience, biotechnology, and biochemistry; vol. 56; nb. 8; (1992); p. 1261 1265, View in Reaxys 2 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein degradation; inhibition of Bioassay : GFP-V5-ΔF508-CFTR: plasmid with mutant cystic fibrosis transmembrane conductance regulator (ΔF508-CFTR) fused to green fluorescent protein (GFP); ALLN: Nacetyl-leucyl-leucyl-norleucynal (proteasome inhibitor); DMEM: Dulbecco's modified Eagle's medium transfection with GFP-V5-ΔF508-CFTR; incubation in DMEM with title comp. for 24 h; pulse-labeling with <35S>methionine/cysteine for 30 min; chase period for 0 - 4 h with/without ALLN; amount of B and C forms of GFP-CFTR measured with anti-V5 antibody

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Qualitative Results

title comp. did not affect amount of core-glycosylated B-form or complex-glycosylated Cform of CFTR, but degradation of B-form of CFTR in title comp.-treated cells was reduced by ALLN, suggesting slight stimulation of CFTR degradation by title comp.

Measurement Parameter

Qualitative

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 3 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein degradation; inhibition of Bioassay : GFP-V5-ΔR-CFTR: plasmid containing mutant cystic fibrosis transmembrane conductance regulator (ΔR-CFTR) fused to green fluorescent protein (GFP); ALLN: Nacetyl-leucyl-leucyl-norleucynal (proteasome inhibitor); DMEM: Dulbecco's modified Eagle's medium transfection with GFP-V5-ΔR-CFTR; incubation in DMEM with title comp. for 24 h; pulse-labeling with <35S>methionine/cysteine for 30 min; chase period for 0 - 4 h with or without ALLN; amount of B and C forms of GFP-CFTR measured using anti-V5 antibody

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

12/365

2017-08-01 06:49:42

Qualitative Results

Measurement Parameter

Qualitative

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 4 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein degradation; inhibition of Bioassay : GFP-V5-wt-CFTR: plasmid containing normal cystic fibrosis transmembrane conductance regulator (CFTR) fused to green fluorescent protein (GFP); DMEM: Dulbecco's modified Eagle's medium; further investigations using proteasome inhibitor ALLN transfection with GFP-V5-wt-CFTR; incubation in DMEM with title comp. for 24 h; pulselabeling with <35S>methionine/cysteine for 30 min; 0 - 4 h later amount of core- and complex-glycosylated B- and C-forms of GFP-CFTR measured using anti-V5 antibody

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Qualitative Results

title comp. enhanced stability of B-form of CFTR, but did not affect amount of C-form; proteasome inhibition was not involved

Measurement Parameter

Qualitative

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 5 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein degradation; inhibition of Bioassay : pEGFP-C1-CFTR: vector with normal cystic fibrosis transmembrane conductance regulator (wt-CFTR) fused to green fluorescent protein (GFP); pEGFP-ΔR-CFTR: vector containing deletion mutant of CFTR (ΔR-CFTR); DMEM: Dulbecco's modified Eagle's medium cells transfected with 0.25 - 2 μg pEGFP-C1-CFTR or pEGFP-ΔR-CFTR plasmid; incubation in DMEM with 10 percent fetal bovine serum with title comp. for 24 h and with cycloheximide for 1 - 2 h; GFP-wt-CFTR and GFP-ΔR-CFTR expression assessed by immunoblotting

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Qualitative Results

title comp. reduced disappearance rate of core-glycosylated B-form of GFP-wt-CFTR, but not of GFP-ΔR-CFTR, at various expression levels; it had no effect on degradation of complex-glycosylated C-form of GFP-wt-CFTR or GFP-ΔR-CFTR

Measurement Parameter

Qualitative

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 6 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; effect on Bioassay : CFTR: cystic fibrosis transmembrane conductance regulator; GFP: green fluorescent protein; DMEM: Dulbecco's modified Eagle's medium; further investigations using mitogen-activated protein kinase kinase (MAPKK/MEK) inhibitor PD98059 transfection with GFP-V5-wt-CFTR or GFP-V5-ΔR-CFTR (plasmids with normal wt-CFTR or mutant

13/365

2017-08-01 06:49:42

ΔR-CFTR fused to GFP); incubation in DMEM with title comp. for 24 h; Hsc70/CFTR complex formation determined by coimmunoprecipitation using anti-V5 antibodies Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Qualitative Results

title comp. reduced complex formation between Hsc70 and wt-CFTR or ΔR-CFTR; PD98059 further reduced complex formation with wt-CFTR, but not with ΔR-CFTR

Measurement Parameter

Qualitative

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 7 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Bioassay : CFTR: cystic fibrosis transmembrane conductance regulator; GFP: green fluorescent protein; further invest. with mitogen-activated protein kinase kinase (MAPKK/ MEK), p38, and phosphatidylinositol 3-kinase inhibitors, or using active MAPKK/MEK mutant cells transfected with pEGFP-wt-CFTR or pEGFP-CFTR (plasmids with normal wtCFTR or mutant ΔR-CFTR fused to GFP); 12 - 36 h later incubation with title comp. in Dulbecco's modified Eagle's medium for 24 h; GFP-CFTR expression assessed by immunoblotting

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Qualitative Results

title comp. dose-dependently enhanced expression of both complex-glycosylated C form and core-glycosylated B form of wt-CFTR, and slightly of ΔR-CFTR; no effect on C form/B form ratio; mechanism involved MAPKK/MEK activation

Measurement Parameter

Qualitative

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 8 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Bioassay : CFTR: cystic fibrosis transmembrane conductance regulator; GFP: green fluorescent protein; further investigations using mitogen-activated protein kinase kinase (MAPKK/MEK) inhibitor or using transfection with constitutively active MAPKK/MEK mutant transfection with pEGFP-CFTR or pEGFP-ΔR-CFTR (plasmids with normal wt-CFTR or mutant ΔR-CFTR fused to GFP); incubation with title comp. in Dulbecco's modified Eagle's medium for 0 - 34.5 h; cellular GFP-CFTR visualized by GFP fluorescence

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Qualitative Results

title comp. induced expression of CFP-wt-GFTR around 10 to 27 h after addition; title comp. caused GFP-wt-CFTR to accumulate in plasma membrane region, while GFP-ΔRCFTR remained accumulated perinuclearly; mechanism involved MAPKK/MEK activation

Measurement Parameter

Qualitative

14/365

2017-08-01 06:49:42

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 9 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein activation; induction of Bioassay : CFTR: cystic fibrosis transmembrane conductance regulator; GFP: green fluorescent protein; DMEM: Dulbecco's modified Eagle's medium; MAPK: mitogen-activated protein kinase; MAPKK: MAPK kinase; ERK: extracellular signal-regulated kinase cells transfected with plasmids containing normal or mutant CFTR fused with GFP, and some also with LA-SDSE-MAPKK (constitutively active mutant MAPK); incubation in DMEM with title comp. for 24 h; MAPKK and phospho-ERK/MAPK detected by immunoblotting

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Measurement Parameter

Qualitative

Qualitative value

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 10 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; effect on Bioassay : CFTR: cystic fibrosis transmembrane conductance regulator; GFP: green fluorescent protein; DMEM: Dulbecco's modified Eagle's medium cells transfected with GFPV5-wt-CFTR or GFP-V5-ΔR-CFTR (plasmids with normal or mutant CFTR fused to GFP); incubation in DMEM with title comp. for 24 h; cellular expression level of Hsc70 determined by Western blotting using anti-Hsc70 antibodies

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Measurement Parameter

Qualitative

Qualitative value

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 11 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; effect on Bioassay : GFP-V5-ΔR-CFTR and GFP-V5-ΔF508-CFTR: plasmids containing mutant forms of cystic fibrosis transmembrane conductance regulator (CFTR) fused to green fluorescent protein (GFP); DMEM: Dulbecco's modified Eagle's medium transfection with GFP-V5-ΔR-CFTR or GFP-V5-ΔF508-CFTR; 24 h incubation in DMEM with title comp.; pulse-labeling with <35S>methionine/cysteine for 30 min; incubation for 0 - 4 h in unlabeled DMEM; GFP-CFTR amount measured using anti-V5 antibody

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

15/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Qualitative value

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 12 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; effect on Bioassay : pEGFP-V5-wt-CFTR: vector with normal cystic fibrosis transmembrane conductance regulator (wt-CFTR) fused to green fluorescent protein (GFP); DMEM: Dulbecco's modified Eagle's medium cells transfected with 1 μg GFP-V5-wt-CFTR; incubation in DMEM with title comp. for 24 h; cells were pulse-labeled with <35S>methionine/cysteine for 30 min; incubation for 0 - 4 h in unlabeled DMEM; GFP-wt-CFTR amount measured using anti-V5 antibody

Cells/Cell Lines

COS7

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Measurement Parameter

Qualitative

Qualitative value

Sugita, Makoto; Kongo, Hiroyasu; Shiba, Yoshiki; Molecular Pharmacology; vol. 66; nb. 5; (2004); p. 1248 1259, View in Reaxys 13 of 131

Substance Effect

Developmental

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Alcaligenes faecalis strain TUD (LMD 89.147) Bioassay : culture established in Applikon fermenters; volume: 2 l; dilution rate (D): 0.05 h-1; PHB: poly-β-hydroxybutyrate continuous steady state (SS) experiment; under anaerobic conditions; under acetate limitation (15 mM) and 35 mM NaNO2; pulse additions of 4.2 mM title comp.; CO2, N2O, N2 analysed by GC; biomass production by measuring OD at 450, 660 nm, or wt.

Substance RN

3601060View in Reaxys

Substance Name

1479191

Qualitative Results

at SS/after pulse: 203/166 (NO2(1-) reduction rate, nmol N min-1 mg dw-1), 164/214 (title comp. conc. maximal rate, nmol C min-1 mg dw-1), 18.5/10.4 (N2O:NO2(1-), percent), 64.4 (N2O:NO2(1-), percent during

Measurement Parameter

Qualitative

Schalk-Otte; Seviour; Kuenen; Jetten; Water Research; vol. 34; nb. 7; (2000); p. 2080 - 2088, View in Reaxys 14 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Target : neuroblastoma SH-SY5Y cells of human expressing BCL-2 Bioassay : controls: untreated and wild-type cells cells treated with title comp. for 24 h; cell death determined

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Qualitative Results

title comp. at 3 mM induced cell death; fig.

16/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 15 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : control: untreated cells cells incubated with title comp. for 12 h at 37 deg C; fixed; incubated with anti-cytochrome c; cytochrome c release detected by confocal microscopy

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced cytochrome c release into cytosol

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 16 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : control: untreated cells cells incubated with title comp. for 12 h; lysed; homogenized; centrifuged; membrane and cytosolic fraction prepared; cytochrome c localization analyzed by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced cytochrome c release into cytosol

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 17 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : control: untreated cells cells treated with title comp. for 24 h; DRAG5 DNA dye added for 5 min; fixed; mounted onto coverslip; visualized with confocal microscopy; nuclear fragmentation determined

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

17/365

2017-08-01 06:49:42

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced nuclear fragmentation

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 18 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Bioassay : control: untreated cells; BCL-XL: BCL-2 (B-cell chronic lymphocytic leukemia / lymphoma 2) X-analogue; NOXA: phorbol-12-myristate-13-acetate-induced protein 1; BAX: BCL-2-X antagonist of cell death protein cells incub. with title comp. for 12 h; lysed; homogenized; centrifuged; mitochondrial and cytosolic fraction prepared; BAD, BID, BCLXL, BAX, BCL-2, or α- p53-upregulated modulator of apoptosis (PUMA) localization analyzed by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced BAX and PUMA mitochondrial localization after 12 h while, simultaneously lowering BCL-2; BID, BAD and BCL-XL expressions were not modulated and their subcellular localization was not modified following title comp. treatment

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 19 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Bioassay : control: untreated cells; BCL-XL: BCL-2 (B-cell chronic lymphocytic leukemia / lymphoma 2) X-analogue; NOXA: phorbol-12-myristate-13-acetate-induced protein 1; BAX: BCL-2-X antagonist of cell death protein cells treated with title comp. for 12-24 h; whole cell extracts prepared; BAD, BID, BAX, BCL-XL, BCL-2, NOXA or α- p53-upregulated modulator of apoptosis (PUMA) levels analyzed by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. up-regulated NOXA, α-PUMA proteins but down-regulated BCL-2 protein levels; title comp. increased α-PUMA levels within first 12 h and delayed NOXA and BCL-2 modulation; title comp. did not modulate BAD, BID, BAX and BCL-XL

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys

18/365

2017-08-01 06:49:42

20 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : control: untreated cells cells incubated with title comp. for 12 h at 37 deg C; fixed; incubated with anti-cytochrome c; cytochrome c release detected by confocal microscopy

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced cytochrome c release into cytosol; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 21 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced cytochrome c release into cytosol; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 22 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. induced nuclear fragmentation; fig.

19/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 23 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 24 of 131

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Bioassay : control: untreated cells; BCL-XL: BCL-2 (B-cell chronic lymphocytic leukemia / lymphoma 2) X-analogue; NOXA: phorbol-12-myristate-13-acetate-induced protein 1; BAX: BCL-2-X antagonist of cell death protein cells treated with title comp. for 12-24 h; whole cell extracts prepared; BAD, BID, BAX, BCL-XL, BCL-2, NOXA or α- p53-upregulated modulator of apoptosis (PUMA) levels analyzed by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 25 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : transport; effect on Target : neuroblastoma SH-SY5Y cells of human expressing BCL-2

20/365

2017-08-01 06:49:42

Bioassay : control: untreated cells cells treated with title comp. for 6 h; nuclear protein extracts prepared; subcellular localization of p53 protein determined by confocal microscopy Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp.-induced p53 nuclear translocation was not affected in BCL2 overexpressed cells; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 26 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : transport; effect on Target : neuroblastoma SK-N-BE cells of human expressing BCL-2 Bioassay : control: untreated cells cells treated with title comp. for 6 h; nuclear protein extracts prepared; subcellular localization of p53 protein determined by confocal microscopy

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp.-induced p53 nuclear translocation was not affected in BCL2 overexpressed cells; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 27 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell cycling; effect on Bioassay : control; untreated cells serum deprived cells treated with title comp. for 16 h; stained with propidium iodide; cell DNA content measured using flow cytometry; cycle distribution determined

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. markedly affected cell-cycle distribution, causing a G2 block with a clear reduction in the G1 phase population; title comp. redistributed the different steps of cell cycle inverted the G1/G2 ratio

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 28 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; effect on Bioassay : control: untreated cells; NOXA: phorbol-12-myristate-13-acetate-induced protein 1; BAX: BCL-2-X antagonist of cell death protein cells treated with title comp. for 12 h; total RNA isolated; BAX, B-cell chronic lymphocytic leukemia /lymphoma 2 (BCL-2),

21/365

2017-08-01 06:49:42

NOXA or α-p53-upregulated modulator of apoptosis (PUMA) mRNA levels analyzed by RT-PCR Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. significantly down-regulated BCL-2 mRNA levels as early as 12 h post-treatment and up-regulated NOXA or α-PUMA mRNA levels at earlier times; title comp. did not modulate BAX mRNA levels

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 29 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; induction of Bioassay : control; untreated cells cells treated with title comp. for 6 h; p21/Waf1/Cip1 mRNA expression analyzed by RT-PCR analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. increased p21/Waf1/Cip1 mRNA levels

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 30 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein binding; effect on Bioassay : control: untreated cells cells treated with title comp. for 24 h; nuclear protein extracts prepared; specific binding of p53 protein determined using electromobility shift assay

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. caused p53 to specifically bind its consensus DNA

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 31 of 131

Bioassay Category

In Vitro (Efficacy)

22/365

2017-08-01 06:49:42

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; effect on Bioassay : controls: untreated cells and wild-type cells cells transfected with pKD-p53-v1 plasmid encoding a p53-specific short hairpin RNA (p53i cells); treated with title comp. for 8 h; p21/Waf1/Cip1 protein expression analyzed by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp.-induced p21/Waf1/Cip1 protein expression prevented in p53i cells; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 32 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Bioassay : control; untreated cells cells treated with title comp. for 8 h; p21/Waf1/Cip1 protein expression analyzed by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. increased p21/Waf1/Cip1 protein levels

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 33 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein levels; increase of Bioassay : control: untreated cells cells treated with title comp. for 4 h; nuclear proteins extracted in acid conditions; acetylated histone protein levels determined by Western blot analysis using anti-acetyl-H3 antibody

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Qualitative Results

title comp. enhanced levels of acetylated histone protein

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys

23/365

2017-08-01 06:49:42

34 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : transport; effect on Bioassay : control: untreated cells cells treated with title comp. for 4 h; nuclear protein extracts prepared; subcellular distribution of p53 protein determined using Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. induced nuclear translocation of p53 protein as early as 4 h

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 35 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : transport; effect on Bioassay : control: untreated cells cells treated with title comp. for 4 h; nuclear subcellular fractions prepared; p53 lysine acylation in cytosolic and nuclear compartments analyzed by Western blot analysis using anti-acetyl-p53 antibody

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

acylated p53 lysine protein found in nuclear compartment of title comp.-treated cells

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 36 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell morphology; effect on Bioassay : controls: untreated cells and retinoic acid (positive); GAP-43 and β-tubulin III were chosen as molecular markers of differentiation cells treated with title comp. for 14 days; whole-cell extracts prepared; GAP-43 or β-tubulin III levels determined by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Measurement Parameter

Qualitative

Qualitative value

24/365

2017-08-01 06:49:42

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 37 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell morphology; effect on Bioassay : controls: untreated cells and retinoic acid (positive); GAP-43 and β-tubulin III were chosen as molecular markers of differentiation cells treated with title comp.; wholecell extracts prepared; GAP-43 or β-tubulin III levels determined by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Measurement Parameter

Qualitative

Qualitative value

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 38 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein levels; effect on Bioassay : control: untreated cells cells treated with title comp. for 24 h; whole cell extracts prepared; total levels of p53 protein determined using Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Measurement Parameter

Qualitative

Qualitative value

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 39 of 131

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : cells treated with title comp. for 24 h; cell viability determined by MTT assay

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.100000 mM

Qualitative Results

title comp. at 3 mM induced striking reduction in cell viability; fig.

Measurement Parameter

Qualitative

25/365

2017-08-01 06:49:42

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 40 of 131

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : cells treated with title comp. for 24 h; cell viability determined by MTT assay

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.100000 mM

Qualitative Results

title comp. at 3 mM induced striking reduction in cell viability; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 41 of 131

Substance Effect

Toxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : controls: untreated and wild-type cells cells transfected with pKD-p53-v1 plasmid encoding a p53-specific short hairpin RNA (p53i cells); treated with title comp. for 24 h; cell viability determined by MTT assay

Biological Species/NCBI Human ID Cells/Cell Lines

SK-N-BE

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Qualitative Results

p53i cells more resistant to title comp. at 0.3 and 0.9 mM; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 42 of 131

Substance Effect

Toxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Qualitative Results

p53i cells more resistant to title comp. at 0.3 and 0.9 mM; fig.

26/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 43 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 44 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. significantly down-regulated BCL-2 mRNA levels as early as 12 h post-treatment and up-regulated NOXA or α-PUMA mRNA levels at earlier times; title comp. did not modulate BAX mRNA levels; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 45 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; induction of Bioassay : control; untreated cells cells treated with title comp. for 6 h; p21/Waf1/Cip1 mRNA expression analyzed by RT-PCR analysis

Biological Species/NCBI Human ID

27/365

2017-08-01 06:49:42

Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. increased p21/Waf1/Cip1 mRNA levels; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 46 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

3 mM

Qualitative Results

title comp. caused p53 to specifically bind its consensus DNA; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 47 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp.-induced p21/Waf1/Cip1 protein expression prevented in p53i cells; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 48 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Bioassay : control; untreated cells cells treated with title comp. for 8 h; p21/Waf1/Cip1 protein expression analyzed by Western blot analysis

28/365

2017-08-01 06:49:42

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. increased p21/Waf1/Cip1 protein levels; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 49 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Qualitative Results

title comp. enhanced levels of acetylated histone protein; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 50 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

title comp. induced nuclear translocation of p53 protein as early as 4 h; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 51 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : transport; effect on

29/365

2017-08-01 06:49:42

Bioassay : control: untreated cells cells treated with title comp. for 4 h; nuclear subcellular fractions prepared; p53 lysine acylation in cytosolic and nuclear compartments analyzed by Western blot analysis using anti-acetyl-p53 antibody Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Qualitative Results

acylated p53 lysine protein found in nuclear compartment of title comp.-treated cells; fig.

Measurement Parameter

Qualitative

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 52 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Measurement Parameter

Qualitative

Qualitative value

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 53 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell morphology; effect on Bioassay : controls: untreated cells and retinoic acid (positive); GAP-43 and β-tubulin III were chosen as molecular markers of differentiation cells treated with title comp.; wholecell extracts prepared; GAP-43 or β-tubulin III levels determined by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.900000 mM

Measurement Parameter

Qualitative

Qualitative value

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 54 of 131

Bioassay Category

In Vitro (Efficacy)

30/365

2017-08-01 06:49:42

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

0.300000 mM

Measurement Parameter

Qualitative

Qualitative value

Condorelli; Gnemmi; Vallario; Genazzani; Canonico; British Journal of Pharmacology; vol. 153; nb. 4; (2008); p. 657 - 668, View in Reaxys 55 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : ion transport stimulating Bioassay : buffered at pH 6.0 and 7.3 with phosphate; title compd. is present in solution; mucosal-serosal (MS) and serosal-mucosal (SM) fluxes and net flux measured; electric parameters (ISC) and epithelial resistance (R) detd. rumen tissues collected; Ringer-type sol.; mucosa stripped off; sheets of epithelial tissue mounted in Ussing chambers; voltage clamped; tissues bathed on both sides; (22)Na+ and (36)Cl- added; ion fluxes measured

Biological Species/NCBI taurine cattle ID Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

20 mM

Qualitative Results

at pH 7.3 sodium MS flux was lower than with acetate; SM fluxes tended to increase with increasing chain length; at pH 6.0 sodium net flux increased (MS increased, SM decreased); ISC and R decreased with increasing chain length

Measurement Parameter

Qualitative

Sehested; Diernaes; Moller; Skadhauge; Experimental Physiology; vol. 81; nb. 1; (1996); p. 79 - 94, View in Reaxys 56 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : ion transport stimulating Bioassay : buffered at pH 7.3 with bicarbonate and phosphate; title compd. is present in solution; mucosal-serosal (MS) and serosal-mucosal (SM) fluxes and net flux measured; electric parameters (ISC) and epithelial resistance (R) detd. rumen tissues collected; Ringer-type sol.; mucosa stripped off; sheets of epithelial tissue mounted in Ussing chambers; voltage clamped; tissues bathed on both sides; (22)Na+ and (36)Cl- added; ion fluxes measured

Biological Species/NCBI taurine cattle ID Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

20 mM

Qualitative Results

title compd. caused positive sodium net flux; sodium SM flux increased with chain length; ISC and R decreased with chain length

31/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Sehested; Diernaes; Moller; Skadhauge; Experimental Physiology; vol. 81; nb. 1; (1996); p. 79 - 94, View in Reaxys 57 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : ion transport stimulating Bioassay : buffered at pH 7.3 with phosphate; title compd. is present in solution; mucosalserosal (MS) and serosal-mucosal (SM) fluxes and net flux measured; electric parameters (ISC) and epithelial resistance (R) detd. rumen tissues collected; Ringer-type sol.; mucosa stripped off; sheets of epithelial tissue mounted in Ussing chambers; voltage clamped; tissues bathed on both sides; (22)Na+ and (36)Cl- added; ion fluxes measured

Biological Species/NCBI taurine cattle ID Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

5 mM

Qualitative Results

5-20 mmol/l sodium net flux increased; not stimulated further with increasing of title compd. conc.; max. of sodium transport in 20 mmol/l; higher conc. of title compd. decreased sodium flux; increased chloride net flux (lower SM flux)

Measurement Parameter

Qualitative

Sehested; Diernaes; Moller; Skadhauge; Experimental Physiology; vol. 81; nb. 1; (1996); p. 79 - 94, View in Reaxys 58 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |agonist Bioassay : 11β-hydrosteroid dehydrogenase (11βHSD) enzyme activity was determined by corticosterone conversion in vitro; pieces of ileum were incubated in presence of title comp., add. of corticosterone and <3H>-labeled one

Biological Species/NCBI Rattus norvegicus ID Substance RN

3601060View in Reaxys

Substance Name

1479191

Qualitative Results

title comp. stimulated 11βHSD activity only 96 percent

Measurement Parameter

Qualitative

Pacha, Jiri; Lisa, Vera; Miksik, Ivan; Steroids; vol. 67; nb. 2; (2002); p. 119 - 126, View in Reaxys 59 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell differentiation; induction of Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : RPMI-1640 medium (pH 7.8) with 10 percent FBS; 37 deg C; further investigation of 500 μmol/l title comp. incubated for up to 6 d cells incubated with title comp. for 6 d; differentiaton of cells into eosinophils assessed by detection of major basic protein (MBP) in cell lysate by immunoblotting

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

100 µM

Qualitative Results

title comp. induced differentiation of HL-60 clone 15 cells into eosinophils (induced expression of MBP) in conc.-dependent manner at 6 days incubation and in time-dependent manner at 500 μmol/l (figure)

32/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 60 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell differentiation; induction of Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : RPMI-1640 medium (pH 7.8) with 10 percent FBS; 37 deg C; further investigation of 500 μmol/l title comp. incubated for up to 6 days cells incubated with title comp. for 6 d; differentiaton of cells into eosinophils assessed by counting of number of eosinophilic cells using hemocytometer

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

100 µM

Qualitative Results

title comp. at 100 and 500 nmol/l conc.-dependently induced differentiation of HL-60 clone 15 cells into eosinophils (increased number and percent of eosinophilic cells to 66.0 percent at 100 nmol/l; effect was time-dependent at 500 μmol/l (figures)

Measurement Parameter

Qualitative

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 61 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell differentiation; induction of Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : RPMI-1640 medium (pH 7.8) with 10 percent FBS, 37 deg C; H: hematoxylin; Eos: eosinophils cells incubated with title comp. for up to 6 d; stained with Luxol-fast-blue, H, microscopically observed; markers for differentiation into Eos (changes in intracellular structure as cell side scatter, integrin β7 expression) asssayed by flowcytometry

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

title comp. changed shape of nucleus and increased cytoplasmic area, induced changes in intracellular structure, time-dependently induced expression of integrin β7 (figure)

Measurement Parameter

Qualitative

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 62 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : CDK: cyclin-dependent kinase; further investigation of 500 μmol/l title comp. for 2-6 days cells incubated in RMPI-1640 medium with 10 percent FBS at 37 deg C in presence of title comp. for 6 days; expression of CDK inhibitor proteins p15INK4b, p21Wafl/Cip1 and p27Kip1 determined by immunoblotting

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

100 µM

Qualitative Results

title comp. induced expression of p15INK4b, p21Wafl/Cip1 and p27Kip1 in conc.-dependent manner at 6 days incubation and in time-dependent manner on treatment with 500 μmol/l title comp.(figure)

33/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 63 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : transcription factor; activation of Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : C/EBP: CCAAT/enhancer binding protein; further investigations with anti-C/ EPPα, anti-C/EBPβ or anti-C/EBPε antibodies cells were incubated in RMPI-1640 medium with 10 percent FBS at 37 deg C in presence of title comp. for 4-72 h; nuclear extract; DNA binding activity of C/EBP detected by EMSA

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

title comp. induced continuous activation of C/EBPα, C/EBPβ and C/EBPε until 72 h (figure)

Measurement Parameter

Qualitative

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 64 of 131

Target Mutant/Chimera Details

Histone:Wild

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone acetylation; induction of Bioassay : further investigation of 500 μmol/l title comp. for 4-48 h or 2-6 days cells incubated in RMPI-1640 medium (pH 7.8) with 10 percent FBS at 37 deg C in presence of various conc. of title comp. for 6 days; acetylation of histones H4 and lysine14 residue on histone H3 (histone H3 K14) assessed in supernatant by EMSA

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

100 µM

Qualitative Results

title comp. conc.-dependently acetylated histone H4 and histone H3 K14 after 6 days incubation; 500 μmol/l title comp. acetylated histone H4 at 2-6 days (plateau reached at 4 h) and histone H3 K14 at 4-6 days incubation (figure)

Measurement Parameter

Qualitative

Target, Subunit, Species Histone Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 65 of 131

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : further investigation of 500 μmol/l title comp. for 1-6 days; reference comp.: cyclin-dependent kinase inhibitor roscovitine cells incubated in RMPI-1640 medium with 10 percent FBS at 37 deg C in presence of title comp. for 6 days; cell proliferation assessed by hemocytometry

34/365

2017-08-01 06:49:42

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

100 µM

Qualitative Results

title comp. at 500 μmol/l time-dependently inhibited cell proliferation, significantly after 3 days of incubation; after 6 days of incubation, 100 μmol/l title comp. had no effect (figure)

Measurement Parameter

Qualitative

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 66 of 131

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human eosinophilic leukemia HL-60 clone 15 cells Bioassay : cells incubated in RMPI-1640 medium with 10 percent FBS at 37 deg C in presence of title comp. for 6 days; cell viability assessed

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Measurement Parameter

Qualitative

Qualitative value

Ishihara, Kenji; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; British Journal of Pharmacology; vol. 142; nb. 6; (2004); p. 1020 - 1030, View in Reaxys 67 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : binding to HDAC-3-N-CoR1 Target : recombinant Bioassay : HDAC-3-N-CoR1 radiological analysis

Substance RN

3601060View in Reaxys

Substance Name

1479191

Measurement Parameter

% Inhibition

Unit

Quantitative value

Doyle, Kelly; Fitzpatrick; Journal of Biological Chemistry; vol. 285; nb. 23; (2010); p. 17417 - 17424, View in Reaxys 68 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : binding to HDAC-3-N-CoR1 Target : recombinant Bioassay : HDAC-3-N-CoR1 radiological analysis

Substance RN

3601060View in Reaxys

Substance Name

1479191

Measurement Parameter

IC50

Unit

µM

Quantitative value

140

35/365

2017-08-01 06:49:42

Measurement pX

3.85

Doyle, Kelly; Fitzpatrick; Journal of Biological Chemistry; vol. 285; nb. 23; (2010); p. 17417 - 17424, View in Reaxys 69 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Transactivation assay

Bioassay Details

Effect : LEF1β-catenin transcription Target : LEF1β-catenin MAD-LEF1 Bioassay : STF3 cells LEF: lymphoid enhancer factor

Substance RN

3601060View in Reaxys

Substance Name

1479191

Qualitative Results

effective concentration 150 μmol/l

Measurement Parameter

Qualitative

Doyle, Kelly; Fitzpatrick; Journal of Biological Chemistry; vol. 285; nb. 23; (2010); p. 17417 - 17424, View in Reaxys 70 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Bioassay : cells incubated with title comp. at 37 deg C for 0 to 8 days; cell lysates were electrophoresed and expression of cyclin-dependent kinase inhibitor p27Kip1 determined by Western blot analysis

Cells/Cell Lines

eol I

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

title comp. continuously induced the expression of p27Kip1 until day 8; fig.

Measurement Parameter

Qualitative

Ishihara, Kenji; Takahashi, Aki; Kaneko, Motoko; Sugeno, Hiroki; Hirasawa, Noriyasu; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; Life Sciences; vol. 80; nb. 13; (2007); p. 1213 - 1220, View in Reaxys 71 of 131

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Bioassay : cells incubated with title comp. at 37 deg C for 8 days; expression of chemokine receptor 1, 3 and integrin β7 determined by flowcytometry

Cells/Cell Lines

eol I

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

title comp. induced the expression of the markers of eosinophils, chemokine receptor 1 and 3; title comp. slightly increased the expression of integrin β7; fig.

Measurement Parameter

Qualitative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; effect on

36/365

2017-08-01 06:49:42

Bioassay : FIP1L1-PDGFRA: fip1-like 1 gene and platelet- derived growth factor receptor cells incubated with title comp. at 37 deg C for 8 days; FIP1L1-PDGFRA mRNA levels determined by RT-PCR Cells/Cell Lines

eol I

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Measurement Parameter

Qualitative

Qualitative value

Target Mutant/Chimera Details

Histone:Wild

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone acetylation; effect on Bioassay : cells incubated with title comp. at 37 deg C for 0 to 8 days; cell lysates were electrophoresed and levels of acetylated-histones H4 and H3 were detected by Western blot analysis

Cells/Cell Lines

eol I

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

title comp. dramatically induced the acetylation of histone H4; acetylation of the lysine14 residue on histone H3 (histone H3K14) was induced by title comp. on days 2 to 8; fig.

Measurement Parameter

Qualitative

Target, Subunit, Species Histone Ishihara, Kenji; Takahashi, Aki; Kaneko, Motoko; Sugeno, Hiroki; Hirasawa, Noriyasu; Hong, JangJa; Zee, OkPyo; Ohuchi, Kazuo; Life Sciences; vol. 80; nb. 13; (2007); p. 1213 - 1220, View in Reaxys 74 of 131

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : control: untreated cells cells incubated with title comp. at 37 deg C for 0 to 8 days; cell viability determined using hemocytometer

Cells/Cell Lines

eol I

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

title comp. inhibited the proliferation of cells until day 8; fig.

Measurement Parameter

Qualitative

Substance Effect

Cytotoxic

37/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : cells incubated with title comp. at 37 deg C for 1 day or 8 days; cell viability determined by flowcytometry using 7-amino-actinomycin D

Cells/Cell Lines

eol I

Substance RN

3601060View in Reaxys

Substance Name

1479191

Substance Dose

500 µM

Qualitative Results

viability of cells was decreased ca. 15% after 8 days incubation with title comp.; no significant change in viability observed after 1 day incubation; fig.

Measurement Parameter

Qualitative

Target Mutant/Chimera Details

Histone deacetylase [Eimeria tenella]:Wild

Target Species (Bioactivity)

Eimeria tenella

Target Subunit Proteins

Histone deacetylase [Eimeria tenella]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of compound against Histone deacetylase in Eimeria tenella oocytes using [3H]apicidin A upon incubation in 50 mM Hepes buffer, pH 7.4 for 1 hour at 25 degree C by Scintillation counting method

Biological Species/NCBI Eimeria tenella ID Cells/Cell Lines

Oocyte

Substance RN

3601060View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

1.5

Measurement pX

2.82

Target, Subunit, Species Histone deacetylase [Eimeria tenella] 77 of 131

Target Mutant/Chimera Details

Histone deacetylase [Eimeria tenella]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Eimeria tenella

Target Subunit Proteins

Histone deacetylase [Eimeria tenella]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of compound (dissolved in DMSO) against Histone deacetylase from Eimeria tenella oocytes using 280 nM Ac-Gly-Ala-Lys(epsilon-[3H]Ac)-Arg-His-ArgLys(epsilon-[3H]Ac)-Val-NH2 as substrate upon incubation in 10 mM Hepes-Na+ buffer, PH 7.4 at 25 degree C for 30 min

Biological Species/NCBI Eimeria tenella ID Cells/Cell Lines

Oocyte

38/365

2017-08-01 06:49:42

Substance RN

3601060View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.42

Target, Subunit, Species Histone deacetylase [Eimeria tenella] 78 of 131

Target Mutant/Chimera Details

Histone deacetylase 1:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase 1

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against histone deacetylase 1(class 1) was determined

Substance RN

3601060View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

0.3

Measurement pX

3.52

Target, Subunit, Species Histone deacetylase 1 79 of 131

Target Mutant/Chimera Details

Histone deacetylase 3:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase 3

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against histone deacetylase 3(class 1) was determined

Substance RN

3601060View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

0.3

Measurement pX

3.52

Target, Subunit, Species Histone deacetylase 3 80 of 131

Target Mutant/Chimera Details

D-beta-hydroxybutyrate dehydrogenase, mitochondrial:Wild

Target Subunit Proteins

D-beta-hydroxybutyrate dehydrogenase, mitochondrial

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Rate of oxidation of 3-hydroxybutyrate (3 umoles) mediated by 2.3 ug D-3-hydroxybutyrate dehydrogenase and 1 umole of NAD upon incubation with compound (30 umoles) at 25 degree C in Tris buffer at pH 7.4; Activity measured as %

39/365

2017-08-01 06:49:42

Substance RN

3601060View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

100

Target, Subunit, Species D-beta-hydroxybutyrate dehydrogenase, mitochondrial 81 of 131

Target Mutant/Chimera Details

D-beta-hydroxybutyrate dehydrogenase, mitochondrial:Wild

Target Subunit Proteins

D-beta-hydroxybutyrate dehydrogenase, mitochondrial

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Substance RN

3601060View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

100

Target, Subunit, Species D-beta-hydroxybutyrate dehydrogenase, mitochondrial 82 of 131

Target Mutant/Chimera Details

D-beta-hydroxybutyrate dehydrogenase, mitochondrial:Wild

Target Subunit Proteins

D-beta-hydroxybutyrate dehydrogenase, mitochondrial

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Substance RN

3601060View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

100

Target, Subunit, Species D-beta-hydroxybutyrate dehydrogenase, mitochondrial 83 of 131

Target Mutant/Chimera Details

Solute Carrier Family 16 [Mus musculus]:Wild

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Solute Carrier Family 16 [Mus musculus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Ability of the compound (50-500 uM) to induce currents in Xenopus laevis oocytes transfected with mouse kidney sodium-coupled monocarboxylate transporter in presence of NaCl in the perfusion buffer

Biological Species/NCBI Mus musculus ID Substance RN

3601060View in Reaxys

40/365

2017-08-01 06:49:42

Measurement Parameter

Current

Unit

Qualitative value

Quantitative value

Deviation

Target, Subunit, Species Solute Carrier Family 16 [Mus musculus] 84 of 131

Target Mutant/Chimera Details

Free fatty acid receptor 2 [human]:Wild

Target Species (Bioactivity)

human

Target Subunit Proteins

Free fatty acid receptor 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Tested activity against human G-protein coupled receptor 43 expressed in CHO-K1 cells; Active

Biological Species/NCBI Human ID Cells/Cell Lines

CHO-K1

Substance RN

3601060View in Reaxys

Qualitative Results

Active

Measurement Parameter

Activity

Qualitative value

Target, Subunit, Species Free fatty acid receptor 2 [human] 85 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum bactericidal concentration of compound against Helicobacter pylori ATCC 43504 upon incubation for 48 h at 37 degree C

Biological Species/NCBI Helicobacter pylori ATCC 43504 ID Substance RN

3601060View in Reaxys

Substance Dose

Measurement Parameter

MBC

Unit

mg/mL

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 86 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Lactobacillus reuteri JC 71112 upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

41/365

2017-08-01 06:49:42

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 87 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Bifidobacterium bifidum ATCC 14614 upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 88 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Staphylococcus aureus ATCC 29213 upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Biological Species/NCBI Staphylococcus aureus ATCC 29213 ID Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 89 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Salmonella enterica upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Biological Species/NCBI Salmonella enterica ID Substance RN

3601060View in Reaxys

Substance Dose

42/365

2017-08-01 06:49:42

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 90 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Proteus mirabilis upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Biological Species/NCBI Proteus mirabilis ID Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 91 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Biological Species/NCBI Pseudomonas aeruginosa ATCC 27853 ID Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 92 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Klebsiella pneumoniae upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

43/365

2017-08-01 06:49:42

Biological Species/NCBI Klebsiella pneumoniae ID Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 93 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum bactericidal concentration of compound against Helicobacter pylori upon incubation for 48 h at 37 degree C

Biological Species/NCBI Helicobacter pylori ID Substance RN

3601060View in Reaxys

Substance Dose

Measurement Parameter

MBC

Unit

mg/mL

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 94 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Escherichia coli ATCC 25922 upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Biological Species/NCBI Escherichia coli ATCC 25922 ID Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 95 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

44/365

2017-08-01 06:49:42

Bioassay Details

Antibacterial activity against Helicobacter pylori 238 upon incubation with 4 mg/disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Substance RN

3601060View in Reaxys

Substance Dose

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 96 of 131

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity against Helicobacter pylori ATCC 43504 upon incubation with 4 mg/ disc compound for 48 hours at 37 degree C measured as diameter of zone of inhibition by disc diffusion method

Biological Species/NCBI Helicobacter pylori ATCC 43504 ID Substance RN

3601060View in Reaxys

Substance Dose

Qualitative Results

No inhibition

Measurement Parameter

Unit

Qualitative value

Quantitative value

Lo, Chung-Yi; Cheng, Hsueh-Ling; Hsu, Jue-Liang; Liao, Ming-Hui; Yen, Rong-Lang; Chen, Yo-Chia; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 6; (2013); p. 604 - 610, View in Reaxys 97 of 131

Target Mutant/Chimera Details

ACSF4-U26 [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

ACSF4-U26 [Mus musculus]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

HEK293T

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Not active

Measurement pX

Target, Subunit, Species ACSF4-U26 [Mus musculus]

45/365

2017-08-01 06:49:42

98 of 131

Target Mutant/Chimera Details

Histone deacetylase 10 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 10 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

1932

Measurement pX

2.71

Target, Subunit, Species Histone deacetylase 10 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 99 of 131

Target Mutant/Chimera Details

Histone deacetylase 11 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 11 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

2771

Measurement pX

2.56

Target, Subunit, Species Histone deacetylase 11 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 100 of 131 Substance Effect Bioassay Category

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

46/365

2017-08-01 06:49:42

Substance Dose

2.5 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

2.6

Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 101 of 131 Substance Effect Bioassay Category

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

5 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

2.3

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

47/365

2017-08-01 06:49:42

Substance Name

butyrate

Measurement Parameter

IC50

Unit

Quantitative value

0.485

Measurement pX

3.31

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

48/365

2017-08-01 06:49:42

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

% Increase

Qualitative value

Not active

Measurement pX

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

% Increase

Qualitative value

Not active

Measurement pX

Apoptotic Toxicity/Safety Pharmacology

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

0.25 - 5 mM

Measurement Parameter

Qualitative

Qualitative value

Not active

Measurement pX

Antiinflammatory In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

49/365

2017-08-01 06:49:42

Substance Name

butyrate

Substance Dose

5 mM

Measurement Parameter

% Increase50

Qualitative value

Active

Measurement pX

2.3

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

0.25 - 5 mM

Measurement Parameter

Qualitative

Qualitative value

Not active

Measurement pX

Substance Effect

Antiinflammatory

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

Healthy

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Decrease

Qualitative value

Active

Measurement pX

Substance Effect

Antiinflammatory

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

gout

Cells/Cell Lines

peripheral blood mononuclear cell

50/365

2017-08-01 06:49:42

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

Substance Effect

Antiinflammatory

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Population State

gout

Cells/Cell Lines

peripheral blood mononuclear cell

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

Target Mutant/Chimera Details

Histone deacetylase 1 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 1 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

712

Measurement pX

3.15

Target, Subunit, Species Histone deacetylase 1 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 115 of 131

Target Mutant/Chimera Details

Histone deacetylase 2 [Human]:Wild

51/365

2017-08-01 06:49:42

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 2 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

300

Measurement pX

3.52

Target, Subunit, Species Histone deacetylase 2 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 116 of 131

Target Mutant/Chimera Details

Histone deacetylase 3 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 3 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

543

Measurement pX

3.27

Target, Subunit, Species Histone deacetylase 3 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 117 of 131

Target Mutant/Chimera Details

Histone deacetylase 8 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 8 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

52/365

2017-08-01 06:49:42

Substance Name

butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

106

Measurement pX

3.97

Target, Subunit, Species Histone deacetylase 8 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 118 of 131

Target Mutant/Chimera Details

Histone deacetylase 4 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 4 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

Measurement pX

Target, Subunit, Species Histone deacetylase 4 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 119 of 131

Target Mutant/Chimera Details

Histone deacetylase 5 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 5 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

Measurement pX

53/365

2017-08-01 06:49:42

Target, Subunit, Species Histone deacetylase 5 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 120 of 131 Target Mutant/Chimera Details

Histone deacetylase 7 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 7 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

Measurement pX

Target, Subunit, Species Histone deacetylase 7 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 121 of 131 Target Mutant/Chimera Details

Histone deacetylase 9 [Human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 9 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

Measurement pX

Target, Subunit, Species Histone deacetylase 9 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 122 of 131 Target Mutant/Chimera Details

Histone deacetylase 6 [Human]:Wild

54/365

2017-08-01 06:49:42

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Human

Target Subunit Proteins

Histone deacetylase 6 [Human]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

Measurement pX

Target, Subunit, Species Histone deacetylase 6 [Human] Cleophas, Maartje C. P.; Crian, Tania O.; Lemmers, Heidi; Toenhake-Dijkstra, Helga; Fossati, Gianluca; Jansen, Tim L.; Dinarello, Charles A.; Netea, Mihai G.; Joosten, Leo A. B.; Annals of the Rheumatic Diseases; vol. 75; nb. 3; (2016); p. 593 - 600, View in Reaxys 123 of 131 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

HCT 116

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

3 mM

Measurement Parameter

% Degradation

Qualitative value

Active

Measurement pX

2.52

Patent; UNIVERSITÄT REGENSBURG; FRIEDRICH-SCHILLER-UNIVERSITÄT JENA; UNIVERSITÄTSKLINIKUM JENA; MAHBOOBI, Siavosh; SELLMER, Andreas; PONGRATZ, Herwig; LEONHARDT, Michel; KRÄMER, Oliver; BÖHMER, Frank-Dietmar; KELTER, Gerhard; (257 pag.); WO2016/20369; (2016); (A1) English, View in Reaxys 124 of 131 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

HCT 116

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

3 mM

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.52

Monocarboxylate transporter:Wild

55/365

2017-08-01 06:49:42

Substance Action on Target

Inhibitor

Target Subunit Proteins

Monocarboxylate transporter

Bioassay Category

Metabolism/Transport

Cells/Cell Lines

CACO2

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

10 mM

Measurement Parameter

% Inhibition

Qualitative value

Active

Measurement pX

Target, Subunit, Species Monocarboxylate transporter 126 of 131 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

NCI-H716

Substance RN

3601060View in Reaxys

Substance Name

butyrate

Substance Dose

2.5 μM

Measurement Parameter

Concentration

Unit

pmol/mg protein

Quantitative value

100.77

Patent; California Institute of Technology; The Regents of the University of California; The United States Government Represented by the Department of Veterans Affairs; Goddard, III, William A.; Menna, Mark; Pandol, Stephen; Abrol, Ravinder; (48 pag.); US9272051; (2016); (B2) English, View in Reaxys 127 of 131 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

TC7

Substance RN

3601060View in Reaxys

Substance Dose

1 μM

Measurement Parameter

% Live cells

Unit

Quantitative value

55.85

Sánchez-de-Diego, Cristina; Mármol, Inés; Pérez, Rocío; Gascón, Sonia; Rodriguez-Yoldi, Mª Jesús; Cerrada, Elena; Journal of Inorganic Biochemistry; vol. 166; (2017); p. 108 - 121, View in Reaxys 128 of 131 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

TC7

Substance RN

3601060View in Reaxys

Substance Dose

1 μM

Measurement Parameter

% Early apoptotic cells

Unit

Quantitative value

32.11

56/365

2017-08-01 06:49:42

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

TC7

Substance RN

3601060View in Reaxys

Substance Dose

1 μM

Measurement Parameter

% Late apoptotic cells

Unit

Quantitative value

11.75

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

TC7

Substance RN

3601060View in Reaxys

Substance Dose

1 μM

Measurement Parameter

% Necrotic cells

Unit

Quantitative value

0.29

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

TC7

Substance RN

3601060View in Reaxys

Measurement Parameter

% induction

Qualitative value

Not active

Measurement pX

Reaxys ID 1701672 View in Reaxys

3/23 CAS Registry Number: 38765-83-2 Chemical Name: <1-13C>butyric acid; <1-13C>Butansaeure; butylic acid-1-(13)C; [1-13 C]butyric acid; [1-13 C]Buttersaeure; <1-13C(1)>-Buttersaeure; <1-13C>-Buttersaeure Linear Structure Formula: C3 (13)CH8O2 Molecular Formula: C4H8O2 Molecular Weight: 89.0953 Type of Substance: acyclic InChI Key: FERIUCNNQQJTOY-AZXPZELESA-N Note:

C O

Substance Label (3)

57/365

2017-08-01 06:49:42

Label

References

3(R=C3H7)

Brobst; Townsend; Canadian Journal of Chemistry; vol. 72; nb. 1; (1994); p. 200 - 207, View in Reaxys

Weiske, Thomas; Schwarz, Helmut; Chemische Berichte; vol. 116; nb. 1; (1983); p. 323 - 347, View in Reaxys

Baretz et al.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 15; (1978); p. 369,374, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.742

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

Boiling Point (1) Boiling Point [°C]

References

163 - 164

Pasto; Timony; Organic Mass Spectrometry; vol. 10; (1975); p. 222,239, View in Reaxys

NMR Spectroscopy (2) 1 of 2

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Kirillova, Marina V.; Da Silva, Jose A. L.; Da Silva, Joao J. R. Frausto; Palavra, Antonio F.; Pombeiro, Armando J. L.; Advanced Synthesis and Catalysis; vol. 349; nb. 10; (2007); p. 1765 - 1774, View in Reaxys 2 of 2

Description (NMR Spec- NMR troscopy) Comment (NMR Spectroscopy)

13C

Omura et al.; Biochemistry; vol. 16; (1977); p. 2860,2861, View in Reaxys; Marshall; Ihrig; Tetrahedron Letters; (1972); p. 2139, View in Reaxys

Reaxys ID 1701165 View in Reaxys

4/23 CAS Registry Number: 25117-78-6 Chemical Name: O-deuterio-butyric acid; O-Deuterio-buttersaeure; Buttersaeure<2H>; O-Deuterobuttersaeure; O-d(1)-Buttersaeure; Buttersaeure-O-d Linear Structure Formula: C4H7DO2 Molecular Formula: C4H8O2 Molecular Weight: 89.0984 Type of Substance: acyclic InChI Key: FERIUCNNQQJTOY-DYCDLGHISA-N Note:

O O

Substance Label (2) Label References Table I, entry 3

McAdoo, David J.; Hudson, Charles E.; Griffin, Lawrence L.; Journal of Physical Chemistry; vol. 88; nb. 8; (1984); p. 1481 - 1485, View in Reaxys

D-butyric acid

Tsvetkov; Rabinovich; Russian Journal of Physical Chemistry; vol. 46; (1972); p. 1692; ; p. 2962, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.742

58/365

2017-08-01 06:49:42

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

Boiling Point (1) Boiling Point [°C] 162 - 163

References Maskill; Whiting; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1976); p. 1462,1469, View in Reaxys

Further Information (2) Description (Fur- References ther Information) Further information

Smith; Mc Lafferty; Organic Mass Spectrometry; vol. 5; (1971); p. 483, View in Reaxys

Further information

Fairweather; McLafferty; Organic Mass Spectrometry; vol. 2; (1969); p. 755, View in Reaxys

Liquid/Liquid Systems (MCS) (1) 1 of 1

Description (Liquid/ Liquid Systems (MCS))

Critical solution temperature

Solvent (Liquid/Liquid Systems (MCS))

D2O

Rabinowitsch et al.; Doklady Akademii Nauk SSSR; vol. 105; (1955); p. 108,109; Chem. Zentralbl.; vol. 127; (1956); p. 9845, View in Reaxys Mechanical & Physical Properties (MCS) (1) 1 of 1

Description (Mechanical & Physical Properties (MCS))

Adiabatic compressibility

Tsvetkov; Rabinovich; Russian Journal of Physical Chemistry; vol. 46; (1972); p. 1692; ; p. 2962, View in Reaxys Sound Properties (1) Description References (Sound Properties) Velocity of sound

Tsvetkov; Rabinovich; Russian Journal of Physical Chemistry; vol. 46; (1972); p. 1692; ; p. 2962, View in Reaxys

IR Spectroscopy (3) 1 of 3

Description (IR Spectroscopy)

Spectrum

Excoffon; Marechal; Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy; vol. 28; (1972); p. 269, View in Reaxys 2 of 3

Description (IR Spectroscopy)

Spectrum

Comment (IR Spectroscopy)

1500 - 700 cm**(-1); des Dampfes.

Hadzi; Pintar; Spectrochimica Acta; vol. 12; (1958); p. 162,163, View in Reaxys 3 of 3

Description (IR Spectroscopy)

Spectrum

Comment (IR Spectroscopy)

Dampf.

Herman; Journal of Chemical Physics; vol. 8; (1940); p. 256, View in Reaxys Mass Spectrometry (2) Description (Mass References Spectrometry)

59/365

2017-08-01 06:49:42

spectrum

McAdoo, David J.; Hudson, Charles E.; Griffin, Lawrence L.; Journal of Physical Chemistry; vol. 88; nb. 8; (1984); p. 1481 - 1485, View in Reaxys McAdoo et al.; Journal of the American Chemical Society; vol. 99; (1977); p. 7265, View in Reaxys; Fairweather; McLafferty; Organic Mass Spectrometry; vol. 2; (1969); p. 755, View in Reaxys; Smith; Mc Lafferty; Organic Mass Spectrometry; vol. 5; (1971); p. 483, View in Reaxys

Reaxys ID 1904033 View in Reaxys

5/23 CAS Registry Number: 19136-92-6 Chemical Name: 2,2-d2-butanoic acid; 2,2-dideuteriobutyric acid; α-d2-butanoic acid; (2,2-2H2)-butyric acid; [2,2-2H]2-butyric acid; butanoic-2,2-d2 acid; butyric acid-2,2-d2 Linear Structure Formula: C4H6D2O2 Molecular Formula: C4H8O2 Molecular Weight: 90.0904 Type of Substance: acyclic InChI Key: FERIUCNNQQJTOY-SMZGMGDZSA-N Note:

HO O

Substance Label (4) Label References 7

Heinsen, Melissa J.; Pochapsky, Thomas C.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 43; nb. 5; (2000); p. 473 - 480, View in Reaxys

CH3CH2CD2CO2 McAdoo, David J.; Hudson, Charles E.; Skyiepal, Mark; Broido, Ellen; Griffin, Lawrence L.; Journal of H the American Chemical Society; vol. 109; nb. 25; (1987); p. 7648 - 7653, View in Reaxys 4

Boden, Neville; Bushby, Richard J.; Clark, Leslie D.; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999); (1983); p. 543 - 551, View in Reaxys

Benz; Biemann; Journal of the American Chemical Society; vol. 86; (1964); p. 2375,2376, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.742

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

Derivative (1) Comment (Derivative) K-Salz: RamanSpektrum Boiling Point (1) Boiling Point [°C] 60 - 80

References Okabayashi; Kitagawa; Journal of Physical Chemistry; vol. 82; (1978); p. 1830,1833, View in Reaxys

References Boden; Bushby; Clark; Molecular crystals and liquid crystals; vol. 104; nb. 1-2; (1984); p. 179 - 135, View in Reaxys

Association (MCS) (1) 1 of 1

Description (Association NMR spectrum of the complex (MCS)) Temperature (Association (MCS)) [°C]

110

Partner (Association (MCS))

4-octyloxybenzoic acid

60/365

2017-08-01 06:49:42

Delikatny, E. J.; Heldman, M. A.; Burnell, E. E.; Journal of Magnetic Resonance (1969-1992); vol. 95; nb. 1; (1991); p. 32 - 40, View in Reaxys Further Information (1) Description (Fur- References ther Information) Further information

Okabayashi; Kitagawa; Journal of Physical Chemistry; vol. 82; (1978); p. 1830,1833, View in Reaxys

NMR Spectroscopy (4) 1 of 4

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Frequency (NMR Spectroscopy) [MHz]

400

Heinsen, Melissa J.; Pochapsky, Thomas C.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 43; nb. 5; (2000); p. 473 - 480, View in Reaxys 2 of 4

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Frequency (NMR Spectroscopy) [MHz]

100

Heinsen, Melissa J.; Pochapsky, Thomas C.; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 43; nb. 5; (2000); p. 473 - 480, View in Reaxys 3 of 4

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- CDCl3 scopy) Temperature (NMR Spectroscopy) [°C]

Matta, Michael S.; Broadway, Dale E.; Stroot, Michele K.; Journal of the American Chemical Society; vol. 109; nb. 16; (1987); p. 4916 - 4918, View in Reaxys 4 of 4

Description (NMR Spec- Spin-spin coupling constants troscopy) Solvents (NMR Spectro- CDCl3 scopy) Temperature (NMR Spectroscopy) [°C]

Comment (NMR Spectroscopy)

2D-13C.

Matta, Michael S.; Broadway, Dale E.; Stroot, Michele K.; Journal of the American Chemical Society; vol. 109; nb. 16; (1987); p. 4916 - 4918, View in Reaxys IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

neat (no solvent)

Comment (IR Spectroscopy)

3000 - 1700 cm**(-1)

Laurent, Eliane; Thomalla, Marc; Marquet, Bernard; Burger, Ulrich; Journal of Organic Chemistry; vol. 45; nb. 21; (1980); p. 4193 - 4198, View in Reaxys Mass Spectrometry (1)

61/365

2017-08-01 06:49:42

References McAdoo et al.; Journal of the American Chemical Society; vol. 99; (1977); p. 7265, View in Reaxys; Smith; Williams; Journal of the American Chemical Society; vol. 91; (1969); p. 5254,5259, View in Reaxys; McAdoo et al.; Journal of the American Chemical Society; vol. 100; (1978); p. 6639,6641, 6642, View in Reaxys

Reaxys ID 1701675 View in Reaxys

6/23 CAS Registry Number: 41130-44-3 Chemical Name: [14C]-Butyric acid; [1-13C]butyric acid; [1-14 C]butyric acid; [1-14 C]Buttersaeure; Buttersaeure-<carbonyl-14C>; 14C-Buttersaeure; Buttersaeure Linear Structure Formula: C3H7 (14)COOH Molecular Formula: C4H8O2 Molecular Weight: 90.0953 Type of Substance: acyclic InChI Key: FERIUCNNQQJTOY-DOMIDYPGSA-N Note:

14C

Substance Label (1) Label References %14&C-7

Lewin, Anita; Jeffcoat, Robert; Berrang, Bertold; Journal of Labelled Compounds and Radiopharmaceuticals; vol. 50; nb. 3; (2007); p. 171 - 175, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.742

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

Boiling Point (1) Boiling Point [°C]

References

158 - 159

Biland et al.; Helvetica Chimica Acta; vol. 43; (1960); p. 1436,1439, View in Reaxys

(0) Medchem (31) 1 of 31

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : drug interaction Target : Crl:CD-1 (ICR) BR Swiss mice Bioassay : animal placed in a plastic cage swept by an air flow; the outflow bubbled into ethanolamine-2-methoxyethanol mixture; exhalation of (14C)CO2 measured for 15 min after title comp. administration fed mice recieved both estradiol (E) (36 Μmol/kg i.p daily) and progesterone (P) (150 μmol/kg i.p daily) for 7 ds; 24 hs after the last administration title comp. administered by gastric intubation

Substance RN

1701675View in Reaxys

Substance Name

%14&C-7

Substance Dose

69 nmol/kg

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

no significant decrease of exhalation of (14C)CO2 ater 7 ds treatment with E+P when expressed as the percentage of radioctivity administered; results expressed per gram of liver exhalation of (14C)CO2 from title comp. decreased ca 41-46 percent (larger

62/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Grimbert; Fisch; Deschamps; Berson; Fromenty; Feldmann; Pessayre; American Journal of Physiology - Gastrointestinal and Liver Physiology; vol. 268; nb. 1 31-1; (1995); p. G107-G115, View in Reaxys 2 of 31

Target Mutant/Chimera Details

Solute carrier family 22 member 9 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Solute carrier family 22 member 9 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

Substance RN

1701675View in Reaxys

Substance Name

[14C]-Butyrate

Measurement Parameter

Unit

µM

Quantitative value

35.7

Measurement pX

4.45

Target, Subunit, Species Solute carrier family 22 member 9 [human] 3 of 31

Target Mutant/Chimera Details

Solute carrier family 22 member 9 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Solute carrier family 22 member 9 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

Substance RN

1701675View in Reaxys

Substance Name

[14C]-Butyrate

Measurement Parameter

Vmax

Unit

pmol/min/mg protein

Quantitative value

42.1

Target, Subunit, Species Solute carrier family 22 member 9 [human] 4 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

63/365

2017-08-01 06:49:42

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

86.8

Deviation

6.60000

Target, Subunit, Species Monocarboxylate transporter 1 [human] Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 5 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

2.83

Deviation

0.380000

Measurement pX

2.55

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

64/365

2017-08-01 06:49:42

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

86.8

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 7 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

2.83

Measurement pX

2.55

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 8 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

86.8

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 9 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

65/365

2017-08-01 06:49:42

Quantitative value

2.83

Measurement pX

2.55

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 10 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

86.8

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 11 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

2.83

Measurement pX

2.55

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 12 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

86.8

66/365

2017-08-01 06:49:42

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 13 of 31

Substance Action on Target

Substrate

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

2.83

Measurement pX

2.55

Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 14 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

HK-2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-Butyrate

Measurement Parameter

Unit

Quantitative value

0.8

Deviation

0.300000

Measurement pX

3.1

Target, Subunit, Species Monocarboxylate transporter 1 [human] 15 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

67/365

2017-08-01 06:49:42

Cells/Cell Lines

HK-2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-Butyrate

Measurement Parameter

Vmax

Unit

nmol/min/mg protein

Quantitative value

29.3

Deviation

0.400000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 16 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

HK-2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-Butyrate

Measurement Parameter

Clint

Unit

µL/min/mg protein

Quantitative value

2.1

Deviation

0.400000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 17 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

13.3

Deviation

0.500000

68/365

2017-08-01 06:49:42

Target, Subunit, Species Monocarboxylate transporter 1 [human] 18 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

26.6

Deviation

2.30000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 19 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

93.3

Deviation

4.10000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 20 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

69/365

2017-08-01 06:49:42

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

11.8

Deviation

0.600000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 21 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

11.9

Deviation

0.900000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 22 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

70/365

2017-08-01 06:49:42

Quantitative value

12.8

Deviation

0.900000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 23 of 31

Target Mutant/Chimera Details

Monocarboxylate transporter 1 [human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

human

Target Subunit Proteins

Monocarboxylate transporter 1 [human]

Target Transfection

Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]butyrate

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

13.3

Deviation

0.500000

Target, Subunit, Species Monocarboxylate transporter 1 [human] 24 of 31

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

106.2

Deviation

17.2000

Target, Subunit, Species MCT1 [Human] Goncalves, Pedro; Araujo, Joao Ricardo; Pinho, Maria Joao; Martel, Fatima; Naunyn-Schmiedeberg's Archives of Pharmacology; vol. 379; nb. 4; (2009); p. 325 - 336, View in Reaxys 25 of 31

Target Mutant/Chimera Details

MCT1 [Human]:Wild

71/365

2017-08-01 06:49:42

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

5.83

Deviation

1.35000

Measurement pX

2.23

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

113.6

Deviation

35.6000

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

72/365

2017-08-01 06:49:42

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

6.59

Deviation

2.86000

Measurement pX

2.18

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

151.2

Deviation

41.2700

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

73/365

2017-08-01 06:49:42

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

5.94

Deviation

2.31000

Measurement pX

2.23

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Vmax

Unit

nmol/x min/mg protein

Quantitative value

154.4

Deviation

82.9000

Target Mutant/Chimera Details

MCT1 [Human]:Wild

Substance Action on Target

Substrate

Target Species (Bioactivity)

Human

Target Subunit Proteins

MCT1 [Human]

74/365

2017-08-01 06:49:42

Target Transfection

Non Transfected

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Cells/Cell Lines

CACO2

Substance RN

1701675View in Reaxys

Substance Name

[14C]-BT

Substance Dose

0.0100000 mM

Measurement Parameter

Unit

Quantitative value

14.8

Deviation

9.40000

Measurement pX

1.83

Reaxys ID 1756015 View in Reaxys

7/23 CAS Registry Number: 36789-14-7 Chemical Name: (4,4,4-2H3)-butyric acid; 4,4,4-trideuterio-butyric acid; 4,4,4-Trideuterio-buttersaeure Linear Structure Formula: C4H5D3O2 Molecular Formula: C4H8O2 Molecular Weight: 91.0825 Type of Substance: acyclic InChI Key: FERIUCNNQQJTOY-FIBGUPNXSA-N Note:

2H 2H

Druglikeness (1) 1 of 1

LogP

0.742

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

Derivative (1) Comment (Derivative) K-Salz: RamanSpektrum Boiling Point (2) Boiling Point [°C] 60 - 61

References Okabayashi; Kitagawa; Journal of Physical Chemistry; vol. 82; (1978); p. 1830,1833, View in Reaxys

Pressure (Boiling Point) [Torr]

References

Hudson,H.R. et al.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1979); p. 57 - 66, View in Reaxys

163

Woller; Garbisch; Journal of Organic Chemistry; vol. 37; (1972); p. 4281, View in Reaxys

Refractive Index (1)

75/365

2017-08-01 06:49:42

Refractive Index

Wavelength (Refractive Index) [nm]

Temperature (Refractive Index) [°C]

References

1.4025

589

Hudson,H.R. et al.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1979); p. 57 - 66, View in Reaxys

Further Information (2) Description (Fur- References ther Information) Further information

Okabayashi; Kitagawa; Journal of Physical Chemistry; vol. 82; (1978); p. 1830,1833, View in Reaxys

Further information

Smith; Mc Lafferty; Organic Mass Spectrometry; vol. 5; (1971); p. 483, View in Reaxys

NMR Spectroscopy (1) 1 of 1

Description (NMR Spec- NMR troscopy) Hudson,H.R. et al.; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1979); p. 57 - 66, View in Reaxys

Mass Spectrometry (3) Description (Mass Comment (Mass Spectrometry) Spectrometry) spectrum

References

collisional activation

McAdoo, David J.; Hudson, Charles E.; Griffin, Lawrence L.; Journal of Physical Chemistry; vol. 88; nb. 8; (1984); p. 1481 - 1485, View in Reaxys

metastable ions

McAdoo, David J.; Hudson, Charles E.; Journal of the American Chemical Society; vol. 103; nb. 26; (1981); p. 7710 - 7713, View in Reaxys McAdoo et al.; Journal of the American Chemical Society; vol. 99; (1977); p. 7265, View in Reaxys; Smith; Mc Lafferty; Organic Mass Spectrometry; vol. 5; (1971); p. 483, View in Reaxys; McAdoo et al.; Journal of the American Chemical Society; vol. 100; (1978); p. 6639,6641, 6642, View in Reaxys

Reaxys ID 3701541 View in Reaxys

8/23 CAS Registry Number: 21303-03-7 Chemical Name: butyric acid Li-salt; Lithium n-butanoate; lithium butyrate; butyric acid ; lithium butyrate; Buttersaeure; Lithiumbutyrat Linear Structure Formula: Li(1+)*O2CC3H7 (1-)=LiO2CC3H7 Molecular Formula: C4H7O2*Li Molecular Weight: 94.0394 Type of Substance: acyclic InChI Key: WIAVVDGWLCNNGT-UHFFFAOYSA-M Note:

Li+ O O–

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (1) 1 of 1

Melting Point [°C]

317.84

Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys

76/365

2017-08-01 06:49:42

Crystal Phase (2) Description (Crys- References tal Phase) Crystal growth

Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys

Dimensions of the Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. unit cell Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys Crystal System (1) Comment (Crystal References System) Crystal system given

Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys

Enthalpy of Fusion (1) Comment (EnReferences thalpy of Fusion) Enthalpy of melting given

Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys

Heat Capacity Cp (1) Temperature Comment (Heat (Heat Capacity Capacity Cp) Cp) [°C] -268.2 - 76.9

References

Heat capacity cp Ngeyi, S. P.; Westrum, E. F.; Franzosini, P.; Journal of Chemical Thermodynamics; vol. (range begins): 18; nb. 7; (1986); p. 609 - 618, View in Reaxys 0.025 <unit not given>; Heat capacity cp (range ends): 21.03 <unit not given>

Liquid/Liquid Systems (MCS) (1) 1 of 1

Description (Liquid/ Liquid Systems (MCS))

Liquid/liquid phase diagram

Partner (Liquid/Liquid Systems (MCS))

lead(II) butyrate

Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys Liquid/Solid Systems (MCS) (4) 1 of 4

Description (Liquid/Solid Liquid/solid phase diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

lead(II) butyrate

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 1:7(?).

Partner (Liquid/Solid Systems (MCS))

lithium nitrate

Zindrik; Sokolow; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1728,1729,1730;engl.Ausg.S.1775, View in Reaxys 3 of 4

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium nitrate

Zindrik; Sokolow; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1728,1729,1730;engl.Ausg.S.1775, View in Reaxys 4 of 4

Description (Liquid/Solid Solidification diagram Systems (MCS))

77/365

2017-08-01 06:49:42

Partner (Liquid/Solid Systems (MCS))

sodium butyrate

Zindrik; Sokolow; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1728,1729,1730;engl.Ausg.S.1775, View in Reaxys Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -57.2

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys

Space Group (1) Comment (Space Group)

References

Space group(s) given

Casado, F. J. Martinez; Riesco, M. Ramos; Silva, I. Da; Yelamos, M. I. Redondo; Labrador; Cheda, J. A. Rodriguez; Crystal Growth and Design; vol. 11; nb. 3; (2011); p. 759 - 767, View in Reaxys

IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

ATR-FTIR (attenuated total reflectance Fourier transform infrared spectroscopy); Spectrum

Location

References

Pharmaceuticals

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

histone deacetylase inhibitor (HDACi)

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

angiogenic material

Patent; Wright, Emma Jayne; Huckle, James William; Ali, Saad Aboul Majeed; US2004/265282; (2004); (A1) English, View in Reaxys

fixation devices for tissue repair

Patent; Wright, Emma Jayne; Huckle, James William; Ali, Saad Aboul Majeed; US2004/265282; (2004); (A1) English, View in Reaxys

Medchem (1) 1 of 1

Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against Histone deacetylase was determined

Substance RN

3701541View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase

Reaxys ID 3914929 View in Reaxys H

9/23 CAS Registry Number: 14287-04-8 Chemical Name: Ammonium n-butyrate; ammonium butyrate; butyric acid ; ammonium butyrate; Buttersaeure; Ammoniumbutyrat; Buttersaeure; Ammonium-Verbindung; ammonium n-butanoate; Ammoniumbutyrat Linear Structure Formula: C4H8O2*H3N

H HO O

78/365

2017-08-01 06:49:42

Molecular Formula: C4H8O2*H3N Molecular Weight: 105.137 Type of Substance: acyclic InChI Key: YNTQKXBRXYIAHM-UHFFFAOYSA-N Note: Patent-Specific Data (1) Prophetic ComReferences pound prophetic catalyst

Patent; Childress, R. Shawn; McIntyre, James L.; US2006/235221; (2006); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.742

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

37.3

Lipinski Number

Veber Number

Melting Point (2) 1 of 2

Melting Point [°C]

108

Comment (Melting Point)

in NH3-Atmosphere.

Zuffanti; Journal of the American Chemical Society; vol. 63; (1941); p. 3124, View in Reaxys 2 of 2

Melting Point [°C]

70 - 85

Falciola; Gazzetta Chimica Italiana; vol. 40 II; (1910); p. 434, View in Reaxys Density (1) 1 of 1

Density [g·cm-3]

0.974

Reference Temperature [°C]

Measurement Temperature [°C]

Biltz; Balz; Zeitschrift fuer Anorganische und Allgemeine Chemie; vol. 170; (1928); p. 339, View in Reaxys Crystal Property Description (1) Colour & Other References Properties weiss

Falciola; Gazzetta Chimica Italiana; vol. 40 II; (1910); p. 434, View in Reaxys

Further Information (1) Description (Fur- References ther Information) Further information

Lindenberg; Zeitschrift fuer Naturforschung, Teil B: Anorganische Chemie, Organische Chemie, Biochemie, Biophysik, Biologie; vol. 21; (1966); p. 396, View in Reaxys

Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -63.4

Prasad et al.; Journal of Chemical Physics; vol. 20; (1952); p. 129, View in Reaxys

Use (4) Use Pattern

Location

References

Pharmaceuticals

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

histone deacetylase inhibitor (HDACi)

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

79/365

2017-08-01 06:49:42

angiogenic material

Patent; Wright, Emma Jayne; Huckle, James William; Ali, Saad Aboul Majeed; US2004/265282; (2004); (A1) English, View in Reaxys

fixation devices for tissue repair

Patent; Wright, Emma Jayne; Huckle, James William; Ali, Saad Aboul Majeed; US2004/265282; (2004); (A1) English, View in Reaxys

Reaxys ID 3629439 View in Reaxys

10/23 CAS Registry Number: 156-54-7 Chemical Name: sodium butyrate; butyric acid sodium salt; sodium n-butyrate; sodium butanoate; sodium Butyrate; NaB; Butyrate sodium salt Linear Structure Formula: Na(1+)*C3H7CO2 (1-)=Na(C3H7CO2) Molecular Formula: C4H7O2*Na Molecular Weight: 110.088 Type of Substance: acyclic InChI Key: MFBOGIVSZKQAPD-UHFFFAOYSA-M Note:

Na + O O–

Substance Label (28) Label References NaB

Fraser; Brandt; Kroll; Molecular Pharmacology; vol. 47; nb. 4; (1995); p. 696 - 706, View in Reaxys; Gao, Ning; Dai, Yun; Rahmani, Mohamed; Dent, Paul; Grant, Steven; Molecular Pharmacology; vol. 66; nb. 4; (2004); p. 956 - 963, View in Reaxys; Gruchlik, Arkadiusz; Orchel, Arkadiusz; Wilczok, Adam; Zajdel, Alicja; Parfiniewicz, Beata; Dzierzewicz, Zofia; Weglarz, Ludmila; Wilczok, Tadeusz; Acta poloniae pharmaceutica; vol. 61 Suppl; (2004); p. 88 - 90, View in Reaxys; Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys; Patent; Sutter, Thomas Robert; Sutter, Carrie Hayes; US2008/269339; (2008); (A1) English, View in Reaxys; Patent; THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY; DREXEL UNIVERSITY; LIEBERMAN, Paul, M.; TIKHMYANOVA, Nadezhda; SALVINO, Joseph, M.; WO2015/31759; (2015); (A1) English, View in Reaxys; McNulty, James; D'Aiuto, Leonardo; Zhi, Yun; McClain, Lora; Zepeda-Velázquez, Carlos; Ler, Spencer; Jenkins, Hilary A.; Yee, Michael B.; Piazza, Paolo; Yolken, Robert H.; Kinchington, Paul R.; Nimgaonkar, Vishwajit L.; ACS Medicinal Chemistry Letters; vol. 7; nb. 1; (2016); p. 46 - 50, View in Reaxys; Patent; The University of Western Australia; Jiang, Fang-Xu; (47 pag.); US2016/45554; (2016); (A1) English, View in Reaxys; Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys; Ren, Jianwai; Chen, George G.; Liu, Yi; Su, Xianwei; Hu, Baoguang; Leung, Billy C.S.; Wang; Ho, Rocky L.K.; Yang, Shengli; Lu, Gang; Lee; Lai, Paul B.S.; PLoS ONE; vol. 11; nb. 4; (2016); Art.No: E0153863, View in Reaxys; Patent; UNIVERSITY OF SOUTH AUSTRALIA; HAN, Yanchuang; KIM, JiHee; YANG, JunYong; KIM, WooKyung; ZHOU, Xin-Fu; (85 pag.); WO2016/101010; (2016); (A1) English, View in Reaxys; Patent; Takara Bio Europe AB; Brolén, Gabriella; Edsbagge, Josefina; (95 pag.); US9394522; (2016); (B2) English, View in Reaxys; Wagley, Yadav; Law, Ping-Yee; Wei, Li-Na; Loh, Horace H.; Molecular Pharmacology; vol. 91; nb. 4; (2017); p. 357 - 372, View in Reaxys; Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE J. DAVID GLADSTONE INSTITUTES; HEBROK, Matthias; RUSS, Holger Andreas; DING, Sheng; ZHU, Saiyong; (259 pag.); WO2017/19702; (2017); (A1) English, View in Reaxys

Hojo, Elza T. Sakamoto; Balajee, A. S.; Natarajan, A. T.; Mutation Research; vol. 309; nb. 2; (1994); p. 165 - 174, View in Reaxys; Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys; Rosato, Roberto R.; Almenara, Jorge A.; Yu, Chunrong; Grant, Steven; Molecular Pharmacology; vol. 65; nb. 3; (2004); p. 571 581, View in Reaxys; Rahmani, Mohamed; Reese, Erin; Dai, Yun; Bauer, Cheryl; Kramer, Lora B.; Huang, Mei; Jove, Richard; Dent, Paul; Grant, Steven; Molecular Pharmacology; vol. 67; nb. 4; (2005); p. 1166 - 1176, View in Reaxys; Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys; Hyeon, Ju Kim; Rowe, Michael; Ren, Ming; Hong, Jau-Shyong; Chen, Po-See; Chuang, De-Maw; Journal of Pharmacology and Experimental Therapeutics; vol. 321; nb. 3; (2007); p. 892 - 901, View in Reaxys; Banipal, Tarlok S.; Singh, Kultar; Banipal, Parampaul K.; Journal of Solution Chemistry; vol. 36; nb. 11-12; (2007); p. 1635 - 1667, View in Reaxys; Patent; NatureWise Biotech and Medicals Corporation; EP2045247; (2009); (A1) English, View in Reaxys; Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys; Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys; Pant, Kishor; Yadav, Ajay K.; Gupta, Parul; Islam, Rakibul; Saraya, Anoop; Venugopal, Senthil K.; Redox Biology; vol. 12; (2017); p. 340 - 349, View in Reaxys

C&3%H&7%COO Yang, Qi-Liang; Li, Yi-Qian; Ma, Cong; Fang, Ping; Zhang, Xiu-Jie; Mei, Tian-Sheng; Journal of the Na American Chemical Society; vol. 139; nb. 8; (2017); p. 3293 - 3298, View in Reaxys

80/365

2017-08-01 06:49:42

NaB; NaBu

Patent; The Scripps Research Institute; Zhu, Saiyong; Ding, Sheng; (45 pag.); US9315779; (2016); (B2) English, View in Reaxys

Salvia, Marie-Virginie; Ramadori, Federico; Springhetti, Sara; Diez-Castellnou, Marta; Perrone, Barbara; Rastrelli, Federico; Mancin, Fabrizio; Journal of the American Chemical Society; vol. 137; nb. 2; (2015); p. 886 - 892, View in Reaxys

Patent; THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN; LOTHIAN HEALTH BOARD; DOCHERTY, Kevin; DOCHERTY, Hilary, Margaret; MARQUES DE LIMA, Maria, Joao; MUIR, Kenneth, Ross; CASEY, John, Joseph; (58 pag.); WO2015/173576; (2015); (A1) English, View in Reaxys

But

Yan, Hui; Ajuwon, Kolapo M.; PLoS ONE; vol. 10; nb. 12; (2015); Art.No: E0145940, View in Reaxys

Liu, Chi-Hsien; Huang, Hsin-Ying; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 4; (2013); p. 419 425, View in Reaxys

Patent; THE JOHNS HOPKINS UNIVERSITY; WO2006/127977; (2006); (A1) English, View in Reaxys

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 - 406, View in Reaxys

1A, R1=C3H7

Kunishima, Munetaka; Imada, Hiroko; Kikuchi, Kanako; Hioki, Kazuhito; Nishida, Jin; Tani, Shohei; Angewandte Chemie - International Edition; vol. 44; nb. 44; (2005); p. 7254 - 7257, View in Reaxys

Du, Jinfa; Watanabe, Kyoichi A.; Synthetic Communications; vol. 34; nb. 11; (2004); p. 1925 - 1930, View in Reaxys

NaBu

Xia, Zuping; Wiebe, Leonard I.; Miller, Gerald G.; Knaus, Edward E.; Archiv der Pharmazie; vol. 332; nb. 8; (1999); p. 286 - 294, View in Reaxys; Okamura, Takayuki; Gohda, Eiichi; Kohge, Takashi; Yamamoto, Itaru; Biological and Pharmaceutical Bulletin; vol. 22; nb. 12; (1999); p. 1288 - 1292, View in Reaxys; McRae; Patterson; Origlia-Luster; Sorenson; Woolley; Journal of Chemical Thermodynamics; vol. 35; nb. 2; (2003); p. 301 - 329, View in Reaxys

run 13

Brinchi; Germani; Savelli; Tetrahedron Letters; vol. 44; nb. 10; (2003); p. 2027 - 2029, View in Reaxys

but

Mikkelsen, Idun Merete; Huseby, Nils-Erik; Visvikis, Athanase; Moens, Ugo; Biochemical Pharmacology; vol. 64; nb. 2; (2002); p. 307 - 315, View in Reaxys

C3-CO2(-)

Kano, Koji; Kitae, Takashi; Shimofuri, Yoshiaki; Tanaka, Norihiro; Mineta, Yuki; Chemistry - A European Journal; vol. 6; nb. 15; (2000); p. 2705 - 2713, View in Reaxys

Nair, Ranjeet V.; Patil, Prashant N.; Salunkhe, Manikrao M.; Synthetic Communications; vol. 29; nb. 15; (1999); p. 2559 - 2566, View in Reaxys

Cho, Chan Sik; Baek, Dong Yeol; Shim, Sang Chul; Journal of Heterocyclic Chemistry; vol. 36; nb. 1; (1999); p. 289 - 291, View in Reaxys

NaBut

Diener; Scharrer; Experimental Physiology; vol. 80; nb. 3; (1995); p. 411 - 428, View in Reaxys

Huang; Dredar; Manneh; Blankenship; Fries; Journal of medicinal chemistry; vol. 35; nb. 13; (1992); p. 2414 - 2418, View in Reaxys

H(CH2)nCOONa n=3

Tamaki, Kunio; Ohara, Yoko; Watanabe, Sumiko; Bulletin of the Chemical Society of Japan; vol. 62; nb. 8; (1989); p. 2497 - 2501, View in Reaxys

C4H7O2Na

Heatley, Frank; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 82; (1986); p. 255 - 262, View in Reaxys

Pr%n&CO2Na

Nakamura, Shigeaki; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1983); p. 1 - 4, View in Reaxys

R2COONa, R2=C3H7

Braun, Dietrich; Jakobi, Rolf; Monatshefte fuer Chemie; vol. 113; (1982); p. 1403 - 1414, View in Reaxys

Table 2, entry 6

Pointud; Juillard; Journal of the Chemical Society Faraday Transactions I; vol. 77; nb. 1; (1981); p. 1 - 8, View in Reaxys

CH3(CH2)2COONa

Anacker, E. W.; Underwood, A. L.; Journal of Physical Chemistry; vol. 85; nb. 17; (1981); p. 2463 - 2466, View in Reaxys

Patent; Bayer AG; DE2214057; (1973) German; Chem.Abstr.; vol. 80; nb. 3282; (1974), View in Reaxys

NaC4

Oedberg et al.; Journal of Colloid and Interface Science; vol. 41; (1972); p. 298, View in Reaxys

Patent-Specific Data (3) Prophetic ComLocation in Patent References pound

81/365

2017-08-01 06:49:42

Page/Page column prophetic catalyst

Patent; SHANGHAI TECHWELL BIOPHARMACEUTICAL CO., LTD.; Jiao, Guangjun; Liu, Shidong; He, Bingming; Tang, Zhijun; Ji, Xiaoming; US2014/114049; (2014); (A1) English, View in Reaxys Patent; Childress, R. Shawn; McIntyre, James L.; US2006/235221; (2006); (A1) English, View in Reaxys Patent; UNIVERSITY OF EAST ANGLIA; WO2006/18657; (2006); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Highest Clinical Phase (1) Highest Clinical Phase Phase II Melting Point (3) 1 of 3

Melting Point [°C]

252

Bonekamp, J. E.; Artaki, I.; Phillips, M. L.; Plesko, S.; Jonas, J.; Journal of Physical Chemistry; vol. 87; nb. 24; (1983); p. 4991 - 4995, View in Reaxys 2 of 3

Melting Point [°C]

244.5 - 246

Comment (Melting Point)

schmilzt zu einer anisotropen Fluessigkeit, die bei 274-279grad klar wird.

Symons; Buswell; Industrial and Engineering Chemistry; vol. 24; (1932); p. 460, View in Reaxys 3 of 3

Comment (Melting Point)

Ist ungefaehr zwischen 210grad und 310grad krystallinisch-fluessig.

Vorlaender; Chemische Berichte; vol. 43; (1910); p. 3122,3132, View in Reaxys; Vorlaender; Huth; Zeitschrift fuer Physikalische Chemie, Stoechiometrie und Verwandtschaftslehre; vol. 75; (1911); p. 642, View in Reaxys Density (2) 1 of 2

Density [g·cm-3]

1.2067

Comment (Density)

Solid

Huang, Qiang; Meng, Qingyi; Ban, Chunlan; Zhang, Rui; Gao, Yingyu; Russian Journal of Physical Chemistry A; vol. 90; nb. 8; (2016); p. 1552 - 1556, View in Reaxys 2 of 2

Density [g·cm-3]

1.324

Reference Temperature [°C]

Measurement Temperature [°C]

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys Adsorption (MCS) (6) 1 of 6

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

methanol

Partner (Adsorption (MCS))

charcoal

Henstock; Journal of the American Chemical Society; vol. 61; (1939); p. 672, View in Reaxys

82/365

2017-08-01 06:49:42

2 of 6

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

methanol

Partner (Adsorption (MCS))

soot

Henstock; Journal of the American Chemical Society; vol. 61; (1939); p. 672, View in Reaxys 3 of 6

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

methanol

Partner (Adsorption (MCS))

kieselguhr

Henstock; Journal of the American Chemical Society; vol. 61; (1939); p. 672, View in Reaxys 4 of 6

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

methanol

Partner (Adsorption (MCS))

kaolin

Henstock; Journal of the American Chemical Society; vol. 61; (1939); p. 672, View in Reaxys 5 of 6

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

H2O

Partner (Adsorption (MCS))

coal

Ito; Bulletin of the Agricultural Chemical Society of Japan; vol. 13; (1937); p. 18; Chem. Zentralbl.; vol. 108; nb. II; (1937); p. 4306, View in Reaxys 6 of 6

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

H2O

Partner (Adsorption (MCS))

silicic acid-gel

Bartell; Fu; Journal of Physical Chemistry; vol. 33; (1929); p. 680, View in Reaxys Association (MCS) (7) 1 of 7

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

dimethylsulfoxide-d6

Comment (Association (MCS))

diagram

Partner (Association (MCS))

C64H88N5O12P

Consoli, Grazia M.L.; Granata, Giuseppe; Galante, Eva; Cunsolo, Francesca; Geraci, Corrada; Tetrahedron Letters; vol. 47; nb. 19; (2006); p. 3245 - 3249, View in Reaxys 2 of 7

Description (Association Enthalpy of association (MCS)) Solvent (Association (MCS))

H2O

83/365

2017-08-01 06:49:42

Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

alpha cyclodextrin

Buschmann, Hans-Juergen; Schollmeyer, Eckhard; Journal of Solution Chemistry; vol. 34; nb. 6; (2005); p. 731 737, View in Reaxys 3 of 7

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

H2O

Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

alpha cyclodextrin

Buschmann, Hans-Juergen; Schollmeyer, Eckhard; Journal of Solution Chemistry; vol. 34; nb. 6; (2005); p. 731 737, View in Reaxys 4 of 7

Description (Association Further physical properties of the complex (MCS)) Temperature (Association (MCS)) [°C]

5 - 95

Pressure (Association (MCS)) [Torr]

2625.21

Comment (Association (MCS))

concentration dependence. Object(s) of Study: temperature dependence

Partner (Association (MCS))

H2O

McRae; Patterson; Origlia-Luster; Sorenson; Woolley; Journal of Chemical Thermodynamics; vol. 35; nb. 2; (2003); p. 301 - 329, View in Reaxys 5 of 7

Description (Association Formation constant of a complex (MCS)) Solvent (Association (MCS))

dimethylsulfoxide-d6

Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

β-CD

Kano, Koji; Tanaka, Norihiro; Negi, Shigeru; European Journal of Organic Chemistry; nb. 19; (2001); p. 3689 3694, View in Reaxys 6 of 7

Description (Association IR spectrum of the complex (MCS)) Partner (Association (MCS))

SO2Cl2

Nakamura, Shigeaki; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1983); p. 1 - 4, View in Reaxys 7 of 7

Description (Association Further physical properties of the complex (MCS)) Solvent (Association (MCS))

H2O

Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

Trimethyldecylammonium bromide

84/365

2017-08-01 06:49:42

Anacker, E. W.; Underwood, A. L.; Journal of Physical Chemistry; vol. 85; nb. 17; (1981); p. 2463 - 2466, View in Reaxys Boundary Surface Phenomena (MCS) (14) 1 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

cetyltrimethylammonim bromide

Sinha, Sujata; Dogra, Arti; Jain, Nirmesh; Bahadur; Indian Journal of Chemistry - Section A Inorganic, Physical, Theoretical and Analytical Chemistry; vol. 37; nb. 2; (1998); p. 118 - 124, View in Reaxys 2 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Comment (Boundary Surface Phenomena (MCS))

bei verschiedenem pH.

Ito; Bulletin of the Agricultural Chemical Society of Japan; vol. 13; (1937); p. 18; Chem. Zentralbl.; vol. 108; nb. II; (1937); p. 4306, View in Reaxys 3 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Godbole; Sadgopal; Kolloid-Zeitschrift; vol. 75; (1936); p. 194, View in Reaxys 4 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

NaCl

Godbole; Sadgopal; Kolloid-Zeitschrift; vol. 75; (1936); p. 194, View in Reaxys 5 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

85/365

2017-08-01 06:49:42

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

glycerol

Godbole; Sadgopal; Kolloid-Zeitschrift; vol. 75; (1936); p. 194, View in Reaxys 6 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Comment (Boundary Surface Phenomena (MCS))

bei verschiedenen Temperaturen.

Lottermoser; Baumguertel; Transactions of the Faraday Society; Koll.Beih.; vol. 41; (1935); p. 203,80, View in Reaxys 7 of 14

Description (Boundary Surface Phenomena (MCS))

Interfacial tension

Comment (Boundary Surface Phenomena (MCS))

von wss.Loesungen gegen Paraffinoel bei 20grad und 80grad.

Lottermoser; Winter; Kolloid-Zeitschrift; vol. 66; (1934); p. 283, View in Reaxys 8 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys; Lascaray; Kolloid-Zeitschrift; vol. 34; p. 75; Chem. Zentralbl.; vol. 95; nb. I; (1924); p. 2413, View in Reaxys 9 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

nitrobenzene

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys 10 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

86/365

2017-08-01 06:49:42

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

aniline

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys 11 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys 12 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O; aniline

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys 13 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O; nitrobenzene

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys 14 of 14

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

0 - 50

Morgan; Mc Kirahan; Journal of the American Chemical Society; vol. 35; (1913); p. 1762, View in Reaxys Conformation (1) Object of Investi- References gation Conformation

Heatley, Frank; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 82; (1986); p. 255 - 262, View in Reaxys

Crystal Phase (1) Description (Crys- Comment (Crystal References tal Phase) Phase) Crystal structure determination

Roentgendiagram.

Hanawalt; Rinn; Frevel; Industrial and Engineering Chemistry, Analytical Edition; vol. 10; (1938); p. 495, View in Reaxys

Dielectric Constant (1)

87/365

2017-08-01 06:49:42

Dielectric Constant

Frequency (Dielectric Constant) [Hz]

Temperature (Die- References lectric Constant) [°C]

3.82

3E+06

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys

Electrical Data (4) 1 of 4

Description (Electrical Data)

Electrical conductivity

Comment (Electrical Da- in Wasser bei 25grad. ta) Dippy; Journal of the Chemical Society; (1938); p. 1226,1227, View in Reaxys 2 of 4

Description (Electrical Data)

Electrical conductivity

Comment (Electrical Da- in waessrigen und methylalkoholischen Loesungen. ta) Lifschitz; Beck; Helvetica Chimica Acta; vol. 2; (1919); p. 142, View in Reaxys 3 of 4

Description (Electrical Data)

Electrical conductivity

Comment (Electrical Da- in aethylalkoh.Loesung. ta) Dhar; Bhattacharyya; Zeitschrift fuer Anorganische und Allgemeine Chemie; vol. 82; (1913); p. 359, View in Reaxys 4 of 4

Description (Electrical Data)

Electrical conductivity

Comment (Electrical Da- sehr verduennter waessriger Loesungen zwischen 0grad und 35grad. ta) White; Jones; American Chemical Journal; vol. 44; (1910); p. 182, View in Reaxys Electrochemical Behaviour (1) Description (Elec- Comment (Electrochemical Betrochemical Behaviour) haviour) pH of aqueous solutions

(0.015-2.0 m).

References

v.Kuthy; Biochemische Zeitschrift; vol. 244; (1932); p. 323, View in Reaxys

Energy Data (MCS) (4) 1 of 4

Description (Energy Data (MCS))

Heat capacity Cp

Temperature (Energy Data (MCS)) [°C]

5 - 120

Pressure (Energy Data (MCS)) [Torr]

2625.21

Comment (Energy Data (MCS))

concentration dependence. Object(s) of Study: temperature dependence

Partner (Energy Data (MCS))

H2O

McRae; Patterson; Origlia-Luster; Sorenson; Woolley; Journal of Chemical Thermodynamics; vol. 35; nb. 2; (2003); p. 301 - 329, View in Reaxys 2 of 4

Description (Energy Data (MCS))

Enthalpy of solution

Comment (Energy Data (MCS))

H2O

Snell; Greyson; Journal of Physical Chemistry; vol. 74; (1970); p. 2148, View in Reaxys 3 of 4

Description (Energy Data (MCS))

Enthalpy of solution

88/365

2017-08-01 06:49:42

Comment (Energy Data (MCS))

D2O

Snell; Greyson; Journal of Physical Chemistry; vol. 74; (1970); p. 2148, View in Reaxys 4 of 4

Description (Energy Data (MCS))

Thermodynamic properties of system with

Comment (Energy Data (MCS))

Salzuebertragung D2O -> H2O bei 25grad: ΔH, EMF, ΔF, ΔS

Snell; Greyson; Journal of Physical Chemistry; vol. 74; (1970); p. 2148, View in Reaxys Liquid Phase (1) Description (Liquid Phase) Self-association in solution

Comment (Liquid Phase)

References

in Wasser, Wasser-MethanolGemischen, Wasser-Propan-1-ol-Gemischen und Wasser-Butan-1-olGemischen.

Bose; Misra; Kolloid-Zeitschrift; vol. 139; (1954); p. 163,165; Kolloid-Zeitschrift; vol. 163; (1959); p. 18, View in Reaxys

Liquid/Liquid Systems (MCS) (1) 1 of 1

Description (Liquid/ Liquid Systems (MCS))

Distribution between solvent 1 + 2

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Partner (Liquid/Liquid Systems (MCS))

octanol; Krebs improved Ringer solution

Kreydiyyeh; Bitar; Bikhazi; Journal of Pharmaceutical Sciences; vol. 79; nb. 6; (1990); p. 494 - 499, View in Reaxys Liquid/Solid Systems (MCS) (17) 1 of 17

Description (Liquid/Solid Eutectic Systems (MCS)) Temperature (Liquid/ Solid Systems (MCS)) [°C]

151.9

Partner (Liquid/Solid Systems (MCS))

barium n-butanoate

Mirnaya; Polishchuk; Bereznitski; Ferloni; Journal of Chemical and Engineering Data; vol. 41; nb. 6; (1996); p. 1337 - 1339, View in Reaxys 2 of 17

Description (Liquid/Solid Melting diagram Systems (MCS)) Temperature (Liquid/ Solid Systems (MCS)) [°C]

99.9 - 323.9

Partner (Liquid/Solid Systems (MCS))

barium n-butanoate

Mirnaya; Polishchuk; Bereznitski; Ferloni; Journal of Chemical and Engineering Data; vol. 41; nb. 6; (1996); p. 1337 - 1339, View in Reaxys 3 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

lithium nitrate

Zindrik; Sokolow; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1728,1729,1730;engl.Ausg.S.1775, View in Reaxys 4 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS))

89/365

2017-08-01 06:49:42

Comment (Liquid/Solid Systems (MCS))

Verbindung 3:1(?).

Partner (Liquid/Solid Systems (MCS))

sodium nitrate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1150;engl.Ausg.S.1145, View in Reaxys; Dmitrewskaja; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 2007,2009,2010;engl.Ausg.S.2046, View in Reaxys 5 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

potassium nitrate

Dmitrewskaja; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 2007,2009,2010;engl.Ausg.S.2046, View in Reaxys 6 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

lithium butyrate

Zindrik; Sokolow; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1728,1729,1730;engl.Ausg.S.1775, View in Reaxys; Sokolow; Potschtakowa; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1693,1695; engl. Ausg. S. 1741, 1742, View in Reaxys 7 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

potassium n-butyrate

Dmitrewskaja; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 2007,2009,2010;engl.Ausg.S.2046, View in Reaxys 8 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

potassium thioacyanate

Sokolow; Potschtakowa; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1693,1695; engl. Ausg. S. 1741, 1742, View in Reaxys 9 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 3:1.

Partner (Liquid/Solid Systems (MCS))

sodium nitrite

Sokolow; Zhurnal Obshchei Khimii; vol. 27; (1957); p. 840;engl.Ausg.S.917, View in Reaxys 10 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 3:1.

Partner (Liquid/Solid Systems (MCS))

sodium formate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 11 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 2:3.

Partner (Liquid/Solid Systems (MCS))

sodium acetate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 12 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS))

90/365

2017-08-01 06:49:42

Partner (Liquid/Solid Systems (MCS))

isobutyric acid sodium salt

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 13 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium isovalerate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 14 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 4:1.

Partner (Liquid/Solid Systems (MCS))

sodium caproate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 15 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 3:2.

Partner (Liquid/Solid Systems (MCS))

sodium stearate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 16 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium benzoate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1581; engl. Ausg. S. 1567, View in Reaxys 17 of 17

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium thiocyanate

Sokolow; Zhurnal Obshchei Khimii; vol. 24; (1954); p. 1150;engl.Ausg.S.1145, View in Reaxys Liquid/Vapour Systems (MCS) (2) 1 of 2

Description (Liquid/ Critical data for mixtures Vapour Systems (MCS)) Solvent (Liquid/Vapour Systems (MCS))

H2O

Temperature (Liquid/ 40 Vapour Systems (MCS)) [°C] Partner (Liquid/Vapour Systems (MCS))

cetyltrimethylammonim bromide

Description (Liquid/ Activity coefficients of the components in the mixture Vapour Systems (MCS)) Solvent (Liquid/Vapour Systems (MCS))

H2O

Temperature (Liquid/ 25 Vapour Systems (MCS)) [°C]

91/365

2017-08-01 06:49:42

Comment (Liquid/ aus dem Dampfdruck ermittelt. Vapour Systems (MCS)) Smith; Robinson; Transactions of the Faraday Society; vol. 28; (1942); p. 70,76, View in Reaxys Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -61.6

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys

Mechanical & Physical Properties (MCS) (2) 1 of 2

Description (Mechanical & Physical Properties (MCS))

Adiabatic compressibility

Temperature (Mechanical & Physical Properties (MCS)) [°C]

25 - 55

Partner (Mechanical & Physical Properties (MCS))

water

Bhowmik, S.; Mohanty, R. K.; Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical; vol. 25; nb. 5; (1986); p. 416 - 419, View in Reaxys 2 of 2

Description (Mechanical & Physical Properties (MCS))

Partial molal volume

Temperature (Mechanical & Physical Properties (MCS)) [°C]

25 - 55

Partner (Mechanical & Physical Properties (MCS))

H2O

Pointud; Juillard; Journal of the Chemical Society Faraday Transactions I; vol. 77; nb. 1; (1981); p. 1 - 8, View in Reaxys Comment (Optics)

References

Mechanical birefringence

einer 47prozenti- Vorlaender; Kirchner; Zeitschrift fuer Physikalische Chemie, Abteilung A: Chemische gen wss.Loesung. Thermodynamik, Kinetik, Elektrochemie, Eigenschaftslehre; vol. 152; (1931); p. 52, View in Reaxys

Natural birefringence

Doppelbrechung einer rotierenden waessrigen Loesung.

Vorlaender; Walter; Zeitschrift fuer Physikalische Chemie, Stoechiometrie und Verwandtschaftslehre; vol. 118; (1925); p. 10; Phys.Z.; vol. 25; p. 572; Chem. Zentralbl.; vol. 96; nb. I; (1925); p. 617, View in Reaxys

Solubility (MCS) (6) 1 of 6

Solubility [g·l-1]

100

Saturation

in pure solvent

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

water

92/365

2017-08-01 06:49:42

Gurka, András A.; Szőri, Kornél; Bartók, Mihály; London, Gábor; Tetrahedron Asymmetry; vol. 27; nb. 19; (2016); p. 936 - 942, View in Reaxys 2 of 6

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

methanol

Comment (Solubility (MCS))

100 g solvent dissolves. 15.31 g Substance.

Henstock; Journal of the Chemical Society; (1934); p. 1341, View in Reaxys 3 of 6

Temperature (Solubility (MCS)) [°C]

68.2

Solvent (Solubility (MCS))

methanol

Comment (Solubility (MCS))

100 g solvent dissolves. 20.70 g Substance.

Henstock; Journal of the Chemical Society; (1934); p. 1341, View in Reaxys 4 of 6

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

acetone

Comment (Solubility (MCS))

100 g solvent dissolves. 0.14 g Substance.

Henstock; Journal of the Chemical Society; (1934); p. 1341, View in Reaxys 5 of 6

Solvent (Solubility (MCS))

pentan-1-ol

Comment (Solubility (MCS))

Solubility :0.1 percent.in boiling solvent.

Holzmann; Archiv der Pharmazie (Weinheim, Germany); vol. 236; (1898); p. 433, View in Reaxys 6 of 6

Solvent (Solubility (MCS))

acetone

Comment (Solubility (MCS))

Solubility :0.4 percent.in boiling solvent.

Holzmann; Archiv der Pharmazie (Weinheim, Germany); vol. 236; (1898); p. 433, View in Reaxys Solution Behaviour (MCS) (12) 1 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Partner (Solution Behaviour (MCS))

octanol

Winsor; Transactions of the Faraday Society; vol. 44; (1948); p. 391 - 393; Chem.Abstr.; (1949); p. 466, View in Reaxys 2 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Partner (Solution Behaviour (MCS))

digitoxin

de Kuthy; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 32; (1935); p. 407, View in Reaxys 3 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

93/365

2017-08-01 06:49:42

Solvent (Solution Behaviour (MCS))

H2O

Partner (Solution Behaviour (MCS))

cholesterol

de Kuthy; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 32; (1935); p. 407, View in Reaxys 4 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Partner (Solution Behaviour (MCS))

calcium phosphate

de Kuthy; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 32; (1935); p. 407, View in Reaxys 5 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Partner (Solution Behaviour (MCS))

calcium(II) oxalate

de Kuthy; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 32; (1935); p. 407, View in Reaxys 6 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Temperature (Solution Behaviour (MCS)) [°C]

Partner (Solution Behaviour (MCS))

i-Amyl alcohol

Traube; Schoening; Weber; Chemische Berichte; vol. 60; (1927); p. 1811, View in Reaxys 7 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Temperature (Solution Behaviour (MCS)) [°C]

Partner (Solution Behaviour (MCS))

ethyl acetate

Traube; Schoening; Weber; Chemische Berichte; vol. 60; (1927); p. 1811, View in Reaxys 8 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Temperature (Solution Behaviour (MCS)) [°C]

Partner (Solution Behaviour (MCS))

aniline

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys; Traube; Schoening; Weber; Chemische Berichte; vol. 60; (1927); p. 1811, View in Reaxys 9 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

94/365

2017-08-01 06:49:42

Temperature (Solution Behaviour (MCS)) [°C]

Partner (Solution Behaviour (MCS))

metaboric acid

Dhar; Zeitschrift fuer Anorganische und Allgemeine Chemie; vol. 153; (1926); p. 329, View in Reaxys 10 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Temperature (Solution Behaviour (MCS)) [°C]

Partner (Solution Behaviour (MCS))

arsenous acid

Dhar; Zeitschrift fuer Anorganische und Allgemeine Chemie; vol. 153; (1926); p. 329, View in Reaxys 11 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Solvent (Solution Behaviour (MCS))

H2O

Temperature (Solution Behaviour (MCS)) [°C]

Partner (Solution Behaviour (MCS))

nitrobenzene

v.Euler; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 23; (1917); p. 195, View in Reaxys 12 of 12

Description (Solution Behaviour (MCS))

Dissolving capacity

Partner (Solution Behaviour (MCS))

carbon dioxide

Dhar; Datta; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 19; (1913); p. 407, View in Reaxys Transition Point(s) of Liquid Modification(s) (5) Temperature Change of Modifi- References (Transition cation Point(s) of Liquid Modification(s)) [°C] 324

From smectic to isotropic

Bonekamp, J. E.; Artaki, I.; Phillips, M. L.; Plesko, S.; Jonas, J.; Journal of Physical Chemistry; vol. 87; nb. 24; (1983); p. 4991 - 4995, View in Reaxys

264

From crystalline to -

Bonekamp; Hegemann; Jonas; Molecular crystals and liquid crystals; vol. 87; nb. 1-2; (1982); p. 13 - 28, View in Reaxys

333

From - to isotropic Bonekamp; Hegemann; Jonas; Molecular crystals and liquid crystals; vol. 87; nb. 1-2; (1982); p. 13 - 28, View in Reaxys

262

Transition point(1) Baum et al.; Wiss.Z.Univ.Halle-Wittenberg; vol. 19; nb. 5; (1970); p. 37, View in Reaxys from:crystalline to:smectic.

321

Transition point(1) Baum et al.; Wiss.Z.Univ.Halle-Wittenberg; vol. 19; nb. 5; (1970); p. 37, View in Reaxys from:smectic to:isotropic liquid (clearing point).

Transport Phenomena (MCS) (6) 1 of 6

Description (Transport Phenomena (MCS))

Viscosity

Temperature (Transport 25 Phenomena (MCS)) [°C]

95/365

2017-08-01 06:49:42

Comment (Transport Phenomena (MCS))

concentration dependence

Partner (Transport Phenomena (MCS))

rac-Ala-OH

Yan, Zhenning; Wang, Jianji; Lu, Jinsuo; Journal of Chemical and Engineering Data; vol. 46; nb. 2; (2001); p. 217 - 222, View in Reaxys 2 of 6

Description (Transport Phenomena (MCS))

Viscosity

Temperature (Transport 25 Phenomena (MCS)) [°C] Comment (Transport Phenomena (MCS))

concentration dependence

Partner (Transport Phenomena (MCS))

glycine

Yan, Zhenning; Wang, Jianji; Lu, Jinsuo; Journal of Chemical and Engineering Data; vol. 46; nb. 2; (2001); p. 217 - 222, View in Reaxys 3 of 6

Description (Transport Phenomena (MCS))

Viscosity

Temperature (Transport 25 Phenomena (MCS)) [°C] Comment (Transport Phenomena (MCS))

concentration dependence

Partner (Transport Phenomena (MCS))

D,L-valine

Yan, Zhenning; Wang, Jianji; Lu, Jinsuo; Journal of Chemical and Engineering Data; vol. 46; nb. 2; (2001); p. 217 - 222, View in Reaxys 4 of 6

Description (Transport Phenomena (MCS))

Viscosity

Temperature (Transport 25 Phenomena (MCS)) [°C] Comment (Transport Phenomena (MCS))

concentration dependence

Partner (Transport Phenomena (MCS))

2-aminobutanoic acid

Yan, Zhenning; Wang, Jianji; Lu, Jinsuo; Journal of Chemical and Engineering Data; vol. 46; nb. 2; (2001); p. 217 - 222, View in Reaxys 5 of 6

Description (Transport Phenomena (MCS))

Viscosity

Temperature (Transport 15 - 35 Phenomena (MCS)) [°C] Partner (Transport Phenomena (MCS))

water

Miyajima, Koichiro; Sawada, Masahiro; Nakagaki, Masayuki; Bulletin of the Chemical Society of Japan; vol. 55; nb. 10; (1982); p. 3101 - 3103, View in Reaxys; Tamaki, Kunio; Ohara, Yoko; Watanabe, Sumiko; Bulletin of the Chemical Society of Japan; vol. 62; nb. 8; (1989); p. 2497 - 2501, View in Reaxys 6 of 6

Description (Transport Phenomena (MCS))

Viscosity

Solvent (Transport Phenomena (MCS))

H2O

Hess; Philippoff; Kiessig; Kolloid-Zeitschrift; vol. 88; (1939); p. 43, View in Reaxys NMR Spectroscopy (14) 1 of 14

Description (NMR Spec- Spectrum troscopy)

96/365

2017-08-01 06:49:42

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- water-d2 scopy) Salvia, Marie-Virginie; Ramadori, Federico; Springhetti, Sara; Diez-Castellnou, Marta; Perrone, Barbara; Rastrelli, Federico; Mancin, Fabrizio; Journal of the American Chemical Society; vol. 137; nb. 2; (2015); p. 886 - 892, View in Reaxys 2 of 14

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- water-d2 scopy) Frequency (NMR Spectroscopy) [MHz]

400

Rangarajan; Sathyamoorthi; Velayutham; Noel; Singh; Brahma, Raju; Journal of Fluorine Chemistry; vol. 132; nb. 2; (2011); p. 107 - 113, View in Reaxys 3 of 14

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- water-d2 scopy) Frequency (NMR Spectroscopy) [MHz]

250.1

Ramezani, Mohammad; White, Robert L.; Tetrahedron Asymmetry; vol. 22; nb. 13; (2011); p. 1473 - 1478, View in Reaxys 4 of 14

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- water-d2 scopy) Frequency (NMR Spectroscopy) [MHz]

62.9

Ramezani, Mohammad; White, Robert L.; Tetrahedron Asymmetry; vol. 22; nb. 13; (2011); p. 1473 - 1478, View in Reaxys 5 of 14

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Bonekamp, J. E.; Eguchi, T.; Plesko, S.; Jonas, J.; Journal of Chemical Physics; vol. 79; nb. 3; (1983); p. 1203 1210, View in Reaxys; Briggs, Andrew D.; Camplo, Michel; Freeman, Sally; Lundstroem, Jan; Pring, Brian G.; Tetrahedron; vol. 52; nb. 47; (1996); p. 14937 - 14950, View in Reaxys 6 of 14

Description (NMR Spec- Spin-spin coupling constants troscopy) Comment (NMR Spectroscopy)

1H-1H

Briggs, Andrew D.; Camplo, Michel; Freeman, Sally; Lundstroem, Jan; Pring, Brian G.; Tetrahedron; vol. 52; nb. 47; (1996); p. 14937 - 14950, View in Reaxys 7 of 14

Description (NMR Spec- Chemical shifts troscopy)

97/365

2017-08-01 06:49:42

Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- D2O scopy) Temperature (NMR Spectroscopy) [°C]

Heatley, Frank; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 82; (1986); p. 255 - 262, View in Reaxys 8 of 14

Description (NMR Spec- Spin-spin coupling constants troscopy) Solvents (NMR Spectro- D2O scopy) Temperature (NMR Spectroscopy) [°C]

Comment (NMR Spectroscopy)

1H-1H.

Heatley, Frank; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 82; (1986); p. 255 - 262, View in Reaxys 9 of 14

Description (NMR Spec- Spin-spin coupling constants troscopy) Solvents (NMR Spectro- D2O scopy) Temperature (NMR Spectroscopy) [°C]

Comment (NMR Spectroscopy)

1H-13C.

Heatley, Frank; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 82; (1986); p. 255 - 262, View in Reaxys 10 of 14

Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)

23Na

Temperature (NMR Spectroscopy) [°C]

312.4 - 337.3

Bonekamp, J. E.; Eguchi, T.; Plesko, S.; Jonas, J.; Journal of Chemical Physics; vol. 79; nb. 3; (1983); p. 1203 1210, View in Reaxys 11 of 14

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

Solvents (NMR Spectro- D2O scopy) Kondo, Satoshi; Nagai, Kiyofumi; Ouchi, Akira; Bulletin of the Chemical Society of Japan; vol. 56; nb. 4; (1983); p. 1237 - 1238, View in Reaxys 12 of 14

Description (NMR Spec- NMR in liquid-crystal phase troscopy) Bonekamp, J. E.; Artaki, I.; Phillips, M. L.; Plesko, S.; Jonas, J.; Journal of Physical Chemistry; vol. 87; nb. 24; (1983); p. 4991 - 4995, View in Reaxys

13 of 14

Description (NMR Spec- Spin-lattice relaxation time (T1) troscopy) Bonekamp, J. E.; Artaki, I.; Phillips, M. L.; Plesko, S.; Jonas, J.; Journal of Physical Chemistry; vol. 87; nb. 24; (1983); p. 4991 - 4995, View in Reaxys; Bonekamp, J. E.; Eguchi, T.; Plesko, S.; Jonas, J.; Journal of Chemical Physics; vol. 79; nb. 3; (1983); p. 1203 - 1210, View in Reaxys

98/365

2017-08-01 06:49:42

14 of 14

Description (NMR Spec- NMR troscopy) Comment (NMR Spectroscopy)

1H: T(1)<D2O, D2O+NaCl; concentration dependence>

Oedberg et al.; Journal of Colloid and Interface Science; vol. 41; (1972); p. 298, View in Reaxys IR Spectroscopy (6) 1 of 6

Description (IR Spectroscopy)

Bands

Location

supporting information

Tabrizi, Leila; Chiniforoshan, Hossein; Journal of Organometallic Chemistry; vol. 818; (2016); p. 98 - 105, View in Reaxys 2 of 6

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

H2O

Comment (IR Spectroscopy)

2000 - 1000 cm**(-1)

Cabaniss, Stephen E.; McVey, Iain F.; Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy; vol. 51; (1995); p. 2384 - 2396, View in Reaxys 3 of 6

Description (IR Spectroscopy)

Spectrum

Comment (IR Spectroscopy)

1800 - 650 cm**(-1)

Chapman; Journal of the Chemical Society; (1958); p. 784,786, View in Reaxys 4 of 6

Description (IR Spectroscopy)

Spectrum

Comment (IR Spectroscopy)

1429 - 1111 cm**(-1)

Meiklejohn et al.; Analytical Chemistry; vol. 29; (1957); p. 329,333, View in Reaxys 5 of 6

Description (IR Spectroscopy)

Spectrum

Comment (IR Spectroscopy)

1429 - 667 cm**(-1)

Childers; Struthers; Analytical Chemistry; vol. 27; (1955); p. 737,738, View in Reaxys 6 of 6

Description (IR Spectroscopy)

Spectrum

Lenormant; Bulletin de la Societe Chimique de France; (1948); p. 33,38; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 228; (1949); p. 1861, View in Reaxys UV/VIS Spectroscopy (1) 1 of 1

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

H2O

Wright; Journal of the Chemical Society; vol. 103; (1913); p. 529; Journal of the Chemical Society; vol. 105; (1914); p. 670, View in Reaxys; Hantzsch; Scharf; Chemische Berichte; vol. 46; (1913); p. 3580, View in Reaxys; Leuthardt; Pfister; Helvetica Chimica Acta; vol. 16; (1933); p. 229, View in Reaxys NQR Spectroscopy (1) Description (NQR Nucleus (NQR Spectroscopy) Spectroscopy) Nuclear quadrupole coupling constants

23Na

References Bonekamp, J. E.; Artaki, I.; Phillips, M. L.; Plesko, S.; Jonas, J.; Journal of Physical Chemistry; vol. 87; nb. 24; (1983); p. 4991 - 4995, View in Reaxys

Other Spectroscopic Methods (1)

99/365

2017-08-01 06:49:42

Description (Other Spectroscopic Methods)

References

ESCA

Gerin, P.A.; Dengis, P.B.; Rouxhet, P.G.; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 92; nb. 5; (1995); p. 1043 - 1065, View in Reaxys

Use (734) Use Pattern

Location

References

Page/Page column 21

Patent; HANMI SCIENCE CO., LTD; Kim, Chang Hwan; Hong, Sung Kap; Lee, Byung Sun; Hong, Sung Hwan; Kwon, Se Chang; (13 pag.); US9243237; (2016); (B2) English, View in Reaxys

ingredient of a Page/Page colmedium for proumn 21 ducing human coagulation Factor VII using Chinese hamster ovarian carcinoma cell line transfected with pXOGC-FVII vector

Patent; HANMI SCIENCE CO., LTD; Kim, Chang Hwan; Hong, Sung Kap; Lee, Byung Sun; Hong, Sung Hwan; Kwon, Se Chang; (13 pag.); US9243237; (2016); (B2) English, View in Reaxys

Pharmaceuticals

Page/Page column 67; 69

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; JIANG, Guochun; DANDEKAR, Satya; (87 pag.); WO2016/22358; (2016); (A1) English, View in Reaxys

reactivation of a latent virus in a subject infected with cytomegalovirus (CMV)

Page/Page column 67; 69

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; JIANG, Guochun; DANDEKAR, Satya; (87 pag.); WO2016/22358; (2016); (A1) English, View in Reaxys

reactivation of a latent virus in a subject infected with adenovirus

Page/Page column 67; 69

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; JIANG, Guochun; DANDEKAR, Satya; (87 pag.); WO2016/22358; (2016); (A1) English, View in Reaxys

reactivation of a latent virus in a subject infected with human immunodeficiency virus (HIV)

Page/Page column 67; 69

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; JIANG, Guochun; DANDEKAR, Satya; (87 pag.); WO2016/22358; (2016); (A1) English, View in Reaxys

reactivation of a latent virus in a subject infected with the virus in comnination with ingenol-3-angelate (PEP005)

Page/Page column 67; 69

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; JIANG, Guochun; DANDEKAR, Satya; (87 pag.); WO2016/22358; (2016); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

histone deacetylase inhibitor (HDACi)

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

HDAC-inhibitor

Page/Page colPatent; Takara Bio Europe AB; Brolén, Gabriella; Edsbagge, Josefina; (95 pag.); umn title page; 27 US9394522; (2016); (B2) English, View in Reaxys

Pharmaceuticals

Page/Page colPatent; Takara Bio Europe AB; Brolén, Gabriella; Edsbagge, Josefina; (95 pag.); umn title page; 27 US9394522; (2016); (B2) English, View in Reaxys

Chemical processes/laboratory use

directing the difPage/Page colPatent; Takara Bio Europe AB; Brolén, Gabriella; Edsbagge, Josefina; (95 pag.); ferentiation of hu- umn title page; 27 US9394522; (2016); (B2) English, View in Reaxys man definitive endoderm cells into human hepatocyte-like cells

100/365

2017-08-01 06:49:42

Dravet's syndrome

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

attention deficit hyperactivity disorder

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

autism spectrum disorder

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

controlling hippo- Page/Page colcampal neural cir- umn 29-32 cuit hyperexcitability occurring in a neurological disease with combination of adenosine, an adenosine mimetic, an adenosine modulator, an adenosine transport inhibitor and an adenosine receptor agonist

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

disorder associated with epileptogenesis

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

febrile seizures

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

intractable epilep- Page/Page colsy umn 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

neurological disease

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

severe myoclonic epilepsy

Page/Page column 29-32

Patent; UNIVERSITY OF HOUSTON; ZIRBURKUS, Jokubas; ERIKSEN, Jason; GU, Feng; WO2014/28883; (2014); (A1) English, View in Reaxys

Alzheimer's disease

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Down syndrome

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Huntington's disease

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Multiple System Atrophy

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Parkinson's disease

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Progressive Supranuclear Palsy

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

amyotrophic later- Page/Page colal sclerosis umn 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

101/365

2017-08-01 06:49:42

diffuse Lewy body Page/Page coldisease umn 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

histone deacetylase (HDAC) inhibitor

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

increases the activity of DJ-1 protein

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

neurodegenerative disease

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

upregulates DJ-1 gene expression

Page/Page column 27

Patent; THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE; FREED, Curt, R.; ZHOU, Wenbo; WO2013/149091; (2013); (A1) English, View in Reaxys

Notch1 signaling pathway modulator; histone deacetylase (HDAC) inhibitor; Neuroendocrine (NE) hormone production inhibitor; hedgehog signaling pathway activity inhibitor; hASH1 activity inhibitor; HES1 expression reducer

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

Neuroendocrine (NE) tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

Medullary thyroid cancer (MTC)

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

gastrointestinal (GI) carcinoid cancer

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

carcinoid tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

gastroenteropancreatic tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

insulinomas

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

gastrinomas

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

glucagonomas

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

VIPomas

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

Verner Morrison syndrome

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

somatostatinomas

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

pituitary gland tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

melanoma tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

102/365

2017-08-01 06:49:42

acoustic neuroma tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

paraganglioma tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

pheochromocytoma tumor

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

extra-adrenal paragangliomas

Patent; Chen, Herbert; Kunnimalaiyaan, Muthusamy; US2008/45445; (2008); (A1) English, View in Reaxys

inducing apoptosis of a cancer cell; tumor, cancers and other neoplastic tissues growth inhibitor; histone deacetylase inhibitor (HDACi)

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Sarcoma

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

uretal cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Bladder cancer

Rectal cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Stomach cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Liver cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

kidney cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Endocrine cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Skin cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Melanoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Brain cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Central nervous system (CNS) cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

103/365

2017-08-01 06:49:42

Tumor

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Refractory solid tumor

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Neoplastic diseases

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

hematologic malignancies

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

lymphomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

non-hodgkin's lymphoma

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

multiple myelomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

osteosarcomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

angiosarcomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

fibrosarcomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

sarcomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

sinus tumors

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Ovarian cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Prostate cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

genitourinary cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Esophageal cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

gastrointestinal cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

small cell carcinoma

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

bronchioloalveolar carcinoma

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

104/365

2017-08-01 06:49:42

teratomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

pancreatic cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

eye cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

cervical cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

anal carcinomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

hepatocellular carcinomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

laryngeal cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

renal cell carcinomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

testicular cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

thyroid cancers

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

chondrosarcomsa

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

rhabdomyosarcomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Microbial infections

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

Infectious diseases

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys

histone deacetylase (HDAC) inhibitor; peroxisome proliferator activated factor γ2 (PPARγ2) gene modulator; SLUG protein activity modulator

Patent; UNIVERSIDAD DE SALAMANCA; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; WO2008/47235; (2008); (A2) English, View in Reaxys

Disorders associated with increased fat storage

Patent; UNIVERSIDAD DE SALAMANCA; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; WO2008/47235; (2008); (A2) English, View in Reaxys

Lipodystrophy

Patent; UNIVERSIDAD DE SALAMANCA; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; WO2008/47235; (2008); (A2) English, View in Reaxys

Disorders associated with de-

Patent; UNIVERSIDAD DE SALAMANCA; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; WO2008/47235; (2008); (A2) English, View in Reaxys

105/365

2017-08-01 06:49:42

creased fat storage histone deacetylase inhibitor (HDACi); non-selective histone deacetylase inhibitor (HDACi)

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

medullary thyroid carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

medulloblastoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

meningioma mesothelioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

myelomas

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

myxosarcoma neuroblastoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

neurofibrosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

oligodendroglioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

osteogenic sarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

epithelial ovarian cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

papillary carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

papillary adenocarcinomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

parathyroid tumors

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

pheochromocytoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

pinealoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

plasmacytomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

retinoblastoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

rhabdomyosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

sebaceous gland carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

seminoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Small lung cell carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Squamouscell carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Sweat gland carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

106/365

2017-08-01 06:49:42

Synvioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

uveal melanoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Wilm's tumor

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Myeloproliferative disease

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Refractory anemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Indolent lymphomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Low grade lymphomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Mantle cell lymphoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

acute promyelocytic leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

acute myeloideleukaemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

chronic myeloide leukaemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

chronic lymphatic leukaemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Neuroendocrine cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Metastasis

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Nausea

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Emesis

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Alopecia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Fatigue

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Anorexia

Patent; UNIVERSIDAD DE SALAMANCA; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; WO2008/47235; (2008); (A2) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Anhedonia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Depression

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Immunoeuppression

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Infection

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Breast cancer

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

107/365

2017-08-01 06:49:42

Ovarian cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Stage IV breast cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Rectal carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Endometrial cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

acute myeloid leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

thymus cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

brain cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

squamous cell cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

skin cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

eye cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Solid tumor

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Solid tumor cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Drug-resistant cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

malignant fibrous histiocytoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

malignant mesothelioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

malignant thymoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

tumors

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

leukemias

neoplasms

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

carcinomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

pancreatic cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

renal cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

myeloid leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

108/365

2017-08-01 06:49:42

glioblastoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

follicular lymphoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

pre-B acute leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

chronic lymphocytic B-leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

mesothelioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

small cell lung cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Hematologic cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

multiple myeloma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

acute leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

acute nonlymphocytic leukemia (ANLL)

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Hodgkin's lymphoma

cutaneous t-cell lymphoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

mantle cell lymphoma (MCL)

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Non-hematologic cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the head and neck

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the reproductive system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the gastro-intestinal system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the urinary system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancer of the upper digestive tract

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

renal cell carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

epithelial malignancies

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Premalignant cancers

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Premalignant tumors

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

actinic keratoses

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

109/365

2017-08-01 06:49:42

arsenic keratoses

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

xeroderma pigmentosum

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Bowen's disease

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

leukoplakias

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

metaplasias

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

dysplasias

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

papillomas of mucous membranes

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Papillomas of the mouth

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Papillomas of the tongue

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Papillomas of the pharynx

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Papillomas of the larynx

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

precancerous changes of the bronchial mucous membrane

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

dysplasias of the cervix uteri

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Chronic myelogenous leukemia (CML)

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

leukoplakias of the cervix uteri

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

vulval dystrophy

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

precancerous changes of the bladder

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

papillomas of the bladder

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

polyps of the intestinal tract

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Semi-malignant cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Semi-malignant tumor

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Malignant cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Malignant tumor

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

basal cell carcinomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

superficial bladder carcinomas

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

110/365

2017-08-01 06:49:42

colon cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

gastro-intestinal (GI) cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

uterine cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cervical cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

esophageal cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

stomach cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

laryngeal cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of oral cavity

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Cancers of the pharynx

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the respiratory system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of bones

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Cancers of the joints

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of soft tissue

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

skin cancers

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the genital system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the eye

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Cacners of the orbit

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the nervous system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the lymphatic system

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the endocrine system in combination with ERα+ ligand

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancer of the small intestine

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

anal cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

anorectal cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancer of the liver

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

111/365

2017-08-01 06:49:42

intrahepatic bile duct cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

gallbladder cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

pancreas cancer

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

biliary cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

digestive organ cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

bronchial cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancers of the respiratory organs

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

heart cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

melanoma

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

basal cell carcinoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

squamous cell carcinoma

non-epithelial skin cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

uterine corpus cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

vulvar cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

vaginal cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

female genital cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

testicular cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

penile cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

male genital cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

urinary bladder cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancer of the kidney

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

pelvic cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

urethral cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cancer of the genito-urinary organs

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

112/365

2017-08-01 06:49:42

thyroid cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

endocrine cancer

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

chronic lymphocytic leukemia

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

granulocytic cutaneous T-cell lymphoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

monocytic cutaneous T-cell lymphoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

adenocarcinoma

angiosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

astrocytoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

acoustic neuroma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

anaplastic astrocytoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

blastoglioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

chondrosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

choriocarcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

chordoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

craniopharyngioma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cutaneous melanoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

cystadenocarcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

endotheliosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

embryonal carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

ependymoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Ewing's tumor

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

epithelial carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

fibrosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

gastric cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

113/365

2017-08-01 06:49:42

genitourinary tract cancers

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

glioblastoma multiforme

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

hemangioblastoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

hepatocellular carcinoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

hepatoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

Kaposi's sarcoma

large cell carcinoma

leiomyosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

liposarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

lymphangiosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

lymphangioendotheliosarcoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys

prostate cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys; Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

bladder cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys; Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

lung cancer

Cognitive function

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Cognitive impairment

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Learning disability

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Increasing brain derived neurotrophic factor (BDNF) level

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Increasing brain derived neurotrophic factor (BDNF) activity

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Down's syndrome

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

114/365

2017-08-01 06:49:42

autism

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Rett's syndrome

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

nonsyndromic Xlinked mental retardation

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

fragile X syndrome

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Improving memory

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Autistic-like behavior

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Improving attention

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Hypersensitivity

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Mental retardation

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Cognitive disorders

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Symptoms of fragile X syndrome

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Cognitive deficit not associated with cell death

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Cognitive impairment associated with diseases

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Mental retardation associated with diseases

Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys

Proliferative disorder

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Cutaneous T-cell lymphoma (CTCL)

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Cancer

Lymphoma

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

non-Hodgkin's lymphoma

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Lung cancer

Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

115/365

2017-08-01 06:49:42

non-small cell lung cancer (NSCLC)

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

small cell lung cancer (SCLC)

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Leukemia

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

acute myelogenous leukemia (AML)

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

cardiovascular disorders

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

restenosis

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

cardiomyopathy

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

auto-immune disorders

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

glomerulonephritis

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

rheumatoid arthritis

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

dermatological disorders

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

psoriasis

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

anti-inflammatory

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

anti-fungal

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

antiparasitic

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

malaria

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

emphysema

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

alopecia

Mycosis fungoides

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Sezary syndrome

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

reticulum cell sarcoma of the-skin

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

acute lymphocytic leukemia (ALL)

Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

116/365

2017-08-01 06:49:42

chronic myelogenous leukemia (CML)

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

chronic lymphocytic leukemia (CLL)

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Testicular cancer

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

Colorectal cancer

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys

inhibitor of histone deacetylase

Patent; LifeScan, Inc.; EP1949916; (2008); (A1) English, View in Reaxys

chromatin-remodeling agent

Patent; LifeScan, Inc.; EP1949916; (2008); (A1) English, View in Reaxys

Spinal muscular atrophy (SMA)

Patent; Academia Sinica; US2008/187512; (2008); (A1) English, View in Reaxys

Spinal muscular atrophy (SMA)deficiency

Patent; Academia Sinica; US2008/187512; (2008); (A1) English, View in Reaxys

induces the differentiation of brushborder enterocytes, changes in the surface of microvilli and the secretion of mucin

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

inflammatory bowel diseases

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

colorectal cancer

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys; Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys; Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

gastrointestinal diseases

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Acute intestinal inflammations

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Chronic intestinal inflammations

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Short bowel syndrome

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Crohn's disease

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys; Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

ulcerative colitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys; Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

non-specific bowel inflammation following proctocolectomy with ileo-anal anastomosis

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

diversion colitis

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Colon cancer

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

117/365

2017-08-01 06:49:42

ulcerated colon inflammation

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Intestinal mucosa

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

intestinal mucosa Inflammation

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Intestinal mucosa ulcers

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Intestinal mucosa tumours

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Intestinal inflammation

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

ulcers bowel inflammations

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

ulcerations

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Tumors

Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

Inflammation

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys; Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys; Patent; NEREUS PHARMACEUTICALS, INC.; DANA-FARBER CANCER INSTITUTE; UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER; WO2008/124699; (2008); (A1) English, View in Reaxys; Patent; BIOLEK SP. Z O.O.; WO2008/91170; (2008); (A1) English, View in Reaxys

association with charge transfer complexes (CTCs)

Patent; GHISALBERTI, Carlo; WO2008/44099; (2008); (A1) English, View in Reaxys

histone deacetylase (HDAC) inhibitor

Patent; YAMANOUCHI PHARMACEUTICAL CO. LTD.; EP1547617; (2005); (A1) English, View in Reaxys; Patent; U.S. Department of Veterans Affairs; US2006/135612; (2006); (A1) English, View in Reaxys; Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys; Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys; Patent; Academia Sinica; US2008/187512; (2008); (A1) English, View in Reaxys; Patent; BERAND LIMITED; WO2008/90534; (2008); (A1) English, View in Reaxys

Obesity

Patent; UNIVERSIDAD DE SALAMANCA; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; WO2008/47235; (2008); (A2) English, View in Reaxys; Patent; BERAND LIMITED; WO2008/90534; (2008); (A1) English, View in Reaxys

Excessive weight gain

Patent; BERAND LIMITED; WO2008/90534; (2008); (A1) English, View in Reaxys

Inappropriate eating behaviours

Patent; BERAND LIMITED; WO2008/90534; (2008); (A1) English, View in Reaxys

Binge eating

Patent; BERAND LIMITED; WO2008/90534; (2008); (A1) English, View in Reaxys

Disease characterised by abnormal weight gain

Patent; BERAND LIMITED; WO2008/90534; (2008); (A1) English, View in Reaxys

histone deacetylase inhibitor

Patent; The Regents of the University of California; US2007/270462; (2007); (A1) English, View in Reaxys; Patent; UNIVERSITY OF ROCHESTER; WO2008/11113; (2008); (A2) English, View in Reaxys; Patent; The University of chicago; US2006/106049; (2006); (A1) English, View in Reaxys; Patent; THE REGENTS OF THE UNIVERSITY OF CALIFORNINA; WO2008/60375; (2008); (A2) English, View in Reaxys; Patent; UNIVERSITY OF MARYLAND, BALTIMORE; WO2008/154382; (2008); (A1) English, View in Reaxys

to sensitize hormone resistant cancer cells to hormonal therapy

Patent; UNIVERSITY OF MARYLAND, BALTIMORE; WO2008/154382; (2008); (A1) English, View in Reaxys

118/365

2017-08-01 06:49:42

osteoarthritis

Patent; YAMANOUCHI PHARMACEUTICAL CO. LTD.; EP1547617; (2005); (A1) English, View in Reaxys; Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

ovarian cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

Hodgkin's disease

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

vomiting

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys; Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Acaricidepharmaceutical composition for treating, preventing, or ameliorating the symptoms of Parkinson's disease

Patent; BodyBio, Inc.; US2007/4639; (2007); (A1) English, View in Reaxys

an histone deacetylase (HDAC) inhibitor

Patent; ANTROMED INC; US2007/21508; (2007); (A1) English, View in Reaxys

G1 phase arresting/cytostatic agent; reduce transcription of CCR5; potentiates antiviral activities (both coreceptor antagonist and antibody neutralization activities) of full length single chain vaccine complex (FLSC)

Patent; UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE; WO2007/11827; (2007); (A2) English, View in Reaxys

Antiviral drug

Patent; UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE; WO2007/11827; (2007); (A2) English, View in Reaxys

Immunodeficiency virus infection

Patent; UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE; WO2007/11827; (2007); (A2) English, View in Reaxys

HIV-1 infection

Patent; UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE; WO2007/11827; (2007); (A2) English, View in Reaxys

histone deacetylase 4 (HDAC4) modulator

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

genitourinary cancer

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

gastrointestinal cancer

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

epidermoid cancer

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

head and/or neck cancer

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

broader sense renal

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

brain or gastric cancer

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

119/365

2017-08-01 06:49:42

breast tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

epidermoid tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

epidermoid head and/or neck tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

mouth tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

lung tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

small cell or nonsmall cell lung tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

gastrointestinal tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

colorectal tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

genitourinary tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

prostate tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

hormone-refractory prostate tumor

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

proliferative disease

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

chronic myeloid leukemia (CML)

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

acute myelogenous leukaemia (AML)

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

hyperplasias

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

fibrosis

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

renal fibrosis

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

angiogenesis

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

atherosclerosis

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

stenosis

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

Non-small cell lung cancer (NSCLC)

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

Solid tumours

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

Melanomas

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

Squamous cell carcinomas

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

Prostate cancer

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

Lung cancers

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

anti-inflammatory disorders

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

120/365

2017-08-01 06:49:42

anti-fungal disorders

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

antiparasitic disorders

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

neuroblastoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys; Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys

deacetylase inhibitor (DI)

Patent; United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health; The Salk Institute for Biological Study; US7229963; (2007); (B2) English, View in Reaxys

disease associated with degeneration of muscle tissue

deficiency in myogenesis

muscular dystrophy

enhancing progenitor cell differentiation

histone deacetylase inhibitor (HDAI)

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/58992; (2007); (A2) English, View in Reaxys

HDAC6 modulating agent

Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/58992; (2007); (A2) English, View in Reaxys

deacetylase inhibitor

Patent; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE CHILDREN'S HOSPITAL OF PHILADELPHIA; WO2007/84775; (2007); (A2) English, View in Reaxys

inhibits deacetylation of histone proteins including H2A, H2B, H3 and H4 histone proteins

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Hemorrhagic shock

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

alleviates cellular and tissue damage associated with hemorrhagic shock

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Surgical procedures involving cardiopulmonary by-pass machine

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Organ transplantation

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Cardiac by-pass surgery

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Hemorrhage-associated conditions and symptoms

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Cellular injuries

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

121/365

2017-08-01 06:49:42

Hemorrhagic shock caused by penetrating or blunt trauma

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Hemorrhagic shock caused by gastrointestinal bleeding

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Hemorrhagic shock caused by bleeding associated with obstetrical procedure

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Cardiac by-pass surgery comprising atrial valve replacement

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

Cardiac by-pass surgery comprisig ventricle valve replacement

Patent; THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE; WO2007/117272; (2007); (A2) English, View in Reaxys

prostaglandin agonist

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Cyclo-oxygenase (COX)-related gastric injuries

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastrointestinal (GI) toxicity

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastritis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

peptic erosions

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

ulceration

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastric lesions

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastrointestinal (GI) bleeding

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

fever

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

arthritis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

asthma

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

bronchitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

menstrual cramps

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

tendinitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

bursitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

inflammatory disorders of the skin

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

122/365

2017-08-01 06:49:42

gastrointestinal conditions

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

vascular diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

migraine headaches

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

periarteritis nodosa

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

thyroiditis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

aplastic anemia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

sclerodoma

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

rheumatic fever

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

myasthenia gravis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

sarcoidosis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

nephrotic syndrome

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Behcet's syndrome

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

polymyositis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

hypersensitivity

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

conjunctivitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gingivitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

swelling occurring after injury

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

myocardial ischemia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

spondyloarthopathies

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gouty arthritis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

systemic lupus erythematosus

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

juvenile arthritis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

eczema

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

burns

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

dermatitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

inflammatory bowel syndrome

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

123/365

2017-08-01 06:49:42

irritable bowel syndrome

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

menstrual pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

low back pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

neck pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

skeletal pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

post-partum pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

headache

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain associated with migraine

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

toothache

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

sprains

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

strains

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

degenerative joint diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gout

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

ankylosing spondylitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

radiation injuries

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

corrosive chemical injuries

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

sunburns

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

bone fracture

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

immune diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

autoimmune diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

cellular neoplastic transformations

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

metastic tumor growth

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain following surgical procedures

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain following dental procedures

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastric lesion

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

ischemia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

124/365

2017-08-01 06:49:42

reperfusion

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

damage to the gastric mucosa

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

peptic erosion

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

inflammation-associated disorder

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

NSAID-associated diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

chronic pains

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

arthritis pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

neuropathic pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

post-operative pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

chronic lower back pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

cluster headaches

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

herpes neuralgia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

phantom limb pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

central pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

dental pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

opioid-resistant pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

visceral pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

surgical pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

bone injury pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain during labor and delivery

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain resulting from burns

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

sunburn

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

post partum pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

migraine

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

angina pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

genitourinary tract-related pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

125/365

2017-08-01 06:49:42

cystitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

nociceptive pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

nociception

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

diabetic neuropathy

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

fibromyalgia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain associated with somatoform disorders

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

arthritic pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

cancer pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

shoulder pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

back pain

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

tension-type headache

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

pain traditionally resistant to treatment with NSAIDs

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

atopic dermatitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

psoriatic arthropathy

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

post operative inflammation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

dental inflammation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Acute ocular inflammatory diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Chronic ocular inflammatory diseases

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

neurogenic inflammation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

diabetes

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

rhinitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

inflammation of sciatic nerves

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Inflammation of lumbar nerves

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastrointestinal processes

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

126/365

2017-08-01 06:49:42

ocular inflammation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

acute allergic response

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Acute joint inflammation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Chronic joint inflammation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

Early-forming diarrhea

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

late-forming diarrhea

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

flatulence

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

nausea

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

anorexia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

leukopenia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

anemia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

neutropenia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

asthenia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

abdominal cramping

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

loss of body weight

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

dehydration

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

dyspnea

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

insomnia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

dizziness

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

mucositis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

xerostomia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

kidney failure

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

inflammatory bowel disease

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

constipation

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

peptic ulcer

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

partial enteritis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

127/365

2017-08-01 06:49:42

diverticulitis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastrointestinal haemorrhagia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

regional enteritis

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

gastrointestinal (GI) lesion

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

coagulation disorders

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

hypoprothrombinemia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

hemophilia

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

bleeding problems

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

kidney disease

Patent; Pharmena North America Inc.; US2007/259861; (2007); (A1) English, View in Reaxys

neurological dysfunction

Patent; The Regents of the University of California; US2007/270462; (2007); (A1) English, View in Reaxys

Huntington's disease

Patent; The Regents of the University of California; US2007/270462; (2007); (A1) English, View in Reaxys

breast cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys; Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; WO2007/16532; (2007); (A2) English, View in Reaxys; Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

Antiproliferative agent

Page/Page column 3-4

Patent; ORCHID RESEARCH LABORATORIES LIMITED; WO2007/17728; (2007); (A2) English, View in Reaxys

Anti-tumor agent

Page/Page column 3-4

Patent; ORCHID RESEARCH LABORATORIES LIMITED; WO2007/17728; (2007); (A2) English, View in Reaxys

increasing histone acetylation; histone decaetylase (HDAC) inhibitor

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

neurodegenerative disorder

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

Huntington's disease (HD)

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

increase survival

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

neuroprotection

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

improve motor performance

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

improve gross brain weight

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

atrophy

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

striatal neuron atrophy

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

body weight loss

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

protecting neural cells

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys

128/365

2017-08-01 06:49:42

amyotrophic lateral sclerosis (ALS)

Patent; U.S. Department of Veterans Affairs; US2006/135612; (2006); (A1) English, View in Reaxys

pharmaceutical composition effective in reducing replication of HIV

Patent; University of Maryland Biotechnology Institute; US2006/154857; (2006); (A1) English, View in Reaxys

G1 phase arresting compound

Patent; University of Maryland Biotechnology Institute; US2006/154857; (2006); (A1) English, View in Reaxys

method for inducing increased levels of anti-HIV βchemokines and reducing HIV replication in activated lymphocytes

Patent; University of Maryland Biotechnology Institute; US2006/154857; (2006); (A1) English, View in Reaxys

maintaining viral control of an HIV infection

Patent; University of Maryland Biotechnology Institute; US2006/154857; (2006); (A1) English, View in Reaxys

Acute gastrointestinal distress

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Chronic gastrointestinal distress

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Lactrose intolerance

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Obstructive symptoms

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Diarrhea

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Mucositis

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Bleeding

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

weight loss

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Malnutrition

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Cachexia

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Cancer-related fatigue

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Chronic fatigue syndrome

Patent; Chung, Yih-Lin; Pui, Nam-Mew; US2006/229237; (2006); (A1) English, View in Reaxys

Treating bacterial infection

Patent; SANDOZ AG; WO2006/72577; (2006); (A1) English, View in Reaxys

inhibitor of PARP-3 activity

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

gliomas

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

Schwannoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

paraganlioma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

meningioma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

129/365

2017-08-01 06:49:42

adrenalcortical carcinoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

vascular cancer of various types

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

osteoblastic osteocarcinoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

uterine leiomyomas

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

salivary gland cancer

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

choroid plexus carcinoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

mammary cancer

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

megakaryoblastic leukemia

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

malignant melanoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

Karposi's sarcoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

moles dysplastic nevi

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

lipoma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

angioma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

dermatofibroma

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

keloids

Patent; Lahav, Ronit; Patterson, Paul H.; US2006/94676; (2006); (A1) English, View in Reaxys

histone deacetylase (HDAC) inhibitor; transcriptional derepressor; reducing or eliminating the repression of neurotransmitter receptor gene expression

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

onset of epilepsy

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

status epilepticus

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

brain injury

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

concussive injuries or penetrating head wounds

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

brain tumor

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

alcoholism

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

Alzheimer's disease

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys; Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

stroke

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

heart attack

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

130/365

2017-08-01 06:49:42

meningitis

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

AIDS

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

viral encephalitis

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

hydrocephalus

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys

an agent for the treatment of articular cartilage extracellular matrix degradation

Patent; YAMANOUCHI PHARMACEUTICAL CO. LTD.; EP1547617; (2005); (A1) English, View in Reaxys

arthrosteitis

Patent; YAMANOUCHI PHARMACEUTICAL CO. LTD.; EP1547617; (2005); (A1) English, View in Reaxys

rheumatic arthritis

Patent; YAMANOUCHI PHARMACEUTICAL CO. LTD.; EP1547617; (2005); (A1) English, View in Reaxys

histone deacetylase (HDAC) inhibitor; remarkably enhance the antitumor effect of an antitumor agent

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

component of antitumor composition for cancerous diseases

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

malignant lymphoma

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

cancer of digestive organ

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

musculoskeletal sarcoma

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

leukemia (e.g., acute leukemia including blast crisis of chronic myeloid leukemia)

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

blood cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

solid tumor

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

reticulosarcoma

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

lymphosarcoma

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

bile duct cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

liver cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

rectal cancer

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

osteosarcoma

Patent; Naoe, Yoshinori; Inoue, Takeshi; Kano, Yasuhiko; US2005/187148; (2005); (A1) English, View in Reaxys

venlafaxine-containing osmotic device

Patent; Feleder, Ethel C.; Meyer, Glenn A.; Ricci, Marcelo A.; Faour, Joaquina; Pastini, Ana C.; Befumo, Marcelo F.; US2005/163851; (2005); (A1) English, View in Reaxys

131/365

2017-08-01 06:49:42

osmotic salt

Patent; Feleder, Ethel C.; Meyer, Glenn A.; Ricci, Marcelo A.; Faour, Joaquina; Pastini, Ana C.; Befumo, Marcelo F.; US2005/163851; (2005); (A1) English, View in Reaxys

NADPH oxidase inhibitor; inducing release of neurotrophic factors; inhibiting over-activation of innate immune cells; attenuating toxin-induced death; attenuating damage tissues

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Inflammation-related disorder

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Neuroprotection

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Neurodegenerative disorders

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Parkinson's disease

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Amyotrophic lateral sclerosis (ALS)

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Multiple sclerosis (MS)

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Atherosclerosis

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Diabetes

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Arthritis

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Sepsis

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Septic shock

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Endotoxemia

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Multiple organ failure

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

Organ damage

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

neurological condition

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

132/365

2017-08-01 06:49:42

Bipolar disorders

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys

HDAC (histone deacetylases) inhibitor

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

HDAC inhibitor component of composition

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

cancer therapy

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

oesophageal cancer

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

colonic cancer

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

myeloid leukaemia

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

reducing proliferation of and/or inducing programmed cell death (e. g. apoptosis) in neoplastic cells

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

epithelial cells from prostate

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

epithelial cells from bladder

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

epithelial cells from colon

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

epithelial cells from breast

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

epithelial cells from squamous and normal myeloid progenitors

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys

(0) Medchem (552) 1 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : long-term memory formation; enhancement of Bioassay : Example 8 An Inhibitor of Histone Deacetylase Enhances Formation of LongTerm Memory Synaptic plasticity is believed to be a mechanism involved in the formation of memory in vivo. It was observed that 2 distinct inhibitors of HDAC activity enhanced induction of LTP in vitro (FIGS. 7 and 10). Therefore,

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound administration had no effect on short-term memory formation, but specifically enhanced formation of long-term contextual fear memory (figure given)

Measurement Parameter

Qualitative

Patent; BAYLOR COLLEGE OF MEDICINE; US2006/18921; (2006); (A1) English, View in Reaxys 2 of 552

Bioassay Category

In Vitro (Efficacy)

133/365

2017-08-01 06:49:42

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : long-term memory formation; enhancement of Bioassay : Example 9 Enhancement of Long-Term Memory with Histone Deacetylase Inhibitor as Demonstrated with Passive Avoidance The effect of the exemplary histone deacetylase inhibitor sodium butyrate (NaB) on the exemplary hippocampus-dependent long-term memory paradigm of passive avoidance was determined. In

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

passive avoidance task; title compound administration did not affect long-term passive avoidance memory when tested 1 day after training, however, significantly enhanced longterm passive avoidance memory when tested 7 and 14 days after training (figure

Measurement Parameter

Qualitative

Patent; BAYLOR COLLEGE OF MEDICINE; US2006/18921; (2006); (A1) English, View in Reaxys 3 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : long-term potentiation (LTP); enhancement of Target : brain hippocampus slices of Sprague-Dawley rat Bioassay : Example 7 Enhancement of LTP by a Second Histone Deacetylase Inhibitor To determine whether the enhancement of LTP by TSA was due to the inhibition of histone deacetylases, we used a structurally dissimilar inhibitor of histone deacetylases, sodium butyrate (NaB). Exposure of slices to NaB for 40 min

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound induced enhancement of long-term potentiation (LTP) at all times assayed without effects on synaptic transmission (figure given)

Measurement Parameter

Qualitative

Patent; BAYLOR COLLEGE OF MEDICINE; US2006/18921; (2006); (A1) English, View in Reaxys 4 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : long-term memory formation; enhancement of Bioassay : Example 10 Enhancement of Long-Term Memory with Histone Deacetylase Inhibitor as Demonstrated with Novel Object Recognition The effect of the exemplary histone deacetylase inhibitor sodium butyrate (NaB) on the exemplary hippocampus-dependent long-term memory paradigm of novel object recognition was

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

novel object recognition test; title compound administration significantly enhanced longterm memory 1 and 7 days after training (figure given)

Measurement Parameter

Qualitative

Patent; BAYLOR COLLEGE OF MEDICINE; US2006/18921; (2006); (A1) English, View in Reaxys 5 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : neuroregulator Bioassay : This example described additional experiments related to dosage determination of HDAC inhibitors. Using Westerns and commercially available antibodies to acetyla-

134/365

2017-08-01 06:49:42

ted histones H3 and H4, hippocampal and neocortical tissue are collected 4 h, 12 h, 1 and 3 days following ICV administration of trichostatin Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

administration of doses of title comp. which were effective in altered brain histone acetylation will prevent or blunt the status epilepticus-induced down regulation of neurotransmitter receptor expression and function in dentate granule cells

Measurement Parameter

Qualitative

Patent; Coulter, Douglas; US2005/75282; (2005); (A1) English, View in Reaxys 6 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : differentiation induction Bioassay : morphological changes of F9 cells incubation of F9 cells in Eagle's minimum essential medium with title comp.; determination of plasminogen activator production by the agar-overlay method

Biological Species/NCBI murine ID Cells/Cell Lines

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 µM

Qualitative Results

reversibly induction of differentiation

Measurement Parameter

Qualitative

Muto; Dota; Tanaka; Itoh; Okabe; Inada; Nakanishi; Biological and Pharmaceutical Bulletin; vol. 18; nb. 11; (1995); p. 1576 - 1579, View in Reaxys 7 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : PMN to HUVEC cell adhesion; inhibition of Target : polymorphonuclear cells; Human umbilical vein endothelial cells (HUVEC cells) of human Bioassay : EXAMPLE 2 Adhesion assayHuman umbilical vein endothelial cells (HUVEC cells) were suitably treated, grown to confluence in 24 well plates, washed and maintained for one day in M 199 medium supplemented with 10% BCS (Bovine Calf Serum).Polymorphonuclear cells (PMN) were prepared from citrated venous

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

IC50

Unit

Quantitative value

4E-07

Measurement pX

6.4

Patent; GASCO, Maria Rosa; WO2006/128888; (A1); (2006), View in Reaxys 8 of 552

Substance Effect

Antineoplastic

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : tumor volume of 500 mm3

135/365

2017-08-01 06:49:42

Bioassay : tumor growth delay time calculated 8 mice, wt 17-21 g; 1E6 cells of EMT6 murine mammary tumor (cultivated as monolayer in RPMI 1640, 37 deg C, 5 percent CO2 humidified atmosphere) implanted s.c. into the flank; measurement of tumor size using a caliper once a day starting at day 7 after implan. Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.00750000 mmol/kg

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Qualitative

Qualitative value

Xia, Zuping; Wiebe, Leonard I.; Miller, Gerald G.; Knaus, Edward E.; Archiv der Pharmazie; vol. 332; nb. 8; (1999); p. 286 - 294, View in Reaxys 9 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell differentiation Target : human promyelocytic leukemia cells ATCC HL60 Bioassay : 2E5 cells/ml; preincubation time 24 h suspension in RPMI 1640; incubation time 7 d; 24-well culture plate; humidified 5 percent CO2 atmosphere; 37 deg C; cell viability by trypan blue exclusion technique; morphological analysis using light microscopy; counts on Wright-stained cytospin preparation

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.00000E-06 M

Measurement Parameter

EC50

Unit

Quantitative value

0.0068

Measurement pX

2.17

Xia, Zuping; Wiebe, Leonard I.; Miller, Gerald G.; Knaus, Edward E.; Archiv der Pharmazie; vol. 332; nb. 8; (1999); p. 286 - 294, View in Reaxys 10 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |agonist Target : human cystic fibrosis (CF) airway epithelial monolayers Bioassay : cystic fibrosis (CF) airway epithelial monolayers grown on semipermeable filters at the air-liquid interface incubated for 24 h with increasing concns. of title comp.; monolayers were studied in Ussing chambers in presence of Cl- concn. gradient

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0 mM

Qualitative Results

title comp. had no significant effect on cAMP-stimulated Cl- current; no effect on transepithelial resistance (Rt) except at the highest dose (300 mM), where Rt decreased; 30 mM title comp. Rt=585 Ο*cm-1;

Measurement Parameter

Qualitative

Cheng; Fang; Zabner; Marshall; Piraino; Schiavi; Jefferson; Welsh; Smith; American Journal of Physiology Lung Cellular and Molecular Physiology; vol. 268; nb. 4 12-4; (1995); p. L615-L624, View in Reaxys

136/365

2017-08-01 06:49:42

11 of 552

Target Mutant/Chimera Details

Cystic fibrosis transmembrane conductance regulator:Wild

Target Subunit Proteins

Cystic fibrosis transmembrane conductance regulator

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |agonist Bioassay : Δ-F508-cystic fibrosis transmembrane conductance regulator (CFTR) generated; cells stimulated 4 min with 20 μM forskolin and 100 μM100 μM IBMX

Cells/Cell Lines

C127

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp.-enhanced expression of recombinant ΔF508-CFTR from a metallothionein promoter results in functional CAMP-regulated Cl- channels at the cell surface

Measurement Parameter

Qualitative

Target, Subunit, Species Cystic fibrosis transmembrane conductance regulator Cheng; Fang; Zabner; Marshall; Piraino; Schiavi; Jefferson; Welsh; Smith; American Journal of Physiology Lung Cellular and Molecular Physiology; vol. 268; nb. 4 12-4; (1995); p. L615-L624, View in Reaxys 12 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : proline-rich acidic protein (PRAP) gene expression; effect on Bioassay : Regulation of PRAP Expression by Butyrate and Epigenetic Modifiers We studied the regulation of PRAP gene expression in HT29 cells by butyrate. Treatment of HT29 cells with 5 mM butyrate has been shown to induce cell differentiation within 24 h after treatment (McBain et al., 1997; Heerdt et al., 1997;

Cells/Cell Lines

HT 29

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

PRAP gene expression was significantly increased 20-fold within 24 h after administration of the title compound at a dose of 5 mM; increase in expression was sustained for up to 6 days after treatment, at which time the cells were beginning to show

Measurement Parameter

Qualitative

Patent; NATIONAL UNIVERSITY OF SINGAPORE; US2007/160596; (2007); (A1) English, View in Reaxys 13 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : modulatory Target : Chinese hamster ovary CHO-9 cells Bioassay : complete medium; 1-4 U/ml AluI pretreatment with sodium butyrate; treatment with AluI by electroporation or streptolysin O method; fixing 20 h later; analysis of metaphases

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Qualitative Results

induction of 2-4-fold increase in AluI-induced chromosomal aberrations

Measurement Parameter

Qualitative

137/365

2017-08-01 06:49:42

Hojo, Elza T. Sakamoto; Balajee, A. S.; Natarajan, A. T.; Mutation Research; vol. 309; nb. 2; (1994); p. 165 - 174, View in Reaxys 14 of 552

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Chinese hamster ovary CHO-9 cells Bioassay : complete medium treatment with sodium butyrate; fixing; analysis of metaphases

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Qualitative Results

number and type of chromosomal aberrations; percentage of abnormal cells

Measurement Parameter

Qualitative

Hojo, Elza T. Sakamoto; Balajee, A. S.; Natarajan, A. T.; Mutation Research; vol. 309; nb. 2; (1994); p. 165 - 174, View in Reaxys 15 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : acetyl CoA level; effect on Bioassay : RESULTSPrevious studies have analyzed the fold change in histone acetylation in response to HDACIs. There was interest in determining a measure of the fold change in protein acetylation on a cellular scale as influenced by HDACIs. In short, the question presented was whether HDACIs would induce a significant

Biological Species/NCBI Human ID Cells/Cell Lines

OPM-2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

~30% decrease was observed in acetyl carnitine in cells treated with title compound; figure is given

Measurement Parameter

Qualitative

Patent; DUKE UNIVERSITY; WO2007/67516; (2007); (A2) English, View in Reaxys 16 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : RESULTSPrevious studies have analyzed the fold change in histone acetylation in response to HDACIs. There was interest in determining a measure of the fold change in protein acetylation on a cellular scale as influenced by HDACIs. In short, the question presented was whether HDACIs would induce a significant

Biological Species/NCBI Human ID Cells/Cell Lines

OPM-2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound induced significant (60-90%) and comparable apoptosis within 96 hours, although no more than 10-20% apoptosis is observed at this time point of 48 hours; figure is given

Measurement Parameter

Qualitative

138/365

2017-08-01 06:49:42

Patent; DUKE UNIVERSITY; WO2007/67516; (2007); (A2) English, View in Reaxys 17 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

inhibitory effect on progression of root meristem cells and DNA synthesis in soybean (Glycine max.), pinto bean (Phaseolus vulgaris) and broad bean (Vicia faba)

Measurement Parameter

Qualitative

Tramontano; Scanlon; Phytochemistry; vol. 41; nb. 1; (1996); p. 85 - 88, View in Reaxys 18 of 552

Target Mutant/Chimera Details

enzyme:Wild

Target Subunit Proteins

enzyme

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |enzyme; examination of Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine; PARP: poly(ADP-ribose) polymerase cells ectopically expressing empty vector pCEP4 or full-length Bcl-2 were treated with title comp. for 12 h in incubator; cells harvested and lysed; caspase-3, cleaved caspase-3, Bcl-2 and PARP determined in lysate by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Measurement Parameter

Qualitative

Qualitative value

Target, Subunit, Species enzyme Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 19 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : Bcl-2-ΔN: phosphorylation loop-deleted Bcl-2 mutant; Bcl-2-S70A: mutant Bcl-2 in which Ser70 substituted for Ala; FP: flavopiridol cells ectopically expressing empty vector pSFFV, Bcl-2-ΔN or Bcl-2-S70A were treated with title comp. with 100 nmol/l FP for 24 h in incubator; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. potentiated cytotoxic effect of FP in pSFFV-expressing cells to significantly greater extent (ca. 70 percent cell death) than in Bcl-2-ΔN- and Bcl-2-S70A-expressing cells (ca. 35 percent cell death)

139/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 20 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine; Bcl-2-ΔN: phosphorylation loop-deleted Bcl-2 mutant; FP: flavopiridol; Smac: second mitochondria-derived activator of caspases; DIABLO: direct IAP binding protein with low pI cells ectopically expressing empty vector pSFFV or Bcl-2-ΔN were treated with title comp. with 100 nmol/l FP for 12 24 h in incubator; cells lysed; cytosolic fraction prepared; Smac/DIABLO and cytochrome c determined by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title comp. markedly potentiated effect of FP on Smac/DIABLO and cytochrome c release into cytosol in pSFFV-expressing cells after 12 h and Bcl-2-ΔN-expressing cells after 24 h but not after 12 h

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 21 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine; FP: flavopiridol cells ectopically expressing empty vector pcDNA3.1 or Bcl-xL were treated with title comp. with 100 nmol/l FP for 24 h; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. substantially potentiated cytotoxic effect of FP in pcDNA3.1- and Bcl-xL-expressing cells to similar extent (from ca. 20 percent to ca. 60 - 70 percent cell death)

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 22 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine; FP: flavopiridol; PARP: poly(ADP-ribose) polymerase cells ectopically expressing empty vector pCEP4, full-length Bcl-2, or Bcl-xL were treated with title comp. with 100 nmol/l FP for 12 h; cells harvested and lysed; caspase-3, cleaved caspase-3, Bcl-2, PARP determined in lysate by Western blot analysis

140/365

2017-08-01 06:49:42

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. potentiated effect of FP on caspase-3 activation/cleavage, formation of Bcl-2 cleavage product and PARP degradation in pCEP4-, Bcl-2-, and Bcl-xL-expressing cells

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 23 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine; FP: flavopiridol; Smac: second mitochondria-derived activator of caspases; DIABLO: direct IAP binding protein with low pI; AIF: apoptosis-inducing factor cells expressing empty vector pCEP4 or Bcl-2 were treated with title comp. with 100 nmol/l FP for 12 h in incubator; cells harvested and lysed; S-100 (cytosolic) fraction prepared; Smac/DIABLO, cytochrome c and AIF determined by Western blot analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title comp. potentiated effect of FP on Smac/DIABLO, cytochrome c and AIF release into cytosol in pCEP4- and Bcl-2-expressing cells

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 24 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine; WT: wild-type; FP: flavopiridol WT cells or cells ectopically expressing empty vector pCEP4 or full-length Bcl-2 were treated with title comp. with 100 nmol/l FP for 24 h; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. substantially potentiated cytotoxic effect of FP in WT, pCEP4- and Bcl-2-expressing cells to similar extent (from ca. 20 - 25 percent to ca. 60 - 75 percent cell death)

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys

141/365

2017-08-01 06:49:42

25 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : WT: wild-type; Bcl-2-ΔN: phosphorylation loop-deleted Bcl-2 mutant; Bcl-2S70A: mutant Bcl-2 in which Ser70 substituted for Ala; FP: flavopiridol WT cells or cells expressing empty vector pSFFV, Bcl-2-ΔN or Bcl-2-S70A were treated with title comp. with 75 nmol/l FP for 48 h in incubator; cells harvested, washed, stained with Annexin V/ propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.750000 mM

Qualitative Results

title comp. potentiated cytotoxic effect of FP in WT and pSFFV-expressing cells (ca. 70 75 percent cell death) to the extent comparable to that observed in Bcl-2-ΔN- and Bcl-2S70A-expressing cells (ca. 65 percent cell death)

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 26 of 552

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : Bcl-2-ΔN: phosphorylation loop-deleted Bcl-2 mutant; Bcl-2-S70A: mutant Bcl-2 in which Ser70 substituted for Ala cells ectopically expressing empty vector pSFFV, Bcl-2-ΔN or Bcl-2-S70A were treated with title comp. for 24 h in incubator; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. increased cell death in pSFFV-expressing cells to slightly greater extent (ca. 20 percent cell death) than in Bcl-2-ΔN- and Bcl-2-S70A-expressing cells (ca. 10 - 15 percent cell death)

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 27 of 552

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine cells ectopically expressing empty vector pcDNA3.1 or Bcl-xL were treated with title comp. for 24 h in incubator; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

142/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. increased cell death in pcDNA3.1- and Bcl-xL-expressing cells to ca. 15 percent

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 28 of 552

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : reference comp.: 1-β-D-arabinofuranosylcytosine wild-type cells or cells ectopically expressing empty vector pCEP4 or full-length Bcl-2 were treated with title comp. for 24 h in incubator; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. increased cell death in wild-type, pCEP4- and Bcl-2-expressing cells to ca. 15 20 percent

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 29 of 552

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : WT: wild-type; Bcl-2-ΔN: phosphorylation loop-deleted Bcl-2 mutant; Bcl-2S70A: mutant Bcl-2 in which Ser70 substituted for Ala WT cells or cells ectopically expressing empty vector pSFFV, Bcl-2-ΔN or Bcl-2-S70A were treated with title comp. for 48 h in incubator; cells harvested, washed, stained with Annexin V/propidium iodide and analyzed by flow cytometry analysis

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.750000 mM

Qualitative Results

title comp. increased cell death in WT and pSFFV-expressing cells to slightly greater extent (ca. 15 - 20 percent cell death) than in Bcl-2-ΔN- and Bcl-2-S70A-expressing cells (ca. 10 - 15 percent cell death)

Measurement Parameter

Qualitative

Dasmahapatra, Girija; Almenara, Jorge A.; Grant, Steven; Molecular Pharmacology; vol. 69; nb. 1; (2006); p. 288 - 298, View in Reaxys 30 of 552

Substance Effect

Antifungal

143/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Candida albicans CaLL Bioassay : YPD: 1 percent yeast extract, 2 percent peptone, 2 percent dextrose, pH 6.3 broth microdilution assay; cells in YPD (1E4 cells/ml) incubated with fluconazole (0.13 to 8 μg/ml) in presence of title comp. at 35 deg C for 18 h and 42 h; optical density was measured at 630 nm in optical reader

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. significantly increased activity of fluconazole, especially after 48 h of incubation (diagram)

Measurement Parameter

Qualitative

Smith, W. Lamar; Edlind, Thomas D.; Antimicrobial Agents and Chemotherapy; vol. 46; nb. 11; (2002); p. 3532 3539, View in Reaxys 31 of 552

Substance Effect

Antifungal

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Candida albicans CaLL Bioassay : YPD: 1 percent yeast extract, 2 percent peptone, 2 percent dextrose, pH 6.3 broth microdilution assay; cells in YPD (1E4 cells/ml) incubated with terbinafine (0.25 to 8 μg/ml) in presence of title comp. at 35 deg C for 18 h and 66 h; optical density was measured at 630 nm in optical reader

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. increased activity of terbinafine and decreased MIC of terbinafine (two or fourfold)

Measurement Parameter

Qualitative

Smith, W. Lamar; Edlind, Thomas D.; Antimicrobial Agents and Chemotherapy; vol. 46; nb. 11; (2002); p. 3532 3539, View in Reaxys 32 of 552

Substance Effect

Antifungal

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Candida albicans CaLL Bioassay : YPD: 1 percent yeast extract, 2 percent peptone, 2 percent dextrose, pH 6.3 broth microdilution assay; cells in YPD (1E4 cells/ml) incubated with title comp. at 35 deg C or 42 deg C for 24 h; optical density was measured at 630 nm in optical reader

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. in dose-dependent manner weakly inhibited cell growth with more prominent activity at 42 deg C (diagram)

Measurement Parameter

Qualitative

Smith, W. Lamar; Edlind, Thomas D.; Antimicrobial Agents and Chemotherapy; vol. 46; nb. 11; (2002); p. 3532 3539, View in Reaxys 33 of 552

Substance Effect

Antifungal

144/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Candida albicans CaLL Bioassay : YPD: 1 percent yeast extract, 2 percent peptone, 2 percent dextrose, pH 6.3 broth microdilution assay; cells in YPD (1E4 cells/ml) incubated with amphotericin B (0.06 to 4 μg/ml) in presence of title comp. at 35 deg C for 18 h and 66 h; optical density was measured at 630 nm in optical reader

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Measurement Parameter

Qualitative

Qualitative value

Smith, W. Lamar; Edlind, Thomas D.; Antimicrobial Agents and Chemotherapy; vol. 46; nb. 11; (2002); p. 3532 3539, View in Reaxys 34 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : permeation, inhibition of Target : human cystic fibrosis transmembrane conductance regulator Bioassay : CFTR = cystic fibrosis transmembrane conductance regulator; BHK = baby hamster kidney; CHO = Chinese hamster ovary BHK and CHO cells stably expressing human CFTR; effect of title comp. on macroscopic (BHK), and single channel (CHO) chloride currents determined using inside-out patch clamp technique at -100 - 50 mV

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. concentration- and voltage-dependently reduced macroscopic (Kd = 8.3/14.2/58.3 mmol/l at -100/-50/50 mV) and single channel currents; graphical representation

Measurement Parameter

Qualitative

Linsdell, Paul; European Journal of Pharmacology; vol. 411; nb. 3; (2001); p. 255 - 260, View in Reaxys 35 of 552

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : DJ-1 protein expression; effect on Target : C57BL6 mouse Bioassay : Sodium butyrate also increased DJ-I protein levels in mouse brain in vivo as shown in Figure 7. For analysis of DJ-I protein levels in mouse brains, C57BL6 mice were injected intraperitoneally with vehicle(PBS) or sodium butyrate (1200 mg/kg) daily for fourteen days. Mice were euthanized and the cortical

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

title compound (1200 mg/kg) increased DJ-1 protein levels in cortical and midbrain tissues; figure given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 36 of 552

Bioassay Category

In Vitro (Efficacy)

145/365

2017-08-01 06:49:42

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DJ-1 mRNA expression; effect on Target : neuroblastoma -1000DJ-Luc-SH-SY5Y cells of human Bioassay : Cells treated with the HDAC inhibitor, sodium butyrate (5mM), also exhibited a transient increase in DJ-I mRNA levels. SH-SY5Y cells were treated with 5 mM of sodium butyrate. Cells were then harvested for mRNA one, two, four, eight, and twelve hours after treatment. DJ-I mRNA levels were quantitated

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound (5 mmol/l) caused transient increase in DJ-1 mRNA levels; diagram given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 37 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DJ-1 protein expression; effect on Target : cortical neurons and glia cells of human Bioassay : HDAC inhibitors also increased DJ-I protein levels as shown in Figures 6C and 6D. SH-SY5Y cells (Figure 6C), human primary neuronal cultures containing cortical neurons and glia (Figure 6D), or mouse embryonic stem cells (Figure 6D) were treated with increasing doses of TSA (0, 50, or 100 ng/ml) and

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

title compound increased DJ-1 protein levels in a dose dependent fashion; figure given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 38 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DJ-1 protein expression; effect on Target : embryonic stem cells of mouse Bioassay : HDAC inhibitors also increased DJ-I protein levels as shown in Figures 6C and 6D. SH-SY5Y cells (Figure 6C), human primary neuronal cultures containing cortical neurons and glia (Figure 6D), or mouse embryonic stem cells (Figure 6D) were treated with increasing doses of TSA (0, 50, or 100 ng/ml) and

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

title compound increased DJ-1 protein levels in a dose dependent fashion; figure given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 39 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DJ-1 protein expression; effect on Target : neuroblastoma -1000DJ-Luc-SH-SY5Y cells of human

146/365

2017-08-01 06:49:42

Bioassay : Consistent with the activation of the DJ-I promoter, total endogenous DJ-I protein levels increased markedly in these cells treated with TSA or sodium butyrate as shown in Figure 4. Figure 4 shows the accumulation of endogenous DJ-I protein in cells treated with HDAC inhibitors. SHS Y5 Y cells stably Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

title compound (2.5 - 10 mmol/l) significantly increased DJ-1 protein level; figure given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 40 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : human DJ-1 gene promoter; activation of Target : neuroblastoma 0DJ-Luc-SH-SY5Y cells of human Bioassay : SH-S Y5 Y cells stably expressing -lOOODJ-Luc or ODJ-Luc were treated with HDAC inhibitors suberoylanilide hydroxamic acid (SAHA), TSA and sodium butyrate for twenty-four hours. Cells were then lysed in passive lysis buffer (Promega), and the resulting lysates were used in luciferase and protein assays.

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

title compound (5 mmol/l) slightly activated the DJ-1 gene promoter; diagram given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 41 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : human DJ-1 gene promoter; activation of Target : neuroblastoma -1000DJ-Luc-SH-SY5Y cells of human Bioassay : The -1000DJ-LUC-SH-SY5Y cells were treated with increasing concentrations of Trichostatin A (TSA), an organic zinc chelator that potently inhibits the zinc hydrolase activity of HDACs, or a structurally distinct HDAC inhibitor, sodium butyrate, and analyzed abationof the luciferase ies. SH-S Y5 Y cells

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

title compound (2.5 - 10 mmol/l) significantly activated the DJ-1 gene promoter; diagram given

Measurement Parameter

Qualitative

Patent; ID BIOMEDICAL CORPORATION OF QUEBEC; BRIGHAM AND WOMEN'S HOSPITAL; WO2006/4749; (2006); (A2) English, View in Reaxys 42 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : apoptotic

147/365

2017-08-01 06:49:42

HDAC inhibitors are known to induce apoptosis specifically in tumor cells (Nakata, S. et al. (2004) Oncogene 23:6261-6271; Insing a, A. et al. (2005) Nat. Med. 11:71-76; Nebbioso, A. et al. (2005) Nat. Med. 11:77-84). The direct relationship between the expression of SMCT1 and the histone acetylation Biological Species/NCBI Human ID Cells/Cell Lines

HMEC

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 43 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : apoptotic HDAC inhibitors are known to induce apoptosis specifically in tumor cells (Nakata, S. et al. (2004) Oncogene 23:6261-6271; Insing a, A. et al. (2005) Nat. Med. 11:71-76; Nebbioso, A. et al. (2005) Nat. Med. 11:77-84). The direct relationship between the expression of SMCT1 and the histone acetylation

Biological Species/NCBI Human ID Cells/Cell Lines

T47D

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound produced apoptosis time-dependently; figure given

Measurement Parameter

Qualitative

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 44 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound produced apoptosis time-dependently; figure given

Measurement Parameter

Qualitative

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 45 of 552

Substance Effect

Apoptotic

148/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Cells/Cell Lines

MCF-10A

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 46 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : apoptotic Bioassay : breast cancer ZR75.1 cells HDAC inhibitors are known to induce apoptosis specifically in tumor cells (Nakata, S. et al. (2004) Oncogene 23:6261-6271; Insing a, A. et al. (2005) Nat. Med. 11:71-76; Nebbioso, A. et al. (2005) Nat. Med. 11:77-84). The direct relationship between the expression of SMCT1 and the histone acetylation

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound produced apoptosis time-dependently; figure given

Measurement Parameter

Qualitative

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 47 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : apoptotic Bioassay : mammary epithelial HBL100 cells HDAC inhibitors are known to induce apoptosis specifically in tumor cells (Nakata, S. et al. (2004) Oncogene 23:6261-6271; Insing a, A. et al. (2005) Nat. Med. 11:71-76; Nebbioso, A. et al. (2005) Nat. Med. 11:77-84). The direct relationship between the expression of SMCT1 and the histone acetylation

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

149/365

2017-08-01 06:49:42

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 48 of 552

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : apoptotic Bioassay : human breast cancer MCF7 cells expressed SMCT1 (Sodium-coupled monocarboxylate transporter 1) The findings that pyruvate is an endogenous HDAC inhibitor and a tumor suppressor have important implications in cancer biology. It is well known that tumor cells up-regulate glycolysis and convert the glycolytic end product pyruvate effectively into lactate (Stubbs, M., McSheehy, P. M. J., Griffiths,

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

IC50

Unit

µM

Quantitative value

Measurement pX

4.43

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 49 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : current; induction of Electrophysiological Studies of SLC5A8We then examined the transport function of SLC5A8 by electrophysiological methods. Exposure of cRNA-injected oocytes to various short-chain fatty acids induced marked inward currents under voltage clamp conditions and the magnitude of these currents increased as

Biological Species/NCBI Xenopus laevis ID Cells/Cell Lines

Oocyte

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 50 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone deacetylase (HDAC); inhibition of The findings that pyruvate is an endogenous HDAC inhibitor and a tumor suppressor have important implications in cancer biology. It is well known that tumor cells up-regulate glycolysis and convert the glycolytic end product pyruvate effectively into lactate (Stubbs, M., McSheehy, P. M. J., Griffiths,

Biological Species/NCBI Human ID Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

Substance Name

1481199

150/365

2017-08-01 06:49:42

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.22

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 51 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : SMCT1 (Sodium-coupled monocarboxylate transporter 1) and C/EBPδ genes; induction of Bioassay : cancer breast MCF7 cells HDAC inhibitors are known to induce apoptosis specifically in tumor cells (Nakata, S. et al. (2004) Oncogene 23:6261-6271; Insing a, A. et al. (2005) Nat. Med. 11:71-76; Nebbioso, A. et al. (2005) Nat. Med. 11:77-84). The direct relationship between the expression of SMCT1 and the histone acetylation

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound induced C/EBPδ and SMCT1 genes expression; figures given

Measurement Parameter

Qualitative

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 52 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : ATB0,+ transporter; inhibition of Bioassay : rat ATB0,+ expressed in the human retinal pigment epithelial cells Transport of Short-Chain Fatty Acids in the Form of L-Serine Esters Via Amino Acid Transporter ATB0,+ The results of Example 1 prompted evaluation of the utility of the ATB0,+ transporter as a potential candidate for delivering the amino acid prodrug of butyrate, namely O-butyryl-L-serine

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 53 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : SLC5A8 transporter; affinity to Bioassay : Xenopus laevis oocytes injected with SLC5A8 cRNA Comparative Affinities of Short-Chain Fatty Acids for SLC5A8We determined the K0.5 values for L-lactate, D-lactate, acetate, propionate, and butyrate to compare the affinities of these fatty acids for interaction with SLC5A8. The affinities were found to be in the following order: butyrate

Substance RN

3629439View in Reaxys

Substance Name

1481199

151/365

2017-08-01 06:49:42

Qualitative Results

title compound affinity was 81 μM

Measurement Parameter

Qualitative

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 54 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : current; induction of Bioassay : Xenopus laevis oocytes injected with SLC5A8 cRNA Electrophysiological Studies of SLC5A8We then examined the transport function of SLC5A8 by electrophysiological methods. Exposure of cRNA-injected oocytes to various short-chain fatty acids induced marked inward currents under voltage clamp conditions and the magnitude of these currents increased as

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound (5 mM) induced approximately 70% of L-lactate induced current (100%, 489 nA); figure given

Measurement Parameter

Qualitative

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 55 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone H4 acetylation status; effect on colony formation assay Bioassay : human breast cancer MCF7 cells transfected with pcDNA3.1 The findings that pyruvate is an endogenous HDAC inhibitor and a tumor suppressor have important implications in cancer biology. It is well known that tumor cells up-regulate glycolysis and convert the glycolytic end product pyruvate effectively into lactate (Stubbs, M., McSheehy, P. M. J., Griffiths,

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Patent; MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE; WO2006/76734; (2006); (A3) English, View in Reaxys 56 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : survival motor neuron 2 (SMN2) expression; effect on Bioassay : SMA-like mouse embryonic fibroblasts (Smn-/-) (SMA-MEFs) Example 1-Screening of Compounds for SMN2-Enhancing ActivityScreening of compounds for SMN2-enhancing activity was performed as follows. We used SMA-like mouse embryonic fibroblasts (Smn-/-, SMN2) (MEFs) with a similar SMN2 copy number (FIG. 1A, SMN2 copy number=1.54) to mimic Type I SMA patients for

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Academia Sinica; US2008/187512; (2008); (A1) English, View in Reaxys

152/365

2017-08-01 06:49:42

57 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : survival motor neuron 2 (SMN2) expression; effect on Bioassay : SMN2-transfected motor neuron-like NSC34 cells (SMN2-NSC34) Example 1-Screening of Compounds for SMN2-Enhancing ActivityScreening of compounds for SMN2-enhancing activity was performed as follows. We used SMA-like mouse embryonic fibroblasts (Smn-/-, SMN2) (MEFs) with a similar SMN2 copy number (FIG. 1A, SMN2 copy number=1.54) to mimic Type I SMA patients for

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Academia Sinica; US2008/187512; (2008); (A1) English, View in Reaxys 58 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Li; (55 pag.); US2008/187512; (A1); (2008), View in Reaxys 59 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Li; (55 pag.); US2008/187512; (A1); (2008), View in Reaxys 60 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : survival motor neuron protein 2 (SMN2) expression; effect on Bioassay : SMA-like embryonic fibroblasts (Smn-/-, SMN2) Example 1-Screening of Compounds for SMN2-Enhancing ActivityScreening of compounds for SMN2-enhancing activity was performed as follows. We used SMA-like mouse embryonic fibroblasts (Smn-/-, SMN2) (MEFs) with a similar SMN2 copy number (FIG. 1A, SMN2 copy number=1.54) to mimic Type I SMA patients for

153/365

2017-08-01 06:49:42

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Li; (55 pag.); US2008/187512; (A1); (2008), View in Reaxys 61 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : survival motor neuron protein 2 (SMN2) expression; effect on Bioassay : SMN2-transfected motor neuron-like NSC34 cells (SMN2-NSC34) Example 1-Screening of Compounds for SMN2-Enhancing ActivityScreening of compounds for SMN2-enhancing activity was performed as follows. We used SMA-like mouse embryonic fibroblasts (Smn-/-, SMN2) (MEFs) with a similar SMN2 copy number (FIG. 1A, SMN2 copy number=1.54) to mimic Type I SMA patients for

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Li; (55 pag.); US2008/187512; (A1); (2008), View in Reaxys 62 of 552

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : antiproliferative Bioassay : glioblastoma multiforme (hGBM-1, WHO grade IV) cells Materials and Methods: Tissue source, processing, and primary culture Tumour tissue specimens were obtained from patients during open surgical resection of glioblastoma multiforme (GBM, WHO grade IV) according to per-operative diagnosis on cryostat sections. Recovery of tissue was done with the permission

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Title compound at concentrations up to 100 mM have a slight antiproliferative effect on hGBM-1 culture cells; figure is given.

Measurement Parameter

Qualitative

Patent; ZGene A/S; WO2005/79849; (2005); (A2) English, View in Reaxys 63 of 552

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : antiproliferative Bioassay : glioblastoma multiforme (hGBM-14, WHO grade IV) cells Materials and Methods: Tissue source, processing, and primary culture Tumour tissue specimens were obtained from patients during open surgical resection of glioblastoma multiforme (GBM, WHO grade IV) according to per-operative diagnosis on cryostat sections. Recovery of tissue was done with the permission

Biological Species/NCBI Human ID

154/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Title compound at concentrations up to 100 mM have a slight antiproliferative effect on hGBM-14 culture cells; figure is given.

Measurement Parameter

Qualitative

Patent; ZGene A/S; WO2005/79849; (2005); (A2) English, View in Reaxys 64 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Target : Jurkat lymphoblastic leukemia cells Bioassay : FP: flavopiridol, 200 nmol/l; PI: propidium iodide cells treated with title comp. alone or in combination with FP for 24 h; morphology of Wright-Giemsa-stained cytospin preparations and annexin V/PI staining assessed; extent of apoptosis determined by flow cytometry

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. alone induced apoptosis only moderately, but combination with FP resulted in pronounced apoptotic response (>= 60 percent cell death)

Measurement Parameter

Qualitative

Rosato, Roberto R.; Almenara, Jorge A.; Yu, Chunrong; Grant, Steven; Molecular Pharmacology; vol. 65; nb. 3; (2004); p. 571 - 581, View in Reaxys 65 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; effect on Target : rat colon carcinoma CC531 cells Bioassay : control: untreated cells cells transiently transfected with reporter plasmid pGL3II-luc, containing rat γ-glutamyltransferase (GGT) P2 linked to luciferase gene were stimulated with title comp. for 6-24 h; luciferase activity was measured using luminometer

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Qualitative Results

title comp.-treated cells showed 4-fold enhanced luciferase activity at 24 h incubation; incubation for 6 or 12 h did not result in any increased activity from GGT P2; fig.

Measurement Parameter

Qualitative

Mikkelsen, Idun Merete; Huseby, Nils-Erik; Visvikis, Athanase; Moens, Ugo; Biochemical Pharmacology; vol. 64; nb. 2; (2002); p. 307 - 315, View in Reaxys 66 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; effect on Target : rat colon carcinoma CC531 cells Bioassay : control: untreated cells cells were stimulated with title comp. for 6 and 12 h; total RNA extracted; γ-glutamyltransferase mRNA II levels determined using RT-PCR; quantified by scanning after ethidium bromide staining

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

155/365

2017-08-01 06:49:42

Qualitative Results

title comp. treated cells showed 150 percent-fold increase in γ-glutamyltransferase mRNA II levels; fig.

Measurement Parameter

Qualitative

Mikkelsen, Idun Merete; Huseby, Nils-Erik; Visvikis, Athanase; Moens, Ugo; Biochemical Pharmacology; vol. 64; nb. 2; (2002); p. 307 - 315, View in Reaxys 67 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; effect on Target : rat colon carcinoma CC531 cells Bioassay : control: untreated cells; further study done following Sp1 site destruction by site-directed mutagenesis cells transiently transfected with plasmid containing putative Sp1 motif present in rat γ-glutamyltransferase P2 linked to luciferase gene were stimulated with title comp.; luciferase activity measured using luminometer

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Qualitative Results

title comp. stimulation resulted in 6- to 7-fold induction of luciferase activity; mutation completely abolished basal activity of promoter and abrogated title comp.-induced activation; fig.

Measurement Parameter

Qualitative

Mikkelsen, Idun Merete; Huseby, Nils-Erik; Visvikis, Athanase; Moens, Ugo; Biochemical Pharmacology; vol. 64; nb. 2; (2002); p. 307 - 315, View in Reaxys 68 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; effect on Target : rat colon carcinoma CC531 cells Bioassay : cells transiently transfected with promoter- and enhancer-free reporter plasmid pGL3, containing rat γ-glutamyltransferase P2 linked to luciferase gene were stimulated with title comp. for 6-24 h; luciferase activity measured using luminometer

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

Qualitative

Qualitative value

Mikkelsen, Idun Merete; Huseby, Nils-Erik; Visvikis, Athanase; Moens, Ugo; Biochemical Pharmacology; vol. 64; nb. 2; (2002); p. 307 - 315, View in Reaxys 69 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DNA binding; inhibition of Target : pancreatic stellate cells of LEW.1W inbred rats Bioassay : control: solvent (water); EMSA: electrophoretic mobility shift assay; NF-κB: nuclear factor-κB cells treated with title comp. for 24 h; stimulated with PDGF for 60 min; nuclear extracts were prepared and subjected to EMSA analysis using <32P>-labelled oligonucleotide probe with an AP-1 motif; DNA binding of activator protein (AP)-1 determined

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. inhibited DNA binding of AP-1 in a dose-dependent manner but not DNA binding of NF-κB and Smad proteins; fig.

156/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 70 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; inhibition of Target : pancreatic stellate cells of LEW.1W inbred rats Bioassay : control: solvent (water) cells growing in 6-well plates were exposed to title comp. for 24; mRNA expression of endothelin (ET)-1 and transforming growth factor (TGF)-β1 were analyzed by real-time PCR

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. inhibited mRNA expression of ET-1 and had no effect on TGF-β1; fig.

Measurement Parameter

Qualitative

Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 71 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; suppression of Target : pancreatic stellate cells of LEW.1W inbred rats Bioassay : α-SMA: α-smooth muscle actin; control: solvent (water) cells growing in 6-well plates were exposed to title comp. for 24; mRNA expression of α-SMA were analyzed by real-time PCR

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. strongly and dose-dependently suppressed α-SMA mRNA expression; fig.

Measurement Parameter

Qualitative

Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 72 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; inhibition of Target : pancreatic stellate cells of LEW.1W inbred rats Bioassay : α-SMA: α-smooth muscle actin; control: solvent (water) cells growing on glass coverslips were treated with title comp. for 24; expression and structural organization of αSMA were analyzed by immunofluorescence staining of the protein and documented by fluorescence microscopy

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. inhibited α-SMA expression and stress fiber formation; fig.

Measurement Parameter

Qualitative

Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys

157/365

2017-08-01 06:49:42

73 of 552

Target Mutant/Chimera Details

enzyme:Wild

Target Subunit Proteins

enzyme

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : enzyme activity; inhibition of Bioassay : control: untreated cells cells growing in 6-well plates were treated with title comp. for 24 h; histone H3 acetylation was analyzed by immunoblotting

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. induced histone H3 acetylation in a dose-dependent manner, suggesting inhibition of histone deacetylase activity; fig.

Measurement Parameter

Qualitative

Target, Subunit, Species enzyme Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 74 of 552

Target Mutant/Chimera Details

Collagen:Wild

Target Subunit Proteins

Collagen

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : collagen synthesis; inhibition of Bioassay : control: solvent (water) cells growing in 12-well plates were exposed to title comp. for 48 h; collagen synthesis was analyzed through the quantification of <3H>-proline incorporation into acetic acid-soluble proteins

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

incubation of cells with title comp. at >=1 mM was associated with decrease of <3H>-proline incorporation into acetic acid-soluble proteins, suggesting inhibition of collagen synthesis; fig.

Measurement Parameter

Qualitative

Target, Subunit, Species Collagen Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 75 of 552

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : pancreatic stellate cells of LEW.1W inbred rats Bioassay : control: solvent (water); BrdU: 5-bromo-2'-deoxyuridine cells plated in 96-well plates in complete culture medium supplemented with title comp. for 24 h; subsequently, cells were labeled with BrdU for 24 h; proliferation assessed with BrdU DNA-incorporation assay; ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

158/365

2017-08-01 06:49:42

Substance Dose

0.100000 mM

Qualitative Results

title comp. inhibited DNA synthesis in a dose-dependent manner; fig.

Measurement Parameter

Qualitative

Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 76 of 552

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : pancreatic stellate cells of LEW.1W inbred rats Bioassay : control: solvent (water) cells were plated in 6-well plates in complete culture medium supplemented with title comp. for 24 h; cell counts of live cells and dead cells were detd. by trypan blue staining assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. showed decrease of cell counts (no. of live cells); title comp. at 10 mM did not cause significant increase of dead cells; fig.

Measurement Parameter

Qualitative

Buelow, Robin; Fitzner, Brit; Sparmann, Gisela; Emmrich, Joerg; Liebe, Stefan; Jaster, Robert; Biochemical Pharmacology; vol. 74; nb. 12; (2007); p. 1747 - 1757, View in Reaxys 77 of 552

Substance Effect

Adipogenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : C/EBPβ expression C/EBP: CAAT/enhancer-binding protein; quantitative real-time PCR

Cells/Cell Lines

3T3 L1

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Haberland, Michael; Carrer, Michele; Mokalled, Mayssa H.; Montgomery, Rusty L.; Olson, Eric N.; Journal of Biological Chemistry; vol. 285; nb. 19; (2010); p. 14663 - 14670, View in Reaxys 78 of 552

Substance Effect

Adipogenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : Fabp4 expression Fabp4: adipocyte lipid-binding protein; quantitative real-time PCR

Cells/Cell Lines

3T3 L1

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Haberland, Michael; Carrer, Michele; Mokalled, Mayssa H.; Montgomery, Rusty L.; Olson, Eric N.; Journal of Biological Chemistry; vol. 285; nb. 19; (2010); p. 14663 - 14670, View in Reaxys

159/365

2017-08-01 06:49:42

79 of 552

Substance Effect

Adipogenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : PPARγ expression PRAR: peroxisome proliferator-activated receptor; quantitative real-time PCR

Cells/Cell Lines

3T3 L1

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Haberland, Michael; Carrer, Michele; Mokalled, Mayssa H.; Montgomery, Rusty L.; Olson, Eric N.; Journal of Biological Chemistry; vol. 285; nb. 19; (2010); p. 14663 - 14670, View in Reaxys 80 of 552

Substance Effect

Adipogenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

protein expression

Bioassay Details

Effect : SREBP-1c expression SREBP: sterol regulatory element-binding protein; quantitative real-time PCR

Cells/Cell Lines

3T3 L1

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Haberland, Michael; Carrer, Michele; Mokalled, Mayssa H.; Montgomery, Rusty L.; Olson, Eric N.; Journal of Biological Chemistry; vol. 285; nb. 19; (2010); p. 14663 - 14670, View in Reaxys 81 of 552

Substance Effect

Adipogenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : adipogenesis Oil red O staining; cells induced with mixture of isobutylmethylxanthine, insulin, rosiglitazone and dexamethasone; effect abolished by trichostatin A

Cells/Cell Lines

3T3 L1

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 µM

Qualitative Results

effective concentration 1000 μmol/l

Measurement Parameter

Qualitative

Haberland, Michael; Carrer, Michele; Mokalled, Mayssa H.; Montgomery, Rusty L.; Olson, Eric N.; Journal of Biological Chemistry; vol. 285; nb. 19; (2010); p. 14663 - 14670, View in Reaxys 82 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cartilage degradation; inhibition of Target : nasal septum cartilage of bovine Bioassay : Cartilage degradation assay. Bovine nasal cartilage was cultured as previously described (30) . Briefly, discs (approximately lmm3) were punched from bovine nasal sep-

160/365

2017-08-01 06:49:42

tum cartilage; three discs per well in a 24-well plate were incubated overnight in control, serum-free medium (DMEM containing 25mM HEPES, Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound reduced in dose-dependent IL-1α/OSM-induced both proteoglycan and collagen release (at day 7 and 14 respectively) (figure is given)

Measurement Parameter

Qualitative

Patent; UNIVERSITY OF EAST ANGLIA; WO2006/18657; (2006); (A1) English, View in Reaxys 83 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : gene expression; inhibition of Bioassay : Cell culture. SW1353 human chondrosarcoma cells were routinely cultured in Dulbecco's modified Eagle medium (DMEM, Invitrogen) containing 10% foetal bovine serum (FBS, Invitrogen) , 2mM glutamine, lOOIU/ml penicillin and lOOμg/ml streptomycin. Serum-free conditions used identical medium without

Biological Species/NCBI Human ID Cells/Cell Lines

SW-1353

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound reduced IL-1α/OSM-induced expression of MMPl, MMP3, MMP7, MMP8, MMPlO, MMP12, MMP13 and ADAMTS9 but not ADAMTS4 genes (figure is given)

Measurement Parameter

Qualitative

Patent; UNIVERSITY OF EAST ANGLIA; WO2006/18657; (2006); (A1) English, View in Reaxys 84 of 552

Target Mutant/Chimera Details

Prostaglandin G/H synthase 1:Wild

Target Subunit Proteins

Prostaglandin G/H synthase 1

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cyclooxygenase-1 expression; induction of Bioassay : effect of selected microbial metabolites and of Bifidobacterium sp. 420 on COX-1/COX-2 EXPRESSION PATTERN Materials and methods The human colorectal carcinoma cell line Caco-2 was grown at 37 &deg;C and 5 % CO2 in serum-free Dulbeccos'MEM (Gibco) supplemented with 1 mM sodium pyruvate (Gibco) and 1

Biological Species/NCBI Human ID Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title comp. at 5 mM increased COX-1 expression 30.96-fold and decreased COX-2 expression 0.15-fold

Measurement Parameter

Qualitative

Target, Subunit, Species Prostaglandin G/H synthase 1 85 of 552

Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

161/365

2017-08-01 06:49:42

Bioassay Details

Target : HCT116 human colorectal adenocarcinoma cells Bioassay : p21: p21Waf protein; Rb: retinoblastoma protein; PI: propidium iodide; cells with a sub-2n DNA content identified as apoptotic; mechanism of apoptosis induction studied, activation of caspase-3 determined (Western blotting) exponentially growing cells (parental, p21- and Rb-knockdown cultures) were treated with title comp. for 10 days; apoptosis detection: 48 h post-treatment analyzed for total DNA content by FACS analysis (PI staining) by colony counting

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Qualitative Results

at 0.5 mmol/l inhibited formation of p21-deficient colonies completely, those of p-21- and Rb-deficient colonies partly; at 2 mmol/l apoptotic effect on Rb-deficient cells significantly smaller, than that on parental cells; graphs

Measurement Parameter

Qualitative

Wagner, Sascha; Roemer, Klaus; Biochemical Pharmacology; vol. 69; nb. 7; (2005); p. 1059 - 1067, View in Reaxys 86 of 552

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : fungicidal MIC: the lowest concentration that inhibited the formation of mycelium after 14 days incubation; MFC: the lowest concentration which results in unviable spores after 21 days incubation

Biological Species/NCBI Penicillium brevicompactum ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MFC

Unit

Qualitative value

Quantitative value

Measurement pX

Petkovic, Marija; Ferguson, Jamie L.; Gunaratne, H. Q. Nimal; Ferreira, Rui; Leitao, Maria C.; Seddon, Kenneth R.; Rebelo, Luis Paulo N.; Pereira, Cristina Silva; Green Chemistry; vol. 12; nb. 4; (2010); p. 643 - 649, View in Reaxys 87 of 552

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Penicillium brevicompactum ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

162/365

2017-08-01 06:49:42

Measurement Parameter

MIC

Unit

Quantitative value

0.25

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Penicillium corylophilum ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MFC

Unit

Quantitative value

0.5

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Penicillium corylophilum ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MIC

Unit

Quantitative value

0.4

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : fungicidal

163/365

2017-08-01 06:49:42

MIC: the lowest concentration that inhibited the formation of mycelium after 14 days incubation; MFC: the lowest concentration which results in unviable spores after 21 days incubation Biological Species/NCBI Talaromyces diversus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MFC

Unit

Quantitative value

0.075

Measurement pX

1.12

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Talaromyces diversus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MIC

Unit

Quantitative value

0.05

Measurement pX

1.3

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Penicillium glandicola ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MFC

164/365

2017-08-01 06:49:42

Unit

Quantitative value

0.6

Substance Effect

Toxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Biological Species/NCBI Penicillium glandicola ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Measurement Parameter

MIC

Unit

Quantitative value

0.4

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Bioassay Details

Effect : astrocytes-conditioned medium (ACM)-induced dopamine (DA) uptake; effect on Bioassay : primary astroglial cultures treated with astrocytes-conditioned medium (ACM) Example 27: The HDAC inhibitor sodium butyrate mimics the neurotrophic effect of VPA on DA neurons HDAC is inhibited by therapeutically relevant concentrations of VPA and plays important roles in gene regulation; it could be the target of VPA-induced neuronal survival-promoting effects. We then asked

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

condition medium derived from incubation of astrocytes in the presence of 0.6 mM title compound showed a more robust increased in dopamine uptake compared with treatedastrocytes-conditioned medium (ACM) only; 0.6 mM title compound for 7 days caused

Measurement Parameter

Qualitative

Patent; HONG, Jau-Shyong; QIN, Liya; LI, Guorong; BLOCK, Michelle; ZHANG, Wei; CHEN, Po-See; PENG, Giia-Shuen; HONG, Jau-Shyong; QIN, Liya; LI, Guorong; BLOCK, Michelle; ZHANG, Wei; CHEN, Po-See; PENG, Giia-Shuen; (151 pag.); WO2005/112931; (A2); (2005), View in Reaxys 95 of 552

Bioassay Category

Metabolism/Transport

Bioassay Name

Flux uptake

Bioassay Details

Effect : dopamine uptake; effect on Bioassay : primary mesencephalic neuron-glia cells Example 27: The HDAC inhibitor sodium butyrate mimics the neurotrophic effect of VPA on DA neurons HDAC is inhibited by therapeutically relevant concentrations of VPA and plays important roles in gene regulation; it could be the target of VPA-induced neuronal survival-promoting effects. We then asked

165/365

2017-08-01 06:49:42

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound at 03, 0.6 and 1.2 mM enhanced dopamine uptake in a dose-dependent manner; figure is given

Measurement Parameter

Qualitative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : bezafibrate; interaction with Bioassay : SAHA, but not TSA augments the actions of clinically relevant PPAR and FXR ligands The actions of SAHA and TSA are different with some areas of commonality. Both agents are potent inhibitors of proliferation, and both display a range of combinatorial activities. However these are not the same. TSA augments

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compaund co-operated with bezafibrate

Measurement Parameter

Qualitative

Patent; THE UNIVERSITY OF BIRMINGHAM; WO2005/87206; (2005); (A2) English, View in Reaxys 97 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : astrocytes-conditioned medium (ACM)-induced dopamine (DA) uptake; effect on Target : primary astroglial cultures treated with astrocytes-conditioned medium (ACM) of rat Bioassay : Example 27: The HDAC inhibitor sodium butyrate mimics the neurotrophic effect of VPA on DA neurons HDAC is inhibited by therapeutically relevant concentrations of VPA and plays important roles in gene regulation; it could be the target of VPA-induced neuronal survival-promoting effects. We then asked

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Measurement Parameter

Qualitative

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys 98 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : dopamine uptake; effect on Target : primary mesencephalic neuron-glia cells of rat Bioassay : Example 27: The HDAC inhibitor sodium butyrate mimics the neurotrophic effect of VPA on DA neurons HDAC is inhibited by therapeutically relevant concentrations of VPA and plays important roles in gene regulation; it could be the target of VPA-induced neuronal survival-promoting effects. We then asked

Substance RN

3629439View in Reaxys

166/365

2017-08-01 06:49:42

Substance Name

1481199

Qualitative Results

title compound at 03, 0.6 and 1.2 mM enhanced dopamine uptake in a dose-dependent manner; figure is given

Measurement Parameter

Qualitative

Patent; THE GOVERNMENT OF THE UNITED STATES as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; WO2005/112931; (2005); (A2) English, View in Reaxys 99 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

no utilization as the sole source of carbon by Hyphomicrobium sp. JTS-811

Measurement Parameter

Qualitative

Kanamaru, Koichiro; Hieda, Tadaharu; Iwamuro, Yoshiaki; Mikami, Yoichi; Obi, Yukiteru; Kisaki, Takuro; Agricultural and Biological Chemistry; vol. 46; nb. 10; (1982); p. 2411 - 2418, View in Reaxys 100 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

effect on the formation of biotinyl-CoA synthetase by strain No. 166

Measurement Parameter

Qualitative

Yamada, Hideaki; Osakai, Miyako; Izumi, Yoshikazu; Agricultural and Biological Chemistry; vol. 48; nb. 8; (1984); p. 2039 - 2046, View in Reaxys 101 of 552 Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : growth inhibition |microorganisms Target : Salmolella typhi Bioassay : T: 20 deg C; metabolite of anaerobic treatments of rabbit waste slurry; 100 percent counts: 3E5 cfu ml-1

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 g/L

Qualitative Results

inhibited the growth of pathogen

Measurement Parameter

Qualitative

Singh; Ram; Alam; Maurya; Bulletin of Environmental Contamination and Toxicology; vol. 54; nb. 3; (1995); p. 472 - 478, View in Reaxys 102 of 552 Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : growth inhibition |microorganisms Bioassay : T: 20 deg C; metabolite of anaerobic treatments of rabbit waste slurry; 100 percent counts: 9.71E5 cfu ml-1

Biological Species/NCBI Escherichia coli ID Substance RN

3629439View in Reaxys

Substance Name

1481199

167/365

2017-08-01 06:49:42

Substance Dose

4 g/L

Qualitative Results

inhibited the growth of pathogen

Measurement Parameter

Qualitative

Singh; Ram; Alam; Maurya; Bulletin of Environmental Contamination and Toxicology; vol. 54; nb. 3; (1995); p. 472 - 478, View in Reaxys 103 of 552 Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : growth inhibition |microorganisms Bioassay : T: 20 deg C; metabolite of anaerobic treatments of rabbit waste slurry; 100 percent counts: 4E5 cfu ml-1

Biological Species/NCBI Staphylococcus aureus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 g/L

Qualitative Results

inhibited the growth of pathogen

Measurement Parameter

Qualitative

Singh; Ram; Alam; Maurya; Bulletin of Environmental Contamination and Toxicology; vol. 54; nb. 3; (1995); p. 472 - 478, View in Reaxys 104 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : effect in presence of flavopiridol and nuclear factor-κB DNA binding activity, mitochondrial injury and caspase activation further studied; title comp. is histone deacetylase inhibitor cells stably transfected with Ser32/Ser36 mutant IκBα cDNA treated with title comp. for 24 h, then stained with Annexin V-fluorescein isothiocyanate/propidium iodide; apoptosis determined by flow cytometry

Biological Species/NCBI Human ID Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. caused modest, but significant increase in apoptosis; greater effect in presence of flavopiridol

Measurement Parameter

Qualitative

Gao, Ning; Dai, Yun; Rahmani, Mohamed; Dent, Paul; Grant, Steven; Molecular Pharmacology; vol. 66; nb. 4; (2004); p. 956 - 963, View in Reaxys 105 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : STAT5-N642H: constitutively active STAT5 mutant; 17-AAG: 17-allylamino 17demethoxygeldanamycin; STAT: signal transducer and activator of transcription; STAT: signal transducer and activator of transcription cells expressing STAT5-N642H or empty vector pMX-neo were treated with title comp. with or without 1.5 μmol/l 17-AAG for 24 h; apoptosis determined by annexin V staining

Cells/Cell Lines

K562R

168/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 µM

Qualitative Results

title comp. with 17-AAG but not title comp. alone significantly increased apoptosis

Measurement Parameter

Qualitative

Rahmani, Mohamed; Reese, Erin; Dai, Yun; Bauer, Cheryl; Kramer, Lora B.; Huang, Mei; Jove, Richard; Dent, Paul; Grant, Steven; Molecular Pharmacology; vol. 67; nb. 4; (2005); p. 1166 - 1176, View in Reaxys 106 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : STI571: imatinib mesylate; 17-AAG: 17-allylamino 17-demethoxygeldanamycin logarithmically growing STI571-resistant cells treated with title comp. with or without 1.5 μmol/l 17-AAG for 24 h; apoptosis determined by annexin V staining

Cells/Cell Lines

K562R

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Qualitative Results

title comp. alone was minimally toxic; title comp. with 17-AAG markedly increased apoptosis

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : 17-AAG: 17-allylamino 17-demethoxygeldanamycin cells treated with title comp. with or without 1.5 μmol/l 17-AAG for 24 h; cells lysed; lysate immunopecipitated with anti-Bax monoclonal antibody; Bax determined in immunoprecipitate by Western blotting

Cells/Cell Lines

K562R

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 µM

Qualitative Results

title comp. alone modestly induced conformational change in Bax; title comp. with 17-AAG produced very marked Bax conformational change

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : 17-AAG: 17-allylamino 17-demethoxygeldanamycin; MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt cells treated with title comp. with or without 1.5 μmol/l 17-AAG for 24 - 72 h; cell growth determined using MTS assay

Cells/Cell Lines

K562R

Substance RN

3629439View in Reaxys

169/365

2017-08-01 06:49:42

Substance Name

1481199

Substance Dose

2 mM

Qualitative Results

title comp. with 17-AAG dramatically reduced number of surviving cells relative to effect of title comp. alone

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : 17-AAG: 17-allylamino 17-demethoxygeldanamycin logarithmically growing cells treated with title comp. with or without 1 μmol/l 17-AAG for 24 h; apoptosis determined by annexin V staining

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Qualitative Results

title comp. alone was minimally toxic; title comp. with 17-AAG markedly increased apoptosis

Measurement Parameter

Qualitative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Bioassay : 17-AAG: 17-allylamino 17-demethoxygeldanamycin; PARP: poly(ADP-ribose) polymerase cells treated with title comp. with or without 1 μmol/l 17-AAG for 24 h; whole cell lysate prepared; procaspase-3 and PARP determined by Western blotting

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Qualitative Results

title comp. with 17-AAG but not title comp. alone markedly increased procaspase-3 activation and PARP degradation

Measurement Parameter

Qualitative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |antagonist Target : rabbit renal cortical mitochondria Bioassay : determination of <1-14C>pyruvate or <1-14C>butyrate uptake (nmol/g protein) in vitro, renal mithochondrium was prepared from New Zealand White rabbits (1.6-2.0 kg); add. of Na <1-14C>pyruvate (3.6 μM) or <1-14C>butyrate (2 μM): radioligand binding assay

Substance RN

3629439View in Reaxys

170/365

2017-08-01 06:49:42

Substance Name

1481199

Substance Dose

0.500000 mM

Qualitative Results

title comp. inhibited the transport of <1-14C>butyrate at dose 2.5 mM, but had no effect on <1-14C>pyruvate uotake at 2.5 mM

Measurement Parameter

Qualitative

Tune; Hsu; Journal of Pharmacology and Experimental Therapeutics; vol. 274; nb. 1; (1995); p. 194 - 199, View in Reaxys 112 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : parenchymal cell differentiation; induction of Target : DDY mouse liver slices Bioassay : in supplemented Dulbecco Modified Eagle Medium:Nutrient Mixture F-12 containing insulin, epidermal growth factor, and nicotinamide; in rotating tubes (10 rev/h); untreated tissue as control; Cx32 is a gap junctional protein in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 d; tissues fixed 1-2 weeks after culture; immunocytochemistry for connexin (Cx) 32

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 mM

Qualitative Results

number of Cx32-positive plaques increased in treated tissues compared to control (photomicrographs): 1.8 versus 0.8 after 1 week and 0.9 versus 0.7 after 2 weeks; gap junctional structures or cell-to-cell communication preserved in treated tissues

Measurement Parameter

Qualitative

Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys 113 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : parenchymal cell differentiation; induction of Target : DDY mouse liver slices Bioassay : in supplemented Dulbecco Modified Eagle Medium:Nutrient Mixture F-12 containing insulin, epidermal growth factor, and nicotinamide; in rotating tubes (10 rev/h); untreated tissue as control; cytokeratin (CK) as marker for epithelium in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 d; tissues fixed 1 or 2 weeks after culture; immunocytochemistry for CK-19

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 mM

Qualitative Results

clusters of CK-19-positive cells were more numerous in treated tissues than in control (photomicrographs): 8.4 percent versus 6.5 percent after 1 week and 11.2 percent versus 6.7 percent after 2 weeks

Measurement Parameter

Qualitative

Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys 114 of 552

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

171/365

2017-08-01 06:49:42

treated tissue as control in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 days; tissues examined 1 week after replacing; phase-contrast microscopy Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 mM

Qualitative Results

spreading of liver tissues is reduced; glandular structures are scattered at periphery; polygonal cells in monolayer are swollen and flattened (photomicrographs)

Measurement Parameter

Qualitative

Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys 115 of 552

Target Mutant/Chimera Details

Serum albumin:Wild

Target Subunit Proteins

Serum albumin

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : albumin expression; increase in Bioassay : in supplemented Dulbecco Modified Eagle Medium:Nutrient Mixture F-12 containing insulin, epidermal growth factor, and nicotinamide; in rotating tubes (10 rev/h); untreated tissue as control in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 days; tissues fixed 1 or 2 weeks after culture; immunocytochemistry for albumin

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 mM

Qualitative Results

albumin-positive cells were more numerous in treated tissues than in control (photomicrographs): 68.3 percent versus 62.2 percent after 1 week and 74.2 percent versus 57.3 percent after 2 weeks

Measurement Parameter

Qualitative

Target, Subunit, Species Serum albumin Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys 116 of 552

Target Mutant/Chimera Details

Serum albumin:Wild

Target Subunit Proteins

Serum albumin

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : albumin synthesis; induction of Bioassay : in supplemented Dulbecco Modified Eagle Medium:Nutrient Mixture F-12 containing insulin, epidermal growth factor, and nicotinamide; in rotating tubes (10 rev/h); untreated tissue as control in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 d and cultured for 1-3 weeks; albumin level in medium measured by ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

172/365

2017-08-01 06:49:42

Substance Dose

10 mM

Qualitative Results

albumin level in medium was significantly higher in treated tissues than in control; albumin level versus time in treated and intact tissues (graphic representation)

Measurement Parameter

Qualitative

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : DDY mouse liver slices Bioassay : in supplemented Dulbecco Modified Eagle Medium:Nutrient Mixture F-12 containing insulin, epidermal growth factor, and nicotinamide; in rotating tubes (10 rev/h); untreated tissue as control; PCNA, proliferating cell nuclear antigen in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 d; tissues fixed 1 or 2 weeks after culture; immunocytochemistry for PCNA

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 mM

Qualitative Results

number of PCNA-positive cells decreased in treated tissues compared to control: 30.1 percent versus 33.3 percent after 1 wk and 18.2 percent versus 31.5 percent after 2 wk; no PCNA-immunoreactivity in enlarged hepatocytes; title comp. may decrease parenchymal

Measurement Parameter

Qualitative

Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys 118 of 552

Target Mutant/Chimera Details

Alpha-fetoprotein:Wild

Target Subunit Proteins

Alpha-fetoprotein

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : α-fetoprotein expression; decrease in Bioassay : in supplemented Dulbecco Modified Eagle Medium:Nutrient Mixture F-12 containing insulin, epidermal growth factor, and nicotinamide; in rotating tubes (10 rev/h); untreated tissue as control in vivo; fetal livers of gestational day 18; 400 μm slices; organotypic slice culture; 37 deg C; 5 percent CO2; culture medium replaced with or without title comp. at 3 and 10 d; tissues fixed 1 or 2 weeks after culture; immunocytochemistry for αfetoprotein

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 mM

Qualitative Results

α-fetoprotein-positive cells reduced in number in treated tissues compared to control: 55.6 percent versus 64.3 percent after 1 week and 51.9 percent versus 61.5 percent after 2 weeks; most swollen hepatocytes do not show α-fetoprotein-immunoreactivity

Measurement Parameter

Qualitative

Target, Subunit, Species Alpha-fetoprotein

173/365

2017-08-01 06:49:42

Iwai, Masaki; Tanaka; Mori; Harada; Muramatsu; Morikawa; Kashima; Fushiki; Cell Biology and Toxicology; vol. 18; nb. 3; (2002); p. 147 - 156, View in Reaxys 119 of 552

Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : cytotoxic Bioassay : non-small cell lung cancer (NSCLC) cells H1299 Antiproliferative effects of CNDAC and sodium butyrate against non-small cell lung cancer cells (H460 and Hl 299)Table 3 shows the effects of CNDAC and sodium butyrate against H460 and H 1299 cells. These results demonstrate that CNDAC and butyrate generate moderate to strong synergy in H460 and H 1299

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED50

Quantitative value

0.36

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 120 of 552 Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : cytotoxic Bioassay : non-small cell lung cancer (NSCLC) cells H460 Antiproliferative effects of CNDAC and sodium butyrate against non-small cell lung cancer cells (H460 and Hl 299)Table 3 shows the effects of CNDAC and sodium butyrate against H460 and H 1299 cells. These results demonstrate that CNDAC and butyrate generate moderate to strong synergy in H460 and H 1299

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED50

Quantitative value

0.99

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 121 of 552 Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED75

Quantitative value

0.48

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 122 of 552 Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

174/365

2017-08-01 06:49:42

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED75

Quantitative value

0.89

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 123 of 552 Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED90

Quantitative value

1.04

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 124 of 552 Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED90

Quantitative value

0.83

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 125 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |antagonist Target : BALB/c mouse splenic B cells Bioassay : 5 d incub.; 15 μg of histones isolated after 12 h of incubation; level of histone H4 acetylation analyzed by densitometry; number of anti-TNP PFC determined; TNP: trinitrophenyl; PFC: plaque-forming cells; TSA: trichostatin A in vitro; effect on TSA-enhanced anti-TNP PFC response and histone H4 acetylation assayed; 3.5E6 cells/well cultured with 5 μg/ml TNP-LPS; RPMI 1640 with 10 percent heat inactivated FCS; 3 nmol/l TSA; also with 100 U/ml IL-2; 5 percent CO2/95 percent air; 37 deg C;

175/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Qualitative Results

title comp. markedly inhibited TSA-enhanced anti-TNP antibody response in the absence but not in the presence of IL-2 (graphical representation)

Measurement Parameter

Qualitative

Okamura, Takayuki; Gohda, Eiichi; Kohge, Takashi; Yamamoto, Itaru; Biological and Pharmaceutical Bulletin; vol. 22; nb. 12; (1999); p. 1288 - 1292, View in Reaxys 126 of 552 Substance Effect

Immunostimulant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : BALB/c mouse splenic B cells Bioassay : level of histone acetylation analyzed by densitometry; cells cultured for another 5 days; number of anti-TNP PFC determined; TNP: trinitrophenyl; PFC: plaque-forming cells in vitro; effect on anti-TNP antibody production measured by histone H4 acetylation; 3.5E6 cells/well cultured with 5 μg/ml TNP-LPS in RPMI 1640 with 10 percent heat inactivated FCS; 100 U/ml IL-2; 5 percent CO2/95 percent air; 37 deg C; 12 h incub.; histones isolated

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.100000 mM

Qualitative Results

title comp. dose-dependently increased the acetylation levels of histone H4 and enhanced anti-TNP antibody production (graphical representation)

Measurement Parameter

Qualitative

Okamura, Takayuki; Gohda, Eiichi; Kohge, Takashi; Yamamoto, Itaru; Biological and Pharmaceutical Bulletin; vol. 22; nb. 12; (1999); p. 1288 - 1292, View in Reaxys 127 of 552 Substance Effect

Immunostimulant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : BALB/c mouse splenic B cells Bioassay : number of anti-TNP PFC determined; 15 μg of histones isolated after 12 h of incubation; level of histone H4 acetylation analyzed by densitometry; TNP: trinitrophenyl; PFC: plaque-forming cells in vitro; effect on anti-TNP PFC response and histone H4 acetylation assayed; 3.5E6 cells/well cultured with 5 μg/ml TNP-LPS in RPMI 1640 with 10 percent heat inactivated FCS; also in the presence of 100 U/ml IL-2; 5 percent CO2/95 percent air; 37 deg C; 5 d incub.

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.300000 mM

Qualitative Results

title comp. increased anti-TNP antibody response in the presence of IL-2 (graphical representation)

Measurement Parameter

Qualitative

Okamura, Takayuki; Gohda, Eiichi; Kohge, Takashi; Yamamoto, Itaru; Biological and Pharmaceutical Bulletin; vol. 22; nb. 12; (1999); p. 1288 - 1292, View in Reaxys 128 of 552 Substance Effect

Immunostimulant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : BALB/c mouse splenic B cells

176/365

2017-08-01 06:49:42

Bioassay : 15 μg of histones isolated after 12 h of incubation; level of histone H4 acetylation analyzed by densitometry; number of anti-TNP PFC determined; TNP: trinitrophenyl; PFC: plaque-forming cells; TSA: trichostatin A in vitro; effect on anti-TNP PFC response and histone H4 acetylation assayed; 3.5E6 cells/well cultured with 5 μg/ml TNP-LPS in RPMI 1640 with 10 percent heat inactivated FCS; also with 100 U/ml IL-2 and/or 3 nmol/l TSA; 5 percent CO2/95 percent air; 37 deg C; 5 d incub. Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Qualitative Results

title comp. increased anti-TNP antibody response in the presence of IL-2 (graphical representation)

Measurement Parameter

Qualitative

Okamura, Takayuki; Gohda, Eiichi; Kohge, Takashi; Yamamoto, Itaru; Biological and Pharmaceutical Bulletin; vol. 22; nb. 12; (1999); p. 1288 - 1292, View in Reaxys 129 of 552 Substance Effect

Immunostimulant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : BALB/c mouse splenocytes Bioassay : TNP: trinitrophenyl; PFC: plaque-forming cells in vitro; effect on anti-TNP PFC response assayed; 8E6 cells/well cultured with 5 μg/ml TNP-LPS in RPMI 1640 with 10 percent heat inactivated FCS; 5 percent CO2/95 percent air; 37 deg C; 5 d incub.; number of anti-TNP PFC determined

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.300000 mM

Qualitative Results

title comp. increased anti-TNP antibody production (graphical representation)

Measurement Parameter

Qualitative

Okamura, Takayuki; Gohda, Eiichi; Kohge, Takashi; Yamamoto, Itaru; Biological and Pharmaceutical Bulletin; vol. 22; nb. 12; (1999); p. 1288 - 1292, View in Reaxys 130 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric lymph node lymphocytes Bioassay : control: untreated cells cells stimulated with concanavalin A; incubated with title comp. alone or with acetate and/or propionate at 37 deg C; after 48 h, incubated with <6-3H>thymidine for 18 h; thymidine incorporation measured by liquid scintillation counting

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.250000 mM

Qualitative Results

title comp. and its combinations significantly decreased thymidine incorporation by more than 99%; title comp. effect apparent at 0.25 mmol/l and 0.5 mmol/l title comp. caused 50% inhibition of thymidine incorporation; table

Measurement Parameter

Qualitative

Cavaglieri, Claudia R.; Nishiyama, Anita; Fernandes, Luis Claudio; Curi, Rui; Miles, Elizabeth A.; Calder, Philip C.; Life Sciences; vol. 73; nb. 13; (2003); p. 1683 - 1690, View in Reaxys 131 of 552 Substance Effect Bioassay Category

Cytotoxic In Vitro (Efficacy)

177/365

2017-08-01 06:49:42

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric lymph node lymphocytes Bioassay : control: untreated cells cells stimulated with concanavalin A; incubated with title comp. alone or with acetate and/or propionate at 37 deg C; cell viability assessed by trypan blue exclusion assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Measurement Parameter

Qualitative

Qualitative value

Antiinflammatory

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric lymph node lymphocytes Bioassay : control: untreated cells cells stimulated with concanavalin A; incubated with title comp. alone or with acetate and/or propionate at 37 deg C; interleukin (IL)-2 production measured after 24 or 48 h using cytoscreenTM ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Qualitative Results

title comp. signif. inhibited IL-2 level by over 80%, 90% at 24 h, 48 h, resp.; in combination with propionate and/or acetate, title comp. signif. inhibited IL-2 level; acetate and/or propionate partly prevent inhibitory effect of title comp.; table

Measurement Parameter

Qualitative

Antiinflammatory

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric lymph node lymphocytes Bioassay : control: untreated cells; ratio of concn. of IFN-γ to IL-10 used as measure of pro-vs. anti-inflammatory cytokine balance cells stimulated with concanavalin A; incubated with title comp. alone or with acetate and/or propionate at 37 deg C; interleukin (IL)-10, interferon (IFN)-γ concentrations measured after 24 or 48 h using cytoscreenTM ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Qualitative Results

title comp. alone had little effect on IL-10 production; in combinations, IL-10 increased by 40-70%, at 48 h; title comp. markedly decreased IFN-γ to IL-10 ratio; ratio was decreased in combination treatment; table

Measurement Parameter

Qualitative

Antiinflammatory In Vitro (Efficacy)

178/365

2017-08-01 06:49:42

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric lymph node lymphocytes Bioassay : control: untreated cells; ratio of concn. of IFN-γ to IL-10 used as measure of pro-vs. anti-inflammatory cytokine balance; Con A: concanavalin A cells stimulated with concanavalin A; incubated with title comp. alone or with acetate and/or propionate at 37 deg C; interleukin (IL)-10, interferon (IFN)-γ concentrations measured after 24 or 48 h using cytoscreenTM ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Qualitative Results

title comp. significantly inhibited IFN-γ production, by over 95%; title comp. effect was abolished in combination treatments; title comp. markedly decreased IFN-γ to IL-10 ratio; ratio was decreased in combination treatment; table

Measurement Parameter

Qualitative

Antiinflammatory

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric lymph node lymphocytes Bioassay : control: untreated cells cells stimulated with concanavalin A; incubated with title comp. alone or with acetate and/or propionate at 37 deg C; interleukin-4 concentrations measured after 24 or 48 h using cytoscreenTM ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.50000 mM

Measurement Parameter

Qualitative

Qualitative value

Antiangiogenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HIF-1 = hypoxia-inducible factor 1; VEGF = vascular endotherial growth factor; title comp. is a histone deacetylase inhibitor cells stably transfected with HIF-1-dependent VEGF promoter reporter gene, incubated in presence of title comp. for 8 h in hypoxia, then inhibition of luciferase activity determined by luciferase assay and inhibition of cell viability by MTT assay

Cells/Cell Lines

CHO

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.0300000 µM

Qualitative Results

at non-cytotoxic concentrations (max. 125 μM) expression of VEGF promoter reporter gene accelerated; at higher concentrations dose-dependent inhibition cell viability observed

Measurement Parameter

Qualitative

179/365

2017-08-01 06:49:42

Yamazaki, Yohko; Egawa, Kiyoshi; Nose, Kiyoshi; Kunimoto, Setsuko; Takeuchi, Tomio; Biological and Pharmaceutical Bulletin; vol. 26; nb. 4; (2003); p. 417 - 420, View in Reaxys 137 of 552 Substance Effect

Antiproliferative

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Target : ICR mouse peritoneal exudate cells Bioassay : MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; control: without title comp.; DSS: dextran sulfate sodium test cells incubated with title comp. in Dulbecco's Modified Eagle Medium at 37 deg C for 30 min in 5 percent humidified CO2 atmosphere; 1 μg/ml DSS added and incubated for 12 h; cell viability measured with MTT test

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

20 µM

Qualitative Results

cell viability was 74.0 percent and 42.6 percent at 20 and 100 μmol/l of title comp., respectively compared to control

Measurement Parameter

Qualitative

Kwon, Ki Han; Murakami, Akira; Ohigashi, Hajime; Bioscience, Biotechnology and Biochemistry; vol. 68; nb. 2; (2004); p. 436 - 439, View in Reaxys 138 of 552 Target Mutant/Chimera Details

cytokine:Wild

Target Subunit Proteins

cytokine

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cytokine production; effect on Bioassay : MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; control: without title comp. and without DSS (IL-1β level 1.37 pg/ml), without title comp. (IL-1β level 103 pg/ml); DSS: dextran sulfate sodium test cells incubated with title comp. in Dulbecco's Modified Eagle Medium at 37 deg C for 30 min in 5 percent humidified CO2 atmosphere; 1 μg/ml DSS added and incubated for 12 h; IL-1β level in medium supernatant measured with ELISA

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

20 µM

Qualitative Results

title comp. caused change of IL-1β level to 31.6 and 157 pg/ml at 20 and 100 μmol/l, respectively

Measurement Parameter

Qualitative

Target, Subunit, Species cytokine Kwon, Ki Han; Murakami, Akira; Ohigashi, Hajime; Bioscience, Biotechnology and Biochemistry; vol. 68; nb. 2; (2004); p. 436 - 439, View in Reaxys 139 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |growth inhibition Target : mouse melanoma B16 2F2 cells Bioassay : B16 2F2 cells: B16-derived sub-clone with high differentiation capability 1E5 cells incubated with title comp. for 72 h, then cell growth and differentiation-inducing activity measured ( percent of highly pigmented cells counted under light microscope)

Substance RN

3629439View in Reaxys

180/365

2017-08-01 06:49:42

Substance Name

1481199

Substance Dose

1 mM

Measurement Parameter

Qualitative

Qualitative value

Hata, Keishi; Ishikawa, Kyoko; Hori, Kazuyuki; Konishi, Tomokazu; Biological and Pharmaceutical Bulletin; vol. 23; nb. 8; (2000); p. 962 - 967, View in Reaxys 140 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |growth inhibition Bioassay : NBT: nitroblue tetrazolium 1E5 cells incubated with title comp. for 72 h, then cell growth and differentiation-inducing activity measured ( percent of NBT-positive cells determined)

Cells/Cell Lines

HL-60/TB

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

cell number (x1E-5) and differentiation ( percent) in control/after title comp.-treatment: 7.9/3.8 and 4.5/40.3, respectively

Measurement Parameter

Qualitative

Hata, Keishi; Ishikawa, Kyoko; Hori, Kazuyuki; Konishi, Tomokazu; Biological and Pharmaceutical Bulletin; vol. 23; nb. 8; (2000); p. 962 - 967, View in Reaxys 141 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : Seliciclib and Butyrate synergistically induce apoptosis in A549 cells.A549 cells were treated with DMSO (control) or with IC50 concentrations of seliciclib, sodium butyrate, or seliciclib and butyrate for 72h, as indicated. Cell culture supernatants were harvested and tested in the M30 apoptosense

Cells/Cell Lines

A 549

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound resulted in an ~300% of control caspase cleavage of cytokeratin 18; figure is given

Measurement Parameter

Qualitative

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 142 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : Seliciclib and Butyrate induce a synergistic increase in apoptotic H460 cells.H460 cells were incubated with 0.25 - 1.5X IC50 butyrate, 0.25 - 1.5 X IC50 seliciclib, or 0.25 - 1.5 X IC50 seliciclib and butyrate for 72h. Cells were then harvested, stained with annexin V and analysed on the flow cytometer.

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

181/365

2017-08-01 06:49:42

Qualitative Results

highest concentration of title compound appeared to contain fewer cells undergoing apoptosis than those treated with 0.67 X or 1 X IC50; figure is given

Measurement Parameter

Qualitative

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 143 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : sub-G1 A549 cells Bioassay : Seliciclib and Butyrate induce a synergistic increase in sub-Gl A549 cells.A549 cells were incubated with IC50 butyrate, 0.25 - 1.5 X IC50 seliciclib, or 0.25 - 1.5 X IC50 seliciclib in the presence of IC50 butyrate for 72h. Cells were then harvested, stained with propidium iodide and their DNA content

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound alone induced a small increase in sub-G1 cells, which are dead or undergoing apoptosis; figure is given

Measurement Parameter

Qualitative

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 144 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : EXAMPLESMethodsCompounds of formula I and formula II Compounds of formula I and formula II were prepared in accordance with the methods disclosed in WO 2004/016612 and WO 2005/042525 (both to Cyclacel Limited).Compound [1] referred to herein is (2R,3S)-3-({9-isopropyl-6-[(pyridin-3- ylmethyl)amino]-9H-purin-2-yl

Cells/Cell Lines

A 549

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

pretreatment with title compound resulted in an ED50, ED75 and ED90 of 0.95, 0.71 and 0.60 respectively; title compound administration resulted in an ED50, ED75 and ED90 of 1.08, 0.88 and 0.75 respectively when cells were pretreated with seliciclib;

Measurement Parameter

Qualitative

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 145 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED50

Quantitative value

0.92

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys

182/365

2017-08-01 06:49:42

146 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-apoptotic protein Mcl-1 level; effect on Bioassay : Seliciclib and Butyrate synergistically induce apoptosis in A549 cells.A549 cells were treated with DMSO (control) or with IC50 concentrations of seliciclib, sodium butyrate, or seliciclib and butyrate for 72h, as indicated. Cell culture supernatants were harvested and tested in the M30 apoptosense

Cells/Cell Lines

A 549

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 147 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-apoptotic protein Bcl-2 level; reduction of Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound reduced the level of anti-apoptotic protein Bcl-2; figure is given

Measurement Parameter

Qualitative

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 148 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-apoptotic protein Mcl-1 level; effect on Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 149 of 552 Target Mutant/Chimera Details

Actin:Wild

Target Subunit Proteins

Actin

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : actin level; effect on

183/365

2017-08-01 06:49:42

Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species Actin Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 150 of 552 Target Mutant/Chimera Details

E3 ubiquitin-protein ligase XIAP:Wild

Target Subunit Proteins

E3 ubiquitin-protein ligase XIAP

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : caspase inhibitor XIAP level; effect on Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species E3 ubiquitin-protein ligase XIAP Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 151 of 552 Target Mutant/Chimera Details

Baculoviral IAP repeat-containing protein 5.1-B:Wild

Target Subunit Proteins

Baculoviral IAP repeat-containing protein 5.1-B

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : caspase inhibitor survivin level; reduction of Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound reduced the level of caspase inhibitor survivin; figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species Baculoviral IAP repeat-containing protein 5.1-B

184/365

2017-08-01 06:49:42

Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 152 of 552 Target Mutant/Chimera Details

Histone:Wild

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : acetylated histone level; effect on Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species Histone Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 153 of 552 Target Mutant/Chimera Details

Caspase-3:Wild

Target Subunit Proteins

Caspase-3

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : caspase 3; effect on Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a time-dependent manner. <n="51"/>H460 cells were treated with IX IC50 butyrate, seliciclib or seliciclib and butyrate for the indicated times. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species Caspase-3 Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 154 of 552 Target Mutant/Chimera Details

Caspase-9:Wild

Target Subunit Proteins

Caspase-9

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : caspase 9; effect on Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a time-dependent manner. <n="51"/>H460 cells were treated with IX IC50 butyrate, seliciclib or seliciclib and

185/365

2017-08-01 06:49:42

butyrate for the indicated times. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species Caspase-9 Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 155 of 552 Target Mutant/Chimera Details

Poly [ADP-ribose] polymerase:Wild

Target Subunit Proteins

Poly [ADP-ribose] polymerase

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cleaved PARP; effect on Bioassay : Seliciclib and Butyrate regulate several apoptotic proteins in a dose-dependent manner.H460 cells were treated with butyrate, seliciclib or seliciclib and butyrate at 1 X or 1.5 X IC50 concentrations for 24h. Cells were harvested and the resulting cell lysates analysed by western blotting with the indicated

Cells/Cell Lines

NCI-H460

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

figure is given

Measurement Parameter

Qualitative

Target, Subunit, Species Poly [ADP-ribose] polymerase Patent; CYCLACEL LIMITED; WO2007/54725; (2007); (A2) English, View in Reaxys 156 of 552 Target Mutant/Chimera Details

Histone:Wild

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : H2B histone acetylation; inhibition of Bioassay : After establishing garcinol as a strong inhibitor of HATs in vitro, we further investigated whether it could also affect the acetylation of histones in vivo. For this purpose HeLa cells were grown in monolayer (see experimental procedures) and were treated with either DMSO (the solvent for garcinol)

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound enhanced the acetylation of histone H2B dramatically

Measurement Parameter

Qualitative

Target, Subunit, Species Histone 157 of 552 Target Mutant/Chimera Details

Histone:Wild

186/365

2017-08-01 06:49:42

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : H4 histone acetylation; inhibition of Bioassay : After establishing garcinol as a strong inhibitor of HATs in vitro, we further investigated whether it could also affect the acetylation of histones in vivo. For this purpose HeLa cells were grown in monolayer (see experimental procedures) and were treated with either DMSO (the solvent for garcinol)

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound enhanced the acetylation of histone H4 dramatically

Measurement Parameter

Qualitative

Target, Subunit, Species Histone 158 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cellular morphology; effect on Target : HEK AD293 (embryonic kidney) cells of human Bioassay : Cell culture methods and supplementation with butyrate derivatives 1- 5For cell culture studies, But4ManNAc (1) (50) was used as a mixture of anomers (a/β = 10/90), But4GlcNAc (2) as pure α-anomer and ButsMan (3) as pure β- anomer (It is noteworthy that the intracellular

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Upon three days of incubation, the test compound induced differentiation of HeLa cells; figure given

Measurement Parameter

Qualitative

Patent; THE JOHNS HOPKINS UNIVERSITY; WO2006/127977; (2006); (A1) English, View in Reaxys 159 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : p21WAF1 level; increasing of Target : Jurkat cells (Clone E- 6) incubated with FITC-conjugated anti-p21WAF1 antibody Bioassay : Cell culture methods and supplementation with butyrate derivatives 1- 5For cell culture studies, But4ManNAc (1) (50) was used as a mixture of anomers (a/β = 10/90), But4GlcNAc (2) as pure α-anomer and ButsMan (3) as pure β- anomer (It is noteworthy that the intracellular

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

The test compound increased p21WAF1 levels over a one week test period ; figure given

Measurement Parameter

Qualitative

Patent; THE JOHNS HOPKINS UNIVERSITY; WO2006/127977; (2006); (A1) English, View in Reaxys 160 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cellular morphology; effect on Bioassay : Cell culture methods and supplementation with butyrate derivatives 1- 5For cell culture studies, But4ManNAc (1) (50) was used as a mixture of anomers (a/β = 10/90),

187/365

2017-08-01 06:49:42

But4GlcNAc (2) as pure α-anomer and ButsMan (3) as pure β- anomer (It is noteworthy that the intracellular Biological Species/NCBI Human ID Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Upon three days of incubation, the test compound induced differentiation of HeLa cells; figure given

Measurement Parameter

Qualitative

Patent; THE JOHNS HOPKINS UNIVERSITY; WO2006/127977; (2006); (A1) English, View in Reaxys 161 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : Cell culture methods and supplementation with butyrate derivatives 1- 5For cell culture studies, But4ManNAc (1) (50) was used as a mixture of anomers (a/β = 10/90), But4GlcNAc (2) as pure α-anomer and ButsMan (3) as pure β- anomer (It is noteworthy that the intracellular

Cells/Cell Lines

Jurkat

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

By day 15, control cells had almost completely recovered from early inhibition but the ManNAc-treated cells showed susceptibility to the test compound at 2.0 mM and above; figure given

Measurement Parameter

Qualitative

Patent; THE JOHNS HOPKINS UNIVERSITY; WO2006/127977; (2006); (A1) English, View in Reaxys 162 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |antagonist Bioassay : in vitro; Balb/c 3T3 cells; cell growth protein assay, tetrazolium blue (MTT) assay, metallothionein assay, glutathione assay; influence on Cd2+ (as CdCl2) cytotoxicity; added simultaneously

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

antagonize Cd2+ cytotoxicity; pretreatment for 24 h followed by removal does not confer protection against Cd2+; does not protect from Zn2+ and Hg2+ cytotoxicity

Measurement Parameter

Qualitative

Shopsis; Cell Biology and Toxicology; vol. 10; nb. 3; (1994); p. 191 - 205, View in Reaxys 163 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : survival motor neuron protein 2 (SMN2) expression; effect on Target : SMA-like embryonic fibroblasts (Smn-/-, SMN2) of mouse Bioassay : Example 1-Screening of Compounds for SMN2-Enhancing ActivityScreening of compounds for SMN2-enhancing activity was performed as follows. We used SMA-like mouse embryonic fibroblasts (Smn-/-, SMN2) (MEFs) with a similar SMN2 copy number (FIG. 1A, SMN2 copy number=1.54) to mimic Type I SMA patients for

188/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Hung, Li; US2008/187512; (A1); (2008), View in Reaxys 164 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : survival motor neuron protein 2 (SMN2) expression; effect on Target : SMN2-transfected motor neuron-like NSC34 cells (SMN2-NSC34) Bioassay : Example 1-Screening of Compounds for SMN2-Enhancing ActivityScreening of compounds for SMN2-enhancing activity was performed as follows. We used SMA-like mouse embryonic fibroblasts (Smn-/-, SMN2) (MEFs) with a similar SMN2 copy number (FIG. 1A, SMN2 copy number=1.54) to mimic Type I SMA patients for

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound treatment at 25 mM effectively enhanced SMN2 expression

Measurement Parameter

Qualitative

Patent; Hung, Li; US2008/187512; (A1); (2008), View in Reaxys 165 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : Materials and Methods: Tissue source, processing, and primary culture Tumour tissue specimens were obtained from patients during open surgical resection of glioblastoma multiforme (GBM, WHO grade IV) according to per-operative diagnosis on cryostat sections. Recovery of tissue was done with the permission

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Title compound at concentrations up to 100 mM have a slight antiproliferative effect on hGBM-1 culture cells; figure is given.

Measurement Parameter

Qualitative

Patent; ZGene A/S; WO2005/79849; (2005); (A2) English, View in Reaxys 166 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DNA-binding activity; inhibition of Bioassay : LPS: lipopolysaccharide; NF: nuclear factor cultured slices treated with title comp. in combination with LPS (10 μg/ml) for 24 h; DNA-binding activity of NF-κB complex measured by EMSA assay

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

5 mmol/l title comp. reduced DNA-binding activity of NF-κB complex in LPS-stimulated slices (figure)

189/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Huuskonen, Jari; Suuronen, Tiina; Nuutinen, Tapio; Kyrylenko, Sergiy; Salminen, Antero; British Journal of Pharmacology; vol. 141; nb. 5; (2004); p. 874 - 880, View in Reaxys 167 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Bioassay : LPS: lipopolysaccharide; IL: interleukin slices treated with title comp. alone or in combination with LPS (10 μg/ml) for 24 h; changes in IL-6 levels measured using special kit

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. concentration-dependently decreased LPS-induced IL-6 level (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Bioassay : LPS: lipopolysaccharide; NO: nitric oxide slices treated with title comp. alone or in combination with LPS (10 μg/ml) for 24 h; changes in NO levels measured using Griess reagent

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

5 mmol/l title comp. decreased LPS-induced NO level (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : DNA-binding activity; inhibition of Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; NF: nuclear factor cells pretreated with title comp. and then treated with LPS (10 μg/ml) for 12 h or treated with title comp. in combination with LPS (10 μg/ml) for 12 h; DNA-binding activity of NF-κB complex measured by EMSA assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.600000 mM

Qualitative Results

title comp. reduced DNA-binding activity of NF-κB complex in LPS-stimulated cells (effects were similar whether cells pretreated with title comp. before LPS exposure or exposed simultaneously) (figure)

190/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; induction of Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; IL: interleukin cells treated with title comp. in combination with LPS (0.1 - 20 μg/ml) for 22 h; IL-6 protein levels measured using Northern blot assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.600000 mM

Qualitative Results

title comp. enhanced LPS-induced expression of IL-6 (highest level of potentiation observed at 5 μg/ml of LPS) (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Target : Wistar rat microglial cells Bioassay : LPS: lipopolysaccharide; IL: interleukin cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; IL-6 levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of IL-6 (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Target : Wistar rat microglial cells Bioassay : LPS: lipopolysaccharide; NO: nitric oxide cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; NO levels measured using Griess reagent

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of NO (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy) In Vitro (others)

191/365

2017-08-01 06:49:42

Bioassay Details

Effect : |transmitter release; inhibition of Target : Wistar rat microglial cells Bioassay : LPS: lipopolysaccharide; TNF: tumour necrosis factor cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; TNF-α levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of TNF-α (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Target : Wistar rat primary microglial cells Bioassay : LPS: lipopolysaccharide; IL: interleukin cells pretreated with title comp. for 22 h and then treated with LPS (5 μg/ml) for 24 h or treated with title comp. in combination with LPS for 24 h; IL-6 levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Qualitative Results

title comp. reduced LPS-induced secretion of IL-6 (effects were similar whether cells pretreated with title comp. before LPS exposure or exposed simultaneously) (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Target : Wistar rat primary microglial cells Bioassay : LPS: lipopolysaccharide; NO: nitric oxide cells pretreated with title comp. for 22 h and then treated with LPS (5 μg/ml) for 24 h or treated with title comp. in combination with LPS for 24 h; NO levels measured using Griess reagent

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Qualitative Results

title comp. reduced LPS-induced secretion of NO after pretreatment before LPS exposure and potentiated after simultaneous treatment (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Target : Wistar rat primary microglial cells Bioassay : LPS: lipopolysaccharide; TNF: tumour necrosis factor cells pretreated with title comp. for 22 h and then treated with LPS (5 μg/ml) for 24 h or treated with title comp. in combination with LPS for 24 h; TNF-α levels measured using special kit

192/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2.50000 mM

Qualitative Results

title comp. reduced LPS-induced secretion of TNF-α only after pretreatment before LPS exposure but not after simultaneous treatment (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; IL: interleukin cells pretreated with title comp. for 17 h and then treated with LPS (10 μg/ml) for 22 h or treated with title comp. in combination with LPS (10 μg/ml) simultaneously for 22 h; IL-6 levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Qualitative Results

title comp. potentiated LPS-induced secretion of IL-6 (potentiation was very similar whether cells pretreated with title comp. before LPS exposure or exposed simultaneously) (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; IL: interleukin cells treated with title comp. alone or in combination with LPS (10 μg/ml) for 24 h; IL-6 levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. potentiated LPS-induced secretion of IL-6 (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; IL: interleukin cells treated with title comp. in combination with LPS (0.1 - 20 μg/ml) for 22 h; IL-6 levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.600000 mM

193/365

2017-08-01 06:49:42

Qualitative Results

title comp. potentiated LPS-induced secretion of IL-6 (highest level of potentiation observed at 1 μg/ml of LPS) (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; NO: nitric oxide cells treated with title comp. alone or in combination with LPS (10 μg/ml) for 24 h; NO levels measured using Griess reagent

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. potentiated LPS-induced secretion of NO (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : NO: nitric oxide; LPS: lipopolysaccharide cells pretreated with title comp. for 17 h and then treated with LPS (10 μg/ml) for 22 h or treated with title comp. in combination with LPS (10 μg/ml) simultaneously for 22 h; NO levels measured using Griess reagent

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Qualitative Results

title comp. potentiated LPS-induced secretion of NO (potentiation was very similar whether cells pretreated with title comp. before LPS exposure or exposed simultaneously) (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : IL: interleukin cells cultured in modified Dulbecco's medium treated with title comp. for 17 h; changes in IL-6 levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Measurement Parameter

Qualitative

Qualitative value

Huuskonen, Jari; Suuronen, Tiina; Nuutinen, Tapio; Kyrylenko, Sergiy; Salminen, Antero; British Journal of Pharmacology; vol. 141; nb. 5; (2004); p. 874 - 880, View in Reaxys

194/365

2017-08-01 06:49:42

183 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter releasing Target : murine N9 microglial cells Bioassay : NO: nitric oxide cells cultured in modified Dulbecco's medium treated with title comp. for 17 h; changes in NO levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Measurement Parameter

Qualitative

Qualitative value

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Bioassay : LPS: lipopolysaccharide; IL: interleukin cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; IL-6 levels measured using special kit

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

astrocyte

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of IL-6 (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of Bioassay : LPS: lipopolysaccharide; NO: nitric oxide cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; NO levels measured using Griess reagent

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

astrocyte

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of NO (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy) In Vitro (others)

195/365

2017-08-01 06:49:42

Bioassay Details

Effect : |transmitter release; inhibition of Bioassay : LPS: lipopolysaccharide; TNF: tumour necrosis factor cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; TNF-α levels measured using special kit

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

astrocyte

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of TNF-α (figure)

Measurement Parameter

Qualitative

Cytoprotective

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; LDH: lactate dehydrogenase cells treated with title comp. alone or in combination with LPS (10 μg/ml) for 24 h; LDH release measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. reduced LPS-induced LDH release from cells (figure)

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : LPS: lipopolysaccharide; LDH: lactate dehydrogenase slices treated with title comp. alone or in combination with LPS (10 μg/ml) for 24 h; changes in LDH levels measured using special kit

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. concentration-dependently increased LPS-induced LDH release (figure)

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

196/365

2017-08-01 06:49:42

Bioassay Details

Target : murine N9 microglial cells Bioassay : LPS: lipopolysaccharide; LDH: lactate dehydrogenase cells treated with title comp. alone or in combination with LPS (0.1 - 20 μg/ml) for 22 h; toxicity measured by LDH release using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.200000 mM

Measurement Parameter

Qualitative

Qualitative value

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat microglial cells Bioassay : LPS: lipopolysaccharide; LDH: lactate dehydrogenase cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h or treated with title comp. alone; changes in LDH levels measured using special kit

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Measurement Parameter

Qualitative

Qualitative value

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : LPS: lipopolysaccharide; LDH: lactate dehydrogenase cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h or treated with title comp. alone; changes in LDH levels measured using special kit

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

astrocyte

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Measurement Parameter

Qualitative

Qualitative value

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

197/365

2017-08-01 06:49:42

nerve cell

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Measurement Parameter

Qualitative

Qualitative value

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

nerve cell

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of IL-6 (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

nerve cell

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of NO (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transmitter release; inhibition of

198/365

2017-08-01 06:49:42

Bioassay : LPS: lipopolysaccharide; TNF: tumour necrosis factor cells pretreated with title comp. for 19 h and then treated with LPS (5 μg/ml) for 24 h; TNF-α levels measured using special kit Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

nerve cell

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced LPS-induced secretion of TNF-α (figure)

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Target : human lung carcinoma EBC-1 cells Bioassay : CI: combination index at IC50 cells cultured with various conc. of doxorubicin (up to 20 ng/ml) in the presence or absence of title comp. for 4 days; cell viability examined using MTT assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.100000 mM

Measurement Parameter

Qualitative

Qualitative value

Niitsu, Nozomi; Kasukabe, Takashi; Yokoyama, Akihiro; Okabe-Kado, Junko; Yamamoto-Yamaguchi, Yuri; Umeda, Masanori; Honma, Yoshio; Molecular Pharmacology; vol. 58; nb. 1; (2000); p. 27 - 36, View in Reaxys 197 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |drug interaction Target : human lymphoma BALM3 cells Bioassay : comparative experiment: title comp. or doxorubicin alone cells cultured with title comp. with or without 10 ng/ml doxorubicin for 2 days; RNA extracted; mRNA expression for cytochrome P450 reductase, DT-diaphorase assayed by RT-PCR

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. in combination with doxorubicin down-regulated mRNA expression of cytochrome P450 reductase and DT-diaphorase

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |metabolism; inhibition of Target : human lung carcinoma EBC-1 cells Bioassay : cells treated with title comp. for 2 days; microsomal fractions incubated with doxorubicin or aclarubicin as substrate

199/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Measurement Parameter

Qualitative

Qualitative value

enzyme:Wild

Target Subunit Proteins

enzyme

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |enzyme; inhib. of Bioassay : cells exposed to the title comp. for periods of time up to 72 h; lysates of cells resolved by SDS-PAGE and 70 kDa protein kinase (p70S6K) detected by Western bloting using a specific antibody

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. reduced enzyme activity (diagram)

Measurement Parameter

Qualitative

Target, Subunit, Species enzyme 200 of 552 Target Mutant/Chimera Details

enzyme:Wild

Target Subunit Proteins

enzyme

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |enzyme; induction of Bioassay : cell lines were deficient in induction of CYP1A1 mRNA for aryl hydrocarbon receptor (AHR) by benzo<a>pyrene 15 independently derived B phenotype clones; benzo<a>pyrene-resistant cell lines; effect of title comp. on CYP1A1 inducibility and AHR expression; Northern blot analysis

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title comp. reversibly restored CYP1A1 inducibility and AHR expression to nearly 100 percent

Measurement Parameter

Qualitative

Target, Subunit, Species enzyme 201 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC43504 (HP 43504) of Helicobacter pylori Bioassay : Effect of Short-Chain Fatty Acids on Inhibiting HP Growth Various concentrations of test compounds were used to examine their effect on the growth of HP 43504 and

200/365

2017-08-01 06:49:42

HP 238. The aqueous solutions of tested compounds used in this experiment comprised 4-phenylbutyrate (4-PB), 2-phenylbutyrate (2-PB), butyrate, Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Title compound concentration: 50 mg/ml. The diameter (mm) of each inhibition zone (disc diffusion zone) that indicates zones of bacterium non-growth was measured 48 hours later: 8 (CDC agar plate); nd (Brucella agar plate).

Measurement Parameter

Qualitative

Patent; ANTROMED INC; US2007/21508; (2007); (A1) English, View in Reaxys 202 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : HP 238 of Helicobacter pylori Bioassay : Effect of Short-Chain Fatty Acids on Inhibiting HP Growth Various concentrations of test compounds were used to examine their effect on the growth of HP 43504 and HP 238. The aqueous solutions of tested compounds used in this experiment comprised 4-phenylbutyrate (4-PB), 2-phenylbutyrate (2-PB), butyrate,

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Measurement Parameter

Qualitative

Patent; ANTROMED INC; US2007/21508; (2007); (A1) English, View in Reaxys 203 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : MyoD protein acetylation; effect on Target : muscle myoblast C2C12 cells (ATCC CRL-1772) of mouse Bioassay : C2C12 and CC42 cells were exposed to sodium butyrate 5 mM (Sigma), trichostatin A 50 nM (Upstate Biotechnologies), or valproic acid 10 mM (Sigma) for 24 hours in GM (GM regimen). TSA was removed and the cells cultured in DM for 48 hrs before being analyzed. When indicated (DM regimen), the cells were

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound (5 μmol/l) stimulated incorporation of (3)H-acetate into a MyoD protein; figure given

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : myosin heavy chain (MHC) protein expression; effect on Target : muscle myoblast C2C12 cells (ATCC CRL-1772) of mouse Bioassay : C2C12 and CC42 cells were exposed to sodium butyrate 5 mM (Sigma), trichostatin A 50 nM (Upstate Biotechnologies), or valproic acid 10 mM (Sigma) for 24 hours in GM (GM regimen). TSA was removed and the cells cultured in DM for 48 hrs before being analyzed. When indicated (DM regimen), the cells were

Substance RN

3629439View in Reaxys

201/365

2017-08-01 06:49:42

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : nucleated myosin heavy chain (MHC) positive cells; effect on Target : muscle myoblast C2C12 cells (ATCC CRL-1772) of mouse Bioassay : C2C12 and CC42 cells were exposed to sodium butyrate 5 mM (Sigma), trichostatin A 50 nM (Upstate Biotechnologies), or valproic acid 10 mM (Sigma) for 24 hours in GM (GM regimen). TSA was removed and the cells cultured in DM for 48 hrs before being analyzed. When indicated (DM regimen), the cells were

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound (5 μmol/l) caused 83 - 84% increase in nucleated MHC-positive cells

Measurement Parameter

Qualitative

Myogenin:Wild

Target Subunit Proteins

Myogenin

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : myogenin expression; effect on Bioassay : C2C12 and CC42 cells were exposed to sodium butyrate 5 mM (Sigma), trichostatin A 50 nM (Upstate Biotechnologies), or valproic acid 10 mM (Sigma) for 24 hours in GM (GM regimen). TSA was removed and the cells cultured in DM for 48 hrs before being analyzed. When indicated (DM regimen), the cells were

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Target, Subunit, Species Myogenin Patent; United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health; The Salk Institute for Biological Study; US7229963; (2007); (B2) English, View in Reaxys 207 of 552 Target Mutant/Chimera Details

Tubulin:Wild

Target Subunit Proteins

Tubulin

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : tubulin expression; effect on

202/365

2017-08-01 06:49:42

Bioassay : C2C12 and CC42 cells were exposed to sodium butyrate 5 mM (Sigma), trichostatin A 50 nM (Upstate Biotechnologies), or valproic acid 10 mM (Sigma) for 24 hours in GM (GM regimen). TSA was removed and the cells cultured in DM for 48 hrs before being analyzed. When indicated (DM regimen), the cells were Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Target, Subunit, Species Tubulin Patent; United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health; The Salk Institute for Biological Study; US7229963; (2007); (B2) English, View in Reaxys 208 of 552 Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : muscle myoblast C2C12 cells (ATCC CRL-1772) of mouse Bioassay : C2C12 and CC42 cells were exposed to sodium butyrate 5 mM (Sigma), trichostatin A 50 nM (Upstate Biotechnologies), or valproic acid 10 mM (Sigma) for 24 hours in GM (GM regimen). TSA was removed and the cells cultured in DM for 48 hrs before being analyzed. When indicated (DM regimen), the cells were

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound (5 μmol/l) caused cell apoptosis; figure given

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : non-small cell lung cancer (NSCLC) cells H1299 Bioassay : Antiproliferative effects of CNDAC and sodium butyrate against non-small cell lung cancer cells (H460 and Hl 299)Table 3 shows the effects of CNDAC and sodium butyrate against H460 and H 1299 cells. These results demonstrate that CNDAC and butyrate generate moderate to strong synergy in H460 and H 1299

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED50

Quantitative value

0.36

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 210 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : non-small cell lung cancer (NSCLC) cells H460 Bioassay : Antiproliferative effects of CNDAC and sodium butyrate against non-small cell lung cancer cells (H460 and Hl 299)Table 3 shows the effects of CNDAC and sodium butyrate against H460 and H 1299 cells. These results demonstrate that CNDAC and butyrate generate moderate to strong synergy in H460 and H 1299

203/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED50

Quantitative value

0.99

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 211 of 552

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED75

Quantitative value

0.48

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 212 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED75

Quantitative value

0.89

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 213 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED90

Quantitative value

1.04

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 214 of 552 Substance Effect

Cytotoxic

204/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

ED90

Quantitative value

0.83

Patent; CYCLACEL LIMITED; WO2008/75042; (2008); (A1) English, View in Reaxys 215 of 552 Substance Effect

Antiproliferative

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : cells growth; inhibition of Example 15 Inhibition of HDAC Activity and Change of the Morphology of Cancer Cells by the Compound of the Invention (NBM-HD-1) The breast cancer MCF-7 cells, were cultured in Dulbecco's modified Eagle's medium (DMEM ; Gibco) supplemented with penicillin G, streptomycin sulphate, 0.5 mM of L-glutamine

Biological Species/NCBI Human ID Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

test compound inhibited the growth of cells; figure is given

Measurement Parameter

Qualitative

Patent; NatureWise Biotech and Medicals Corporation; EP2045247; (2009); (A1) English, View in Reaxys 216 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : antiproliferative Bioassay : giloblastoma DBTRG-05MG cancer cells Example 15 Inhibition of HDAC Activity and Change of the Morphology of Cancer Cells by the Compound of the Invention (NBM-HD-1) The human giloblastoma DBTRG-05MG cancer cells were cultured in RPMI medium 1640 (Gibco) supplemented with penicillin G, streptomycin sulphate, 0.5 mM of L-glutamine and 10%

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

test compound could inhibit the proliferation of 05MG cancer cells; figure is given

Measurement Parameter

Qualitative

Patent; NatureWise Biotech and Medicals Corporation; EP2045247; (2009); (A1) English, View in Reaxys 217 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : acetylation of histone H4; induction of

205/365

2017-08-01 06:49:42

Bioassay : C6 glioma cells Example 13 Increase of the Accumulation of Hyperacetylated Histone in the Cancer Cells Treated with the Compound of the Invention (NBM-HD-1) Accumulation of hyperacetylated histone H4 was analyzed in the cell lysates by using Western Blotting and the antibody directed against acetylated histone H4 Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

test compound can increase the accumulation of hyperacetylated histone H4; figure is given

Measurement Parameter

Qualitative

Patent; NatureWise Biotech and Medicals Corporation; EP2045247; (2009); (A1) English, View in Reaxys 218 of 552 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-cancer Example 15Inhibition of HDAC Activity and Change of the Morphology of Cancer Cells by the Compound of the Invention (NBM-HD-1)The human giloblastoma DBTRG-05MG cancer cells were cultured in RPMI medium 1640 (Gibco) supplemented with penicillin G, streptomycin sulphate, 0.5 mM of L-glutamine and 10%

Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

4 mM title compound was able to inhibit the growth of MCF-7 cells; figures are given

Measurement Parameter

Qualitative

Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys 219 of 552 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-cancer Bioassay : giloblastoma DBTRG-05MG cancer cells Example 15Inhibition of HDAC Activity and Change of the Morphology of Cancer Cells by the Compound of the Invention (NBM-HD-1)The human giloblastoma DBTRG-05MG cancer cells were cultured in RPMI medium 1640 (Gibco) supplemented with penicillin G, streptomycin sulphate, 0.5 mM of L-glutamine and 10%

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

title compound (4mM) inhibited the proliferation of 05MG cancer cells; figure is given

Measurement Parameter

Qualitative

Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys 220 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell cycle; modulation of

206/365

2017-08-01 06:49:42

Example 15Inhibition of HDAC Activity and Change of the Morphology of Cancer Cells by the Compound of the Invention (NBM-HD-1)The human giloblastoma DBTRG-05MG cancer cells were cultured in RPMI medium 1640 (Gibco) supplemented with penicillin G, streptomycin sulphate, 0.5 mM of L-glutamine and 10% Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

title compound (4 mM) markedly inhibited MCF-7 cell growth via modulation of the cell cycle, arrested on the G0/G1 phase; figure is given

Measurement Parameter

Qualitative

Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys 221 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : hyperacetylated histone H4; accumulation of Example 15Inhibition of HDAC Activity and Change of the Morphology of Cancer Cells by the Compound of the Invention (NBM-HD-1)The human giloblastoma DBTRG-05MG cancer cells were cultured in RPMI medium 1640 (Gibco) supplemented with penicillin G, streptomycin sulphate, 0.5 mM of L-glutamine and 10%

Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

the accumulation of acetylated histone H4 increased in the cells treated with title compound (4 mM); figure is given

Measurement Parameter

Qualitative

Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys 222 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone deacetylase (HDAC) activity; inhibition of Bioassay : C6 glioma cells Example 14Inhibition of HDAC Activity by the Compound of the Invention (NBM-HD-1)The C6 glioma cells were treated with different doses of NBM-HD-1 and sodium butyrate (SB). After 24 hours, the cells were harvested to extract the nuclear proteins by NucBuster&trade; Protein Extraction Kit (Novagen) as

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

title compound (4 mM) significantly inhibits HDAC activity; figure is given

Measurement Parameter

Qualitative

Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys 223 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : hyperacetylated histone H4; accumulation of Bioassay : C6 glioma cells Example 13Increase of the Accumulation of Hyperacetylated Histone in the Cancer Cells Treated with the Compound of the Invention (NBM-HD-1)Accumulation of hyperacetylated

207/365

2017-08-01 06:49:42

histone H4 was analyzed in the cell lysates by using Western Blotting and the antibody directed against acetylated histone H4 (Upstate). Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

Qualitative Results

the accumulation of acetylated histone H4 increased in the cells treated with title compound (4 mM); figure is given

Measurement Parameter

Qualitative

Patent; NATUREWISE BIOTECH and MEDICALS CORPORATION; US2009/76130; (2009); (A1) English, View in Reaxys 224 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Electrophysiology

Bioassay Details

Effect : membrane polarization Target : SIVZ-50 rat colonic crypts Bioassay : 20-25 deg C rat weight 180-220 g; killed by exsanguination; isolated crypt perfused with isotonic and hypotonic solutions; nystatin-permeabilized patch-clamp technique; electrical recording; current-voltage (I-V) curves

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

50 mM

Qualitative Results

reversible depolarization (large glutamate concn. (140 mmol/l) in the intracellular medium and 0 outside); depolarization inhibited by NDGA; reversible hyperpolarization (glutamate in the extracellular medium)

Measurement Parameter

Qualitative

Diener; Scharrer; Experimental Physiology; vol. 80; nb. 3; (1995); p. 411 - 428, View in Reaxys 225 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

inhibition of the cytoplasmic enzyme N8-AcSpd deacetylase from rat liver cytosol (in vitro)

Measurement Parameter

Qualitative

Huang; Dredar; Manneh; Blankenship; Fries; Journal of Medicinal Chemistry; vol. 35; nb. 13; (1992); p. 2414 2418, View in Reaxys 226 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : short circuit current; effect on Bioassay : enterocytes Effects of sodium butyrate and of compounds 1, 2 and 3 on the transepithelial transport of water and electrolytes. Cell culturesThe experiments were carried out using a human intestinal cell line called Caco-2, obtained from the American Type Culture Collection (ATCC, Rockville, USA). These cells,

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

short circuit current decrease (μA/cm**2) = -0.8 at 10 mM (fig.1)

208/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Patent; BERNI CANANI, Roberto; CALIGNANO Antonio; MAZZONI, Orietta (EREDI); CORUZZO, Anna; (41 pag.); WO2009/130735; (A1); (2009), View in Reaxys 227 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

short circuit current decrease (μA/cm**2) = -0.8 at 10 mM (fig.1)

Measurement Parameter

Qualitative

Patent; BERNI CANANI, Roberto; CALIGNANO Antonio; MAZZONI, Orietta (EREDI); CORUZZO, Anna; (41 pag.); WO2009/130735; (A1); (2009), View in Reaxys 228 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

short circuit current decrease (μA/cm**2) = -0.8 at 10 mM

Measurement Parameter

Qualitative

Patent; BERNI CANANI, Roberto; CALIGNANO Antonio; MAZZONI, Orietta (EREDI); CORUZZO, Anna; (41 pag.); WO2009/130735; (A1); (2009), View in Reaxys 229 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : tissue conductance; effect on Bioassay : enterocytes Cell cultures. The experiments were carried out using a human intestinal cell line called Caco-2, obtained from the American Type Culture Collection (ATCC, Rockville, USA). These cells, 15 days after confluence, form a monolayer of enterocytes with morphological and functional features identical to

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

209/365

2017-08-01 06:49:42

Qualitative value

Patent; BERNI CANANI, Roberto; CALIGNANO Antonio; MAZZONI, Orietta (EREDI); CORUZZO, Anna; (41 pag.); WO2009/130735; (A1); (2009), View in Reaxys 230 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Target : murine normal colonic epithelial cells Bioassay : cells incubated with title comp. at 39 deg C for 24 h; mitochondrial and cytosolic fraction prepared; cytochrome c release from mitochondria analyzed by Western blotting

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

8 mM

Measurement Parameter

Qualitative

Qualitative value

Matsumoto, Tsukasa; Hayasaki, Tomoyuki; Nishimura, Yoshiko; Nakamura, Masahiko; Takeda, Tadahiro; Tabuchi, Yoshiaki; Obinata, Masuo; Hanawa, Toshihiko; Yamada, Haruki; Biological and Pharmaceutical Bulletin; vol. 29; nb. 10; (2006); p. 2041 - 2045, View in Reaxys 231 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Target : murine normal colonic epithelial cells Bioassay : cells incubated with title comp. at 39 deg C for 24 or 48 h; apoptosis observed using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay and propidium iodide staining

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

8 mM

Measurement Parameter

Qualitative

Qualitative value

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Target : murine normal colonic epithelial cells Bioassay : cells incubated with title comp. at 39 deg C for 24 or 48 h; cells stained with 4', 6-diamidino-2-phenylindole and Alexa Fluor594 phalloidin; chromatin condensation observed

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

8 mM

Measurement Parameter

Qualitative

Qualitative value

210/365

2017-08-01 06:49:42

In Vitro (Efficacy)

Bioassay Name

Electrophysiology

Bioassay Details

Effect : mitochondrial membrane potential; effect on Target : murine normal colonic epithelial cells Bioassay : cells incubated with title comp. at 39 deg C for 6 h; mitochondrial membrane potential observed using 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

8 mM

Qualitative Results

title comp. significantly lowered mitochondrial membrane potential (figure)

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : murine normal colonic epithelial cells Bioassay : cells incubated with title comp. at 39 deg C for 24 and 48 h; cells stained with ruthenium red; morphology observed

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

8 mM

Qualitative Results

title comp. significantly induced cell necrosis, swollen mitochondria and vacuolization observed after 24 and 48 h, resp. (figure)

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : murine normal colonic epithelial cells Bioassay : cells incubated with title comp. at 39 deg C for 72 h; cell viability measured using lactate dehydrogenase assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

title comp. significantly dose-dependently induced cell death (figure)

Measurement Parameter

Qualitative

211/365

2017-08-01 06:49:42

236 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : murine normal colonic epithelial cells Bioassay : further investigation with caspase inhibitors zVAD-FMK, zLEHD-FMK, zIETDFMK, zVEID-FMK, zDEVD-FMK, zYVAD-FMK, prednisolone or 5-aminosalicylic acid cells incubated with title comp. at 39 deg C for 24, 48 and 72 h; cell viability measured using 3(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

3.10000 mM

Qualitative Results

title comp. significantly dose- and time-dependently induced cell necrosis; caspases were not involved, prednisolone and 5-aminosalicylic acid dose-dependently inhibited this effect (figures)

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : cells incubated with title comp. at 39 deg C for 24, 48 and 72 h; cell viability measured using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay

Biological Species/NCBI Human ID Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title comp. significantly induced cell death at doses >20 mmol/l

Measurement Parameter

Qualitative

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : cells incubated with title comp. at 39 deg C for 24, 48 and 72 h; cell viability measured using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay

Biological Species/NCBI Human ID Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

3.10000 mM

Measurement Parameter

Qualitative

Qualitative value

212/365

2017-08-01 06:49:42

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : cells incubated with title comp. at 39 deg C for 24 and 48 h; cells stained with ruthenium red; morphology observed

Biological Species/NCBI Human ID Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

8 mM

Measurement Parameter

Qualitative

Qualitative value

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Target : VACO 5 colon cancer cells Bioassay : cell treated with title comp. for various timesed; cells counted at various times and time-course of growth inhibition examined; in another examination after 18 or 30 h incubation DNA fragmentation analyzed by agarose gel electrophoresis

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1.60000 mM

Qualitative Results

title comp. treatment caused apoptosis in cells, which was confirmed with inhibition of cell growth and DNA fragmentation; after 4 d growth in 5 mmol/l title comp. cell death was >=35 percent (diagrams)

Measurement Parameter

Qualitative

McBain, John A.; Eastman, Alan; Nobel, C. Stefan; Mueller, Gerald C.; Biochemical Pharmacology; vol. 53; nb. 9; (1997); p. 1357 - 1368, View in Reaxys 241 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : cells treated with title comp. for 42 h; cell number determined at 0, 42 and 116 h; in another examination after 24 h incubation DNA fragmentation analyzed by agarose gel electrophoresis

Cells/Cell Lines

HCT116

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

title comp. caused fully reversibe growth inhibition, growth resumed upon removal of title comp.; minimal DNA fragmentation was observed (diagrams)

213/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

McBain, John A.; Eastman, Alan; Nobel, C. Stefan; Mueller, Gerald C.; Biochemical Pharmacology; vol. 53; nb. 9; (1997); p. 1357 - 1368, View in Reaxys 242 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell number, DNA fragmentation |drug interaction Target : VACO 5 colon cancer cells Bioassay : TPA: 12-O-tetradecanoylphorbol 13-acetate cells treated with title comp. and 100 nmol/l TPA; apoptosis determined by counting cells after 4 d continuous treatment and by DNA fragmentation analyzed by agarose gel electrophoresis after 18 or 30 h incubation

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

combined treatment decreased cell number by 97 percent within 4 d; apoptotic DNA cleavage and loss of high molecular weight genomic DNA were pronounced (diagrams)

Measurement Parameter

Qualitative

McBain, John A.; Eastman, Alan; Nobel, C. Stefan; Mueller, Gerald C.; Biochemical Pharmacology; vol. 53; nb. 9; (1997); p. 1357 - 1368, View in Reaxys 243 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone acetylation |drug interaction Target : VACO 5 colon cancer cells Bioassay : TPA: 12-O-tetradecanoylphorbol 13-acetate cells treated with title comp. and 20 nmol/l TPA for 2-24 h, then harvested for histone extraction and analyzed for histone by Triton-acetic acid-urea gel electrophoresis

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

combined treatment caused little change in histone hyperacetylation

Measurement Parameter

Qualitative

McBain, John A.; Eastman, Alan; Nobel, C. Stefan; Mueller, Gerald C.; Biochemical Pharmacology; vol. 53; nb. 9; (1997); p. 1357 - 1368, View in Reaxys 244 of 552 Target Mutant/Chimera Details

Histone:Wild

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone acetylation Bioassay : cells treated with title comp. for 24 h, then harvested for histone extraction and analyzed for histone by Triton-acetic acid-urea gel electrophoresis; time course of acetylation onset and decay also examined

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.160000 mM

214/365

2017-08-01 06:49:42

Qualitative Results

after title comp. treatment at conc. of 5 mmol/l for 24 h tetraacetylated histone H4 was the major isoform among H4 species and became faintly visible after 30 min, prominent after 90 min and predominant after 24 h

Measurement Parameter

Qualitative

Target, Subunit, Species Histone McBain, John A.; Eastman, Alan; Nobel, C. Stefan; Mueller, Gerald C.; Biochemical Pharmacology; vol. 53; nb. 9; (1997); p. 1357 - 1368, View in Reaxys 245 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cell number, DNA fragmentation |drug interaction Bioassay : TPA: 12-O-tetradecanoylphorbol 13-acetate cells treated with title comp. and 20 nmol/l TPA for 42 h; cell number determined at 0, 42 and 116 h; in another examination after 24 h incubation DNA fragmentation analyzed by agarose gel electrophoresis

Cells/Cell Lines

HCT116

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

combined treatment decreased cell yields compared with cultures treated with title comp. alone; minimal DNA fragmentation was observed (diagrams)

Measurement Parameter

Qualitative

McBain, John A.; Eastman, Alan; Nobel, C. Stefan; Mueller, Gerald C.; Biochemical Pharmacology; vol. 53; nb. 9; (1997); p. 1357 - 1368, View in Reaxys 246 of 552 Target Mutant/Chimera Details

Histone:Wild

Target Subunit Proteins

Histone

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : histone acetylation Bioassay : cells treated with title comp. for 24 h, then harvested for histone extraction and analyzed for histone by Triton-acetic acid-urea gel electrophoresis

Cells/Cell Lines

HCT116

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.500000 mM

Qualitative Results

title comp. at conc. of 5 mmol/l caused strong acetylation of histone H4

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |DNA; examination of Bioassay : cells obtained from German Collection of Microorganisms and Cell Cultures; level of P21 expression estimated as number of P21 mRNA copies with reference to number of β-actin (or glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) gene mRNA copies cells seeded in 25 cm2 flasks, grow in MEM to confluence; incubated with title

215/365

2017-08-01 06:49:42

comp. for 3, 6, 12, 24, 48 h; total RNA extracted from cells using Trizol Reagent; P21 expression level determined using real time quantitative RT-PCR (TaqMan) technique Biological Species/NCBI Human ID Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

5 mM

Qualitative Results

strongly induced P21 expression at all conc.; characteristic pattern of changes observed up to 48 h; progressive decrease found when results normalized using expression of βactinin mRNA; GAPDH was slightly different; table; graphical representation

Measurement Parameter

Qualitative

Orchel, Arkadiusz; Molin, Izabella; Dzierzewicz, Zofia; Latocha, Malgorzata; Weglarz, Ludmila; Wilczok, Tadeusz; Acta Poloniae Pharmaceutica - Drug Research; vol. 60; nb. 2; (2003); p. 103 - 105, View in Reaxys 248 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; inhibition of Bioassay : effect of title comp. on proteasome subunit β5 expression studied; cells treated with title comp. for 24 h; level of β5 protein determined by immunoblotting in cytosolic extracts

Cells/Cell Lines

SW 480

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. decreased level of β5 protein (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 249 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Cells/Cell Lines

HT 29

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. decreased level of β5 protein (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 250 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

216/365

2017-08-01 06:49:42

Bioassay : effect of title comp. on cell viability studied; cell treated with title comp. for 24 48 h; viable cells determined using neutral red uptake assay by flow cytometry Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Measurement Parameter

Qualitative

Qualitative value

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 251 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : mRNA expression; inhibition of Bioassay : effect of title comp. on proteasome subunits β5, β1, β2, β7, β3, β5i and α4, α2, α6 expression studied; cells treated with title comp. for 24 h; mRNA levels of β- and α-type subunits determined by quantitative real-time PCR

Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. decreased mRNA levels of β5, β1, β2, and α6 subunits but not mRNA levels of β7, β3, β5i and α4, α2 subunits (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 252 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : nuclear factor; inhibition of Bioassay : TNF-α: tumor necrosis factor α (50 ng/ml); IκB: inhibitor κB; MG-132, proteasome inhibitor, used as reference comp. (60 μmol/l) effect of title comp. on TNF-α-induced degradation of IκBα studied; cells incubated with title comp. for 24 h, then exposed to TNF-α for 90 min; cytosolic extracts prepared, and IκBα level determined by immunoblotting

Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. prevented TNF-α-induced degradation of IκBα (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 253 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : nuclear factor; inhibition of Bioassay : TNF-α: tumor necrosis factor α (50 ng/ml); IL-1β: interleukin 1β (4 ng/ml); NFκB: nuclear factor κB; EMSA: electrophoretic mobility shift assay; MG-132, proteasome inhibitor, used as reference comp. (60 μmol/l) effect of title comp. on cytokine-induced acti-

217/365

2017-08-01 06:49:42

vation of NF-κB studied; cells incubated with title comp. for 24 h, then exposed to TNF-α or IL-1β for 30 min; nuclear extracts prepared and analyzed for DNA binding by EMSA Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. blocked TNF-α-induced but not IL-1β-induced activation of NF-κB (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 254 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; inhibition of Bioassay : effect of title comp. on proteasome subunit β5 expression studied; cells treated with title comp. for 24 - 48 h; level of β5 protein determined by immunoblotting in cytosolic extracts; level of β5 mRNA determined by quantitative real-time PCR

Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. time-dependently suppressed expression of β5 proteasome subunit (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 255 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : protein expression; inhibition of Bioassay : effect of title comp. on proteasome subunits β5, β1, β2, β3, β4, β6, and β7 expression studied; cells treated with title comp. for 24 h; protein levels of β-type subunits determined by immunoblotting in cytosolic extracts

Cells/Cell Lines

CACO2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. decreased protein levels of β5, β1, and β2 subunits but not protein levels of other β-type subunits (figure)

Measurement Parameter

Qualitative

Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 256 of 552 Target Mutant/Chimera Details

Proteasome:Wild

Target Subunit Proteins

Proteasome

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : proteasome activity; inhibition of

218/365

2017-08-01 06:49:42

Bioassay : proteasome-independent activity determined in presence of inhibitor MG-132 (60 μmol/l); Suc-LLVY-AMC: N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin effect of title comp. on proteasome activity sudied; cell lysates exposed to title comp. for 24 - 48 h; proteasome activity determined by fluorometry using synthetic fluorogenic substrate Suc-LLVY-AMC Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

4 mM

Qualitative Results

title comp. time-dependently suppressed proteasome activity (by ca. 80 percent at 48 h) (figure)

Measurement Parameter

Qualitative

Target, Subunit, Species Proteasome Place, Robert F.; Noonan, Emily J.; Giardina, Charles; Biochemical Pharmacology; vol. 70; nb. 3; (2005); p. 394 406, View in Reaxys 257 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : kerinocyte differenciation; increase of Target : neonatal foreskin kerinocytes of human Bioassay : The efficacy of the methods of treatment of skin disorders such as psoriasis described above was demonstrated in a study of primary cells in culture. In this study, Keratinocyte Cell Culture-Neonatal foreskin kerinocytes, purchased from Lonza (Walkersville, Md., USA), were grown in keratinocyte-SFM

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

title compound increases kerinocyte differenciation compared with control; value of cornified envelope formation for title compound is ~3%, control: ~0.3%; figures are given

Measurement Parameter

Qualitative

Patent; Sutter, Thomas Robert; Sutter, Carrie Hayes; US2008/269339; (2008); (A1) English, View in Reaxys 258 of 552 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : HT-29 from colon tumor Bioassay : Cell line HT-29 derived from colon tumor was inoculated into McCoy's 5A medium supplemented with 10% fetal calf serum comprising penicillin 50U/ml, streptomycin 50&micro;g/ml and HEPES 10mM on 96-well cell culture plate (7,500 cells/well). The cells were pre-incubated in an atmosphere of 95% air and

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Test compound Growth Inhibition against colon tumor cell line: 0.200 - 0.250 at 0.1 - 2 mM.

Measurement Parameter

Qualitative

Patent; Earthus, Inc.; EP1661574; (2006); (A1) English, View in Reaxys 259 of 552 Target Mutant/Chimera Details

enzyme:Wild

Target Subunit Proteins

enzyme

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Transactivation assay

219/365

2017-08-01 06:49:42

Bioassay Details

Effect : |enzyme; examination of Bioassay : enzyme activity: DNA topoisomerase IIα; luciferase activity measured; <3H>thymidine incorporation; DNA synthesis in vitro; 37 deg C in 5 percent CO2 atmosphere; 5' flanking region of the human topo IIα gene (position -562 to +90) was subcloned into a firefly luciferase reporter plasmid and transiently transfected into HeLa cells; add. of phorbol-12-myristate-13-acetate

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.400000 mM

Qualitative Results

the title compound induced 4-17-fold activation of topo IIα gene promoter activity

Measurement Parameter

Qualitative

Target, Subunit, Species enzyme 260 of 552 Target Mutant/Chimera Details

enzyme:Wild

Target Subunit Proteins

enzyme

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Transactivation assay

Bioassay Details

Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.400000 mM

Qualitative Results

the title compound induced 4-17-fold activation of topo IIα gene promoter activity

Measurement Parameter

Qualitative

Target, Subunit, Species enzyme 261 of 552 Substance Effect

Vasodilator

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Wistar rat mesenteric resistance artery Bioassay : effect of presence of Nω-nitro-L-arginine methyl ester (L-NAME), RP-cAMPS (R) or endothelial denudation of arteries (EDA) on title comp.-induced relaxation arteries (inner diameter ca. 300 μM) in saline; tension (myography) and intracellular pH <pHi, fluorescence with 2',7'-bis(carboxymethyl)-5-(6')-carboxyfluorescein acetoxy methyl ester>; relaxation of noradrenaline (NA)- and/or K+-induced contraction

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Measurement Parameter

EC50

Unit

Quantitative value

Measurement pX

1.66

220/365

2017-08-01 06:49:42

Aaronson; McKinnon; Poston; British Journal of Pharmacology; vol. 117; nb. 2; (1996); p. 365 - 371, View in Reaxys 262 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : 5E4 cells/ml treated with title comp. and 5 μmol/l of vitamin K3; harvested every 8 h until 48 h; mixed with 0.4 percent trypan blue solution for 5 min; stained and unstained cells counted using microscope

Cells/Cell Lines

HL-60/TB

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 µM

Qualitative Results

potentiated anticancer activity of vitamin K3 dose-dependent; at 50 μmol/l significantly reduced cell number to ca. 5E5 compared to vitamin K3 alone: ca. 9.; graphical representation

Measurement Parameter

Qualitative

Lin, Changjun; Kang, Jiuhong; Zheng, Rongliang; Pharmazie; vol. 60; nb. 10; (2005); p. 765 - 771, View in Reaxys 263 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Cells/Cell Lines

HL-60/TB

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 µM

Qualitative Results

potentiated anticancer activity of vitamin K3 dose-dependent; at 50 μmol/l significantly enhanced cell death to ca. 32 percent of total cells compared to vitamin K3 alone: ca. 20 percent of total cells; graphical representation

Measurement Parameter

Qualitative

Lin, Changjun; Kang, Jiuhong; Zheng, Rongliang; Pharmazie; vol. 60; nb. 10; (2005); p. 765 - 771, View in Reaxys 264 of 552 Substance Effect

Oxidant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : generation of intracellular reactive oxygen species in leukemia cells measured; DCFH-DA: 2',7'-dichlorofluorescein diacetate; DCF: dichlorofluorescein cells in RPMI 1640 treated with title comp. and 5 μmol/l vitamin K3; preincubated with DCFH-DA in DMSO, 37 deg C, 30 min; level of H2O2 measured by alteration of fluorescence resulting from oxidation of DCFH-DA to DCF spectrophotometrically at 535 nm

Cells/Cell Lines

HL-60/TB

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 µM

Qualitative Results

did not affect vitamin K3 induced H2O2 generation; graphical representation

221/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Lin, Changjun; Kang, Jiuhong; Zheng, Rongliang; Pharmazie; vol. 60; nb. 10; (2005); p. 765 - 771, View in Reaxys 265 of 552 Substance Effect

Oxidant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : generation of reactive oxygen species in leukemia cells measured; DHE: dihydroethidium; ETH: ethidium; O2.-: superoxide anion; VK3: vitamin K3 cells in RPMI 1640 treated with title comp. and 5 μmol/l VK3; preincubated with DHE in DMSO, 37 deg C, 30 min; level of intracellular O2.- measured by alteration of fluorescence resulting from oxidation of DHE to ETH spectrophotometrically at 585 nm

Cells/Cell Lines

HL-60/TB

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 µM

Qualitative Results

did not affect VK3-induced superoxide anion generation; graphical representation

Measurement Parameter

Qualitative

Lin, Changjun; Kang, Jiuhong; Zheng, Rongliang; Pharmazie; vol. 60; nb. 10; (2005); p. 765 - 771, View in Reaxys 266 of 552 Substance Effect

Oxidant

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : VK3: vitamin K3 histones prepared from cells; after purification 1E6 cells/ml plated for 24 h; treated with title comp. and 0.5 μmol/l of vitamin K3, 24 h, in presence of 10 μCi/ml <3H>acetate; labeled histones determined by liquid scintilation counter

Cells/Cell Lines

HL-60/TB

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

10 µM

Qualitative Results

potentiated anticancer activity of VK3; at 50 μg/ml enhanced histone acetylation from ca. 3556 cpm/1E6 cells caused by VK3 to ca. 4667 cpm/1E6 cells compared to title comp. alone or control ca. 3667 or ca. 2556 cpm/1E6 cells, resp.; figure

Measurement Parameter

Qualitative

Lin, Changjun; Kang, Jiuhong; Zheng, Rongliang; Pharmazie; vol. 60; nb. 10; (2005); p. 765 - 771, View in Reaxys 267 of 552 Substance Effect

Apoptotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Apoptosis

Bioassay Details

Bioassay : EC: cellular adenylate energy charge; EC=<ATP>+0.5<ADP>/<ATP>+<ADP> +<AMP>; MEM: Minimum Essential Medium 1E6 cells/dish in supplemented MEM grown for 48 h, 37 deg C; incubated with title comp. for 1.5, 24 or 48 h; 0.5 M HClO4 added; cells removed; sonificated; aq. KOH added to pH 6.0-7.0, placed at 70 deg C; ATP, ADP, APM analyzed by HPLC; EC evaluated

Cells/Cell Lines

HT 29

Substance RN

3629439View in Reaxys

Substance Name

1481199

222/365

2017-08-01 06:49:42

Substance Dose

1 mM

Qualitative Results

did not affect EC after 24 h incubation; after 48 h changes in EC observed: at 1, 5, 20 mmol/l ca. 0.903, ca. 0.894, ca. 0.871, respectively, compared to control: ca. 0.892; graphical representation

Measurement Parameter

Qualitative

Gruchlik, Arkadiusz; Orchel, Arkadiusz; Wilczok, Adam; Zajdel, Alicja; Parfiniewicz, Beata; Dzierzewicz, Zofia; Weglarz, Ludmila; Wilczok, Tadeusz; Acta poloniae pharmaceutica; vol. 61 Suppl; (2004); p. 88 - 90, View in Reaxys 268 of 552 Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : 5E3 cells/well grown on 96-well plates for 24 h; incubated with title comp., 72 h; fluorescence emission at 535 nm measured; for morphological analysis of cell nuclei harvested cells stained with 5 μg/ml acridine orange in PBS; fluorescence measured

Cells/Cell Lines

HT 29

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

1 mM

Qualitative Results

decreased cell number/well at 1, 5, 20 mmol/l to ca. 15000, ca. 8000, ca. 4000, respectively, compared to control: ca. 28000; typical apoptotic morphology of cells observed; graphical representation

Measurement Parameter

Qualitative

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

effect on alpha-naphthyl butyrate esterase activity in HL60 cells is figured (0.5 and 0.2 mM induced 86 percent and 8 percent alpha-naphthyl butyrate esterase-positive cells, respectively)

Measurement Parameter

Qualitative

Tamagawa; Fukushima; Kobori; Shinmoto; Tsushida; Bioscience, biotechnology, and biochemistry; vol. 62; nb. 8; (1998); p. 1483 - 1487, View in Reaxys 270 of 552 Substance Effect

Neuroprotective

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; HDAC: histone deacetylase; COX: cyclooxygenase; iNOS: inducible nitric-oxide synthase; loading control: β-actin rats subjected to pMCAO; title comp. injected immediately after ischemia onset and 12 h later; at 24 h brain removed; ipsilateral hemisphere lysate prepared; acetylated histone H3, COX-2, iNOS detected by Western blot

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

223/365

2017-08-01 06:49:42

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. inhibited HDAC activity preventing pMCAO-induced decrease of acetylated histone H3, prevented pMCAO-induced COX-2, iNOS (figure)

Measurement Parameter

Qualitative

Hyeon, Ju Kim; Rowe, Michael; Ren, Ming; Hong, Jau-Shyong; Chen, Po-See; Chuang, De-Maw; Journal of Pharmacology and Experimental Therapeutics; vol. 321; nb. 3; (2007); p. 892 - 901, View in Reaxys 271 of 552 Substance Effect

Neuroprotective

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; HSP: heat shock protein; loading control: β-actin rats subjected to pMCAO; title comp. injected immediately after ischemia onset and 12 h later; at 24 h brain removed; ipsilateral hemisphere lysate prepared; HSP70, phospho-Akt detected by Western blot

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. enhanced HSP70 up-regulation induced by pMCAO (ca. 1800% vs. ca. 500%), prevented loss of phospho-Akt (figure)

Measurement Parameter

Qualitative

Neuroprotective

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; loading control: β-actin rats subjected to pMCAO; title comp. injected immediately after ischemia onset and 12 h later; at 24 h brain removed; ipsilateral hemisphere lysate prepared; p53 detected by Western blot

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. prevented pMCAO-induced p53 up-regulation (figure)

Measurement Parameter

Qualitative

Neuroprotective

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

224/365

2017-08-01 06:49:42

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion rats subjected to pMCAO; title comp. injection immediately after ischemia onset followed by injections every 12 h; at 24 h brain removed; immunostaining with anti-OX42-antibody in coronal sections performed

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. inhibited pMCAO-induced microglia activation decreasing OX42-positive cells in anterior, middle, posterior sections of ipsilateral hemisphere by almost 30% (figure)

Measurement Parameter

Qualitative

Neuroprotective

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; TTC: 2,3,5-triphenyltetrazolium chloride rats subjected to pMCAO; title comp. injected 3 or 6 h after pMCAO onset followed by another injection at 12 h; at 24 h brain removed; infarction in coronal sections detected by TTC staining

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. decreased infarct size by ca. 40% or ca. 30% when 1st dose injected 3 or 6 h after pMCAO, resp. (figure)

Measurement Parameter

Qualitative

Neuroprotective

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; TTC: 2,3,5-triphenyltetrazolium chloride rats subjected to pMCAO; title comp. injected immediately after pMCAO onset and 12 h later; at 24 h brain removed; infarction in coronal sections detected by TTC staining

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

200 mg/kg

Substance Route of Adm.

subcutaneous administration

225/365

2017-08-01 06:49:42

Measurement Parameter

ED50

Unit

mg/kg

Quantitative value

200

Behavioural Symptoms

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; eightpoint test included 3 tests where animal suspended by tail, 3 test in open field, pinna reflex, visual placement test title comp. injected 3 or 6 h after pMCAO onset and 12 h after pMCAO; 24 h after pMCAO eight-point behavioral test (each test scored as 1 for normal and 0 for abnormal) and single Rotorod test trial (training trials conducted 1 d before pMCAO)

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. increased total score of eight-point test from ca. 2.1 to 4 (figure), increased retention time on accelerating Rotorod from ca. 15 to 33 s (figure) when 1st dose injected 3 h after pMCAO onset; no sign. effect when injected 6 h after pMCAO

Measurement Parameter

Qualitative

Behavioural Symptoms

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Bioassay : control: vehicle; pMCAO: permanent middle cerebral artery occlusion; eightpoint test included 3 tests where animal suspended by tail, 3 test in open field, pinna reflex, visual placement test 1st title comp. dose injected immediately after pMCAO onset; eight-point behavioral test conducted 1 - 11 days after pMCAO: each test scored as 1 for normal and 0 for abnormal (normal total score 8)

Biological Species/NCBI Rattus norvegicus ID Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

300 mg/kg

Substance Route of Adm.

subcutaneous administration

Qualitative Results

title comp. improved neurological performance increasing total score from ca. 2.5 - 4 to 5 6 on day 1 - 11 after pMCAO, resp. (figure)

Measurement Parameter

Qualitative

Hyeon, Ju Kim; Rowe, Michael; Ren, Ming; Hong, Jau-Shyong; Chen, Po-See; Chuang, De-Maw; Journal of Pharmacology and Experimental Therapeutics; vol. 321; nb. 3; (2007); p. 892 - 901, View in Reaxys

226/365

2017-08-01 06:49:42

278 of 552 Target Mutant/Chimera Details

Histone deacetylase 8:Wild

Target Subunit Proteins

Histone deacetylase 8

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Enzymology inhibition

Bioassay Details

Effect : enzyme activity HDAC: histone deacetylase; fluorometric assay

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

500 µM

Measurement Parameter

% Inhibition

Unit

Quantitative value

Measurement pX

3.16

Target, Subunit, Species Histone deacetylase 8 279 of 552 Target Mutant/Chimera Details

Histone deacetylase 8:Wild

Target Subunit Proteins

Histone deacetylase 8

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Enzymology inhibition

Bioassay Details

Effect : enzyme activity HDAC: histone deacetylase; fluorometric assay

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

% Inhibition

Unit

Quantitative value

137.13

Target, Subunit, Species Histone deacetylase 8 280 of 552 Target Mutant/Chimera Details

Histamine H3 receptor:Wild

Target Subunit Proteins

Histamine H3 receptor

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : hyperacetylation of H3 Target : pGL2

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3629439View in Reaxys

227/365

2017-08-01 06:49:42

Substance Name

1481199

Qualitative Results

effective concentration 2 mmol/l

Measurement Parameter

Qualitative

Target, Subunit, Species Histamine H3 receptor 281 of 552 Target Mutant/Chimera Details

Histamine H4 receptor:Wild

Target Subunit Proteins

Histamine H4 receptor

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : hyperacetylation of H4 Target : pGL2

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

effective concentration 2 mmol/l

Measurement Parameter

Qualitative

Target, Subunit, Species Histamine H4 receptor 282 of 552 Target Mutant/Chimera Details

cholesterol 24-hydroxylase:Wild

Target Subunit Proteins

cholesterol 24-hydroxylase

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : CYP46A1 mRNA levels Target : pGL2

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

effective concentration 1 mmol/l

Measurement Parameter

Qualitative

Target, Subunit, Species cholesterol 24-hydroxylase 283 of 552 Target Mutant/Chimera Details

cholesterol 24-hydroxylase:Wild

Target Subunit Proteins

cholesterol 24-hydroxylase

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Transactivation assay

Bioassay Details

Effect : CYP46A1 promoter activity Target : pGL2

228/365

2017-08-01 06:49:42

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Target, Subunit, Species cholesterol 24-hydroxylase 284 of 552 Target Mutant/Chimera Details

cholesterol 24-hydroxylase:Wild

Target Subunit Proteins

cholesterol 24-hydroxylase

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Transactivation assay

Bioassay Details

Effect : CYP46A1 promoter activity Target : 0.12pGL2

Biological Species/NCBI Human ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3629439View in Reaxys

Substance Name

1481199

Measurement Parameter

Qualitative

Qualitative value

Target, Subunit, Species cholesterol 24-hydroxylase 285 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : acetylated histone 3 (H3) activity; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

The test compound-treated R6/2 mice showed a marked increase in acetylated H3 activity in comparison to wild type littermate control mice (WT) at 600 mg/kg/d and 1.2 g/kg/d of test compound (figure given).

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 286 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : acetylated histone 4 (H4) activity; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

229/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

The test compound-treated R6/2 mice showed a marked increase in acetylated H4 activity in comparison to wild type littermate control mice (WT) at 600 mg/kg/d and 1.2 g/kg/d of test compound (figure given).

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 287 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of α-globin mRNA; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 2 Table 2: Changes in alpha and beta globin and MAP kinase phosphatase-1 gene expression in sodium butyrate-treated R6/2 mice. NaBu Txd R6/2 vs R6/2 Untreated R6/2 vs WT mRNA Region Array PCR Northern Array PCR Northern MKP-1 Striatum I181%a NC &ensp;75%

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

For treatment with the test compound PCR = 206% for striatum and Northern =159% for cortex; for untreated wild type mice PCR = 120% for striatum and Northern = 99% for cortex.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 288 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of arginine vasopressin mRNA (gene M88354); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of arginine vasopressin mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 289 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of β-globin mRNA; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 2 Table 2: Changes in alpha and beta globin and MAP kinase phosphatase-1 gene expression in sodium butyrate-treated R6/2 mice. NaBu Txd R6/2 vs R6/2 Untreated R6/2 vs WT mRNA Region Array PCR Northern Array PCR Northern MKP-1 Striatum I181%a NC &ensp;75%

230/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

For treatment with the test compound PCR = 215% for striatum and Northern =206% for cortex; for untreated wild type mice PCR = 104% for striatum and Northern = 39% for cortex.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 290 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of DNAJ/Heat shock protein 40 mRNA (gene AB028272); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of DNAJ/Heat shock protein 40 mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 291 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of dynamin mRNA (gene L31397); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of dynamin mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 292 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of erythroid differentiation regulator mRNA (gene AJ007909); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

231/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of erythroid differentiation regulator mRNA. 100% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 293 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of heterogeneous nuclear ribonucleoprotein A1 mRNA (gene AI183202); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of heterogeneous nuclear ribonucleoprotein A1 mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 294 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of MAP kinase phosphatase-1 (MKP-1) mRNA (gene X61940); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of MKP-1 mRNA, in comparison to both untreated R6/2 mice and wild type littermate control mice (figure given). For treatment with the test compound PCR = 181% for striatum and Northern = 204%

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 295 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of MAP kinase phosphatase-3 (MKP-3) mRNA (gene AI845584); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Stria-

232/365

2017-08-01 06:49:42

tum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714 Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of MKP-3 mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 296 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of microtubule-associated protein tau mRNA (gene M18775); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of microtubule-associated protein tau mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 297 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of mRNA (gene AA711516); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 298 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of mRNA (gene AI153421); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Stria-

233/365

2017-08-01 06:49:42

tum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714 Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 299 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of mRNA (gene AI451558); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 300 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of mRNA (gene AV330064); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 301 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of mRNA (gene C79248); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Stria-

234/365

2017-08-01 06:49:42

tum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714 Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 302 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of preproenkephalin mRNA; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : Results The dose response effects of intraperitoneal injection of sodium butyrate at 100, 200, 400, 600, and 1,200 mg/kg/d on survival in HD R6/2 transgenic mice are shown in FIG. 1A. Intraperitoneal administration of sodium butyrate at 1,200 mg/kg/d significantly extended survival in R6/2 mice by 20.8%

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

The expression of preproenkephalin mRNA, normally decreased in R6/2 mice, was unaffected by treatment with the test compound. For treatment with the test compound PCR = 101% and Northern = 98% for striatum; for untreated wild type mice PCR = 52% and

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 303 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of protein phosphatase 1B, beta isoform mRNA (gene D45859); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of protein phosphatase 1B, beta isoform mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 304 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : expression of transthyretin mRNA (gene D00073); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Stria-

235/365

2017-08-01 06:49:42

tum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714 Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound decreases the expression of transthyretin mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 305 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : neuroprotective effect Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

The somal area of striatal neurons was ~110 μm2 at treatment with 1.2 g/kg/day of the test compound for 90 days. The somal area of striatal neurons for untreated mouse of wild-type was ~140 μm2 (figure given).

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 306 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : rotarod performance, treatment on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

The percentile increase in rotarod performance at 90 days for the 400, 600, and 1,200 mg/kg doses of test compound was 24.0%, 27.5%, and 34.9%, respectively, in comparison to PBS-treated R6/2 mice.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 307 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : survival level; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from

236/365

2017-08-01 06:49:42

the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Administration of test compound at 1,200 mg/kg/d significantly extended survival in R6/2 mice by 20.8% in contrast with PBS-treated mice.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 308 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : transprotein expression-levels; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

There is no differences in transprotein expression-levels between sodium butyrate-treated R6/2 mice and PBS-treated R6/2 mice.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 309 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : 3-nitropropionic acid (3-NP)-induced striatal lesion volumes; effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound for two weeks at 1.2 g/kg/day with administration of 3NP started the second week resulted in marked neuroprotection from 3-NP striatal damage in R6/2 mice. 73.3% reduction in lesion volume in the test compound-treated

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 310 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : huntingtin-positive striatal aggregates; reduction of Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from

237/365

2017-08-01 06:49:42

the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Qualitative

Qualitative value

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 311 of 552

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : ubiquitin-positive inclusions; reduction of Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Qualitative

Qualitative value

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 312 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : Sp1 acetylation; effect on Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Sp1 acetylation levels were increased in brains of test compound-treated R6/2 mice at 1.2 g/kg/d for 2 weeks (figure given).

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 313 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : basal levels of Sp1; effect on Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

238/365

2017-08-01 06:49:42

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Qualitative

Qualitative value

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 314 of 552 Substance Effect

Body Weight

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Target : Huntington's disease transgenic R6/2 mouse Bioassay : BRIEF DESCRIPTION OF THE DRAWINGS One of the above and other objects, novel features and advantages of the present invention will become apparent from the following detailed description of the preferred embodiment(s) of the invention, as illustrated in the drawings, in which: FIG. 1. Survival, body

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Body weight of mice was ~13 - ~20 g for ~21-~133 days (age of the mice) at treatment with 100-1200 mg/kg/day of the test compound (figure given). Significant reduction in body weight loss was observed only after 12 weeks of age.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 315 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : expression of angiomotin like 2 mRNA (gene AI854404); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Qualitative Results

Treatment with the test compound increases the expression of angiomotin like 2 mRNA. 100% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 316 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : expression of c-fos oncogene mRNA (gene V00727); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

239/365

2017-08-01 06:49:42

Qualitative Results

Treatment with the test compound increases the expression of c-fos oncogene mRNA. 100% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 317 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : expression of hemoglobin, alpha adult chain 1 mRNA (gene V00714); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of hemoglobin, alpha adult chain 1 mRNA. 100% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 318 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : expression of hemoglobin, beta adult major chain mRNA (gene J00413); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Treatment with the test compound increases the expression of hemoglobin, beta adult major chain mRNA. 100% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 319 of 552 Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : expression of hemoglobin, beta 1 mRNA (gene V00722); effect on Target : Huntington's disease transgenic R6/2 mouse Bioassay : TABLE 1 Table 1: Changes in gene expression in sodium butyrate-treated R6/2 mice. Direction % of Change Brain region Genbank ID Probe ID mRNA change calls Striatum + Cortex X61940 104598_at MAP kinase phosphatase-1 (MKP-1) Increase 100 Striatum + Cortex V00714

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Route of Adm.

intraperitoneal administration

240/365

2017-08-01 06:49:42

Qualitative Results

Treatment with the test compound increases the expression of hemoglobin, beta 1 mRNA. 75% change calls was obtained.

Measurement Parameter

Qualitative

Patent; U.S. DEPARTMENT OF VETERANS AFFAIRS; US2006/69157; (2006); (A1) English, View in Reaxys 320 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : C6 glioblastoma cell line of human Bioassay : untreated control in vitro; cells preincubated for 24 h at 37 deg C and incubated with title comp. for 24 and 48 h; trypan blue exclusion test

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

IC10

Unit

Quantitative value

0.22

Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys 321 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : C6 glioblastoma cell line of human Bioassay : untreated control in vitro; cells preincubated for 24 h at 37 deg C and incubated with title comp. for 24 and 48 h; trypan blue exclusion test

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

IC50

Unit

Quantitative value

3.44 - 8.44

Measurement pX

2.46

Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys 322 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : C6 glioblastoma cell line of human Bioassay : untreated control in vitro; cells preincubated for 24 h at 37 deg C and incubated with title comp. for 24 and 48 h; trypan blue exclusion test

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

IC90

Unit

241/365

2017-08-01 06:49:42

Quantitative value

1.89 - 10.78

Measurement pX

3.68

Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys 323 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : untreated control in vitro; cells preincubated for 24 h at 37 deg C and incubated with title comp. for 24 h; trypan blue exclusion test

Biological Species/NCBI Human ID Cells/Cell Lines

HepG 2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

IC10

Unit

Quantitative value

1.33

Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys 324 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : untreated control in vitro; cells preincubated for 24 h at 37 deg C and incubated with title comp. for 24 and 48 h; trypan blue exclusion test

Biological Species/NCBI Human ID Cells/Cell Lines

HepG 2

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

IC50

Unit

Quantitative value

1.47 - 6.17

Measurement pX

2.83

Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys 325 of 552 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : untreated control in vitro; cells preincubated for 24 h at 37 deg C and incubated with title comp. for 24 and 48 h; trypan blue exclusion test

Biological Species/NCBI Human ID Cells/Cell Lines

HepG 2

242/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

2 mM

Measurement Parameter

IC90

Unit

Quantitative value

1.67 - 5.58

Measurement pX

3.73

Joachimiak, Romana; Kaznica, Anna; Drewa, Tomasz; Acta Poloniae Pharmaceutica - Drug Research; vol. 64; nb. 6; (2007); p. 561 - 563, View in Reaxys 326 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : |metabolic Target : Albino wistar rat Bioassay : 6 rats/group, wt 250-300g, maintained at ca. 25 deg C, 60 percent relative humidity, 12 h light/dark cycle, fed with controlled diet and distilled water ad libitum; BSP: bromosulphaphthalein 1 h after last dose of title comp. rats infused through jugular vein with 2.5 mg/min/kg of BSP for 1 h; bile duct cannulated; bile collected at intervals up to 1 h after beginning of infusion; total BSP estimated by spectrophotometric analysis, 580 nm

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.500000 mg/kg

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

after 30 min bile BSP conc. decreased by 34 percent, after 60 min increased by 25 percent compared to control; table

Measurement Parameter

Qualitative

Machavaram, Krishna K.; Gundu; Yamsani; Pharmazie; vol. 59; nb. 12; (2004); p. 957 - 960, View in Reaxys 327 of 552 Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : |metabolic Target : Albino wistar rat Bioassay : 6 rats/group, wt 250-300g, maintained at ca. 25 deg C, 60 percent relative humidity, 12 h light/dark cycle, fed with controlled diet and distilled water ad libitum; BSP: bromosulphaphthalein 1 h after last dose of title comp. 60 mg/kg of BSP in H2O administered i.v. as bolus; aliquots of blood samples collected via orbital plexus after 2, 4, 8, 16, 32 and 64 min; content of BSP in serum determined spectrophotometrically at 580 nm

Substance RN

3629439View in Reaxys

Substance Name

1481199

Substance Dose

0.500000 mg/kg

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

after 32, 64 min serum BSP conc. decreased by 68, 14 percent compared to control; table

Measurement Parameter

Qualitative

Machavaram, Krishna K.; Gundu; Yamsani; Pharmazie; vol. 59; nb. 12; (2004); p. 957 - 960, View in Reaxys 328 of 552 Bioassay Category Bioassay Details

Metabolism/Transport Half life of the compound was determined in mouse

243/365

2017-08-01 06:49:42

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Measurement Parameter

t1/2 el

Unit

minute

Qualitative value

Quantitative value

Elaut, Greetje; Rogiers, Vera; Vanhaecke, Tamara; Current Pharmaceutical Design; vol. 13; nb. 25; (2007); p. 2584 - 2620, View in Reaxys 329 of 552 Bioassay Category Bioassay Details

Metabolism/Transport Half life of the compound was determined in human

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Measurement Parameter

t1/2 el

Unit

minute

Qualitative value

Quantitative value

0.5

Elaut, Greetje; Rogiers, Vera; Vanhaecke, Tamara; Current Pharmaceutical Design; vol. 13; nb. 25; (2007); p. 2584 - 2620, View in Reaxys 330 of 552 Target Mutant/Chimera Details

Histone deacetylase 2 [maize]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase 2 [maize]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of maize histone deacetylase 2 using [3H]acetate-prelabeled chicken reticulocyte histone (1 mg/mL) as substrate upon incubation for 30 min at 30 degree C, compound concentration 5000 uM

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Substance Dose

= 5000 µm

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase 2 [maize] 331 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) In vitro percent inhibition of Propionibacterium acnes (n=3) growth upon incubation for 24 hours with 50 ug/mL compound (Dissolved in DMSO) concentration

Biological Species/NCBI Propionibacterium acnes ID

244/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

2.03

Deviation

0.24

Measurement pX

Liu, Chi-Hsien; Huang, Hsin-Ying; Chemical and Pharmaceutical Bulletin; vol. 61; nb. 4; (2013); p. 419 - 425, View in Reaxys 332 of 552 Target Mutant/Chimera Details

Histone deacetylase [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Histone deacetylase [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro inhibitory activity of the compound against histone deacetylase expressed in human leukemia K562 cells upon incubation using [3H1]Histone for 10 min at 37 degree C

Biological Species/NCBI Human ID Cells/Cell Lines

K 562

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

140

Measurement pX

3.85

Target, Subunit, Species Histone deacetylase [human] 333 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of the compound (10E-5 M) against FMLP induced PMN adhesion in HUVEC cells; n=5

Biological Species/NCBI Human ID Cells/Cell Lines

Umbilical vein endothelial cell

Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Deviation

Measurement pX

245/365

2017-08-01 06:49:42

Dianzani, Chiara; Cavalli, Roberta; Zara, Gian Paolo; Gallicchio, Margherita; Lombardi, Grazia; Gasco, Maria Rosa; Panzanelli, Patrizia; Fantozzi, Roberto; British Journal of Pharmacology; vol. 148; nb. 5; (2006); p. 648 656, View in Reaxys 334 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of the compound (10E-3 to 10E-2 M) against FMLP induced myeloperoxidase secretion in PMN cells

Cells/Cell Lines

polymorphonuclear cell

Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Deviation

Measurement pX

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against IL-1beta induced PMN adhesion in HUVEC cells upon incubation for 10 min at 37 degree C

Biological Species/NCBI Human ID Cells/Cell Lines

Umbilical vein endothelial cell

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

4.4E-07

Deviation

0.6

Measurement pX

6.36

In Vitro (Efficacy) Percent inhibition of the compound (10E-5 M) against IL-1beta induced PMN adhesion in HUVEC cells upon incubation for 10 min at 37 degree C

Biological Species/NCBI Human ID Cells/Cell Lines

Umbilical vein endothelial cell

Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

246/365

2017-08-01 06:49:42

Qualitative value

Quantitative value

Deviation

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against FMLP induced O2 production in PMN cells

Cells/Cell Lines

polymorphonuclear cell

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

0.0028

Deviation

0.00021

Measurement pX

2.55

In Vitro (Efficacy)

Bioassay Details

Ability of compound on FMLP induced O2 production in PMN cells

Cells/Cell Lines

polymorphonuclear cell

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Unit

nmol

Qualitative value

Quantitative value

2.1

Deviation

0.15

In Vitro (Efficacy) Effective dose of the compound to inhibit the proliferation of ovarian cancer cell line; Range = 6.3e-4-7.1e-3 M

Biological Species/NCBI Human ID Cells/Cell Lines

OVCAR

Substance RN

3629439View in Reaxys

Measurement Parameter

ED50

Unit

Qualitative value

Quantitative value

0.0071

247/365

2017-08-01 06:49:42

Measurement pX

2.15

Takai, Noriyuki; Narahara, Hisashi; Current Medicinal Chemistry; vol. 14; nb. 24; (2007); p. 2548 - 2553, View in Reaxys 340 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effective dose of the compound to inhibit the proliferation of endometrial cancer cell line; Range= 8.3e-4-4.1e-3 M

Biological Species/NCBI Human ID Cells/Cell Lines

UTERINE CANCER CELL LINE

Substance RN

3629439View in Reaxys

Measurement Parameter

ED50

Unit

Qualitative value

Quantitative value

0.00083

Measurement pX

3.08

Takai, Noriyuki; Narahara, Hisashi; Current Medicinal Chemistry; vol. 14; nb. 24; (2007); p. 2548 - 2553, View in Reaxys 341 of 552 Bioassay Category

Metabolism/Transport

Bioassay Details

Half Life of the compound

Substance RN

3629439View in Reaxys

Measurement Parameter

t1/2 el

Unit

minute

Qualitative value

Quantitative value

Takai, Noriyuki; Narahara, Hisashi; Current Medicinal Chemistry; vol. 14; nb. 24; (2007); p. 2548 - 2553, View in Reaxys 342 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on rotarod performances of R6/2 mice upon intraperitoneal administration of 600 mg/kg/day compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Improved

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 343 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on functional and histopathological defects associated with bulbar muscular atrophy (SBMA) in transgenic mouse upon oral administration of 4 g/L compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

248/365

2017-08-01 06:49:42

Substance Route of Adm.

oral administration

Qualitative Results

Ameliorated

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 344 of 552 Bioassay Category Bioassay Details

In Vivo (Animal models) Percent increase in survival of R6/2 mice upon intraperitoneal administration of compound was determined

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Activity

Unit

Qualitative value

Quantitative value

20.8

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 345 of 552 Bioassay Category Bioassay Details

In Vivo (Animal models) Effect on histone acetylation in spinal cord tissue of transgenic mouse model of spinal and bulbar muscular atrophy (SBMA) upon oral administration of 4 g/L compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

oral administration

Qualitative Results

Increased

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 346 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on neuronal atrophy in R6/2 mice upon intraperitoneal administration of 400 mg/kg/day compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Decreased

Measurement Parameter

Activity

Qualitative value

249/365

2017-08-01 06:49:42

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 347 of 552 Bioassay Category Bioassay Details

In Vivo (Animal models) Effect on rotarod performances of R6/2 mice upon intraperitoneal administration of 400 mg/kg/day compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Improved

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 348 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on rotarod performances of R6/2 mice upon intraperitoneal administration of 1200 mg/kg/day compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Improved

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 349 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on neuronal atrophy in R6/2 mice upon intraperitoneal administration of 600 mg/kg/day compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Decreased

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 350 of 552 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Concentration of compound required to protect against striatal nitroproprionic acid (3-NP) toxicity in mice

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

250/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 351 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on neuronal atrophy in R6/2 mice upon intraperitoneal administration of 1200 mg/kg/day compound

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Qualitative Results

Decreased

Measurement Parameter

Activity

Qualitative value

Langley, Brett; Gensert, Joann M; Beal, M Flint; Ratan, Rajiv R; Current drug targets. CNS and neurological disorders; vol. 4; nb. 1; (2005); p. 41 - 50, View in Reaxys 352 of 552 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Minimum concentration of compound required for lethal toxicity against Blepharisma japonicum

Biological Species/NCBI Blepharisma japonicum ID Substance RN

3629439View in Reaxys

Measurement Parameter

Concentration

Unit

Qualitative value

Quantitative value

31.3

Koichi Yoshioka; Sohei Tominaga; Yoshiyuki Uruma; Yoshinosuke Usuki; Hideo Iio; Tetrahedron letters; vol. 64; nb. 18; (2008); p. 4103 - 4107, View in Reaxys 353 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on heat shock protein 70 level in rat cortical neurons upon treatment with 1 mM compound for 72 h

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

Brain cortical neuron cell

Substance RN

3629439View in Reaxys

Qualitative Results

Maximum increase observed

Measurement Parameter

Activity

Qualitative value

Marinova, Zoya; Ren, Ming; Wendland, Jens R.; Leng, Yan; Liang, Min-Huei; Yasuda, Shigeru; Leeds, Peter; Chuang, De-Maw; Journal of Neurochemistry; vol. 111; nb. 4; (2009); p. 976 - 987, View in Reaxys 354 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on p21 levels in human SiHa cells transfected with wild type p300 expression vector upon treatment with 5 mM compound for 4 h was analysed by western blotting analysis

Biological Species/NCBI Human ID

251/365

2017-08-01 06:49:42

Cells/Cell Lines

SiHa

Substance RN

3629439View in Reaxys

Qualitative Results

Upregulated

Measurement Parameter

Activity

Qualitative value

Chen, Jihong; Ghazawi, Feras M.; Li, Qiao; Epigenetics; vol. 5; nb. 6; (2010); p. 509 - 515, View in Reaxys 355 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Apoptotic index 50 of the compound against human HepG2 cells was determined by flow cytometric analysis

Biological Species/NCBI Human ID Cells/Cell Lines

HepG 2

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Unit

Qualitative value

Quantitative value

1.5

Carlisi; Vassallo; Lauricella; Emanuele; D'Anneo; Di Leonardo; Di Fazio; Vento; Tesoriere, Giovanni; International Journal of Oncology; vol. 32; nb. 1; (2008); p. 177 - 184, View in Reaxys 356 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Effect on p21 protein levels in bromo defcient p300 human SiHa cells upon treatment with 5 mM compound for 4 h was detected by western blotting analysis

Biological Species/NCBI Human ID Cells/Cell Lines

SiHa

Substance RN

3629439View in Reaxys

Qualitative Results

Increased

Measurement Parameter

Activity

Qualitative value

Chen, Jihong; Ghazawi, Feras M.; Li, Qiao; Epigenetics; vol. 5; nb. 6; (2010); p. 509 - 515, View in Reaxys 357 of 552 Target Mutant/Chimera Details

Histone deacetylase [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Histone deacetylase [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration against histone deacetylase (2 uL) in human leukemia K562 cells using 3H-labeled histone as radioligand (100 ug/mL) upon incubation for 10 min at 37 degree C

Biological Species/NCBI Human ID Cells/Cell Lines

K 562

Substance RN

3629439View in Reaxys

252/365

2017-08-01 06:49:42

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

140

Measurement pX

3.85

Target, Subunit, Species Histone deacetylase [human] 358 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition of germination of mustard (sinapsis alba L.) seeds (n=50) at 1 g/l concentration of the compound incubated in dark at 25 degree C for 3-7 days

Biological Species/NCBI Sinapsis ALBA L. ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

100

N. LE POIDEVIN; Phytochemistry; vol. 4; nb. 3; (1965); p. 525 - 526, View in Reaxys 359 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition of germination of mustard (sinapsis alba L.) seeds (n=50) at 0.1 g/l concentration of the compound incubated in dark at 25 degree C for 3-7 days

Biological Species/NCBI Sinapsis ALBA L. ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

100

N. LE POIDEVIN; Phytochemistry; vol. 4; nb. 3; (1965); p. 525 - 526, View in Reaxys 360 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition of germination of mustard (sinapsis alba L.) seeds (n=50) at 0.5 g/l concentration of the compound incubated in dark at 25 degree C for 3-7 days

Biological Species/NCBI Sinapsis ALBA L. ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

100

253/365

2017-08-01 06:49:42

N. LE POIDEVIN; Phytochemistry; vol. 4; nb. 3; (1965); p. 525 - 526, View in Reaxys 361 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro percent inhibition of histone deacetylase activity at 5 mM using [3H]-acetate prelabeled chicken reticulocyte histones as radioligand

Substance RN

3629439View in Reaxys

Substance Dose

= 5 mM

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Measurement pX

2.03

Target, Subunit, Species Histone deacetylase 362 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in monomac 6 cells (MICA/B) by the compound was determined; Control = 3

Cells/Cell Lines

Mono Mac 6

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 363 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in HeLa cells (MICA/B) by the compound was determined; Control = 65

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 364 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

254/365

2017-08-01 06:49:42

Bioassay Details

Induction of NKG2D-L expression in HeLa cells (ULBP2) by the compound was determined; Control = 3

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 365 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of compound against histone deacetylase in cell-free system

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.22

Target, Subunit, Species Histone deacetylase Thangaraju, Muthusamy; Gopal, Elangovan; Martin, Pamela M.; Ananth, Sudha; Smith, Sylvia B.; Prasad, Puttur D.; Sterneck, Esta; Ganapathy, Vadivel; Cancer Research; vol. 66; nb. 24; (2006); p. 11560 - 11564, View in Reaxys 366 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in HCT 116 cells (ULBP2) by the compound was determined; Control = 2

Cells/Cell Lines

HCT116

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 367 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against colony formation in SLC5A8-expressing human breast tumor MCF7 cells

Biological Species/NCBI Human ID Cells/Cell Lines

MCF-7

Substance RN

3629439View in Reaxys

255/365

2017-08-01 06:49:42

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Deviation

Measurement pX

4.43

Thangaraju, Muthusamy; Gopal, Elangovan; Martin, Pamela M.; Ananth, Sudha; Smith, Sylvia B.; Prasad, Puttur D.; Sterneck, Esta; Ganapathy, Vadivel; Cancer Research; vol. 66; nb. 24; (2006); p. 11560 - 11564, View in Reaxys 368 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in Raji cells (ULBP2) by the compound was determined; Control = 2

Cells/Cell Lines

Raji

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 369 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in HCT 116 cells (MICA/B) by the compound was determined; Control = 27

Cells/Cell Lines

HCT116

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 370 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in U937 cells (MICA/B) by the compound was determined; Control = 2

Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 371 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

256/365

2017-08-01 06:49:42

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in monomac 6 cells (ULBP2) by the compound was determined; Control = 3

Cells/Cell Lines

Mono Mac 6

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 372 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in Daudi cells (ULBP2) by the compound was determined; Control = 2

Cells/Cell Lines

Daudi

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 373 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in THP-1 cells (ULBP2) by the compound was determined; Control = 4

Cells/Cell Lines

THP1

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 374 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in Daudi cells (MICA/B) by the compound was determined; Control = 2

Cells/Cell Lines

Daudi

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein

257/365

2017-08-01 06:49:42

375 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in U937 cells (ULBP2) by the compound was determined; Control = 2

Cells/Cell Lines

U 937

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 376 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in 721.221 cells (MICA/B) by the compound was determined; Control = 3

Cells/Cell Lines

721.221

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 377 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in 721.221 cells (ULBP2) by the compound was determined; Control = 3

Cells/Cell Lines

721.221

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 378 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in THP-1 cells (MICA/B) by the compound was determined; Control = 3

Cells/Cell Lines

THP1

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

258/365

2017-08-01 06:49:42

Target, Subunit, Species Ul16 Binding Protein 379 of 552 Target Mutant/Chimera Details

Ul16 Binding Protein:Wild

Target Subunit Proteins

Ul16 Binding Protein

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Induction of NKG2D-L expression in Raji cells (MICA/B) by the compound was determined; Control = 4

Cells/Cell Lines

Raji

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

Target, Subunit, Species Ul16 Binding Protein 380 of 552 Target Mutant/Chimera Details

Chymotrypsin B:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Chymotrypsin B

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against 0.03 unit of purified chymotrypsin upon incubation in (20 mmol/L) HEPES buffer, pH 8 for 2 hours at 37 degree C in presence of Suc-LLVY-AMC as fluorogenic peptide substrate by chymotrypsin assay

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.4

Target, Subunit, Species Chymotrypsin B 381 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of proteoglycan destruction in rabbit cartilage by stimulating with retinoic acid (1 uM) with trypsin EDTA at 37 degree C with 0.3 nM of compound

Biological Species/NCBI rabbit ID Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Patent; YAMANOUCHI PHARMACEUTICAL CO., LTD.; WO2004/17996; (2004); (A1) japanese, View in Reaxys 382 of 552 Bioassay Category Bioassay Details

In Vivo (Animal models) Survival extension of G93A mouse after daily intraperitoneal administration of compound at a concentration of 200 mg/kg/day; control 126.1+/-2.7

259/365

2017-08-01 06:49:42

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Survival activity

Unit

day

Qualitative value

Quantitative value

129.2

Deviation

4.5

Patent; U.S. Department of Veterans Affairs; US2006/135612; (2006); (A1) English, View in Reaxys 383 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Survival extension of G93A mouse after daily intraperitoneal administration of compound at a concentration of 1200 mg/kg/day; control 126.1+/-2.7

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Survival activity

Unit

day

Qualitative value

Quantitative value

151.3

Deviation

6.8

Patent; U.S. Department of Veterans Affairs; US2006/135612; (2006); (A1) English, View in Reaxys 384 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against histone deacetylase

Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase Patent; SYNDAX PHARMACEUTICALS, INC.; WO2008/58287; (2008); (A1) English, View in Reaxys 385 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of proteoglycan in rabbit cartilage by stimulating with human IL-1beta (10 ng/mL) with 5 nM of compound

Biological Species/NCBI rabbit ID Substance RN

3629439View in Reaxys

260/365

2017-08-01 06:49:42

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Patent; YAMANOUCHI PHARMACEUTICAL CO., LTD.; WO2004/17996; (2004); (A1) japanese, View in Reaxys 386 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against Histone deacetylase was determined

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

280

Measurement pX

3.55

Target, Subunit, Species Histone deacetylase Patent; YAMANOUCHI PHARMACEUTICAL CO., LTD.; WO2004/17996; (2004); (A1) japanese, View in Reaxys 387 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Survival extension of G93A mouse after daily intraperitoneal administration of compound at a concentration of 600 mg/kg/day; control 126.1+/-2.7

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

Survival activity

Unit

day

Qualitative value

Quantitative value

141.8

Deviation

5.9

Patent; U.S. Department of Veterans Affairs; US2006/135612; (2006); (A1) English, View in Reaxys 388 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against histone deacetylase

Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

261/365

2017-08-01 06:49:42

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase Patent; U.S. Department of Veterans Affairs; US2006/135612; (2006); (A1) English, View in Reaxys 389 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory actvity of the compound against histone deacetylase

Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase 390 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent inhibition of proteoglycan destruction in rabbit cartilage by stimulating with retinoic acid (1 uM) with trypsin EDTA at 37 degree C with 3 nM of compound

Biological Species/NCBI rabbit ID Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Patent; YAMANOUCHI PHARMACEUTICAL CO., LTD.; WO2004/17996; (2004); (A1) japanese, View in Reaxys 391 of 552 Target Mutant/Chimera Details

Histone deacetylase 6:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase 6

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Ratio of inhibitory concentration (IC50) of the compound against Histone deacetylase 6 to that of Histone deacetylase 1

Substance RN

3629439View in Reaxys

Measurement Parameter

Ratio

Quantitative value

Target, Subunit, Species Histone deacetylase 6 392 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against Histone Deacetylase

262/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

140

Measurement pX

3.85

Target, Subunit, Species Histone deacetylase 393 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent apoptosis in human K562 cells was determined upon incubation for 24 h with compound dissolved in DMSO; Control = 0.6+/-0.3

Biological Species/NCBI Human ID Cells/Cell Lines

K 562

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

5.1

Deviation

2.2

Patent; VIRGINIA COMMONWEALTH UNIVERSITY; MCGUIRE VA MEDICAL CENTER 111K; WO2004/24160; (2004); (A1) english, View in Reaxys 394 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent apoptosis in human LAMA 84 cells was determined upon incubation for 24 h with compound dissolved in DMSO; Control = 1.8+/-0.5

Biological Species/NCBI Human ID Cells/Cell Lines

LAMA84

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

6.4

Deviation

2.8

Patent; VIRGINIA COMMONWEALTH UNIVERSITY; MCGUIRE VA MEDICAL CENTER 111K; WO2004/24160; (2004); (A1) english, View in Reaxys 395 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against histone deacetylase

Substance RN

3629439View in Reaxys

263/365

2017-08-01 06:49:42

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase Patent; VIRGINIA COMMONWEALTH UNIVERSITY; MCGUIRE VA MEDICAL CENTER 111K; WO2004/24160; (2004); (A1) english, View in Reaxys 396 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) In vitro efficacy was determined as measuring the inhibition of rat tracheal epithelial transformation at 272.4 uM compound concentration

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

Tracheal epithelial cell

Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Unit

Qualitative value

Quantitative value

Steele; Kelloff; Wilkinson; Arnold; Cancer Research; vol. 50; nb. 7; (1990); p. 2068 - 2074, View in Reaxys 397 of 552 Bioassay Category Bioassay Details

In Vivo (Animal models) Percent increase in survival of R6/2 transgenic mouse with Huntington's disease after intraperitoneal administration of the compound at a dose of 200-10,000 mg/kg/d

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Route of Adm.

intraperitoneal administration

Measurement Parameter

% Stimulation

Unit

Qualitative value

Quantitative value

21.7

Qin, Zheng-Hong; Wang, Jin; Gu, Zhen-Lun; Acta Pharmacologica Sinica; vol. 26; nb. 2; (2005); p. 129 - 142, View in Reaxys 398 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 2 [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Carbonic anhydrase 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against human Carbonic anhydrase II upon incubation for 15 min at RT in 10-20 mM Hepes buffer, pH 7.5

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Measurement Parameter

264/365

2017-08-01 06:49:42

Unit

µM

Qualitative value

Quantitative value

1032

Measurement pX

2.99

Target, Subunit, Species Carbonic anhydrase 2 [human] 399 of 552 Target Mutant/Chimera Details

Carbonic anhydrase [Cryptococcus neoformans]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Cryptococcus neoformans

Target Subunit Proteins

Carbonic anhydrase [Cryptococcus neoformans]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against Beta-carbonic anhydrase from Cryptococcus neoformans (Can2) upon incubation for 15 min at RT using in 10-20 mM Tris buffer, pH 8.3

Biological Species/NCBI Cryptococcus neoformans ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

225

Measurement pX

3.65

Target, Subunit, Species Carbonic anhydrase [Cryptococcus neoformans] 400 of 552 Target Mutant/Chimera Details

Carbonic anhydrase [Candida albicans]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Candida albicans

Target Subunit Proteins

Carbonic anhydrase [Candida albicans]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against Beta-carbonic anhydrase from Candida albicans (Nce103) upon incubation for 15 min at RT in 10-20 mM Tris buffer, pH 8.3

Biological Species/NCBI Candida albicans ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

26.9

Measurement pX

4.57

Target, Subunit, Species Carbonic anhydrase [Candida albicans] 401 of 552 Target Mutant/Chimera Details

Histone deacetylase 2 [maize]:Wild

265/365

2017-08-01 06:49:42

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase 2 [maize]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro percent inhibition of maize histone deacetylase 2 upon incubation with 5000 uM compound for 30 min at 30 degree C using [3H]acetate-prelabeled chicken reticulocyte histone (1 mg/mL) as substrate; n = > 3

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Substance Dose

5000 µm

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase 2 [maize] 402 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Growth inhibitory effect of the compound (dissolved in DMSO) against human prostate cancer PC-3 cells upon incubation for 2 hrs at 37 degree C by MTT assay

Biological Species/NCBI Human ID Cells/Cell Lines

PC-3

Substance RN

3629439View in Reaxys

Measurement Parameter

GI50

Unit

µM

Qualitative value

Quantitative value

72.44

Deviation

Measurement pX

4.14

Patent; UNIVERSITY OF MARYLAND, BALTIMORE; WO2008/154372; (2008); (A1) English, View in Reaxys 403 of 552 Target Mutant/Chimera Details

Histone deacetylase 2 [maize]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase 2 [maize]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of maize Histone deacetylase 2 at 5000 uM dose using [3H]acetateprelabelled chicken reticulocyte histones upon incubation for 30 min at 30 degree C

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Substance Dose

= 5000 µm

266/365

2017-08-01 06:49:42

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase 2 [maize] 404 of 552 Target Mutant/Chimera Details

Histone deacetylase 2 [maize]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase 2 [maize]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against maize histone deacetylase 2 was determined; ND = not determined

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Qualitative Results

Measurement Parameter

Qualitative

Target, Subunit, Species Histone deacetylase 2 [maize] 405 of 552 Target Mutant/Chimera Details

Histone deacetylase 2 [maize]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase 2 [maize]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration against maize Histone deacetylase 2 using [3H]acetate-prelabelled chicken reticulocyte upon incubation for 30 min at 30 degree C; ND = Not determined

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Qualitative Results

Measurement Parameter

Qualitative

Target, Subunit, Species Histone deacetylase 2 [maize] 406 of 552 Target Mutant/Chimera Details

Histone deacetylase 2 [maize]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase 2 [maize]

Bioassay Category

In Vitro (Efficacy)

267/365

2017-08-01 06:49:42

Bioassay Details

Percent inhibition of the compound (24.8uM) against maize histone deacetylase using [3H] Acetate-prelabeled chicken reticulocyte histone substrate upon incubation at 30 degree for 30 min

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Substance Dose

5000 µm

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase 2 [maize] 407 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against histone deacetylase

Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase Patent; UNIVERSITY OF MARYLAND, BALTIMORE; WO2008/154372; (2008); (A1) English, View in Reaxys 408 of 552 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Growth inhibitory effect of the compound (dissolved in DMSO) against human breast cancer MDA-MB-231 cells upon incubation for 2 hrs at 37 degree C by MTT assay

Biological Species/NCBI Human ID Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Measurement Parameter

GI50

Unit

µM

Qualitative value

Quantitative value

1000

Deviation

Measurement pX

Patent; UNIVERSITY OF MARYLAND, BALTIMORE; WO2008/154372; (2008); (A1) English, View in Reaxys 409 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent decrease of Tyrosine hydroxylase mRNA (5-10 ug) level in rat PC12 cells upon treatment with the compound at a concentration of 5 mM using RNA blot assay

Biological Species/NCBI Rattus norvegicus ID

268/365

2017-08-01 06:49:42

Cells/Cell Lines

PC-12

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

Aranyi; Sarkis; Berrard; Sardin; Siron; Khalfallah; Mallet; Biochemical and Biophysical Research Communications; vol. 359; nb. 1; (2007); p. 15 - 19, View in Reaxys 410 of 552 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent decrease of Tyrosine hydroxylase mRNA (5-10 ug) level in rat PC12 cells upon treatment with the compound at a concentration of 2.5 mM using RNA blot assay

Biological Species/NCBI Rattus norvegicus ID Cells/Cell Lines

PC-12

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

Qualitative value

Quantitative value

Aranyi; Sarkis; Berrard; Sardin; Siron; Khalfallah; Mallet; Biochemical and Biophysical Research Communications; vol. 359; nb. 1; (2007); p. 15 - 19, View in Reaxys 411 of 552

Target Mutant/Chimera Details

Histone deacetylase [Mus musculus]:Wild

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration required for maximal killing of IMR-32 cell line after 48 h treatment by MTT assay mediated by histone deacetylase; Range is 2-3 mM

Biological Species/NCBI Mus musculus ID Cells/Cell Lines

IMR-32

Substance RN

3629439View in Reaxys

Measurement Parameter

EC50

Unit

Qualitative value

Quantitative value

Measurement pX

2.52

Target, Subunit, Species Histone deacetylase [Mus musculus] 412 of 552 Target Mutant/Chimera Details

Histone deacetylase [maize]:Wild

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase [maize]

Bioassay Category

In Vitro (Efficacy)

269/365

2017-08-01 06:49:42

Bioassay Details

Percent inhibition of histone deacetylase taken from maize at 5mM concentration

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase [maize] 413 of 552 Target Mutant/Chimera Details

Histone deacetylase [maize]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

maize

Target Subunit Proteins

Histone deacetylase [maize]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of histone deacetylase taken from maize at 5000 uM concentration

Biological Species/NCBI Zea mays ID Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase [maize] 414 of 552 Target Mutant/Chimera Details

Histone deacetylase [Mus musculus]:Wild

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration required for maximal killing of SH-SY5Y N-type neuroblastoma cell line after 48 h treatment by MTT assay mediated by histone deacetylase

Biological Species/NCBI Mus musculus ID Cells/Cell Lines

SH-SY-5Y

Substance RN

3629439View in Reaxys

Measurement Parameter

EC50

Unit

Qualitative value

Quantitative value

Measurement pX

2.52

Target, Subunit, Species Histone deacetylase [Mus musculus]

270/365

2017-08-01 06:49:42

415 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against Histone Deacetylase

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

0.14

Measurement pX

3.85

Target, Subunit, Species Histone deacetylase 416 of 552 Target Mutant/Chimera Details

Histone deacetylase 1:Wild

Target Subunit Proteins

Histone deacetylase 1

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Mean inhibitory concentration of the compound against Histone deacetylase 1

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

170000

Measurement pX

3.77

Target, Subunit, Species Histone deacetylase 1 417 of 552 Target Mutant/Chimera Details

Histone deacetylase 6:Wild

Target Subunit Proteins

Histone deacetylase 6

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Ratio of inhibitory concentration of the compound against Histone deacetylase 6 to that of Histone deacetylase 1

Substance RN

3629439View in Reaxys

Measurement Parameter

Ratio

Qualitative value

Quantitative value

Target, Subunit, Species Histone deacetylase 6 418 of 552 Target Mutant/Chimera Details

Histone deacetylase 4:Wild

Target Subunit Proteins

Histone deacetylase 4

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 4 using 10.32 uM fluorophore conjugated substrate-6 upon incubation in 50 mM HEPES buffer, pH 7.4

271/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

1000

Measurement pX

Target, Subunit, Species Histone deacetylase 4 419 of 552 Target Mutant/Chimera Details

Histone deacetylase 6:Wild

Target Subunit Proteins

Histone deacetylase 6

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Mean inhibitory concentration of the compound against Histone deacetylase 6

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

10000000

Measurement pX

Target, Subunit, Species Histone deacetylase 6 420 of 552 Target Mutant/Chimera Details

Histone deacetylase 1:Wild

Target Subunit Proteins

Histone deacetylase 1

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 1 using 6 uM fluorophore conjugated substrate-3 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.54

Target, Subunit, Species Histone deacetylase 1 421 of 552 Target Mutant/Chimera Details

Histone deacetylase 9:Wild

Target Subunit Proteins

Histone deacetylase 9

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 9 using 37 uM fluorophore conjugated substrate-6 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

272/365

2017-08-01 06:49:42

Qualitative value

Quantitative value

1000

Measurement pX

Target, Subunit, Species Histone deacetylase 9 422 of 552 Target Mutant/Chimera Details

Histone deacetylase 7:Wild

Target Subunit Proteins

Histone deacetylase 7

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 7 using 19.8 uM fluorophore conjugated substrate-6 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

1000

Measurement pX

Target, Subunit, Species Histone deacetylase 7 423 of 552 Target Mutant/Chimera Details

Histone deacetylase 3:Wild

Target Subunit Proteins

Histone deacetylase 3

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 3 using 6 uM fluorophore conjugated substrate-3 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.89

Target, Subunit, Species Histone deacetylase 3 424 of 552 Target Mutant/Chimera Details

Histone deacetylase 8:Wild

Target Subunit Proteins

Histone deacetylase 8

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 8 using 190 uM fluorophore conjugated substrate-6 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

273/365

2017-08-01 06:49:42

Measurement pX

4.15

Target, Subunit, Species Histone deacetylase 8 425 of 552 Target Mutant/Chimera Details

Histone deacetylase 5:Wild

Target Subunit Proteins

Histone deacetylase 5

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 5 using 59 uM fluorophore conjugated substrate-6 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

1000

Measurement pX

Target, Subunit, Species Histone deacetylase 5 426 of 552 Target Mutant/Chimera Details

Histone deacetylase 6:Wild

Target Subunit Proteins

Histone deacetylase 6

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 6 using 16 uM fluorophore conjugated substrate-3 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

1000

Measurement pX

Target, Subunit, Species Histone deacetylase 6 427 of 552 Target Mutant/Chimera Details

Histone deacetylase 2:Wild

Target Subunit Proteins

Histone deacetylase 2

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against recombinant full-length HISTONE DEACETYLASE 2 using 3 uM FLUOROPHORE CONJUGATED substrate-3 upon incubation in 50 mM HEPES buffer, pH 7.4

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

Quantitative value

Measurement pX

4.57

Target, Subunit, Species Histone deacetylase 2

274/365

2017-08-01 06:49:42

428 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 2 [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Carbonic anhydrase 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Selectivity is the ratio of inhibition constant of the compound against human carbonic anhydrase II to that of inhibition constant of the compound against Candida albicans NCE103

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Carbonic anhydrase 2 [human] 429 of 552 Target Mutant/Chimera Details

Carbonic anhydrase [Candida albicans]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Candida albicans

Target Subunit Proteins

Carbonic anhydrase [Candida albicans]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against Candida albicans NCE103 upon incubation in 10-20 mM tris buffer at pH 8.3 for 15 minutes at RT

Biological Species/NCBI Candida albicans ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

26.9

Measurement pX

4.57

Target, Subunit, Species Carbonic anhydrase [Candida albicans] 430 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 1 [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Carbonic anhydrase 1 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against human carbonic anhydrase I upon incubation in 10-20 mM HEPES buffer at pH 7.5 for 15 minutes at RT

Biological Species/NCBI Human ID

275/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

511

Measurement pX

3.29

Target, Subunit, Species Carbonic anhydrase 1 [human] 431 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 2 [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Carbonic anhydrase 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against human carbonic anhydrase II upon incubation in 10-20 mM HEPES buffer at pH 7.5 for 15 minutes at RT

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

1032

Measurement pX

2.99

Target, Subunit, Species Carbonic anhydrase 2 [human] 432 of 552 Target Mutant/Chimera Details

Calpain-2 catalytic subunit [Cryptococcus neoformans]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Cryptococcus neoformans

Target Subunit Proteins

Calpain-2 catalytic subunit [Cryptococcus neoformans]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of the compound against Cryptococcus neoformans Can2 upon incubation in 10-20 mM tris buffer at pH 8.3 for 15 minutes at Rt

Biological Species/NCBI Cryptococcus neoformans ID Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

225

Measurement pX

3.65

Target, Subunit, Species Calpain-2 catalytic subunit [Cryptococcus neoformans]

276/365

2017-08-01 06:49:42

433 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 2 [human]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

human

Target Subunit Proteins

Carbonic anhydrase 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Selectivity is the ratio of inhibition constant of the compound against human carbonic anhydrase II to that of inhibition constant of the compound against Cryptococcus neoformans Can2

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Carbonic anhydrase 2 [human] 434 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against Histone deacetylase was determined

Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase 435 of 552 Target Mutant/Chimera Details

NS3 Helicase [Hepatitis C virus]:Wild

Target Species (Bioactivity)

Hepatitis C virus

Target Subunit Proteins

NS3 Helicase [Hepatitis C virus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Percent inhibition of Hepatitis C Virus 1B NS3 Helicase upon incubation in 25 mM MOPS, pH 6.5 using 5 nM MBHA as a substrate in presence of 1 mM ATP at 20 uM compound (dissolved in DMSO)

Biological Species/NCBI Hepatitis C virus ID Substance RN

3629439View in Reaxys

Measurement Parameter

% Inhibition

Unit

Qualitative value

Quantitative value

1.1

Measurement pX

Target, Subunit, Species NS3 Helicase [Hepatitis C virus]

277/365

2017-08-01 06:49:42

436 of 552 Target Mutant/Chimera Details

NS3 Helicase [Hepatitis C virus subtype 1b]:Wild

Target Species (Bioactivity)

Hepatitis C virus subtype 1b

Target Subunit Proteins

NS3 Helicase [Hepatitis C virus subtype 1b]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Interference activity (Ratio) of compound towards Hepatitis C Virus 1B NS3 Helicase upon incubation in 25 mM MOPS, pH 6.5 using 5 nM MBHA as a substrate in presence of 1 mM ATP in relative to three DMSO-only negative control reactions

Biological Species/NCBI Hepatitis C virus subtype 1b ID Substance RN

3629439View in Reaxys

Measurement Parameter

Activity

Quantitative value

0.9

Target, Subunit, Species NS3 Helicase [Hepatitis C virus subtype 1b] 437 of 552 Target Mutant/Chimera Details

Histone deacetylase [taurine cattle]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

taurine cattle

Target Subunit Proteins

Histone deacetylase [taurine cattle]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration against partially purified histone deacetylase using [3H]Acetylated histone as radioligand upon incubation for 30 min at 37 degree C was determined

Biological Species/NCBI taurine cattle ID Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

150000

Measurement pX

3.82

Target, Subunit, Species Histone deacetylase [taurine cattle] 438 of 552 Target Mutant/Chimera Details

acetylspermidine deacetylase [Rattus norvegicus]:Wild

Substance Action on Target

Radioligand (/ligand)

Target Species (Bioactivity)

Rattus norvegicus

Target Subunit Proteins

acetylspermidine deacetylase [Rattus norvegicus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Apparent binding constant of the compound towards N8-Acetylspermidine deacetylase of rat liver cytosol using N8[acetyl-3H]acetylspermidine as radioligand upon incubation in 0.5 M NaH2Po4 (pH 7.4) at 37 degree C for 10 min determined by liquid scintillation spectrometry

Biological Species/NCBI Rattus norvegicus ID

278/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

38500

Measurement pX

1.41

Target, Subunit, Species acetylspermidine deacetylase [Rattus norvegicus] Huang; Dredar; Manneh; Blankenship; Fries; Journal of medicinal chemistry; vol. 35; nb. 13; (1992); p. 2414 2418, View in Reaxys 439 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibition constant of compound towards histone deacetylase in HeLa cells using [BocLys(Ac)-AMC] as substrate by fluorimetric assay

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Measurement Parameter

Unit

µM

Qualitative value

Quantitative value

365

Measurement pX

3.44

Target, Subunit, Species Histone deacetylase 440 of 552 Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of compound against histone deacetylase in HeLa cells using [Boc-Lys(Ac)-AMC] as substrate by fluorimetric assay

Cells/Cell Lines

HeLa

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

0.8

Measurement pX

3.1

Target, Subunit, Species Histone deacetylase 441 of 552 Target Mutant/Chimera Details

Hydroxycarboxylic acid receptor 2 [Mus musculus]:Wild

279/365

2017-08-01 06:49:42

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Hydroxycarboxylic acid receptor 2 [Mus musculus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration of the compound against [35S]GTPgammaS binding to mouse Gi/o-coupled seven-transmembrane receptor PUMA-G expressed in CHO-K1 cells done for 15 min at RT

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Measurement Parameter

EC50

Unit

µM

Qualitative value

Quantitative value

702

Measurement pX

3.15

Target, Subunit, Species Hydroxycarboxylic acid receptor 2 [Mus musculus] 442 of 552 Target Mutant/Chimera Details

Histone deacetylase 4:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

Histone deacetylase 4

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro inhibitory concentration of the compound against Histone deacetylase 4 upon incubation with 0.5 ug HeLa cell nuclear extract in 20 mM Tris buffer, pH 8 for 1 h at 37 degree C

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

200000

Measurement pX

3.7

Target, Subunit, Species Histone deacetylase 4 443 of 552 Target Mutant/Chimera Details

Hydroxycarboxylic acid receptor 2 [human]:Wild

Target Species (Bioactivity)

human

Target Subunit Proteins

Hydroxycarboxylic acid receptor 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration of the compound against [35S]GTPgammaS binding to mouse Gi/o-coupled seven-transmembrane receptor HM74a expressed in CHO-K1 cells done for 15 min at RT

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Measurement Parameter

EC50

Unit

µM

280/365

2017-08-01 06:49:42

Qualitative value

Quantitative value

1590

Measurement pX

2.8

Target, Subunit, Species Hydroxycarboxylic acid receptor 2 [human] 444 of 552 Target Mutant/Chimera Details

Hydroxycarboxylic acid receptor 2 [human]:Wild

Target Species (Bioactivity)

human

Target Subunit Proteins

Hydroxycarboxylic acid receptor 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration of the compound against [35S]GTPgammaS binding to mouse Gi/o-coupled seven-transmembrane receptor HT74 expressed in CHO-K1 cells done for 15 min at RT; IA=inactive

Biological Species/NCBI Human ID Substance RN

3629439View in Reaxys

Qualitative Results

Measurement Parameter

EC50

Qualitative value

Measurement pX

Target, Subunit, Species Hydroxycarboxylic acid receptor 2 [human] 445 of 552 Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Viral infection

Cells/Cell Lines

J-Lat 8.4

Substance RN

3629439View in Reaxys

Substance Name

figure 5B; figure 5C - compound: NaBut

Measurement Parameter

% Stimulation

Unit

Quantitative value

100

Patent; UNIVERSITÉ LIBRE DE BRUXELLES; VAN LINT, Carine; ROHR, Olivier; BOUCHAT, Sophie; GATOT, Jean-Stéphane; WO2013/50422; (2013); (A1) English, View in Reaxys 446 of 552 Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Viral infection

Cells/Cell Lines

J-Lat 8.4

Substance RN

3629439View in Reaxys

Substance Name

figure 5B; figure 5C - compound: NaBut

Measurement Parameter

% Stimulation

Unit

Quantitative value

971

Patent; UNIVERSITÉ LIBRE DE BRUXELLES; VAN LINT, Carine; ROHR, Olivier; BOUCHAT, Sophie; GATOT, Jean-Stéphane; WO2013/50422; (2013); (A1) English, View in Reaxys 447 of 552 Target Mutant/Chimera Details

Survival motor neuron protein [human]:Wild

281/365

2017-08-01 06:49:42

Substance Action on Target

Modulator

Target Species (Bioactivity)

human

Target Subunit Proteins

Survival motor neuron protein [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration of compound required to increase expression of human survival motor neuron protein 2 (SMN2) in transfected HEK 293 cells upon incubation at 37 degree C 24 hrs measured by luciferase activity

Cells/Cell Lines

HEK 293

Substance RN

3629439View in Reaxys

Measurement Parameter

EC50

Unit

mg/mL

Qualitative value

Quantitative value

Measurement pX

2.04

Target, Subunit, Species Survival motor neuron protein [human] 448 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 2 [human]:Wild

Target Species (Bioactivity)

human

Target Subunit Proteins

Carbonic anhydrase 2 [human]

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Enzymology inhibition

Substance RN

3629439View in Reaxys

Substance Name

table 1, compound sodium butyrate

Measurement Parameter

Unit

µM

Quantitative value

1032

Deviation

Measurement pX

2.99

Target, Subunit, Species Carbonic anhydrase 2 [human] 449 of 552 Target Mutant/Chimera Details

Beta-carbonic anhydrase [Cryptococcus neoformans]:Wild

Target Species (Bioactivity)

Cryptococcus neoformans

Target Subunit Proteins

Beta-carbonic anhydrase [Cryptococcus neoformans]

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Enzymology inhibition

Substance RN

3629439View in Reaxys

Substance Name

table 1, compound sodium butyrate

Measurement Parameter

Unit

µM

Quantitative value

225

282/365

2017-08-01 06:49:42

Deviation

Measurement pX

3.65

Target, Subunit, Species Beta-carbonic anhydrase [Cryptococcus neoformans] 450 of 552 Target Mutant/Chimera Details

Carbonic anhydrase Nce103 [Candida albicans]:Wild

Target Species (Bioactivity)

Candida albicans

Target Subunit Proteins

Carbonic anhydrase Nce103 [Candida albicans]

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Enzymology inhibition

Substance RN

3629439View in Reaxys

Substance Name

table 1, compound sodium butyrate

Measurement Parameter

Unit

µM

Quantitative value

26.9

Deviation

Measurement pX

4.57

Target, Subunit, Species Carbonic anhydrase Nce103 [Candida albicans] 451 of 552 Target Mutant/Chimera Details

Carbonic anhydrase 1 [Flaveria bidentis]:Wild

Target Species (Bioactivity)

Flaveria bidentis

Target Subunit Proteins

Carbonic anhydrase 1 [Flaveria bidentis]

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

Enzymology inhibition

Biological Species/NCBI Escherichia coli BL21 (DE3) ID Substance RN

3629439View in Reaxys

Substance Name

table 1, compound sodium butyrate

Measurement Parameter

Unit

µM

Quantitative value

82.3

Deviation

Measurement pX

4.08

Target, Subunit, Species Carbonic anhydrase 1 [Flaveria bidentis] 452 of 552 Target Mutant/Chimera Details

Survival motor neuron protein [human]:Wild

Substance Action on Target

Modulator

Target Species (Bioactivity)

human

Target Subunit Proteins

Survival motor neuron protein [human]

Substance Effect

modulatory activity

283/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Cells/Cell Lines

HEK 293

Substance RN

3629439View in Reaxys

Measurement Parameter

Qualitative

Unit

mg/mL

Qualitative value

Quantitative value

Target, Subunit, Species Survival motor neuron protein [human] 453 of 552 Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI taurine cattle ID Cells/Cell Lines

aortic endothelial cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 mmol/l

Measurement Parameter

Amount increase

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.7

Cho, Du-Hyong; Park, Jung-Hyun; Lee, Eun Joo; Won, Kyung Jong; Lee, Sang-Hee; Kim, Yang-Hoon; Hwang, Soojin; Kwon, Kyoung Ja; Shin, Chan Young; Song, Kee-Ho; Jo, Inho; Han, Seol-Heui; Free Radical Biology and Medicine; vol. 76; (2014); p. 96 - 106, View in Reaxys 454 of 552 Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI taurine cattle ID Cells/Cell Lines

aortic endothelial cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 mmol/l

Measurement Parameter

Amount increase

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.7

In Vitro (Efficacy)

Biological Species/NCBI taurine cattle ID Cells/Cell Lines

aortic endothelial cell

284/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 mmol/l

Measurement Parameter

Amount decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.7

In Vitro (Efficacy)

Biological Species/NCBI taurine cattle ID Cells/Cell Lines

aortic endothelial cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 mmol/l

Measurement Parameter

Amount decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.7

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Substance Effect

inhibitory activity

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against mouse Histone deacetylase activity in FM3A cells upon incubation with HDA buffer pH 7.5, at 37 degree C for 10 min using [3H]acetyl histone as substrate

Cells/Cell Lines

FM3A

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

119000

Measurement pX

3.92

285/365

2017-08-01 06:49:42

Target, Subunit, Species Histone deacetylase [Mus musculus] 458 of 552 Target Mutant/Chimera Details

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Substance Effect

inhibitory activity

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against mouse histone deacetylase upon incubation for 10 minutes at 37 degree C using [3H]acetyl histone as substrate

Substance RN

3629439View in Reaxys

Measurement Parameter

IC50

Unit

Qualitative value

Quantitative value

119000

Measurement pX

3.92

Target, Subunit, Species Histone deacetylase [Mus musculus] 459 of 552 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

HEK 293

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.5 - 2 mg/ml

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.34

Patent; Indiana University Research and Technology Corporation; Androphy, Elliot; Cuny, Gregory D.; Cherry, Jonathan; Glicksman, Marcie A.; US9212209; (2015); (B2) English, View in Reaxys 460 of 552 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

HEK 293

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.8 - 3.2 mg/ml

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.14

In Vitro (Efficacy)

Cells/Cell Lines

HEK 293

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

286/365

2017-08-01 06:49:42

Substance Dose

0.8 - 3.2 mg/ml

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.14

In Vitro (Efficacy)

Cells/Cell Lines

HEK 293

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

EC50

Unit

mg/ml

Quantitative value

Measurement pX

2.04

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

IC50

Unit

Quantitative value

10.9

Measurement pX

1.96

Wang, Zhao-Tong; Chen, Zhuo-Jia; Jiang, Guan-Min; Wu, Ying-Min; Liu, Tao; Yi, Yan-Mei; Zeng, Jun; Du, Jun; Wang, Hong-Sheng; Cellular Signalling; vol. 28; nb. 5; (2016); p. 506 - 515, View in Reaxys 464 of 552 Substance Effect

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

287/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

10 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

20 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

288/365

2017-08-01 06:49:42

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.5 mM

Measurement Parameter

% Inhibition

Qualitative value

Low

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

IC50

Unit

Quantitative value

15.7

Measurement pX

1.8

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% Inhibition

289/365

2017-08-01 06:49:42

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

10 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

20 mM

Measurement Parameter

% Inhibition

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.5 mM

Measurement Parameter

% Inhibition

Qualitative value

Low

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

290/365

2017-08-01 06:49:42

Substance Name

sodium butyrate

Substance Dose

1 mM

Measurement Parameter

% Inhibition

Qualitative value

Low

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 - 5 mM

Measurement Parameter

% increase

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 - 5 mM

Measurement Parameter

% increase

Qualitative value

High

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2 - 5 mM

Measurement Parameter

% decrease

Qualitative value

Low

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

291/365

2017-08-01 06:49:42

Substance Name

sodium butyrate

Substance Dose

2 - 5 mM

Measurement Parameter

% decrease

Qualitative value

High

Statistical sgnificance (Qualitative)

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.5 - 10 mM

Measurement Parameter

% decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

3.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

Amount decrease

Qualitative value

Active

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

Amount decrease

Qualitative value

Active

Measurement pX

2.3

292/365

2017-08-01 06:49:42

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.5 - 10 mM

Measurement Parameter

Amount decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

3.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

Amount decrease

Qualitative value

Active

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

Amount decrease

Qualitative value

Active

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

293/365

2017-08-01 06:49:42

Measurement Parameter

Amount decrease

Qualitative value

Active

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

MDA-MB-231

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.3

294/365

2017-08-01 06:49:42

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% decrease

Qualitative value

Active

Measurement pX

2.3

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

BT-549

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.3

Antidegenerative In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID

295/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

Time

Unit

Quantitative value

11.5

Statistical sgnificance (Qualitative)

Butchbach, Matthew E.R.; Lumpkin, Casey J.; Harris, Ashlee W.; Saieva, Luciano; Edwards, Jonathan D.; Workman, Eileen; Simard, Louise R.; Pellizzoni, Livio; Burghes, Arthur H.M.; Experimental Neurology; vol. 279; (2016); p. 13 - 26, View in Reaxys 495 of 552 Substance Effect Bioassay Category

Antidegenerative In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

Time

Unit

Quantitative value

9.5

Statistical sgnificance (Qualitative)

Metabolism/Transport

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Single men Measurement Parameter

Amount

Unit

pmol/mg protein

296/365

2017-08-01 06:49:42

Quantitative value

Antidegenerative In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Increase

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

Antidegenerative In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Increase

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

297/365

2017-08-01 06:49:42

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Change

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Change

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Change

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

298/365

2017-08-01 06:49:42

In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Change

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

Substance Dosing Regi- Repeated men Measurement Parameter

% Change

Qualitative value

Not active

Statistical sgnificance (Qualitative)

Measurement pX

In Vivo (Animal models)

Biological Species/NCBI Mus musculus ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 g/kg

Substance Route of Adm.

oral administration

299/365

2017-08-01 06:49:42

Substance Dosing Regi- Repeated men Measurement Parameter

Number

Unit

no unit

Quantitative value

192

Lactation : Enhancer In Vivo (Animal models)

Biological Species/NCBI taurine cattle ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

135 g/day

Substance Dosing Regi- Perfusion/Infusion men Measurement Parameter

Amount

Unit

Quantitative value

4.01

Patent; NUTRECO NEDERLAND B.V.; DOELMAN, John Henry; (33 pag.); WO2016/55651; (2016); (A1) English, View in Reaxys 506 of 552 Substance Effect Bioassay Category

Lactation : Enhancer In Vivo (Animal models)

Biological Species/NCBI taurine cattle ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

135 g/day

Substance Dosing Regi- Perfusion/Infusion men Measurement Parameter

Amount

Unit

Quantitative value

2.89

Patent; NUTRECO NEDERLAND B.V.; DOELMAN, John Henry; (33 pag.); WO2016/55651; (2016); (A1) English, View in Reaxys 507 of 552 Substance Effect Bioassay Category

Lactation : Enhancer In Vivo (Animal models)

Biological Species/NCBI taurine cattle ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

135 g/day

Substance Dosing Regi- Perfusion/Infusion men

300/365

2017-08-01 06:49:42

Measurement Parameter

Amount

Unit

Quantitative value

4.82

Patent; NUTRECO NEDERLAND B.V.; DOELMAN, John Henry; (33 pag.); WO2016/55651; (2016); (A1) English, View in Reaxys 508 of 552 Substance Effect Bioassay Category

Lactation : Enhancer In Vivo (Animal models)

Biological Species/NCBI taurine cattle ID Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

135 g/day

Substance Dosing Regi- Perfusion/Infusion men Measurement Parameter

Amount

Unit

mg/dl

Quantitative value

8.5

Patent; NUTRECO NEDERLAND B.V.; DOELMAN, John Henry; (33 pag.); WO2016/55651; (2016); (A1) English, View in Reaxys 509 of 552 Substance Effect

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

HH514-16

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

3 mM

Measurement Parameter

% Viability

Unit

Qualitative value

Quantitative value

Gorres, Kelly L.; Daigle, Derek; Mohanram, Sudharshan; McInerney, Grace E.; Lyons, Danielle E.; Miller, George; mBio; vol. 7; nb. 2; (2016); Art.No: E00113-16, View in Reaxys 510 of 552 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

HH514-16

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

10 mM

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

Gorres, Kelly L.; Daigle, Derek; Mohanram, Sudharshan; McInerney, Grace E.; Lyons, Danielle E.; Miller, George; mBio; vol. 7; nb. 2; (2016); Art.No: E00113-16, View in Reaxys 511 of 552

Bioassay Category

In Vitro (Efficacy)

301/365

2017-08-01 06:49:42

Cells/Cell Lines

HH514-16

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

10 mM

Measurement Parameter

Qualitative

Qualitative value

Active

Measurement pX

In Vitro (Efficacy)

Cells/Cell Lines

HH514-16

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

3 mM

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.52

In Vitro (Efficacy)

Cells/Cell Lines

HH514-16

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

3 mM

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.52

In Vitro (Efficacy)

Cells/Cell Lines

HH514-16

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

3 mM

Measurement Parameter

% Inhibition

Qualitative value

Not active

Measurement pX

Cytotoxic Toxicity/Safety Pharmacology

302/365

2017-08-01 06:49:42

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

221.6

Measurement pX

3.65

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 516 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

Fold-increase

Unit

no unit

Quantitative value

1.3

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 517 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

Fold-decrease

Unit

no unit

Quantitative value

0.6

Statistical sgnificance (Qualitative)

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 518 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

303/365

2017-08-01 06:49:42

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

Amount increase

Qualitative value

Active

Measurement pX

3.65

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 519 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

Fold-increase

Qualitative value

Not active

Measurement pX

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 520 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

Fold-decrease

Unit

no unit

Quantitative value

0.6

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 521 of 552 Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

% increase

Qualitative value

Active

304/365

2017-08-01 06:49:42

Statistical sgnificance (Qualitative)

Measurement pX

3.65

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 522 of 552 Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

% increase

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

3.65

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 523 of 552 Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

Amount decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

3.65

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 524 of 552 Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

250 μM

Measurement Parameter

Fold-increase

Qualitative value

Active

Measurement pX

3.6

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 525 of 552 Substance Effect

Antianemic

305/365

2017-08-01 06:49:42

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

expression rate

Unit

Quantitative value

0.1

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 526 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

expression rate

Unit

Quantitative value

10.8

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 527 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

expression rate

Unit

Quantitative value

87.4

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 528 of 552 Substance Effect Bioassay Category

Antianemic In Vitro (Efficacy)

Biological Species/NCBI human ID Cells/Cell Lines

erythroid cell

306/365

2017-08-01 06:49:42

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

221.6 μM

Measurement Parameter

expression rate

Unit

Quantitative value

1.8

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 529 of 552 Substance Effect

Cytotoxic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

erythroid cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

250 μM

Measurement Parameter

% survival

Unit

Quantitative value

Patent; Academia Sinica; Shen, Che-Kun James; Chou, Yu-Chi; Su, Tsann-Long; (69 pag.); US2016/106728; (2016); (A1) English, View in Reaxys 530 of 552 Substance Effect

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

HT1376

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

3780

Measurement pX

2.42

Patent; Chin, Arnold I.; (17 pag.); US2016/143946; (2016); (A1) English, View in Reaxys 531 of 552 Substance Effect

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Cells/Cell Lines

SW 780

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

IC50

Unit

μM

Quantitative value

8530

Measurement pX

2.07

Patent; Chin, Arnold I.; (17 pag.); US2016/143946; (2016); (A1) English, View in Reaxys 532 of 552 Target Mutant/Chimera Details

Free fatty acid receptor 3:Wild

307/365

2017-08-01 06:49:42

Substance Action on Target

Agonist

Target Subunit Proteins

Free fatty acid receptor 3

Target Transfection

Transfected

Bioassay Category

In Vitro (Efficacy)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Measurement Parameter

EC50

Unit

μM

Quantitative value

10.1

Measurement pX

Target, Subunit, Species Free fatty acid receptor 3 533 of 552 Substance Effect

Anti-Friedreich's ataxia

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

FRDA fibroblast GMO3816

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

1 μM

Measurement Parameter

Fold-increase

Unit

no unit

Quantitative value

1.034

Patent; RaNA Therapeutics, Inc.; Ozsolak, Fatih; (106 pag.); US2016/201063; (2016); (A1) English, View in Reaxys 534 of 552 Substance Effect

Anti-Friedreich's ataxia

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

FRDA fibroblast GMO3816

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 μM

Measurement Parameter

Fold-increase

Unit

no unit

Quantitative value

1.1564

Patent; RaNA Therapeutics, Inc.; Ozsolak, Fatih; (106 pag.); US2016/201063; (2016); (A1) English, View in Reaxys 535 of 552 Substance Effect

Anti-Friedreich's ataxia

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

normal fibroblast GM0321

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

1 μM

Measurement Parameter

Fold-increase

308/365

2017-08-01 06:49:42

Unit

no unit

Quantitative value

1.06

Patent; RaNA Therapeutics, Inc.; Ozsolak, Fatih; (106 pag.); US2016/201063; (2016); (A1) English, View in Reaxys 536 of 552 Substance Effect

Anti-Friedreich's ataxia

Bioassay Category

In Vitro (Efficacy)

Cells/Cell Lines

normal fibroblast GM0321

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 μM

Measurement Parameter

Fold-increase

Unit

no unit

Quantitative value

0.7

Patent; RaNA Therapeutics, Inc.; Ozsolak, Fatih; (106 pag.); US2016/201063; (2016); (A1) English, View in Reaxys 537 of 552 Substance Effect Bioassay Category

Apoptotic In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Cells/Cell Lines

bone marrow cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% Increase

Qualitative value

Not active

Measurement pX

Wang, Hai-Fang; Ning, Fen; Liu, Zong-Cai; Wu, Long; Li, Zi-Qian; Qi, Yi-Fei; Zhang, Ge; Wang, Hong-Sheng; Cai, Shao-Hui; Du, Jun; Cancer Immunology, Immunotherapy; vol. 66; nb. 3; (2017); p. 355 - 366, View in Reaxys 538 of 552 Target Mutant/Chimera Details

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Apoptotic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Cells/Cell Lines

bone marrow cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

309/365

2017-08-01 06:49:42

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.62

Target, Subunit, Species Histone deacetylase [Mus musculus] Wang, Hai-Fang; Ning, Fen; Liu, Zong-Cai; Wu, Long; Li, Zi-Qian; Qi, Yi-Fei; Zhang, Ge; Wang, Hong-Sheng; Cai, Shao-Hui; Du, Jun; Cancer Immunology, Immunotherapy; vol. 66; nb. 3; (2017); p. 355 - 366, View in Reaxys 539 of 552 Target Mutant/Chimera Details

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% Apoptosis

Unit

Quantitative value

44.2

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

Toxicity/Safety Pharmacology

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

310/365

2017-08-01 06:49:42

Substance Dose

2.4 mM

Measurement Parameter

% Viability

Unit

Qualitative value

Quantitative value

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Cells/Cell Lines

bone marrow cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

1.2 - 2.4 mM

Measurement Parameter

% depletion

Qualitative value

High

Statistical sgnificance (Qualitative)

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Cells/Cell Lines

bone marrow cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

0.3 - 0.6 mM

311/365

2017-08-01 06:49:42

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

3.52

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Cells/Cell Lines

bone marrow cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% depletion

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.62

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% depletion

Qualitative value

High

Statistical sgnificance (Qualitative)

312/365

2017-08-01 06:49:42

545 of 552 Target Mutant/Chimera Details

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% Decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

Measurement pX

2.62

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% Decrease

Qualitative value

Active

Statistical sgnificance (Qualitative)

313/365

2017-08-01 06:49:42

Measurement pX

2.62

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% Apoptosis

Unit

Quantitative value

46.4

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

% Apoptosis

314/365

2017-08-01 06:49:42

Unit

Quantitative value

88.8

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

5 mM

Measurement Parameter

% Increase

Qualitative value

Active

Measurement pX

2.3

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse; Mus musculus ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells); splenic T cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

315/365

2017-08-01 06:49:42

Measurement Parameter

Unit

Quantitative value

97.3

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse; Mus musculus ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells); splenic T cell

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

Substance Dose

2.4 mM

Measurement Parameter

Unit

Quantitative value

96.4

Histone deacetylase [Mus musculus]:Wild

Substance Action on Target

Inhibitor

Target Species (Bioactivity)

Mus musculus

Target Subunit Proteins

Histone deacetylase [Mus musculus]

Target Transfection

Non Transfected

Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Biological Species/NCBI Bagg albino mouse ID Population State

breast tumor

Cells/Cell Lines

bone marrow cell (Myeloid-derived suppressor enriched cells)

Substance RN

3629439View in Reaxys

Substance Name

sodium butyrate

316/365

2017-08-01 06:49:42

Substance Dose

2.4 mM

Measurement Parameter

% Apoptosis

Unit

Quantitative value

83.9

Reaxys ID 3914371 View in Reaxys

11/23 CAS Registry Number: 589-39-9 Chemical Name: potassium n-butyrate; potassium butyrate; potassium butyrate (n); potassium n-butanoate; Kaliumbutyrat; Kalium-n-butyrat; nPrCO2K Linear Structure Formula: K(1+)*CH3CH2CH2COO(1-)=CH3CH2CH2COOK Molecular Formula: C4H7O2*K Molecular Weight: 126.197 Type of Substance: acyclic InChI Key: RWMKSKOZLCXHOK-UHFFFAOYSA-M Note:

K+ O O–

Substance Label (1) Label References Pr%n&CO2K

Nakamura, Shigeaki; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1983); p. 1 - 4, View in Reaxys

Patent-Specific Data (1) Location in Patent References Claim

Patent; Mitsubishi Gas Chemical Company, Inc.; US5225594; (1993); (A1) English, View in Reaxys; Patent; Vlahakos, Victor; US6613356; (2003); (B1) English, View in Reaxys; Patent; Neesby; Torben E.; US4721716; (1988); (A1) English, View in Reaxys; Patent; Mitsubishi Gas Chemical Company, Inc.; US5087737; (1992); (A1) English, View in Reaxys; Patent; National Science Council; US5068451; (1991); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (1) 1 of 1

Comment (Melting Point)

Existiert in zwei festen Modifikationen, ist ungefaehr zwischen 295grad und 355grad krystallinisch-fluessig.

Density [g·cm-3]

1.315

Reference Temperature [°C]

Measurement Temperature [°C]

317/365

2017-08-01 06:49:42

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys 2 of 3

Density [g·cm-3]

1.291

Reference Temperature [°C]

Measurement Temperature [°C]

Lomer; Acta Crystallographica; vol. 5; (1952); p. 11,12, View in Reaxys 3 of 3

Density [g·cm-3]

1.289

Reference Temperature [°C]

Measurement Temperature [°C]

Lomer; Acta Crystallographica; vol. 5; (1952); p. 11,12, View in Reaxys Adsorption (MCS) (2) 1 of 2

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

H2O

Partner (Adsorption (MCS))

Kaolinite clay, hydrazine hydrate

Sidheswaran, P.; Mohan, S. V. Ram; Ganguli, P.; Bhat, A. N.; Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical; vol. 26; nb. 12; (1987); p. 994 - 998, View in Reaxys 2 of 2

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

H2O

Partner (Adsorption (MCS))

Kaolinite clay

Description (Association Association with compound (MCS)) Solvent (Association (MCS))

H2O; various solvent(s)

Comment (Association (MCS))

Ratio of solvents: 84.78:15.22

Partner (Association (MCS))

butyric acid

Shevtsova, I. Ya.; Baranov, N. A.; Chernyak, A. S.; J. Gen. Chem. USSR (Engl. Transl.); vol. 62; nb. 10.1; (1992); p. 2194 - 2199,1807 - 1811, View in Reaxys 2 of 3

Description (Association Association with compound (MCS)) Solvent (Association (MCS))

methanol; various solvent(s)

Comment (Association (MCS))

Ratio of solvents: 1:19

Partner (Association (MCS))

butyric acid

Shevtsova, I. Ya.; Baranov, N. A.; Chernyak, A. S.; J. Gen. Chem. USSR (Engl. Transl.); vol. 62; nb. 10.1; (1992); p. 2194 - 2199,1807 - 1811, View in Reaxys

318/365

2017-08-01 06:49:42

3 of 3

Description (Association IR spectrum of the complex (MCS)) Partner (Association (MCS))

SO2Cl2

Nakamura, Shigeaki; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1983); p. 1 - 4, View in Reaxys Boundary Surface Phenomena (MCS) (3) 1 of 3

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Godbole; Sadgopal; Kolloid-Zeitschrift; vol. 75; (1936); p. 195, View in Reaxys 2 of 3

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

NaCl

Godbole; Sadgopal; Kolloid-Zeitschrift; vol. 75; (1936); p. 195, View in Reaxys 3 of 3

Description (Boundary Surface Phenomena (MCS))

Surface tension

Solvent (Boundary Surface Phenomena (MCS))

H2O

Temperature (Boundary Surface Phenomena (MCS)) [°C]

Partner (Boundary Surface Phenomena (MCS))

glycerol

Godbole; Sadgopal; Kolloid-Zeitschrift; vol. 75; (1936); p. 195, View in Reaxys Crystal Phase (2) Description (Crys- Comment (Crystal References tal Phase) Phase) Crystal structure determination Crystal structure determination

Lomer; Acta Crystallographica; vol. 5; (1952); p. 11,12, View in Reaxys Roentgenreflexionsaufnahmen.

Piper; Journal of the Chemical Society; (1929); p. 236, View in Reaxys

Crystal System (1) Crystal System References monoclinic

Lomer; Acta Crystallographica; vol. 5; (1952); p. 11,12, View in Reaxys

Dielectric Constant (1)

319/365

2017-08-01 06:49:42

Dielectric Constant

Frequency (Dielectric Constant) [Hz]

Temperature (Die- References lectric Constant) [°C]

3.9

3E+06

Electrochemical Behaviour (1) Description (Elec- Comment (Electrochemical Betrochemical Behaviour) haviour) pH of aqueous solutions

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys

References

Einfluss auf den Thomas; Kremer; Journal of the American Chemical Society; vol. 57; (1935); p. 2539, pH-Wert von basi- View in Reaxys schen Thoriumchlorid-Hydrosolen.

Enthalpies of Other Phase Transitions (2) Comment (EnReferences thalpies of Other Phase Transitions) Enthalpies of other phase transitions: 32.5 <unit not given>; From crystalline VI to crystalline VB

Franzosini, P.; Ngeyi, S. P.; Westrum, E. F.; Journal of Chemical Thermodynamics; vol. 19; nb. 2; (1987); p. 113 - 124, View in Reaxys

Enthalpies of other phase transitions: 49.3 <unit not given>; From crystalline VII to crystalline VI

Franzosini, P.; Ngeyi, S. P.; Westrum, E. F.; Journal of Chemical Thermodynamics; vol. 19; nb. 2; (1987); p. 113 - 124, View in Reaxys

Heat Capacity Cp (1) Temperature Comment (Heat (Heat Capacity Capacity Cp) Cp) [°C] -265.2 - 70.8

Heat capacity cp (range begins): 0.129 <unit not given>; Heat capacity cp (range ends): 20.932 <unit not given>

References

Franzosini, P.; Ngeyi, S. P.; Westrum, E. F.; Journal of Chemical Thermodynamics; vol. 19; nb. 2; (1987); p. 113 - 124, View in Reaxys

Liquid/Liquid Systems (MCS) (4) 1 of 4

Description (Liquid/ Liquid Systems (MCS))

Solution equilibrium

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Partner (Liquid/Liquid Systems (MCS))

water; butan-1-ol

Lumb; Transactions of the Faraday Society; vol. 47; (1951); p. 1049,1051,1054, View in Reaxys 2 of 4

Description (Liquid/ Liquid Systems (MCS))

Liquid/liquid phase diagram

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Comment (Liquid/Liquid Systems (MCS))

Exsiztenzbereich krystallin-fluessiger Phasen ('Mesophasen').

Partner (Liquid/Liquid Systems (MCS))

water; octanol

320/365

2017-08-01 06:49:42

Lumb; Transactions of the Faraday Society; vol. 47; (1951); p. 1049,1051,1054, View in Reaxys 3 of 4

Description (Liquid/ Liquid Systems (MCS))

Liquid/liquid phase diagram

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Comment (Liquid/Liquid Systems (MCS))

Existenzbereich krystallin-fluessiger Phasen ('Mesophasen').

Partner (Liquid/Liquid Systems (MCS))

water; 1-dodecyl alcohol

Lumb; Transactions of the Faraday Society; vol. 47; (1951); p. 1049,1051,1054, View in Reaxys 4 of 4

Description (Liquid/ Liquid Systems (MCS))

Solution equilibrium

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Partner (Liquid/Liquid Systems (MCS))

water; hexan-1-ol

Lumb; Transactions of the Faraday Society; vol. 47; (1951); p. 1049,1051,1054, View in Reaxys Liquid/Solid Systems (MCS) (5) 1 of 5

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium nitrate

Dmitrewskaja; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 2007,2009,2010;engl.Ausg.S.2046, View in Reaxys 2 of 5

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

potassium nitrate

Dmitrewskaja; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 2007,2009,2010;engl.Ausg.S.2046, View in Reaxys 3 of 5

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium butyrate

Dmitrewskaja; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 2007,2009,2010;engl.Ausg.S.2046, View in Reaxys; Sokolow; Potschtakowa; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1693,1695; engl. Ausg. S. 1741, 1742, View in Reaxys 4 of 5

Description (Liquid/Solid Solidification diagram Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

sodium thiocyanate

Sokolow; Potschtakowa; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1693,1695; engl. Ausg. S. 1741, 1742, View in Reaxys 5 of 5

Description (Liquid/Solid Solidification diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Verbindung 6:1(?).

Partner (Liquid/Solid Systems (MCS))

potassium thioacyanate

Sokolow; Potschtakowa; Zhurnal Obshchei Khimii; vol. 28; (1958); p. 1693,1695; engl. Ausg. S. 1741, 1742, View in Reaxys Magnetic Susceptibility (1)

321/365

2017-08-01 06:49:42

Magnetic Susceptibility [10-6cm3mol-1]

References

-70

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys

Optics (1) Description (Optics)

Comment (Optics)

References

Mechanical birefringence

von wss.Loesungen.

Vorlaender; Kirchner; Zeitschrift fuer Physikalische Chemie, Abteilung A: Chemische Thermodynamik, Kinetik, Elektrochemie, Eigenschaftslehre; vol. 152; (1931); p. 52, View in Reaxys

Other Thermochemical Data (2) Description (Oth- Comment (Other er Thermochemi- Thermochemical cal Data) Data) Entropy

References

Franzosini, P.; Ngeyi, S. P.; Westrum, E. F.; Journal of Chemical Thermodynamics; vol. 19; nb. 2; (1987); p. 113 - 124, View in Reaxys

Cryoscopic constant

kryoskopisches Verhalten in Wasser.

McBain; Bolduan; Journal of Physical Chemistry; vol. 47; (1943); p. 99, View in Reaxys

Solubility (MCS) (2) 1 of 2

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

methanol

Comment (Solubility (MCS))

100 g solvent dissolves. 51.04 g Substance.

Henstock; Journal of the Chemical Society; (1934); p. 1341, View in Reaxys 2 of 2

Temperature (Solubility (MCS)) [°C]

70.9

Solvent (Solubility (MCS))

methanol

Comment (Solubility (MCS))

100 g solvent dissolves. 120.84 g Substance.

Henstock; Journal of the Chemical Society; (1934); p. 1341, View in Reaxys Transition Point(s) of Crystalline Modification(s) (2) Temperature Change of Modifi- References (Transition cation Point(s) of Crystalline Modification(s)) [°C] -149.3

From crystalline VII to crystalline VI

Franzosini, P.; Ngeyi, S. P.; Westrum, E. F.; Journal of Chemical Thermodynamics; vol. 19; nb. 2; (1987); p. 113 - 124, View in Reaxys

-130.85

From crystalline VI to crystalline VB

Franzosini, P.; Ngeyi, S. P.; Westrum, E. F.; Journal of Chemical Thermodynamics; vol. 19; nb. 2; (1987); p. 113 - 124, View in Reaxys

Transition Point(s) of Liquid Modification(s) (2) Temperature Change of Modifi- References (Transition cation Point(s) of Liquid Modification(s)) [°C] 327

Transition point(1) Baum et al.; Wiss.Z.Univ.Halle-Wittenberg; vol. 19; nb. 5; (1970); p. 37, View in Reaxys from:crystalline to:smectic.

390

Transition point(1) Baum et al.; Wiss.Z.Univ.Halle-Wittenberg; vol. 19; nb. 5; (1970); p. 37, View in Reaxys from:smectic

322/365

2017-08-01 06:49:42

to:isotropic liquid (clearing point). Transport Phenomena (MCS) (1) 1 of 1

Description (Transport Phenomena (MCS))

Viscosity

Solvent (Transport Phenomena (MCS))

H2O

Merker; Koll.Beih.; vol. 45; (1937); p. 459, View in Reaxys UV/VIS Spectroscopy (1) 1 of 1

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

H2O

Comment (UV/VIS Spectroscopy)

auch mit MgCl2.

Leuthardt; Pfister; Helvetica Chimica Acta; vol. 16; (1933); p. 229, View in Reaxys Use (4) Use Pattern

Location

References

Pharmaceuticals

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

histone deacetylase inhibitor (HDACi)

Page/Page column 15

Patent; STICHTING DIENST LANDBOUWKUNDING ONDERZOEK; Boutilier, Kimberly; Angenent, Gerrit Cornelis; Soriano Castan, Mercedes; Hui, Li; (32 pag.); US2016/212956; (2016); (A1) English, View in Reaxys

angiogenic material

Patent; Wright, Emma Jayne; Huckle, James William; Ali, Saad Aboul Majeed; US2004/265282; (2004); (A1) English, View in Reaxys

fixation devices for tissue repair

Patent; Wright, Emma Jayne; Huckle, James William; Ali, Saad Aboul Majeed; US2004/265282; (2004); (A1) English, View in Reaxys

Medchem (2) 1 of 2

Target Mutant/Chimera Details

Free fatty acid receptor 3 [Rattus norvegicus]:Wild

Target Species (Bioactivity)

Rattus norvegicus

Target Subunit Proteins

Free fatty acid receptor 3 [Rattus norvegicus]

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Effective concentration of the compound required for activation of rat free fatty acid receptor 3 expressed in MMY22 cells as sodium or potassium salt solutions buffered to pH 7

Biological Species/NCBI Rattus norvegicus ID Substance RN

3914371View in Reaxys

Measurement Parameter

EC50

Unit

Qualitative value

Quantitative value

5E-05

Measurement pX

4.3

Target, Subunit, Species Free fatty acid receptor 3 [Rattus norvegicus] 2 of 2

Target Mutant/Chimera Details

Histone deacetylase:Wild

Substance Action on Target

Inhibitor

323/365

2017-08-01 06:49:42

Target Subunit Proteins

Histone deacetylase

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory activity of the compound against Histone deacetylase was determined

Substance RN

3914371View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Not Published

Target, Subunit, Species Histone deacetylase

Reaxys ID 4006822 View in Reaxys

12/23 CAS Registry Number: 50671-60-8 Chemical Name: copper n-butyrate; copper butanoate; copper butyrate; copper(I) butyrate; cuprous butyrate; Cu(I)-butyrat Linear Structure Formula: Cu(1+)*O2CCH2CH2CH3 (1-)=CuO CCH CH CH 2 2 2 3 Molecular Formula: C4H7O2*Cu Molecular Weight: 150.644 Type of Substance: acyclic; Coordination compound InChI Key: HMRDQEMTHMWRIK-UHFFFAOYSA-M Note:

Cu + O O–

Patent-Specific Data (1) Location in Patent References Claim

Patent; UNION CARBIDE COATINGS, SERVICE TECHNOLOGY CORP.; EP648734; (1995); (A1) English, View in Reaxys; Patent; The Board of Trustees of Southern Illinois University; US6042848; (2000); (A1) English, View in Reaxys; Patent; Phillips Petroleum Company; US4044041; (1977); (A1) English, View in Reaxys; Patent; Suntory Limited; Nippon Soda Company, Ltd.; US5026844; (1991); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Fluorescence Spectroscopy (1) Description (Fluo- References rescence Spectroscopy) Fluorescence

Hardt; Weber; Naturwissenschaften; vol. 65; (1978); p. 594, View in Reaxys; Weber, P.; Hardt, H.-D.; Inorganica Chimica Acta; vol. 64; (1982); p. L51 - L53 ; (from Gmelin), View in Reaxys

Other Spectroscopic Methods (1) Description (Oth- References er Spectroscopic Methods) ESCA

Edwards, D. A.; Inorganica Chimica Acta; vol. 18; (1976); p. 65 - 68 ; (from Gmelin), View in Reaxys

Reaxys ID 3914637 View in Reaxys

13/23

324/365

2017-08-01 06:49:42

CAS Registry Number: 5076-24-4 Chemical Name: silver butyrate; silver(I) n-butyrate; silver nbutyrate; Buttersaeure; Silberbutyrat; Buttersaeure; Silber(I)Verbindung; silver butanoate; Silberbutyrat Linear Structure Formula: Ag(1+)*C4H7O2 (1-) Molecular Formula: Ag*C4H7O2 Molecular Weight: 194.967 Type of Substance: acyclic InChI Key: JKOCEVIXVMBKJA-UHFFFAOYSA-M Note:

Ag+ O O–

Substance Label (3) Label References RCO2Ag, R=CH3CH2CH2-

Carvalho, Emilia; Francisco, Ana Paula; Iley, Jim; Rosa, Eduarda; Bioorganic and Medicinal Chemistry; vol. 8; nb. 7; (2000); p. 1719 - 1725, View in Reaxys

Guillon; Lelong; Rioult; Robba; Pharmacy and Pharmacology Communications; vol. 5; nb. 5; (1999); p. 311 - 313, View in Reaxys

Roberts, Gerald D.; White V, Edward; Organic Mass Spectrometry; vol. 16; nb. 12; (1981); p. 546 - 550, View in Reaxys

Patent-Specific Data (1) References Patent; Shenzhen Wu Weihuasi Biological Technology Co., Ltd.; Nada Bio-technology Corporation; Wang Guoxin; Liao Tao; Tang Meijie; (28 pag.); CN106892904; (2017); (A) Chinese, View in Reaxys Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Density [g·cm-3]

2.4275

Comment (Density)

25grad.

Density (2) 1 of 2

Fischer; Lemke; Zeitschrift fuer Physikalische Chemie, Abteilung A: Chemische Thermodynamik, Kinetik, Elektrochemie, Eigenschaftslehre; vol. 151; (1930); p. 60, View in Reaxys 2 of 2

Density [g·cm-3]

2.4865

Comment (Density)

-78grad.

Fischer; Lemke; Zeitschrift fuer Physikalische Chemie, Abteilung A: Chemische Thermodynamik, Kinetik, Elektrochemie, Eigenschaftslehre; vol. 151; (1930); p. 60, View in Reaxys Crystal Property Description (1) Colour & Other References Properties white

Paramonov; Mychlo; Troyanov; Kuz'mina; Russian Journal of Inorganic Chemistry; vol. 45; nb. 12; (2000); p. 1852 - 1856 ; (from Gmelin), View in Reaxys

Decomposition (2) 1 of 2

Decomposition [°C]

205

Solvent (Decomposition) neat (no solvent, solid phase) Paramonov; Mychlo; Troyanov; Kuz'mina; Russian Journal of Inorganic Chemistry; vol. 45; nb. 12; (2000); p. 1852 - 1856 ; (from Gmelin), View in Reaxys 2 of 2

Decomposition [°C]

Solvent (Decomposition) water

325/365

2017-08-01 06:49:42

Paramonov; Mychlo; Troyanov; Kuz'mina; Russian Journal of Inorganic Chemistry; vol. 45; nb. 12; (2000); p. 1852 - 1856 ; (from Gmelin), View in Reaxys Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -84.9

Prasad et al.; Proceedings - Indian Academy of Sciences, Section A; vol. 31; (1950); p. 389,391, View in Reaxys

Solubility (MCS) (21) 1 of 21

Comment (Solubility (MCS))

water-soluble

Paramonov; Mychlo; Troyanov; Kuz'mina; Russian Journal of Inorganic Chemistry; vol. 45; nb. 12; (2000); p. 1852 - 1856 ; (from Gmelin), View in Reaxys 2 of 21

Solubility [g·l-1]

4.05531

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

water

Sinha, Rangana; Kundu, Kiron K.; Journal of Physical Chemistry B; vol. 102; nb. 35; (1998); p. 6880 - 6888 ; (from Gmelin), View in Reaxys 3 of 21

Solubility [g·l-1]

4.19179

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

water

Sinha, Rangana; Kundu, Kiron K.; Journal of Physical Chemistry B; vol. 102; nb. 35; (1998); p. 6880 - 6888 ; (from Gmelin), View in Reaxys 4 of 21

Solubility [g·l-1]

4.28927

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

water

Sinha, Rangana; Kundu, Kiron K.; Journal of Physical Chemistry B; vol. 102; nb. 35; (1998); p. 6880 - 6888 ; (from Gmelin), View in Reaxys 5 of 21

Solubility [g·l-1]

4.42575

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

water

Sinha, Rangana; Kundu, Kiron K.; Journal of Physical Chemistry B; vol. 102; nb. 35; (1998); p. 6880 - 6888 ; (from Gmelin), View in Reaxys 6 of 21

Solubility [g·l-1]

4.64021

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

water

Sinha, Rangana; Kundu, Kiron K.; Journal of Physical Chemistry B; vol. 102; nb. 35; (1998); p. 6880 - 6888 ; (from Gmelin), View in Reaxys 7 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

326/365

2017-08-01 06:49:42

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 8 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

methanol

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 9 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

ethanol

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 10 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

butan-1-ol

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 11 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

3-methyl-butan-1-ol

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 12 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

acetone

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 13 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

butan-2-one

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 14 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

4-methyl-pentan-2-one

Ismailow; Tschernyi; Trudy Komiss.anal.Chim.; vol. 9; (1958); p. 44,50,51; Chem.Abstr.; (1959); p. 3840, View in Reaxys 15 of 21

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

at:15-50 degreeC.

Tommila; Nyrkioe; Suomen Kemistilehti B; vol. 28; (1955); p. 169, View in Reaxys 16 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

327/365

2017-08-01 06:49:42

Comment (Solubility (MCS))

0.419 part(s) of substance.dissolves in:100 parts of solvent.

Raupenstrauch; Monatshefte fuer Chemie; vol. 6; (1885); p. 587, View in Reaxys 17 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

0.485 part(s) of substance.dissolves in:100 parts of solvent.

Raupenstrauch; Monatshefte fuer Chemie; vol. 6; (1885); p. 587, View in Reaxys 18 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

1.1444 part(s) of substance.dissolves in:100 parts of solvent.

Raupenstrauch; Monatshefte fuer Chemie; vol. 6; (1885); p. 587, View in Reaxys 19 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

0.413 part(s) of substance.dissolves in:100 parts of solvent.

Gruenzweig; Justus Liebigs Annalen der Chemie; vol. 162; (1872); p. 218, View in Reaxys 20 of 21

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

1 part(s) of substance.dissolves in:202 parts of solvent.

Linnemann; Justus Liebigs Annalen der Chemie; vol. 160; (1871); p. 241; Justus Liebigs Annalen der Chemie; vol. 192; (1878); p. 69, View in Reaxys 21 of 21

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

1 part(s) of substance.dissolves in:72 parts of solvent.in boiling solvent.

Linnemann; Justus Liebigs Annalen der Chemie; vol. 160; (1871); p. 241; Justus Liebigs Annalen der Chemie; vol. 192; (1878); p. 69, View in Reaxys IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

not given

Comment (IR Spectroscopy)

400 cm**-1 - 4000 cm**-1

Paramonov; Mychlo; Troyanov; Kuz'mina; Russian Journal of Inorganic Chemistry; vol. 45; nb. 12; (2000); p. 1852 - 1856 ; (from Gmelin), View in Reaxys Mass Spectrometry (1) Description (Mass References Spectrometry) electron impact (EI); spectrum

Roberts, Gerald D.; White V, Edward; Organic Mass Spectrometry; vol. 16; nb. 12; (1981); p. 546 - 550, View in Reaxys

Use (1)

328/365

2017-08-01 06:49:42

Laboratory Use and Handling

References

Aqueous solution of the compound is stable in the light.

Paramonov; Mychlo; Troyanov; Kuz'mina; Russian Journal of Inorganic Chemistry; vol. 45; nb. 12; (2000); p. 1852 - 1856 ; (from Gmelin), View in Reaxys

Reaxys ID 3914643 View in Reaxys

14/23 CAS Registry Number: 556-45-6 Chemical Name: magnesium butyrate; butyric acid ; magnesium butyrate; Buttersaeure; Magnesiumbutyrat; Buttersaeure; Magnesium-Verbindung; magnesium dibutyrate; magnesium butanoate Linear Structure Formula: 2C4H7O2 (1-)*Mg(2+) Molecular Formula: 2C4H7O2*Mg Molecular Weight: 198.502 Type of Substance: acyclic InChI Key: XZXFQZFALWOEBN-UHFFFAOYSA-M Note:

Mg2+ 2

O O–

Substance Label (1) Label References Mg butyrate

Shehata, Hassan A.; Journal of the Chemical Society, Faraday Transactions; vol. 90; nb. 22; (1994); p. 3401 - 3404, View in Reaxys

Patent-Specific Data (1) Location in Patent References Claim

Patent; Neesby; Torben E.; US4735967; (1988); (A1) English, View in Reaxys; Patent; Evans, William T.; McKee, Dwight L.; US2002/48612; (2002); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (1) 1 of 1

Melting Point [°C]

275

Iwanow; Bulletin de la Societe Chimique de France; vol. <4> 43; (1928); p. 445, View in Reaxys Association (MCS) (1) 1 of 1

Description (Association Association with compound (MCS)) Temperature (Association (MCS)) [°C]

24.9 - 54.9

Partner (Association (MCS))

H2O

Shehata, Hassan A.; Journal of the Chemical Society, Faraday Transactions; vol. 90; nb. 22; (1994); p. 3401 3404, View in Reaxys Critical Micelle Concentration (MCS) (4) Critical Micelle Temperature Solvent (Critical Concentration (Critical Micelle Micelle Concen[g·l-1] Concentration tration (MCS)) (MCS)) [°C]

References

329/365

2017-08-01 06:49:42

1.31

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

1.389

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

1.469

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

1.588

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

Crystal Property Description (1) Colour & Other References Properties white

Patent; NOF CORPORATION; EP1415976; (2004); (A1) English, View in Reaxys

Dissociation Exponent (1) 1 of 1

Dissociation Exponent (pK)

5.47 - 5.14

Dissociation Group

COO-Mg

Temperature (Dissociation Exponent) [°C]

35 - 50

Solvent (Dissociation Exponent)

methanol; nitrobenzene

Method (Dissociation Exponent)

conductometric

Type (Dissociation Exponent)

a1/apparent

Comment (Dissociation Exponent)

Ratio of solvents: 70percent : 30percent (v/v)

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys Electrochemical Behaviour (1) Description (Elec- References trochemical Behaviour) Thermodynamic parameters for dissociation / protonation Liquid Phase (2) Description (Liquid Phase) Association in the liquid state

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

Comment (Liquid Phase)

References

in the presence of Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 organic com383, View in Reaxys pounds

Self-association in solution

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

Liquid/Vapour Systems (MCS) (3) 1 of 3

Description (Liquid/ Critical data for mixtures Vapour Systems (MCS)) Temperature (Liquid/ 40 Vapour Systems (MCS)) [°C] Comment (Liquid/ concentration dependence Vapour Systems (MCS)) Partner (Liquid/Vapour Systems (MCS))

butan-1-ol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys

330/365

2017-08-01 06:49:42

2 of 3

2-methyl-propan-1-ol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys 3 of 3

i-Amyl alcohol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -110.6

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys

Reaxys ID 3701714 View in Reaxys

15/23 CAS Registry Number: 5743-36-2 Chemical Name: calcium dibutyrate; Calcium butyrate; calcium butyrate; Calciumbutyrat; calcium butanoate; butyrate calcium Linear Structure Formula: 2C4H7O2 (1-)*Ca(2+) Molecular Formula: 2C4H7O2*Ca Molecular Weight: 214.275 Type of Substance: acyclic InChI Key: POEGPIAGIYEZJB-UHFFFAOYSA-M Note:

Ca 2+ 2

O O–

Substance Label (2) Label References CaBA

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

Ca butyrate

Shehata, Hassan A.; Journal of the Chemical Society, Faraday Transactions; vol. 90; nb. 22; (1994); p. 3401 - 3404, View in Reaxys

Patent-Specific Data (1) Location in Patent References Claim

Patent; Neesby; Torben E.; US4735967; (1988); (A1) English, View in Reaxys; Patent; Evans, William T.; McKee, Dwight L.; US2002/48612; (2002); (A1) English, View in Reaxys; Patent; Vlahakos, Victor; US6613356; (2003); (B1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

331/365

2017-08-01 06:49:42

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Density [g·cm-3]

1.271

Reference Temperature [°C]

Measurement Temperature [°C]

Density (1) 1 of 1

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys Association (MCS) (1) 1 of 1

Description (Association Association with compound (MCS)) Temperature (Association (MCS)) [°C]

24.9 - 54.9

Partner (Association (MCS))

H2O

References

1.5

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

1.586

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

1.607

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

1.779

methanol; nitrobenzene

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

Dielectric Constant (1) Dielectric ConFrequency (Diestant lectric Constant) [Hz]

Temperature (Die- References lectric Constant) [°C]

4.9

3E+06

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys

Dissociation Exponent (1) 1 of 1

Dissociation Exponent (pK)

5.59 - 5.24

Dissociation Group

COO-Ca

Temperature (Dissociation Exponent) [°C]

35 - 50

Solvent (Dissociation Exponent)

methanol; nitrobenzene

Method (Dissociation Exponent)

conductometric

Type (Dissociation Exponent)

a1/apparent

Comment (Dissociation Exponent)

Ratio of solvents: 70percent : 30percent (v/v)

332/365

2017-08-01 06:49:42

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys Electrochemical Behaviour (2) Description (Elec- Comment (Electrochemical Betrochemical Behaviour) haviour) Thermodynamic parameters for dissociation / protonation

References

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

Stability constant

in Wasser.

Colman-Porter; Monk; Journal of the Chemical Society; (1952); p. 4363,4364, View in Reaxys

Liquid Phase (2) Description (Liquid Phase)

Comment (Liquid Phase)

References

Association in the liquid state

in the presence of Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 organic com383, View in Reaxys pounds

Self-association in solution

Kumar, Anil; Polish Journal of Chemistry; vol. 64; nb. 1-6; (1990); p. 273 - 279, View in Reaxys

Liquid/Vapour Systems (MCS) (3) 1 of 3

butan-1-ol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys 2 of 3

2-methyl-propan-1-ol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys 3 of 3

i-Amyl alcohol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1]

333/365

2017-08-01 06:49:42

-119.5

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys

Use (11) Use Pattern

Location

Parkinson's disease

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

disease which is associated with systemic inflammation

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

gout

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

hangover

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

idiopathic subfertility

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

migraine

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

osteoarthritis

Page/Page colPatent; BIRRBEHEER B.V.; VERMEIDEN, Jan Pieter Willem; (22 pag.); umn 16; title page WO2017/91072; (2017); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column title page; 21-23

Patent; Cypress Pharmaceuticals, Inc.; Lewis, Robert L.; Day, Charles E.; (13 pag.); US9339481; (2016); (B2) English, View in Reaxys

calcium salt of composition for treating hyperphosphatemia

Page/Page column title page; 21-23

Patent; Cypress Pharmaceuticals, Inc.; Lewis, Robert L.; Day, Charles E.; (13 pag.); US9339481; (2016); (B2) English, View in Reaxys

References

Calcium component for tooth whitening and remineralization kit

Patent; American Dental Association Foundation; US2006/110340; (2006); (A1) English, View in Reaxys

Reaxys ID 3918930 View in Reaxys

16/23 CAS Registry Number: 5892-23-9; 99283-81-5 Chemical Name: butyric acid ; calcium butyrate; Buttersaeure; Calciumbutyrat; Buttersaeure; Calcium-Verbindung; Buttersaeure; buttersaures Calcium Linear Structure Formula: 2C4H7O2 (1-)*Ca(2+)*H2O Molecular Formula: 2C4H7O2*Ca*H2O Molecular Weight: 232.29 Type of Substance: acyclic InChI Key: DWTDNVZSXNIULO-UHFFFAOYSA-M Note:

Ca 2+

O–

Druglikeness (1) 1 of 1

LogP

-0.206

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

334/365

2017-08-01 06:49:42

Veber Number

Solubility (MCS) (33) 1 of 33

Solubility [g·l-1]

42.4

Saturation

in pure solvent

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

aq. ethanol (80percent)

Comment (Solubility (MCS))

in reinem Loesungsmittel:wasserfreies Salz.

Birkinshaw; Raistrick; Phil.Trans.<B>; vol. 220; (1931); p. 24; Chem. Zentralbl.; vol. 103; nb. I; (1932); p. 1105, View in Reaxys 2 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

20.31 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys; Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 3 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

18.20 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 4 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

16.40 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 5 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.15 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 6 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.00 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 7 of 33

Temperature (Solubility (MCS)) [°C]

335/365

2017-08-01 06:49:42

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

14.92 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 8 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

14.90 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 9 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

14.95 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 10 of 33

Temperature (Solubility (MCS)) [°C]

100

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.85 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Lumsden; Journal of the Chemical Society; vol. 81; (1902); p. 356, View in Reaxys 11 of 33

Temperature (Solubility (MCS)) [°C]

20.5

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

17.92 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 12 of 33

Temperature (Solubility (MCS)) [°C]

53.5

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.73 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 13 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.35 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 14 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

336/365

2017-08-01 06:49:42

Comment (Solubility (MCS))

15.42 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 15 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.25 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 16 of 33

Temperature (Solubility (MCS)) [°C]

118

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

18.12 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 17 of 33

Temperature (Solubility (MCS)) [°C]

127

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

19.82 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 18 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

20.06 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 19 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

17.72 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 20 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.81 part(s) of substance.dissolves in:100 parts of solvent.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 21 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

337/365

2017-08-01 06:49:42

Comment (Solubility (MCS))

15.01 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 22 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.02 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 23 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.15 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 24 of 33

Temperature (Solubility (MCS)) [°C]

100

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

16.13 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Chancel; Parmentier; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1887); p. 1647, View in Reaxys 25 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

19.4 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 26 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

17.56 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 27 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.92 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 28 of 33

Temperature (Solubility (MCS)) [°C]

338/365

2017-08-01 06:49:42

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.05 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 29 of 33

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.0 part(s) of substance.dissolves in:100 parts of solvent.at:65-80 degreeC.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 30 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.04 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 31 of 33

Temperature (Solubility (MCS)) [°C]

100

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

15.81 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Hecht; Justus Liebigs Annalen der Chemie; vol. 213; (1882); p. 72, View in Reaxys 32 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

1 part(s) of substance.dissolves in:3.5 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Linnemann; Zotta; Justus Liebigs Annalen der Chemie; vol. 161; (1872); p. 177, View in Reaxys 33 of 33

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

18.1 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit des wasserhaltigen Salzes.

Gruenzweig; Justus Liebigs Annalen der Chemie; vol. 162; (1872); p. 218, View in Reaxys

Reaxys ID 3701717 View in Reaxys

17/23 CAS Registry Number: 5434-68-4; 19624-55-6 Chemical Name: nickel(II) butyrate; nickel butyrate; butyric acid ; nickel butyrate; Buttersaeure; Nickelbutyrat Linear Structure Formula: Ni(2+)*2CH3CH2CH2COO(1-)=Ni(CH3CH2CH2COO)2 Molecular Formula: 2C4H7O2*Ni Molecular Weight: 232.887 Type of Substance: acyclic InChI Key: QGEGANFLBSUFNR-UHFFFAOYSA-M Note:

Ni 2+ 2

O O–

Patent-Specific Data (1)

339/365

2017-08-01 06:49:42

Location in Patent References Claim

Patent; W. R. Grace and Co.-Conn.; US5177238; (1993); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Density [g·cm-3]

1.4476

Measurement Temperature [°C]

Density (1) 1 of 1

Davis; Logan; Journal of the American Chemical Society; vol. 62; p. 1278, View in Reaxys IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Spectrum

Duval; Lecomte; Douville; Annales de Physique (Paris, France); vol. <11> 17; (1942); p. 5,42, 71, View in Reaxys UV/VIS Spectroscopy (1) 1 of 1

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

H2O

Pestemer; Alslev-Klinker; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 53; (1949); p. 388, View in Reaxys

Reaxys ID 3914642 View in Reaxys

18/23 CAS Registry Number: 19664-96-1; 25442-09-5; 99668-71-0 Chemical Name: cobalt(II) butyrate; butyric acid ; cobalt (II)-butyrate; Buttersaeure; Kobalt(II)-butyrat; Buttersaeure; Kobaltbutyrat; cobalt butyrate; Kobalt(II)-butyrat Linear Structure Formula: Co(2+)*2CH3CH2CH2COO(1-) = Co(CH3CH2CH2COO)2 Molecular Formula: 2C4H7O2*Co Molecular Weight: 233.19 Type of Substance: acyclic InChI Key: ZKMVYMBHIIITDW-UHFFFAOYSA-M Note:

Co 2+ 2

O O–

Patent-Specific Data (1) Location in Patent References Claim

Patent; Mitsubishi Gas Chemical Company, Inc.; US4245078; (1981); (A1) English, View in Reaxys; Patent; Eastman Chemical Company; US5334754; (1994); (A1) English, View in Reaxys; Patent; Eastman Chemical Company; US5359134; (1994); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

340/365

2017-08-01 06:49:42

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (1) 1 of 1

Perinet; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 266; (1968); p. 732, View in Reaxys

Density (1) 1 of 1

Density [g·cm-3]

1.4011

Measurement Temperature [°C]

Davis; Logan; Journal of the American Chemical Society; vol. 62; (1940); p. 1278, View in Reaxys Magnetic Susceptibility (2) Magnetic SusTemperature ceptibility (Magnetic Sus[10-6cm3mol-1] ceptibility) [°C]

References

43 - 147

-193.1 - 19.9

Moreau; Rodier; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 246; (1958); p. 2127, View in Reaxys; Amiel et al.; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 246; (1958); p. 2258, View in Reaxys

45.6

Moreau; Vatteroni; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 237; (1953); p. 1090, View in Reaxys

Other Thermochemical Data (1) Description (Oth- References er Thermochemical Data) Enthalpy

Perinet; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 266; (1968); p. 732, View in Reaxys

IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Spectrum

Duval; Lecomte; Douville; Annales de Physique (Paris, France); vol. <11> 17; (1942); p. 5,42, 71, View in Reaxys

Reaxys ID 3701715 View in Reaxys

19/23 CAS Registry Number: 540-16-9; 32047-80-6; 50671-60-8 Chemical Name: copper(II) butyrate; copper(II) n-butyrate; cuprous butyrate; copper butyrate; copper(II) butanoate; copper n-butyrate; cupric butyrate Linear Structure Formula: Cu(2+)*2CH3CH2CH2CO2 (1-)=Cu(CH CH CH CO )2 3 2 2 2 Molecular Formula: 2C4H7O2*Cu Molecular Weight: 237.743 Type of Substance: acyclic; Coordination compound InChI Key: GXWXBQVBOKVFKU-UHFFFAOYSA-M Note:

Cu 2+ 2

O O–

Substance Label (1) Label References Cu(RCOO)2, R=C3H7

Emori, Shuji; Nonaka, Hiroki; Ikeda, Noriyasu; Muto, Yoneichiro; Bulletin of the Chemical Society of Japan; vol. 61; nb. 5; (1988); p. 1812 - 1814, View in Reaxys

Patent-Specific Data (4) Prophetic ComLocation in Patent References pound Patent; Norel, S.A.; EP1647542; (2006); (A1) English, View in Reaxys prophetic catalyst

Patent; UBE INDUSTRIES, LTD.; US2004/39222; (2004); (A1) English, View in Reaxys

341/365

2017-08-01 06:49:42

Patent; BICBIO CO., LTD; ISTECH CO., LTD; WO2004/36997; (2004); (A1) English, View in Reaxys Claim

Patent; Phillips Petroleum Company; US4237312; (1980); (A1) English, View in Reaxys; Patent; The Board of Trustees of Southern Illinois University; US6042848; (2000); (A1) English, View in Reaxys; Patent; Rhone-Poulenc S.A.; US3968162; (1976); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Related Structure (1) Related Structure References das Salz liegt als zweikerniger Komplex Cu2(C4H7O2)4 vor.

Martin; Waterman; Journal of the Chemical Society; (1957); p. 2545,2547, View in Reaxys; Kato et al.; Chemical Reviews (Washington, DC, United States); vol. 64; (1964); p. 99, View in Reaxys; Martin; Whitley; Journal of the Chemical Society; (1958); p. 1394,1397, View in Reaxys; Yamada et al.; Bulletin of the Chemical Society of Japan; vol. 31; (1958); p. 303, View in Reaxys

Purification (2) Purification (method)

References

purification described

Amiel, J.; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 207; (1938); p. 1097 - 1099 ; (from Gmelin), View in Reaxys

purification described

vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

Association (MCS) (3) 1 of 3

Description (Association Further physical properties of the complex (MCS)) Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

Quinuclidine

Emori, Shuji; Nonaka, Hiroki; Ikeda, Noriyasu; Muto, Yoneichiro; Bulletin of the Chemical Society of Japan; vol. 61; nb. 5; (1988); p. 1812 - 1814, View in Reaxys 2 of 3

Description (Association Further physical properties of the complex (MCS)) Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

1,4-diaza-bicyclo[2.2.2]octane

Emori, Shuji; Nonaka, Hiroki; Ikeda, Noriyasu; Muto, Yoneichiro; Bulletin of the Chemical Society of Japan; vol. 61; nb. 5; (1988); p. 1812 - 1814, View in Reaxys 3 of 3

Description (Association Further physical properties of the complex (MCS)) Temperature (Association (MCS)) [°C]

Partner (Association (MCS))

hexamethylenetetraamine

Emori, Shuji; Nonaka, Hiroki; Ikeda, Noriyasu; Muto, Yoneichiro; Bulletin of the Chemical Society of Japan; vol. 61; nb. 5; (1988); p. 1812 - 1814, View in Reaxys

342/365

2017-08-01 06:49:42

Crystal Property Description (1) Colour & Other References Properties green blue

Casarin, Maurizio; Corvaja, Carlo; Di Nicola, Corrado; Falcomer, Daniele; Franco, Lorenzo; Monari, Magda; Pandolfo, Luciano; Pettinari, Claudio; Piccinelli, Fabio; Inorganic Chemistry; vol. 44; nb. 18; (2005); p. 6265 - 6276 ; (from Gmelin), View in Reaxys

Electrochemical Behaviour (1) Description (Elec- Comment (Electrochemical Betrochemical Behaviour) haviour)

References

Stability constant

Lloyd et al.; Journal of the Chemical Society; (1951); p. 1786,1787, View in Reaxys

in Wasser.

Further Information (3) Description (Fur- References ther Information) Behaviour as catalyst

Akbayeva, Dina N.; Faisova, Farida Kh.; Abdreimova, Rumia R.; Peruzzini, Maurizio; Journal of Molecular Catalysis A: Chemical; vol. 267; nb. 1-2; (2007); p. 181 - 193 ; (from Gmelin), View in Reaxys

Behaviour as catalyst

Dorfman; Abdreimova; Kinetics and Catalysis; vol. 38; nb. 5; (1997); p. 630 - 638 ; (from Gmelin), View in Reaxys

Behaviour as catalyst

Dorfman, A. Ya.; Abdreimova, R. R.; Akbaeva, D. N.; Kinetics and Catalysis; vol. 36; (1995); p. 93 - 100; Kinetika i Kataliz; vol. 36; (1995); p. 103 - 111 ; (from Gmelin), View in Reaxys

Magnetic Susceptibility (4) Magnetic SusTemperature ceptibility (Magnetic Sus[10-6cm3mol-1] ceptibility) [°C]

Comment (Magnetic Susceptibility)

References

von:von Loesungen in Wasser, Benzol und Dioxan.

Martin; Whitley; Journal of the Chemical Society; (1958); p. 1394,1397, View in Reaxys

226 - 814

-171.9 - 113.1

Martin; Waterman; Journal of the Chemical Society; (1957); p. 2545,2547, View in Reaxys

695

Amiel, J.; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 207; (1938); p. 1097 - 1099, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

697

Amiel, J.; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 207; (1938); p. 1097 - 1099, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

IR Spectroscopy (3) 1 of 3

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

not given

Comment (IR Spectroscopy)

1420 cm**-1 - 1585 cm**-1

Battaglia, Luigi Pietro; Corradi, Anna Bonamartini; Menabue, Ledi; Journal of the Chemical Society, Dalton Transactions: Inorganic Chemistry (1972-1999); (1986); p. 1653 - 1658 ; (from Gmelin), View in Reaxys 2 of 3

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

mineral oil

Comment (IR Spectroscopy)

700 cm**-1 - 4000 cm**-1

Kharitonova, I. R.; Kharitonov, Yu. Ya.; Kryachko, E. N.; Journal of General Chemistry USSR (English Translation); vol. 50; (1980); p. 2052 - 2055; Zhurnal Obshchei Khimii; vol. 50; (1980); p. 2535 - 2538 ; (from Gmelin), View in Reaxys

343/365

2017-08-01 06:49:42

3 of 3

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

paraffin

Comment (IR Spectroscopy)

711 cm**-1 - 2952 cm**-1

Kharitonova, R. I.; Kharitonov, G. V.; Russian Journal of Inorganic Chemistry (Translation of Zhurnal Neorganicheskoi Khimii); vol. 24; (1979); p. 213 - 216; Zhurnal Neorganicheskoi Khimii; vol. 24; (1979); p. 384 - 388 ; (from Gmelin), View in Reaxys Mass Spectrometry (1) References Lin,D.C.K.; Westmore,J.B.; Canadian Journal of Chemistry; vol. 51; (1973); p. 2999 - 3005, View in Reaxys UV/VIS Spectroscopy (6) 1 of 6

Description (UV/VIS Spectroscopy)

Band assignment

Solvent (UV/VIS Spectroscopy)

nujol

Comment (UV/VIS Spectroscopy)

371.747 nm - 671.141 nm

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

H2O

Comment (UV/VIS Spectroscopy)

300 - 800 nm

Martin; Whitley; Journal of the Chemical Society; (1958); p. 1394,1397, View in Reaxys 3 of 6

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

dioxane

Comment (UV/VIS Spectroscopy)

300 - 800 nm

Martin; Whitley; Journal of the Chemical Society; (1958); p. 1394,1397, View in Reaxys 4 of 6

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

benzene

Comment (UV/VIS Spectroscopy)

300 - 800 nm

Martin; Whitley; Journal of the Chemical Society; (1958); p. 1394,1397, View in Reaxys 5 of 6

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

ethanol

Comment (UV/VIS Spectroscopy)

200 - 1000 nm

Yamada et al.; Bulletin of the Chemical Society of Japan; vol. 31; (1958); p. 303, View in Reaxys 6 of 6

Description (UV/VIS Spectroscopy)

Band anisotropy

344/365

2017-08-01 06:49:42

Comment (UV/VIS Spectroscopy)

Anisotrope Absorption (Dichroismus) eines Einkrystalls im Bereich von 250 nm bis 800 nm.

Yamada et al.; Bulletin of the Chemical Society of Japan; vol. 31; (1958); p. 303, View in Reaxys ESR Spectroscopy (1) 1 of 1

Description (ESR Spectroscopy)

g-factor

Solvents (ESR Spectroscopy)

neat (no solvent, solid phase)

Temperature (ESR Spectroscopy) [°C]

-150

Edwards, D. A.; Inorganica Chimica Acta; vol. 18; (1976); p. 65 - 68 ; (from Gmelin), View in Reaxys

(0) Medchem (4) 1 of 4

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

3701715View in Reaxys

Substance Name

1486092

Qualitative Results

physiological behaviour discussed

Measurement Parameter

Qualitative

Melnik, M.; Auderova, M.; Hol'ko, M.; Inorganica Chimica Acta; vol. 67; (1982); p. 117 - 120, View in Reaxys 2 of 4

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : style specific S RNase; inhibition of Target : Fuji apple Bioassay : Example 3> Inhibition of the activity of a style-specific S RNase by the agents. Inhibition of S RNase activity by an agent of the present invention was measured as follows : The standard solution of 500L of 10 mM sodium phosphate (pH 7.0) with an agent (2.0 mM), and 500L of torula yeast RRNA (5mg/mL)

Substance RN

3701715View in Reaxys

Substance Name

Cu(RCOO)2, R=C3H7

Qualitative Results

effect was observed potential area of application: agro

Measurement Parameter

Qualitative

Patent; BICBIO CO., LTD; ISTECH CO., LTD; WO2004/36997; (2004); (A1) English, View in Reaxys 3 of 4

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : production parameters; effect on Target : Ross chick Bioassay : Example 10: TEST OF EFFICACY IN EROILERS: (chicken 7 weeks old, ready for consumption) OBJECTIVES: To determine the effectiveness of copper formate and copper butyrate on the production parameters of broilers.MATERIAL AND METHODS Animals and housing: 1600 one-day old broilers of the Ross strain were

Substance RN

3701715View in Reaxys

Substance Name

Cu(RCOO)2, R=C3H7

345/365

2017-08-01 06:49:42

Qualitative Results

0.0073% of title compound produced better production parameters relative to control; see Table 4

Measurement Parameter

Qualitative

Patent; NOREL, S.A.; WO2005/5365; (2005); (A1) spanish, View in Reaxys 4 of 4

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |bioavailability Target : Ross chick Bioassay : Example 10: TEST OF EFFICACY IN EROILERS: (chicken 7 weeks old, ready for consumption) OBJECTIVES: To determine the effectiveness of copper formate and copper butyrate on the production parameters of broilers.MATERIAL AND METHODS Animals and housing: 1600 one-day old broilers of the Ross strain were

Substance RN

3701715View in Reaxys

Substance Name

Cu(RCOO)2, R=C3H7

Qualitative Results

title compound display greater bioavailability, so there is less emission of residues to the environment; see Table 5

Measurement Parameter

Qualitative

Patent; NOREL, S.A.; WO2005/5365; (2005); (A1) spanish, View in Reaxys

Reaxys ID 3701722 View in Reaxys

20/23 CAS Registry Number: 13282-37-6 Chemical Name: zinc(II) butyrate; zinc bis(n-butanoate); zinc(II) butanoate; zinc butyrate; butyric acid ; zinc butyrate; Buttersaeure; Zinkbutyrat; zinc dibutyrate Linear Structure Formula: Zn(2+)*2O2CC3H7 (1-)=Zn(O CC H )2 2 3 7 Molecular Formula: 2C4H7O2*Zn Molecular Weight: 239.587 Type of Substance: acyclic; Coordination compound InChI Key: WECLHXWGEMUJSK-UHFFFAOYSA-M Note:

Zn 2+ 2

O O–

Substance Label (1) Label References ZBA

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

Patent-Specific Data (3) Location in Patent References Patent; Norel, S.A.; EP1647542; (2006); (A1) English, View in Reaxys Patent; BICBIO CO., LTD; ISTECH CO., LTD; WO2004/36997; (2004); (A1) English, View in Reaxys Claim

Patent; SCM Metal Products, Inc.; US4824984; (1989); (A1) English, View in Reaxys; Patent; Kelly; Patrick D.; US5545673; (1996); (A1) English, View in Reaxys; Patent; Chemische Werke Huls Aktiengesellschaft; US4009199; (1977); (A1) English, View in Reaxys; Patent; Kelly; Patrick D.; US5599551; (1997); (A1) English, View in Reaxys; Patent; Neesby; Torben E.; US4721716; (1988); (A1) English, View in Reaxys; Patent; Kelly; Patrick D.; US5208031; (1993); (A1) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

346/365

2017-08-01 06:49:42

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (4) 1 of 4

Melting Point [°C]

157.04 - 160.04

Taylor, Richard A.; Ellis, Henry A.; Maragh, Paul T.; Journal of Molecular Structure; vol. 921; nb. 1-3; (2009); p. 118 - 125 ; (from Gmelin), View in Reaxys 2 of 4

Melting Point [°C]

158.48 - 158.52

Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys 3 of 4

Melting Point [°C]

180

Mirnaya; Yaremchuk; Dradrakh; Volkov; Russian Journal of Inorganic Chemistry; vol. 44; nb. 5; (1999); p. 775 778 ; (from Gmelin), View in Reaxys 4 of 4

Melting Point [°C]

160

Comment (Melting Point)

bei 200grad im Vakuum sublimierbar. Differential-Thermoanalyse (110-180grad).

Semenenko; Chimija chim.Technol.(NDVS); nb. 2; (1958); p. 283; Chem.Abstr.; (1958); p. 17882, View in Reaxys Refractive Index (1) References Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys Density (3) 1 of 3

Density [g·cm-3]

1.3 - 1.42

Taylor, Richard A.; Ellis, Henry A.; Maragh, Paul T.; Journal of Molecular Structure; vol. 921; nb. 1-3; (2009); p. 118 - 125 ; (from Gmelin), View in Reaxys 2 of 3

Density [g·cm-3]

1.36

Type (Density)

crystallographic

Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys 3 of 3

Density [g·cm-3]

1.506

Measurement Temperature [°C]

Type (Density)

crystallographic

Blair, Julian; Howie, R. Alan; Wardell, James L.; Acta Crystallographica, Section C: Crystal Structure Communications; vol. 49; (1993); p. 219 - 221 ; (from Gmelin), View in Reaxys Conformation (1) Object of Investi- References gation Conformation

Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107, View in Reaxys; Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys

Crystal Phase (5) Description (Crys- References tal Phase) Powder X-ray Dif- Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscofraction py; vol. 68; nb. 1; (2007); p. 99 - 107, View in Reaxys; Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys Structure of the solid

Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107, View in Reaxys; Blair, Julian; Howie, R. Alan; Wardell, James L.; Acta Crystallographica, Section C: Crystal Structure Communications; vol. 49; (1993); p. 219 - 221, View in Reaxys; Panevchik, V. V.; Goryaev, V. M.; Zonov, Yu. G.; Russian Journal of Inorganic Chemistry (Translation of Zhurnal Neorganicheskoi Khimii); vol. 26; (1981); p. 1373 - 1375; Zhurnal Neorganicheskoi

347/365

2017-08-01 06:49:42

Khimii; vol. 26; (1981); p. 2554 - 2557, View in Reaxys; Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys pinacoids

Gyoryova; Balek; Behrens; Matuschek; Kettrup; Journal of thermal analysis; vol. 48; nb. 6; (1997); p. 1263 - 1271 ; (from Gmelin), View in Reaxys

Single Crystal Xray Diffraction

Blair, Julian; Howie, R. Alan; Wardell, James L.; Acta Crystallographica, Section C: Crystal Structure Communications; vol. 49; (1993); p. 219 - 221 ; (from Gmelin), View in Reaxys

Crystal structure determination

Semenenko; Chimija chim.Technol.(NDVS); nb. 2; (1958); p. 283; Chem.Abstr.; (1958); p. 17882, View in Reaxys

Crystal Property Description (1) Colour & Other References Properties white

Patent; Norel, S.A.; EP1647542; (2006); (A1) English, View in Reaxys; Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107, View in Reaxys; Gyoryova; Balek; Behrens; Matuschek; Kettrup; Journal of thermal analysis; vol. 48; nb. 6; (1997); p. 1263 - 1271 ; (from Gmelin), View in Reaxys

Crystal System (1) Crystal System References Monoclinic

Decomposition (1) 1 of 1

Decomposition [°C]

149.84

Gyoeryova, K.; Balek, V.; Kovarova, J.; Thermochimica Acta; vol. 269 - 270; (1995); p. 425 - 432 ; (from Gmelin), View in Reaxys Interatomic Distances and Angles (1) Description Comment (Intera- References tomic Distances and Angles) Interatomic distances and angles

Powder X-ray Dif- Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomofraction lecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys

Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -119.5 Optics (2) Description (Optics) Birefringence

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys References Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys

Optical anisotropy Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys Space Group (3) Space Group

Comment (Space Group)

References

atomic positions available

Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys

a = 25.52 Angstroem, b = 4.96 Angstroem, c = 9.69 Angstroem, β = 94.70; Z = 2; T = 25 Deg C; atomic positions available

Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107 ; (from Gmelin), View in Reaxys

348/365

2017-08-01 06:49:42

a = 23.48 Angstroem, b = 4.795 Angstroem, c = 9.38 Angstroem, β = 90.08; Z = 4; T = 25 Deg C; atomic positions available

Blair, Julian; Howie, R. Alan; Wardell, James L.; Acta Crystallographica, Section C: Crystal Structure Communications; vol. 49; (1993); p. 219 - 221 ; (from Gmelin), View in Reaxys

NMR Spectroscopy (2) 1 of 2

Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- neat (no solvent, solid phase) scopy) Temperature (NMR Spectroscopy) [°C]

Comment (NMR Spectroscopy)

Signals given

Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys 2 of 2

Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- neat (no solvent, solid phase) scopy) Temperature (NMR Spectroscopy) [°C]

Comment (NMR Spectroscopy)

Signals given

Taylor, Richard A.; Ellis, Henry A.; Maragh, Paul T.; Journal of Molecular Structure; vol. 921; nb. 1-3; (2009); p. 118 - 125 ; (from Gmelin), View in Reaxys IR Spectroscopy (7) 1 of 7

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

potassium bromide

Temperature (IR Spectroscopy) [°C]

Comment (IR Spectroscopy)

400 cm**-1 - 4000 cm**-1

Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys 2 of 7

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

potassium bromide

Temperature (IR Spectroscopy) [°C]

Comment (IR Spectroscopy)

400 cm**-1 - 4000 cm**-1

Nelson, Peter N.; Ellis, Henry A.; Taylor, Richard A.; Journal of Molecular Structure; vol. 986; nb. 1-3; (2011); p. 10 - 15 ; (from Gmelin), View in Reaxys 3 of 7

Description (IR Spectroscopy)

Bands

349/365

2017-08-01 06:49:42

Solvent (IR Spectroscopy)

not given

Comment (IR Spectroscopy)

500 cm**-1 - 3500 cm**-1

Taylor, Richard A.; Ellis, Henry A.; Maragh, Paul T.; Journal of Molecular Structure; vol. 921; nb. 1-3; (2009); p. 118 - 125 ; (from Gmelin), View in Reaxys 4 of 7

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

not given

Comment (IR Spectroscopy)

500 cm**-1 - 3500 cm**-1

Taylor, Richard A.; Ellis, Henry A.; Maragh, Paul T.; Journal of Molecular Structure; vol. 921; nb. 1-3; (2009); p. 118 - 125 ; (from Gmelin), View in Reaxys 5 of 7

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

potassium bromide

Comment (IR Spectroscopy)

400 cm**-1 - 4000 cm**-1

Taylor, Richard A.; Ellis, Henry A.; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 68; nb. 1; (2007); p. 99 - 107, View in Reaxys; Berkesi, O.; Dreveni, I.; Andor, J. A.; Goggin, P. L.; Inorganica Chimica Acta; vol. 181; (1991); p. 285 - 290 ; (from Gmelin), View in Reaxys 6 of 7

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

neat (no solvent)

Comment (IR Spectroscopy)

350 cm**-1 - 4000 cm**-1

Dreveni; Berkesi; Andor; Mink; Inorganica Chimica Acta; vol. 249; nb. 1; (1996); p. 17 - 23 ; (from Gmelin), View in Reaxys 7 of 7

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

potassium bromide

Comment (IR Spectroscopy)

400 cm**-1 - 4000 cm**-1

Berkesi, O.; Dreveni, I.; Andor, J. A.; Goggin, P. L.; Inorganica Chimica Acta; vol. 181; (1991); p. 285 - 290 ; (from Gmelin), View in Reaxys Use (134) Use Pattern

Location

References

Pharmaceuticals

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

enteric disease challenge

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

enteric disease challenges

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

feed conversion

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

improving feed in- Page/Page coltake umn title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

improving intestinal integrity

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

Page/Page column title page; 6

350/365

2017-08-01 06:49:42

other intestinal stress conditions

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

reducing the effects of heat stress

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

weight gain during heat stress

Page/Page column title page; 6

Patent; Kemin Industries, Inc.; Mani, Venkatesh; Rubach, Jon; Poss, Mitchell; (14 pag.); US2017/27984; (2017); (A1) English, View in Reaxys

Antimicrobial compositions

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Preservatives

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sanitizers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sterilants

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Disinfectants

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sporicides

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

viracides

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Tuberculocidal agents

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sterilization of drinking water

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Beverages

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sterilizing exposed surfaces

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sterilizing exhaust air and ventilation components

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Sterilizing animal feed

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Surgical equipment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Swimming pools

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Saunas

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

kitchens

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Bathrooms

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Factories

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Hospitals

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Dental offices

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Food plants

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

351/365

2017-08-01 06:49:42

Architectural surfaces

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Eating utensils

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Hard-surface medical or surgical instruments

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Hard-surface packaging

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Harvested plant materials including leaves, stems, tubers, roots, seeds

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Deodorizers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Antiseptics

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Fungicides

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

germicides

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Detergents

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Bleaches

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Hard surface cleaners

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Hand soaps

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Pre-surgical scrubs

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Post-surgical scrubs

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Cold aseptic packaging treatments

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Hot aseptic packaging treatments

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Mammalian skin treatments

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Products for sanitizing or disinfecting animal enclosures

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Products for sanitizing or disinfecting animal pens

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Products for sanitizing or disinfecting animal watering stations

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Products for sanitizing or disinfecting veterinary treatment areas

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

352/365

2017-08-01 06:49:42

Products for sanitizing or disinfecting veterinary inspection tables

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Products for sanitizing or disinfecting veterinary operation rooms

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Reduce surface microbial populations in food

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Process water treatment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Food transport lines

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Belt sprays

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Boot and handwash dip pans

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Food storage facilities

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Anti-spoilage air circulation systems

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Refrigeration and cooler equipment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Beverage chillers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Beverage warmers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Blanchers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Cutting boards

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Third sink areas

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Meat chillers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Scalding devices

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Produce transport water treatment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Food packaging materials and equipment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

ware wash machines

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Dishware

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Bottle washers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Bottle chillers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

warmers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

353/365

2017-08-01 06:49:42

Third sink washers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Cutting areas

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Egg washers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Processing equipment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Dairy processing equipment

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Transportation vehicles

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Recreational waters

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Recreational flumes

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Recreational water slides

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Recreational fountains

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Clean-in-place system (CIP)

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Clean-ou-of-place systems (COP)

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

washer decontaminators

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Textile laundry machines

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

ultra filtration systems

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Nano-filtration systems

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Indoor air filters

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

wash tanks

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Soaking vessels

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Mop buckets

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Holding tanks

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Scrub sinks

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

vehicle parts wahers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Non-continuous batch washers and systems

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Controlling biological fouling

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

Preservative for cut flowers

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

354/365

2017-08-01 06:49:42

Preservative for cut plants

Patent; SWISS-AMERICAN PRODUCTS, INC.; WO2007/76125; (2007); (A2) English, View in Reaxys

inhibiting vacuolar H+ -ATPase,H+/K + -ATPase or both H+ -ATPase and H+/K+ -ATPase in the stomach

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

gastroesophageal reflux disease (GERD)

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

Non-erosive reflux disease (NERD)

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

Zollinger-Ellison syndrome (ZE disease)

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

ulcer disease

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

gastric cancer

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

H. pylori infection

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

H. pyloridus infections

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

Inhibit gastric acid secretion

Patent; YALE UNIVERSITY; WO2007/89511; (2007); (A2) English, View in Reaxys

zinc-based compound in a pharmaceutical formulation use for antimicrobial

Patent; Bausch and Lomb Incorporated; US2007/212420; (2007); (A1) English, View in Reaxys

zinc-based compound in a pharmaceutical formulation use for condition of an eye that manifests irritation

Patent; Bausch and Lomb Incorporated; US2007/212420; (2007); (A1) English, View in Reaxys

zinc-based compound in a pharmaceutical formulation use for condition of an eye that manifests inflammation

Patent; Bausch and Lomb Incorporated; US2007/212420; (2007); (A1) English, View in Reaxys

zinc-based compound in a pharmaceutical formulation use for dry eye

Patent; Bausch and Lomb Incorporated; US2007/212420; (2007); (A1) English, View in Reaxys

zinc-based compound in a pharmaceutical formulation use for inflammation

Patent; Bausch and Lomb Incorporated; US2007/212420; (2007); (A1) English, View in Reaxys

zinc-based compound in a pharmaceutical formulation use for infection of the eye

Patent; Bausch and Lomb Incorporated; US2007/212420; (2007); (A1) English, View in Reaxys

355/365

2017-08-01 06:49:42

wound

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Antimicrobial

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Cover openings created on the surface

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Cover cuts created on the surface

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Skin ailments

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Surface ailments

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Mucous membrane ailments

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Nail ailments

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Scalp ailments

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Chronic wound

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Burn wound

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

Acute wound

Patent; Kling, William O.; Parnell, Laura K. S.; US2006/141017; (2006); (A1) English, View in Reaxys

component of a topical composition

Patent; Jaiswal, Ashish; Garg, Mukesh Kumar; Arora, Vinod Kumar; US2005/79228; (2005); (A1) English, View in Reaxys

treatment of acne

Patent; Jaiswal, Ashish; Garg, Mukesh Kumar; Arora, Vinod Kumar; US2005/79228; (2005); (A1) English, View in Reaxys

topical composition for the treatment of acne

Patent; RANBAXY LABORATORIES LIMITED; WO2005/92386; (2005); (A1) English, View in Reaxys

(0) Medchem (4) 1 of 4

Bioassay Category

In Vivo (Animal models)

Bioassay Details

skin dryness and erythema; effect on human

Biological Species/NCBI human ID Substance RN

3701722View in Reaxys

Qualitative Results

after four days treatment with title compound the IGA had fallen to 1.8 (from 7.0); figure is given

Measurement Parameter

Qualitative

Qualitative value

Patent; YORK PHARMA PLC; WO2008/25837; (2008); (A1) English, View in Reaxys 2 of 4

Target Mutant/Chimera Details

style specific S RNase:Wild

Substance Action on Target

Inhibitor

Target Subunit Proteins

style specific S RNase

356/365

2017-08-01 06:49:42

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

style specific S RNase; inhibition of Fuji apple

Substance RN

3701722View in Reaxys

Qualitative Results

effect was observed

Measurement Parameter

Qualitative

Qualitative value

Target, Subunit, Species style specific S RNase Patent; BICBIO CO., LTD; ISTECH CO., LTD; WO2004/36997; (2004); (A1) English, View in Reaxys 3 of 4

Bioassay Category

In Vivo (Animal models)

Bioassay Details

production parameters; effect on cross of Large White and Landrace pig

Substance RN

3701722View in Reaxys

Qualitative Results

0.0797 of title compound produced better production parameters relative to control; see Table 9

Measurement Parameter

Qualitative

Qualitative value

Patent; Norel, S.A.; EP1647542; (2006); (A1) English, View in Reaxys 4 of 4

Bioassay Category

Pharmacokinetic

Bioassay Details

bioavailability cross of Large White and Landrace pig

Substance RN

3701722View in Reaxys

Qualitative Results

title compound display greater bioavailability, so there is less emission of residues to the environment; see Table 10

Measurement Parameter

Qualitative

Qualitative value

Patent; Norel, S.A.; EP1647542; (2006); (A1) English, View in Reaxys

Reaxys ID 3918931 View in Reaxys

21/23 CAS Registry Number: 6046-99-7 Chemical Name: copper(II) n-butyrate monohydrate; copper(II) propionate monohydrate; butyric acid ; copper (II)-salt hydrate; Buttersaeure; Kupfer(II)-Salz-Hydrat; Buttersaeure; Kupfer(II)butyrat; Kupfer(II)-n-butyrat-monohydrat Linear Structure Formula: Cu(2+)*2CH3CH2CH2COO(1-)*H2O=Cu(C4H7O2)2*H2O Molecular Formula: 2C4H7O2*Cu*H2O Molecular Weight: 255.758 Type of Substance: acyclic InChI Key: VYEDFQJONMTEMN-UHFFFAOYSA-M Note:

Cu 2+

O–

Druglikeness (1) 1 of 1

LogP

-0.206

H Bond Donors

357/365

2017-08-01 06:49:42

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Related Structure (1) Related Structure References das Salz liegt als zweikerniger Komplex Cu2(C4H7O2)4+ 2H2O vor.

Martin; Waterman; Journal of the Chemical Society; (1957); p. 2545,2547, View in Reaxys; Kato et al.; Chemical Reviews (Washington, DC, United States); vol. 64; (1964); p. 99, View in Reaxys; Yamada et al.; Bulletin of the Chemical Society of Japan; vol. 31; (1958); p. 303, View in Reaxys

Density (2) 1 of 2

Density [g·cm-3]

1.45

Type (Density)

crystallographic

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 711 ; (from Gmelin), View in Reaxys 2 of 2

Density [g·cm-3]

1.44

Type (Density)

crystallographic

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 711 ; (from Gmelin), View in Reaxys Crystal Phase (4) Description (Crys- References tal Phase) Crystal structure determination

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys

slabs

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; Kohlschuetter, V.; Luethi, M.; Helvetica Chimica Acta; vol. 13; (1930); p. 978 - 1006, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 711 ; (from Gmelin), View in Reaxys

Crystal growth forms

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

rhombohedrons

vol. Cu: MVol.B2; 41, page 709 - 711, View in Reaxys; Behrens, H.; Kley, P. R. C.; Organische mikrochemische Analyse, Leipzig 1922, S. 319 ; (from Gmelin), View in Reaxys

Crystal Property Description (3) Colour & Other Comment (Crystal References Properties Property Description) green

greenish blue

butyraldehyde

Davis; Green; Journal of the American Chemical Society; vol. 62; (1940); p. 3014, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

bluish green

CHCl3, ethanol

French, H. S.; Lowry, T. M.; Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences; vol. 106; (1924); p. 489 - 512, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

Crystal System (2) Crystal System References monoclinic

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys

Monoclinic

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

Magnetic Susceptibility (6)

358/365

2017-08-01 06:49:42

Magnetic Susceptibility [10-6cm3mol-1]

Temperature (Magnetic Susceptibility) [°C]

References

208 - 798

-175.3 - 71.1

Martin; Waterman; Journal of the Chemical Society; (1957); p. 2545,2547, View in Reaxys Amiel; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 207; (1938); p. 1098, View in Reaxys; Bhatnagar; Singh; Ghani; Indian Journal of Physics (1926-1976); vol. 7; (1932); p. 326, View in Reaxys

1438.4

Bhatnagar, S. S.; Singh, B.; Ghani, A.; Indian Journal of Physics (1926-1976); vol. 7; (1932); p. 323 - 330, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

1438

Bhatnagar, S. S.; Singh, B.; Ghani, A.; Indian Journal of Physics (1926-1976); vol. 7; (1932); p. 323 - 330, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

1546.3

Bhatnagar, S. S.; Singh, B.; Ghani, A.; Indian Journal of Physics (1926-1976); vol. 7; (1932); p. 323 - 330, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

1546

Bhatnagar, S. S.; Singh, B.; Ghani, A.; Indian Journal of Physics (1926-1976); vol. 7; (1932); p. 323 - 330, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

Optics (1) Description (Optics)

References

Optical anisotropy vol. Cu: MVol.B2; 41, page 709 - 711, View in Reaxys; Behrens, H.; Kley, P. R. C.; Organische mikrochemische Analyse, Leipzig 1922, S. 319 ; (from Gmelin), View in Reaxys Solubility (MCS) (1) 1 of 1

Comment (Solubility (MCS))

highly soluble in ethanol;

Klein, G.; Wenzl, H.; Mikroch.; vol. 11; (1932); p. 73 - 130, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys Space Group (1) Space Group 9; 15

Comment (Space Group)

References

a = 25.17 AngIball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; vol. Cu: stroem, b = 14.68 MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys Angstroem, c = 26.84 Angstroem, β = 109.7; Z = 32

IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Bands

Comment (IR Spectroscopy)

5000 - 667 cm**(-1)

Lakshmanan; Journal of the Indian Institute of Science, Section A; vol. 38; (1956); p. 217, View in Reaxys UV/VIS Spectroscopy (6) 1 of 6

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

ethanol

Comment (UV/VIS Spectroscopy)

200 - 1000 nm

Yamada et al.; Bulletin of the Chemical Society of Japan; vol. 31; (1958); p. 303, View in Reaxys 2 of 6

Description (UV/VIS Spectroscopy)

Band anisotropy

Comment (UV/VIS Spectroscopy)

Anisotrop Absorption (Dichroismus) eines Einkrystalls von 300 nm bis 800 nm.

359/365

2017-08-01 06:49:42

Yamada et al.; Bulletin of the Chemical Society of Japan; vol. 31; (1958); p. 303, View in Reaxys 3 of 6

Solvent (UV/VIS Spectroscopy)

ethanol

Comment (UV/VIS Spectroscopy)

510 nm - 690 nm

French, H. S.; Lowry, T. M.; Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences; vol. 106; (1924); p. 489 - 512 ; (from Gmelin), View in Reaxys 4 of 6

Solvent (UV/VIS Spectroscopy)

CHCl3

Comment (UV/VIS Spectroscopy)

490 nm - 675 nm

Solvent (UV/VIS Spectroscopy)

ethanol

Comment (UV/VIS Spectroscopy)

510 nm - 690 nm

vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys 6 of 6

Solvent (UV/VIS Spectroscopy)

chloroform

Comment (UV/VIS Spectroscopy)

490 nm - 675 nm

vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys Use (1) Laboratory Use and Handling

References

weathering in air after a few days;

Iball; Nature (London, United Kingdom); vol. 159; (1947); p. 95, View in Reaxys; vol. Cu: MVol.B2; 41, page 709 - 711 ; (from Gmelin), View in Reaxys

(0) Medchem (1) 1 of 1

Bioassay Category

In Vivo (Animal models)

Bioassay Details Substance RN

3918931View in Reaxys

Measurement Parameter

Qualitative

Qualitative value

Melnik, M.; Auderova, M.; Hol'ko, M.; Inorganica Chimica Acta; vol. 67; (1982); p. 117 - 120, View in Reaxys

Reaxys ID 3914638 View in Reaxys

22/23 CAS Registry Number: 31416-33-8 Chemical Name: barium n-butanoate; barium butyrate; butyric acid ; barium butyrate; Buttersaeure; Bariumbutyrat; Buttersaeure; Barium-Verbindung; butanoic acid, barium salt; barium dibutyrate Linear Structure Formula: Ba(2+)*2CH3CH2CH2COO(1-)=Ba(C4H7O2)2 Molecular Formula: Ba*2C4H7O2 Molecular Weight: 311.527 Type of Substance: acyclic InChI Key: ZAQCEMASMWPINY-UHFFFAOYSA-M Note:

Ba2+ 2

O O–

360/365

2017-08-01 06:49:42

Substance Label (1) Label References Ba butyrate

Shehata, Hassan A.; Journal of the Chemical Society, Faraday Transactions; vol. 90; nb. 22; (1994); p. 3401 - 3404, View in Reaxys

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (1) 1 of 1

Melting Point [°C]

Comment (Melting Point)

with:2 Mol.H2O (solvent).

Linnemann; Zotta; Justus Liebigs Annalen der Chemie; vol. 161; (1872); p. 177, View in Reaxys Density (2) 1 of 2

Density [g·cm-3]

1.875

Reference Temperature [°C]

Measurement Temperature [°C]

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys 2 of 2

Density [g·cm-3]

1.885

Measurement Temperature [°C]

Strassmann; Zeitschrift fuer Physikalische Chemie, Abteilung B: Chemie der Elementarprozesse, Aufbau der Materie; vol. 26; (1934); p. 367, View in Reaxys Association (MCS) (1) 1 of 1

Description (Association Association with compound (MCS)) Temperature (Association (MCS)) [°C]

24.9 - 54.9

Partner (Association (MCS))

H2O

Shehata, Hassan A.; Journal of the Chemical Society, Faraday Transactions; vol. 90; nb. 22; (1994); p. 3401 3404, View in Reaxys Critical Micelle Concentration (MCS) (6) Critical Micelle Temperature Solvent (Critical Concentration (Critical Micelle Micelle Concen[g·l-1] Concentration tration (MCS)) (MCS)) [°C]

References

18.692

H2O

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys

20.561

H2O

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys

26.169

H2O

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys

28.038

H2O

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys

361/365

2017-08-01 06:49:42

29.595

H2O

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys

31.153

H2O

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys

Dielectric Constant (1) Dielectric ConFrequency (Diestant lectric Constant) [Hz]

Temperature (Die- References lectric Constant) [°C]

4.55

3E+06

Electrochemical Behaviour (1) Description (Elec- Comment (Electrochemical Betrochemical Behaviour) haviour)

Pathak; Bhide; Journal of the Indian Chemical Society; vol. 30; (1953); p. 47,48, View in Reaxys

References

Stability constant

in Wasser.

Colman-Porter; Monk; Journal of the Chemical Society; (1952); p. 4363,4364, View in Reaxys

Liquid Phase (1) Description (Liquid Phase)

Comment (Liquid Phase)

References

Association in the liquid state

in the presence of Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 organic com383, View in Reaxys pounds

Liquid/Liquid Systems (MCS) (1) 1 of 1

Description (Liquid/ Liquid Systems (MCS))

Solution equilibrium

Solvent (Liquid/Liquid Systems (MCS))

H2O

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

Comment (Liquid/Liquid Systems (MCS))

Minimum der Loeslichkeitskurve (35g in 100cmE3 Loesungsmittel).

Wing; Journal of the American Chemical Society; vol. 49; (1927); p. 2860, View in Reaxys Liquid/Solid Systems (MCS) (2) 1 of 2

Description (Liquid/Solid Eutectic Systems (MCS)) Temperature (Liquid/ Solid Systems (MCS)) [°C]

151.9

Partner (Liquid/Solid Systems (MCS))

butyric acid sodium salt

Mirnaya; Polishchuk; Bereznitski; Ferloni; Journal of Chemical and Engineering Data; vol. 41; nb. 6; (1996); p. 1337 - 1339, View in Reaxys 2 of 2

Description (Liquid/Solid Melting diagram Systems (MCS)) Temperature (Liquid/ Solid Systems (MCS)) [°C]

99.9 - 323.9

Partner (Liquid/Solid Systems (MCS))

butyric acid sodium salt

Mirnaya; Polishchuk; Bereznitski; Ferloni; Journal of Chemical and Engineering Data; vol. 41; nb. 6; (1996); p. 1337 - 1339, View in Reaxys Liquid/Vapour Systems (MCS) (3) 1 of 3

Description (Liquid/ Critical data for mixtures Vapour Systems (MCS))

362/365

2017-08-01 06:49:42

Temperature (Liquid/ 40 Vapour Systems (MCS)) [°C] Comment (Liquid/ concentration dependence Vapour Systems (MCS)) Partner (Liquid/Vapour Systems (MCS))

butan-1-ol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys 2 of 3

2-methyl-propan-1-ol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys 3 of 3

3-methyl-1-butanol

Varma, R. P.; Kumar, A.; Revue Roumaine de Chimie; vol. 37; nb. 3; (1992); p. 375 - 383, View in Reaxys Magnetic Susceptibility (1) Magnetic SusReferences ceptibility [10-6cm3mol-1] -145.6

Prasad et al.; Journal of Chemical Physics; vol. 18; (1950); p. 936,937; Proceedings - Indian Academy of Sciences, Section A; vol. 32; (1950); p. 313,315, View in Reaxys

Solubility (MCS) (9) 1 of 9

Solubility [g·l-1]

370

Saturation

in solution

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Wing; Journal of the American Chemical Society; vol. 49; (1927); p. 2860, View in Reaxys 2 of 9

Solubility [g·l-1]

480

Saturation

in solution

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Wing; Journal of the American Chemical Society; vol. 49; (1927); p. 2860, View in Reaxys 3 of 9

Temperature (Solubility (MCS)) [°C]

363/365

2017-08-01 06:49:42

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

37.42 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 4 of 9

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

36.59 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 5 of 9

Temperature (Solubility (MCS)) [°C]

28.5

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

36.05 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 6 of 9

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

35.82 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 7 of 9

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

37.12 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 8 of 9

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

41.40 part(s) of substance.dissolves in:100 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Deszathy; Monatshefte fuer Chemie; vol. 14; (1893); p. 249, View in Reaxys 9 of 9

Temperature (Solubility (MCS)) [°C]

Solvent (Solubility (MCS))

H2O

Comment (Solubility (MCS))

1 part(s) of substance.dissolves in:2.45 parts of solvent.in reinem Loesungsmittel:Loeslichkeit bezieht sich auf das wasserfreie Salz.

Linnemann; Zotta; Justus Liebigs Annalen der Chemie; vol. 161; (1872); p. 177, View in Reaxys Transport Phenomena (MCS) (1) 1 of 1

Description (Transport Phenomena (MCS))

Viscosity

364/365

2017-08-01 06:49:42

Temperature (Transport 35 - 60 Phenomena (MCS)) [°C] Partner (Transport Phenomena (MCS))

water

Varma, R. P.; Kumar, Anil; Journal of the Indian Chemical Society; vol. 63; (1986); p. 811 - 814, View in Reaxys IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Spectrum

Duval; Lecomte; Douville; Annales de Physique (Paris, France); vol. <11> 17; (1942); p. 5,42, 71, View in Reaxys

Reaxys ID 4156830 View in Reaxys

23/23 CAS Registry Number: 17442-53-4; 19348-32-4; 20525-36-4 Chemical Name: mercuric n-butyrate; Mercuributyrat Linear Structure Formula: Hg(O2CC3H7)2 Molecular Formula: C8H14HgO4 Molecular Weight: 374.787 Type of Substance: acyclic InChI Key: DZIHOYNRDGOJSD-UHFFFAOYSA-M Note:

Hg 2+ 2

O O–

Druglikeness (1) 1 of 1

LogP

0.261

H Bond Donors

H Bond Acceptors

Rotatable Bonds

TPSA

40.13

Lipinski Number

Veber Number

Melting Point (2) 1 of 2

Melting Point [°C]

102 - 103

Solvent (Melting Point)

CHCl3

Ellis,J. et al.; Australian Journal of Chemistry; vol. 24; (1971); p. 1527 - 1529, View in Reaxys 2 of 2

Melting Point [°C]

102 - 103

Larock; Brown; Journal of Organometallic Chemistry; vol. 26; (1971); p. 35,40,43, View in Reaxys IR Spectroscopy (1) 1 of 1

Description (IR Spectroscopy)

Zyat'kov et al.; Journal of Applied Spectroscopy; vol. 15; (1971); p. 1047; ; p. 283, View in Reaxys Mass Spectrometry (1) Comment (Mass References Spectrometry) Molecular peak

Gerbeleu, N. V.; Popovich, G. A.; Indrichan, K. M.; Russian Journal of Inorganic Chemistry (Translation of Zhurnal Neorganicheskoi Khimii); vol. 29; (1984); p. 1691 - 1692; Zhurnal Neorganicheskoi Khimii; vol. 29; (1984); p. 2959 - 2961 ; (from Gmelin), View in Reaxys

365/365

2017-08-01 06:49:42